<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/210631-a-polypeptide-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 03:18:25 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 210631:A POLYPEPTIDE COMPOUND</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A POLYPEPTIDE COMPOUND</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>This invention relates to new polypeptide compounds represented by the following formula (I) : wherein R&lt;sup&gt;1&lt;/sup&gt; is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on &amp;#946;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the I prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
DESCRIPTION NEW COMPOUND<br>
TECHNICAL FIELD<br>
The present invention relates to new polypeptide   compound and a pharmaceutically acceptable salt thereof   which are useful as a medicament.<br>
BACKGROUND ART<br>
In U.S. Pat No. 5,376,634, there are disclosed the polypeptide compound and a pharmaceutically acceptable salt thereof, juicy have antimicrobial activities (especially antifungal activity).<br>
DISCLOSURE OF INVENTION<br>
The present invention relates to new polypeptide compound and a pharmaceutically acceptable salt thereof.<br>
More particularly, it relates to new polypeptide compound and a pharmaceutically acceptable salt thereof, which have antimicrobial activities [especially, antifungal activities, in which the fungi may include Aspergillus.  <br><br>
The object polypeptide compound used in the present invention are new and can be represented by the following general formula [I] :<br><br>
wherein R-'- is lower alkanoyl substituted with unsaturated<br>
6-membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with 1’2,3,4-tetrahydroisoquinoline which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing at least one oxygen atom which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 1 to 3 sulfur atom(s) which may have one or more suitable substituent (s);<br>
lower alkanoyl substituted with<br><br>
unsaturated condensed heterocyclic group containing 2 or more nitrogen atom(s) which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with saturated 3 to 8 membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent(s);<br>
ar(lower)alkenoyl substituted with aryl which may have one or more suitable substituent(s);<br>
naphthyl(lower)alkenoyl which may have one or more higher alkoxy;<br>
lower alkynoyl which may have one or more suitable substituent(s);<br>
(C2-C5)alkanoyl substituted with naphthyl having higher alkoxy;<br>
ar (C2-C6)alkanoyl substituted with aryl having one or more suitable substituent(s), in which ar(C2-C6)alkanoyl may have one or more suitable substituent(s);<br>
aroyl substituted with heterocyclic group which may have one or more suitable substituent(s), in which aroyl may have one or more suitable substituent(s);<br>
aroyl substituted with aryl having heterocyclic(higher)alkoxy, in which heterocyclic group may have one or more suitable substituent(s);<br>
aroyl substituted with aryl having lower alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkenyl(lower)alkoxy;<br>
aroyl substituted with 2 lower alkoxy;<br><br>
aroyl substituted with aryl having lower<br>
alkyl;<br>
aroyl substituted, with aryl having higher<br>
alkyl;<br>
aryloxy(lower)alkanoyl which may have one or more suitable substituent(s);<br>
ar(lower)alkoxy(lower)alkanoyl which may have one or more suitable substituent (s);<br>
arylamino(lower)alkanoyl which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy;<br>
lower alkoxy(higher)alkanoyl, in which higher alkanoyl may have one or more suitable substituent(s);<br>
aroyl substituted with aryl having heterocyclicoxy, in which heterocyclicoxy may have one or more suitable substituent(s);<br>
aroyl substituted with cyclo(lower)alkyl having lower alkyl;<br>
indolylcarbonyl having higher alkyl;<br>
naphthoyl having lower alkyl;<br>
naphthoyl having higher alkyl;<br>
naphthoyl having lower alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy;<br>
aroyl substituted with aryl which has aryl having lower alkoxy;<br>
aroyl substituted with aryl which has aryl having lower alkoxy(lower)alkoxy;<br><br>
aroyl substituted with aryl having heterocyclicoxy(higher)alkoxy;<br>
aroyl substituted with aryl having aryloxy(lower)alkoxy;<br>
aroyl substituted with aryl having heterocycliccarbonyl(higher)alkoxy;<br>
lower alkanoyl substituted with oxazolyl which has aryl having higher alkoxy;<br>
lower alkanoyl substituted with furyl which has aryl substituted with aryl having lower alkoxy;<br>
lower alkanoyl substituted with triazolyl which has oxo and aryl having higher alkyl;<br>
higher alkanoyl having hydroxy;<br>
higher alkanoyl having ar(lower)alkyl and hydroxy;<br>
3-methyl-tridecenoyl; or<br>
(C2-C6)alkanoyl substituted with aryl having higher alkoxy, in which (C2-C6)alkanoyl may have amino or protected amino.<br>
The new polypeptide compound [I] and a pharmaceutically acceptable salt thereof can be prepared by the process as illustrated in the following reaction scheme or can be prepared by elimination reaction of amino protective group in R-'-.<br><br><br><br>
wherein R’ is as defined above.<br>
Suitable pharmaceutically acceptable salts of the object polypeptide compound [I] are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, Pico line salt, ethanolamine salt,.triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tart rate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.).<br>
In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.<br>
The term -lower- is used to intend a group having 1 to 6 carbon atom(s), unless otherwise provided.<br>
The term -higher- is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided.<br>
Suitable 'example of -one or more- may be the number of 1 to 6, in which the preferred one may be the number of 1 to 3.<br>
Suitable example of -lower alkanoyl- may include<br><br>
straight or branched one such as formyl, acetyl, 2-methylacetyl, 2,2-dimethylacetyl, propenyl, butyryl, isobutyryl, pentenyl, 2,2-dimethylpropionyl, hexanoyl, and the like.<br>
Suitable example of -suitable substituent(s)- in the groups such as -lower alkanoyl substituted with unsaturated 6-membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent(s)-, -lower alkanoyl substituted with 1,2, 3, 4-tetrahydroisoquinoline which may have one or more suitable substituent(s)-, etc. may include lower alkoxy as mentioned below, higher alkoxy as mentioned below, lower alkyl as mentioned below, higher alkyl as mentioned below, higher alkoxy(lower)alkyl, lower alkoxycarbonyl, oxo, aryl which may have one or more lower alkoxy, aryl which may have one or more higher alkoxy, aryl which may have one or more lower alkyl, aryl which may have one or more higher alkyl, aryl substituted with aryl which may have one or more lower alkoxy, aryl substituted with aryl which may have one or more higher alkoxy, aryl substituted with aryl which may have one or more lower alkyl, aryl substituted with aryl which may have one or more higher alkyl, aroyl which may have one or more lower alkoxy, aroyl which may have one or more higher alkoxy, aroyl which may have one or more lower alkyl, aroyl which may have one or more higher alkyl, heterocyclic group which may have one or more lower alkoxy, heterocyclic group which may have one or more higher alkoxy, aryl having<br>
heterocyclic (higher)alkoxy, heterocyclic group which may have aryl having higher alkoxy, heterocyclic group which may have aryl having lower alkoxy(higher)alkoxy, heterocyclic group which may have aryl having lower alkoxy, lower alkoxy(lower)alkyl, halo(lower)alkoxy, lower alkynyloxy, halo(higher)alkoxy, lower alkoxy(higher)alkoxy, aryl which may have one or more<br><br>
lower alkoxy(lower)alkoxy, heterocyclic group, aryl which may have one or more lower alkoxy(higher)alkoxy, aryl which may have one or more higher alkenyloxy, cyclo(lower)alkyl which may have aryl, aryl substituted with heterocyclic group which may have lower alkyl and oxo, cyclo(lower)alkyl which may have one or more lower alkyl, aryl which may have cyclo(lower)alkyl, aryl which may have heterocyclic group, and the like-<br>
Suitable example of -lower alkoxy- may include straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pentyloxy, neo-pentyloxy, hexyloxy, isohexyloxy and the like,<br>
in which the preferred one may be methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy and isohexyloxy.<br>
Suitable example of -higher alkoxy- may include straight or branched one such as heptyloxy, octyloxy, 3, 5-dimethyloctyloxy, 3,7-dimethyloctyloxy, tolyloxy, tosyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy, nonadecyloxy, icosyloxy, and the like,<br>
in which the preferred one may be (C7-C24)alkoxy, and the more preferred one may be heptyloxy and octyloxy.<br>
Suitable example of -lower alkyl- may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl and the like,<br>
in which the preferred one may be methyl, pentyl, hexyl and isohexyl.<br>
Suitable example of -higher alkyl- may include straight or branched one having 7 to 20 carbon atoms, such as heptyl, octyl, 3,5-dimethyloctyl, 3,7-dimethyloctyl, nonyl, decyl, undecyl, dodecyl, tridecyloxy, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, monodactyl.<br><br>
icosyl, and the like,<br>
in which the preferred one may be (C7-C24) alkyl, and the more preferred one may be heptyl, octyl, nonyl and decyl.<br>
Suitable example of -aryl- and -ar- moiety may include phenyl which may have lower alkyl (e.g., phenyl, mesityl, tolyl, etc.), naphthyl, napthyl, and the like,<br>
in which the preferred one may be phenyl and naphthyl. Suitable example of -aroyl- may include benzoyl, toluoyl, naphthoyl, anthrylcarbonyl, and the like,<br>
in which the preferred one may be benzoyl and naphthoyl.<br>
Suitable example of -heterocyclic group- and -heterocyclic- moiety may include<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl/ lH-1,2,3-triazolyl, 2H-1,2, 3-triazolyl, etc.) , tetrazolyl (e.g., IH-tetrazolyl, 2H-tetrazolyl, etc.), etc.;<br>
saturated 3 to 8-membered (more preferably 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;<br>
unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isO indolyl, indolently, indolizine, benzimidazolyl, quinolyl, iso quinolyl, imidazolyl, benzo triazolyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and I'to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;<br><br>
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen arom(s), for example, morpholinyl, sydnonyl, etc.;<br>
unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadia2olyl, 1,3,4-thiadiazolyl, 1,2, 5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;<br>
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl, dihydrodithionyl, etc.;<br>
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;<br>
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, tetrahydrofuran, tetrahydropyran, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;<br>
unsaturated condensed heterocyclic group containing 1<br><br>
to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;<br>
unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like.<br>
Suitable example of -halo- may include fluoro, chloro, bromo and iodo.<br>
Suitable example of -lower alkenyloxy- may include vinyloxy, 1-(or 2-)propenyloxy, l-(or 2- or 3-)butenyloxy, l-(or 2- or 3- or 4-)pentenyloxy, 1-(or 2- or 3- or 4- or 5-)hexenyloxy, and the like, in which the preferred one may be (C2-C6)alkenyloxy, and the most preferred one may be 5-hexenyloxy.<br>
Suitable example of -higher alkenyloxy- may include (C7-C2o)alkenyloxy, in which the preferred one may be 6-heptenyloxy and 7-octenyloxy.<br>
Suitable example of -cyclo(lower)alkyl- may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, in which the preferred one may be cyclo(C’-C6)alkyl, and the most preferred one may be cyclohexyl.<br>
Suitable example of -higher alkanoyl- may include heptanoyl, octanoyl, nonanoyl, decanoy1, undecanoyl, lauroyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, and the like, in which the preferred one may be (C7-C9 )alkanoyl, and the most preferred one may be hexadecanoyl.<br>
Suitable example of -ar(lower)alkyl- may include benzyl, phenethyl, phenylpropyl, phenyl butyl, phenylethyl, phenylhexyl, naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, naphthylpentyl, naphthylhexyl, and the like, in which the preferred one may be phenyl   alkyl, and the most preferred one may be benzyl.<br><br>
Suitable example of -protected amino- may include lower or higher alkoxycarbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, t-heptyloxycarbonylamino, heptyloxycarbonylamino/ etc.), ar(lower)alkoxycarbonylamino [e.g./ phenyl(lower)alkoxycarbonylamino (e.g., benzyloxycarbonylamino/ etc.), etc.], an amino group substituted with a conventional protecting group such as ar(lower)alkyl which may have suitable substituent(s) (e.g., benzyl, trityl, etc.) and the like, in which the preferred one may be phenyl(lower)alkoxycarbonylamino, and the most preferred one may be benzyloxycarbonylamino.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with unsaturated 6-membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent(s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be  alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -unsaturated 6-membered heteromonocyclic group containing at least one nitrogen atom- in the term of -lower alkanoyl substituted with unsaturated 6-membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent(s)- may include pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl (e.g., 4H-1,2,4-triazinyl, lH-1,2,3-triazinyl, etc.), tetrazolyl (e.g., 1,2,4,5-tetrazinyl, 1,2,3,4-tetrazinyl, etc.), and the like,<br>
in which the -preferred one may be unsaturated 6-membered heteromonocyclic group containing 1 to 3 nitrogen atom(s), and the most preferred one may be pyridyl and pyridazinyl. Suitable example of -suitable substituent (s)- in the<br><br>
term of -lower alkanoyl substituted with unsaturated 6-membered heteromonocyclic groups containing at least one nitrogen atom which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be higher alkoxy, higher alkoxy(lower)alkyl, heterocyclic group which may have aryl having higher alkoxy, aryl which may have one or more higher alkoxy, aryl substituted with aryl which may have lower alkoxy, heterocyclic group which may have aryl having lower alkoxy(higher)alkoxy, and heterocyclic group which may have aryl having lower alkoxy, and the more preferred one may be (C7-C]’4) alkoxy, (07-03’4) alkoxy ) alkyl, 3 to 8-membered saturated heteromonocyclic group containing at least one nitrogen atom which may have phenyl having 1 to 3 (C7-C]’4) alkoxy, phenyl which may have 1 to 3 (C7-C24)alkoxy, phenyl substituted with phenyl which may have 1 to 3 (03-0’) alkoxy, 3 to 8-membered saturated heteromonocyclic group containing at least one nitrogen atom which may have phenyl having  alkoxy (07-03’4) alkoxy, and 3 to 8-membered saturated heteromonocyclic group containing at least one nitrogen atom which may have phenyl having 1 to 3 (C3-C6)alkoxy, and the most preferred one may be octyloxy, octyloxymethyl, piperazinyl which has phenyl having heptyloxy or octyloxy, phenyl having heptyloxy, phenyl substituted with phenyl having butoxy, piperazinyl which has phenyl having methoxyoctyloxy, and piperazinyl which has phenyl having hexyloxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl' substituted with 1,2,3,4-tetra-hydroisoquinoline which may have one or more suitable substituent(s)- can be referred to aforementioned -lower alkanoyl-.<br><br>
in which the preferred one may be (C1-C4)- alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -suitable substituent(s)- in the term of -lower alkanoyl substituted with 1,2;3,4-tetrahydroisoquinoline which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl, higher alkyl and lower alkoxycarbonyl, and the more preferred one may be (C7-C24)alkoxy and (C2-C4)alkoxycarbonyl, and the most preferred one may be octyloxy and tert-butoxycarbonyl.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing at least one oxygen atom which may have one or more suitable substituent(s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be   alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -unsaturated condensed heterocyclic group containing at least one oxygen atom- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing at least one oxygen atom which may have one or more suitable substituent (s)- may include unsaturated condensed heterocyclic group containing one or more oxygen atom{s) and, optionally,  another hetero atom(s) except oxygen atom,<br>
in which the preferred one may be unsaturated condensed heterocyclic group containing 1 to 3 oxygen atom(s), unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 2 sulfur atom(s) and unsaturated condensed heterocyclic group 1 to 3 oxygen atom(s) and 1 to 3 nitrogen atom(s), and the more preferred one may be<br><br>
benzo[b]furanyl, isobenzofuranyl, chromene, xanthenes, benzoxazolyl; benzoxadiazolyl, dihydrooxathiinyl, phenoxathiinyl, and the like, and the most preferred one may be benzo[b]furanyl, chromene and benzoxazolyl.<br>
Suitable example of -suitable substituent(s)- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing at least one oxygen atom which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, oxo, aryl which may have one or more lower alkoxy, heterocyclic group which may have one  or more higher alkoxy, and aryl substituted with aryl which may have one or more lower alkyl, and the more preferred one may be (07’024)alkoxy,  alkyl, {C7-C3’4) alkyl, 0x0, phenyl which may have 1 to 3 (C3--C6) alkoxy, unsaturated 6-membered heteromonochclic group containing at least one nitrogen atom which may have 1 to 3 (C7-C24)alkoxy, and phenyl substituted with phenyl which may have 1 to 3 (C3-C6)alkyl, and the most preferred one may be octyloxy, methyl, nonyl, 0x0, phenyl having hexyloxy, pyridyl having octyloxy, and phenyl substituted with phenyl having hexyl.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 1 to 3 sulfur atom(s) which may have one or more suitable substituent (s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be (C1-C4)alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -unsaturated condensed heterocyclic group containing 1 to 3 sulfur atom(s)- in the term of -lower alkanoyl substituted with unsaturated<br><br>
condensed heterocyclic group containing 1 to 3 sulfur atom(s) which may have one or more suitable substituent (s)- may include unsaturated condensed heterocyclic group containing only 1 to 3 sulfur atom(s),<br>
in which the preferred one may be benzothienyl and benzodithiinyl, and the most preferred one may be benzothienyl.<br>
Suitable example of -suitable substituent(s)- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 1 to 3 sulfur atom(s) which may have one or more suitable substituent (s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl and higher alkyl, and more preferred one may be (C7-C24)alkoxy, and the most preferred one may be octyloxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 2 or more nitrogen atom(s) which may have one or more suitable substituent(s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be (C]_-C4) alkanoyl, and the most preferred one may be formyl.<br>
Suitable example of -unsaturated condensed heterocyclic group containing 2 or more nitrogen atom(s)- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 2 or more nitrogen atom(s) which may have one or more suitable substituent (s)- may include IH-imidazolyl, prenyl, phthalazinyl, benzo imidazolyl, naphthyridinyl, quinoxalinyl, quinazolyl, quinolinyl, pteridinyl, and the like,<br>
in which the most preferred one may be benzo imidazolyl.<br><br>
Suitable example of -suitable substituent(s)- in the term of -lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 2 or more nitrogen atom(s) which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-’<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, aryl which may have one or more lower alkoxy and aryl which may have one or more higher alkoxy, and the more preferred one may be (C7-0’4) alkyl and phenyl which may have 1 to 3 (Cj’-C6) alkoxy, and the most preferred one may be nonyl and phenyl which may have hexyloxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with saturated 3 to 8-membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent (s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be (€3’-04) alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -saturated 3 to 8-membered heteromonocyclic group containing at least one nitrogen atom- in the term of -lower alkanoyl substituted with saturated 3 to 8-membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent(s)- may include pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, and the like,<br>
in which the preferred one may be piperidyl and piperazinyl.<br>
Suitable example of -suitable substituent(s)- in the term of -lower alkanoyl substituted with saturated 3 to 8--membered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable<br><br>
substituent(s)- may include lower alkoxy, higher alkoxy,<br>
higher alkoxy(lower)alkyl, lower alkyl, higher alkyl, oxo,<br>
aryl which may have one or more lower alkoxy,<br>
aryl which may have one or more higher alkoxy,<br>
aryl which may have one or more lower alkyl,<br>
aryl which may have one or more higher alkyl,<br>
aroyl which may have one or more lower alkoxy,<br>
aroyl which may have one or more higher alkoxy,<br>
aroyl which may have one or more lower alkyl,<br>
aroyl which may have one or more higher alkyl,<br>
and the like,<br>
in which the preferred one may be aryl which may have one or more lower alkoxy, aryl which may have one or more higher alkoxy, aroyl which may have one or more lower alkoxy and aroyl which may have one or more higher alkoxy, and the more preferred one may be aryl which may have 1 to 3 higher alkoxy and aroyl which may have 1 to 3 higher alkoxy, and the much more preferred one may be phenyl which may have 1 to 3 (C7-C14)alkoxy and naphthoyl which may have 1 to 3 (C7-C24)alkoxy, and the most preferred one may be phenyl which may have octyloxy and naphthoyl which may have heptyloxy.<br>
Suitable example of -ar(lower)alkenoyl- in the term of -ar(lower)alkenoyl substituted with aryl which may have one or more suitable substituent(s)- may include phenyl(lower)alkenoyl (e.g., 3-phenylacryloyl, (2- or 3-or 4-)phenyl-(2- or 3-)butenoyl, 3-phenylmethacryloyl, (2- or 3- or 4- or 5-)phenyl-(2- or 3- or 4-)pentanoyl, (2- or 3- or 4- or 5- or 5-)phenyl-(2- or 3- or 4- or 5-)-hexanoyl, etc.'), naphthyl (lower) alkenoyl (e.g., 3-naphthylacryloyl, (2- or 3- or 4-)naphthyl-(2- or 3-)butenoyl, (2- or 3- or 4- or 5-)naphthyl-(2- or 3- or 4-)pentanoyl, (2- or 3- or 4- or 5- or 6-)naphthyl-(2- or<br><br>
3- or 4- or 5-)hexanoyl, etc.), and the like,<br>
in which the preferred one may be 3-phenylacryloyl and 3-methyl-3-phenylacryloyl.<br>
Suitable example of -suitable substituent(s)- in the term of -ar(lower)alkenoyl substituted with aryl which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be lower alkoxy, lower alkyl, higher alkyl, lower alkoxy(lower)alkyl, halo(lower)alkoxy, lower alkenyloxy, halo(higher)alkoxy, and lower alkoxy(higher)alkoxy and the much more preferred one may be (C]’-C6) alkoxy, (C’-C6) alkyl, (C-j-Ci’’) alkyl alkoxy(C3-C6)alkyl, halo alkoxy, (C3-C6) alkenyloxy, halo {C-j-Ci/’) alkoxy, and  ) alkoxy (C7-C24)alkoxy and the most preferred one may be pentyloxy, heptyl, pentyl, methoxy hexyl, fluorohexyloxy, isohexyloxy, 5-hexenyloxy, haloheptyloxy, methoxy heptyloxy, methoxyoctyloxy, and butyloxy.<br>
Suitable example of -naphthyl(lower)alkenoyl- in the term of -naphthyl(lower)alkenoyl which may have one or more higher alkoxy- may include 3-naphthylacryloyl, (2- or 3- or 4-)naphthyl-(2- or 3-)butenoyl, (2- or 3- or 4- or 5-)naphthyl-(2- or 3- or 4-)pentanoyl, (2- or 3- or 4- or 5- or 6-)naphthyl-(2- or 3- or 4- or 5-)hexanoyl, and the like, in which the preferred one may be 3-naphthylacryloyl.<br>
Suitable example of -lower alkynoyl- in the term of -lower alkynoyl which may have one or more suitable substituent (s)- may include 2-propynoyl, (2- or 3-)butynoyl, (2- or 3- or 4-)pentynoyl, (2- or 3- or 4- or 5-)hexynoyl, and the like, in which the preferred one may be 2-propynoyl.<br>
Suitable example of -suitable substituent(s)- in the<br><br>
term of -lower alkynoyl which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be aryl which may have one or more lower alkoxy, aryl which may have one or more higher alkoxy, aryl substituted with aryl which may have one or more lower alkyl and aryl substituted with aryl which may have one or more higher alkyl, and the more preferred one may be aryl substituted with aryl which may have 1 to 3 lower alkyl and aryl which may have 1 to 3 higher alkoxy, and the much more preferred one may be phenyl substituted with phenyl which may have 1 to 3 (C’-C5)alkyl and phenyl which may have 1 to 3   alkoxy, and the most preferred one may be phenyl substituted with phenyl which may have pentyl and naphthyl which may have heptyloxy.<br>
Suitable example of -ar(C2-C5)alkanoyl- in the term of -ar(C2-C5)alkanoyl substituted with aryl having one or more suitable substituent(s), in which ar(C’-C6)alkanoyl may have one or more suitable substituent(s)- may include phenyl(C2-C6)alkanoyl [e.g., phenylacetyl, (2- or 3-)-phenylpropanoyl, (2- or 3- or 4-)phenylbutanoyl, (2- or 3-or 4- or 5-)phenylpentanoyl, (2- or 3- or 4- or 5- or 6-)-phenylhexanoyl, etc.], naphthyl(C2-C6)alkanoyl [e.g. naphthylacetyl, (2- or 3-)naphthylpropanoyl, (2- or 3- or 4-)naphthylbutanoyl, (2- or 3- or 4- or 5-)-naphthylpentanoyl, (2- or 3- or A-  or 5- or 6-)-naphthylhexanoyl, etc.], and the like,<br>
in which the preferred one may be 2-phenylacetyl and 3-phenylpropanoyl.<br>
Suitable ‘example of -suitable substituent(s)- in the term of -ar(C2-C6)alkanoyl substituted with aryl having one or more suitable substituent(s), in which ar(C2-C6)-alkanoyl may have one or more suitable substituent(s)- may<br><br>
include lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, oxo, aryl having one or more lower alkoxy, aryl having one or more higher alkoxy, aryl having one or more lower alkyl, aryl having one or more higher alkyl, aryl substituted with aryl having one or more lower alkoxy, aryl substituted with aryl having one or more higher alkoxy, aryl substituted with aryl having one or more lower alkyl, aryl substituted with aryl having one or more higher alkyl, aryl having one or more lower alkoxy(lower)alkoxy and the like,<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, and phenyl having 1 to 3 lower alkoxy(lower)alkoxy and the much more preferred one may be (C’-C6) alkoxy, (C’-C6) alkyl,   and phenyl having (C’’-C’) alkoxy (C3-C6) alkoxy and the most preferred one may be pentyloxy, pentyl, heptyl and phenyl having methoxy pentyloxy.<br>
Suitable example of -suitable substituent(s)- in the term of -in which ar (C2-C6)alkanoyl may have one or more suitable substituent (s) - may be hydroxy, oxo, amino and aforementioned -protected amino-.<br>
Suitable example of -(C2-C6)alkanoyl- in the term of -(C2-C6)alkanoyl substituted with naphthyl having higher alkoxy- may include acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, and the like, in which the preferred one may be propanoyl.<br>
Suitable example of -higher alkoxy- in the term of -(C1-C6)alkanoyl substituted with naphthyl having higher alkoxy- can be referred to aforementioned -higher alkoxy-, in which the preferred one may be (C7-C24)alkoxy, and the most preferred one may be heptyloxy.<br>
Suitable example of -aroyl- in the term of -aroyl substituted with heterocyclic group which may have one or<br><br>
more suitable substituent(s), in which aroyl may have one or more suitable substituent(s)- may include benzoyl, toluoyl, naphthoyl, and the like, in which the preferred one may be benzoyl.<br>
Suitable example of -heterocyclic group- in the term of -aroyl substituted with heterocyclic group which may have one or more suitable substituent(s), in which aroyl may have one or more suitable substituent(s)- may include unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, lH-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., IH-tetrazolyl, 2H-tetrazolyl, etc.), etc. ;<br>
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;<br>
unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, iso indolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isO quinolyl, imidazolyl, benzothiazolyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;<br>
saturated 3 to 8-membered (more preferably 5 or 6-meinbered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.;<br><br>
unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc. ;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1, 3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;<br>
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl, dihydrodithionyl, etc.;<br>
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;<br>
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, tetrahydrofuran, tetrahydropyran, etc.;<br>
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc. ;<br>
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;<br>
unsaturated condensed heterocyclic group containing<br><br>
an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like,<br>
in which the preferred one may be saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s),<br>
unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) , and<br>
unsaturated 3 to S-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), and the most preferred one may be piperazinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, piperidyl, oxazolyl and pyrimidyl.<br>
Suitable example of -suitable substituent(s)- in the term of -aroyl substituted with heterocyclic group which may have one or more suitable substituent(s), in which aroyl may have one or more suitable substituent(s)-, can be referred to aforementioned -suitable substituent(s)-, in which the preferred one may be aryl which may have 1 to 3 higher alkoxy, aryl which may have 1 to 3 lower alkoxy, higher alkyl, heterocyclic group, aryl which may have 1 to 3 lower alkoxy(higher)alkoxy, aryl which may have higher alkenyloxy, heterocyclic group which may have aryl having lower alkoxy, cyclo(lower)alkyl which may have aryl/ aryl which may have 1 to 3 lower alkyl, aryl which may have cyclo(lower)alkyl, aryl which may have higher alkenyloxy, aryl substituted with heterocyclic group which may have lower alkyl and oxo, cyclo(lower)alkyl which may have lower alkyl, aryl substituted with aryl which may have 1 to 3 lower alkoxy, and aryl which may have heterocyclic group, and the more preferred one may be phenyl which may have 1 to 3 (C7-C24)alkoxy, phenyl which may have 1 to 3 (C3-C6)alkoxy, (C7-CT4)alkyl, saturated 3<br><br>
to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), phenyl which may have 1 to 3 -alkoxy - alkoxv/ phenyl which may have (C7-C2_4) alkenyloxy, saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) substituted with phenyl having (C3-C6)alkoxy, cyclo(C3-C6)alkyl which may have phenyl, phenyl which may have 1 to 3 (C3-C6)alkyl, phenyl which may have cycle(C3-C6)alkyl, phenyl which may have (0-7-02’4) alkenyloxy, phenyl substituted with heterocyclic group which may have (C3’C6)alkyl and 0x0, cyclo(C3-C5)alkyl which may have (C3-C6)alkyl, phenyl substituted with phenyl which may have 1 to 3 (C1-C4)alkoxy, and phenyl which may have 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s}r and the most preferred one may be phenyl having octyloxy, phenyl having pentyloxy, phenyl having hexyloxy, heptyl, piperidyl, phenyl having isohexyloxy, phenyl having heptyloxy, phenyl having methoxy heptyloxy, phenyl having methoxyoctyloxy, phenyl having 6-heptenyloxy, piperidyl substituted with phenyl having hexyloxy, cyclohexyl having phenyl, .phenyl having hexyl, phenyl having cyclohexyl, phenyl having 7-octenyloxy, phenyl substituted with triazolyl having lower alkyl and 0x0, cyclohexyl having pentyl, phenyl having methoxyoctyloxy, nonyl, phenyl substituted with phenyl having propoxy, and phenyl having piperidine.<br>
Suitable example of -suitable substituent (s)- in the term of -in which aroyl may have one or more suitable substituent (s)- may be halogen, in which the preferred one may be fluoric and chloro.<br>
Suitable example of -aroyl- in the term of -aroyl substituted with aryl having heterocyclic(higher)alkoxy, in which heterocyclic group may have one or more suitable substituent(s)- may include benzoyl, toluoyl, naphthoyl.<br><br>
anthrylcarbonyl and the like,<br>
in which the preferred one may be benzoyl.<br>
Suitable example of -heterocyclic- moiety in the term of -aroyl substituted with aryl having<br>
heterocyclic(higher)alkoxy, in which heterocyclic group may have one or more suitable substituent(s)- can be referred to the ones as exemplified before for -heterocyclic group- in the term of -aroyl substituted with heterocyclic group which may have one or more suitable substituent(s)-,<br>
in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) and saturated 3 to 8-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s)  and the most preferred one may be triazolyl, tetrazolyl and morpholinyl.<br>
Suitable example of -(higher)alkoxy- moiety in the term of -aroyl substituted with aryl having heterocyclic(higher)alkoxy, in which heterocyclic group may have one or more suitable substituent(s)- can be referred to aforementioned -higher alkoxy-,<br>
in which the preferred one may be (07-024)alkoxy, and the most preferred one may be octyloxy.<br>
Suitable example of -aryl- in the term of -aroyl substituted with aryl having heterocyclic(higher)alkoxy, in which heterocyclic group may have one or more suitable substituent(s)- can be referred to aforementioned -aryl-,<br>
in which the preferred one may be phenyl.<br>
Suitable example of -suitable substituent(s)- in rhe term of -in which heterocyclic group may have one or more suitable substituent(s)- may be lower alkyl, in which the preferred one may be methyl.<br>
Suitable example of -aroyl- in the term of -aroyl substituted with aryl having lower alkoxy(higher)alkoxy-<br><br>
may include benzoyl; toluoyl, naphthoyl, anthrylcarbonyl and the like,<br>
in which the preferred one may be benzoyl.<br>
Suitable example of -aryl- in the term of -aroyl substituted with aryl having lower alkoxy(higher)alkoxy- can be referred to aforementioned -aryl-,<br>
in which the preferred one may be phenyl.<br>
Suitable example of -lower alkoxy(higher)alkoxy- in the term of -aroyl substituted with aryl having lower alkoxy(higher)alkoxy- may be methoxyheptyloxy, methoxyoctyloxy, methoxynonyloxy, methoxydecyloxy, ethoxyheptyloxy, ethoxyoctyloxy, ethoxynonyloxy, ethoxydecyloxy, ethoxyundecyloxy, propoxyundecyloxy, butoxydodecyloxy, pentyloxytridecyloxy,<br>
hexyloxytetradecyloxy, propoxyheptyloxy, propoxyoctyloxy, propoxynonyloxy, butoxydecyloxy, or the like, in which the preferred one may be (C1-C6)alkoxy(C7-C24)alkoxy, and the more preferred one may be methoxyoctyloxy.<br>
Suitable example of -aroyl- in the term of -aroyl substituted with aryl having lower alkenyl(lower)alkoxy- may include benzoyl, toluoyl, naphthoyl, anthrylcarbonyl and the like, in which the preferred one may be benzoyl.<br>
Suitable example of -aryl- in the term of -aroyl substituted with aryl having lower alkenyl(lower)alkoxy- can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -lower alkenyl(lower)alkoxy- in the term of -aroyl substituted with aryl having lower alkenyl(lower)alkoxy- may be vinylmethoxy, vinylethoxy, vinylpropoxy, vinylbutoxy, vinylpentyloxy, vinylhexyloxy, 1-(or 2-)propenyl methoxy, 1-(or 2-)propenylethoxy, 1-(or 2-)propenyl propoxy, 1-(or 2-)propenyl butoxy, 1-(or 2-)-propenyl pentyloxy, 1-(or 2-)propenylhexyloxy, 1-(or 2- or<br><br>
3-)butenylbutoxy, l-(or 2- or 3-)butenylhexyloxy, 1-(or 2-or 3- or 4-)pentenyl pentyloxy/ l-(or 2- or 3- or 4-)-pentenylhexyloxy, 1-(or 2- or 3- or 4- or 5-)-hexenylbutoxy, l-(or 2- or 3- or 4- or 5-)hexenylhexyloxy, or the like,<br>
in which the preferred one may be (C2-C6) alkenyl  alkoxy, and the more preferred one may be vinylhexyloxy.<br>
Suitable example of -aroyl substituted with 2 lower alkoxy- may include benzoyl substituted with 2 lower alkoxy and naphthoyl substituted with 2 lower alkoxy,<br>
in which the preferred one may be benzoyl substituted with 2   alkoxy, and the most preferred one may be benzoyl substituted with 2 pentyloxy.<br>
Suitable example of -aroyl substituted with aryl having lower alkyl- may include benzoyl substituted with phenyl having lower alkyl, benzoyl substituted with naphthyl having lower alkyl, naphthoyl substituted with phenyl having lower alkyl, naphthoyl substituted with naphthyl having lower alkyl, and the like,<br>
in which the preferred one may be benzoyl substituted with phenyl having   alkyl, and the most preferred one may be benzoyl substituted with phenyl having hexyl and benzoyl substituted with phenyl having pentyl.<br>
Suitable example of -aroyl substituted with aryl having higher alkyl- may include benzoyl substituted with phenyl having higher alkyl, benzoyl substituted with naphthyl having higher alkyl, naphthoyl substituted with phenyl having higher alkyl, naphthoyl substituted with naphthyl having higher alkyl, and the like,<br>
in which the preferred one may be benzoyl substituted with phenyl having (C7-C24)alkyl, and the most preferred<br><br>
one may be benzoyl substituted with phenyl having heptyl.<br>
Suitable example of -aryloxy- moiety in the term of -aryloxy(lower)alkanoyl which may have one or more suitable substituent(s)- may include phenoxy, mesityloxy, tolyloxy, naphthyl, anthryloxy, and the like,<br>
in which the preferred one may be phenoxy.<br>
Suitable example of -lower alkanoyl- moiety in the term of -aryloxy(lower)alkanoyl which may have one or more suitable substituent(s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be formyl, acetyl, 2,2-dimethylacetyl, propynyl, butyryl, isobutyryl and pentanoyl, hexanoyl, and the more preferred one may be (C1-C6) alkanoyl, and the much more preferred one may be formyl, acetyl, propionyl and 2,2-dimethylacetyl.<br>
Suitable example of -suitable substituent(s)- in the term of -aryloxy(lower)alkanoyl which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be (C7-C24)alkoxy, and the more preferred one may be octyloxy.<br>
Suitable example of -ar(lower)alkoxy- moiety in the term of -ar(lower)alkoxy(lower)alkanoyl which may have one or more suitable substituent(s)- may include phenyl(lower)alkoxy [e.g., phenylmethoxy, (1- or 2-)-phenylethoxy, phenylpropoxy, 2-phenyl-1-methylpropoxy, 3-phenyl-2,2-dimethylpropoxy,<br>
(1- or 2- or 3- or 4-)phenylbutoxy, (1- or 2- or 3- or 4-or 5-)phenylpentyloxy, (1- or 2- or 3- or 4- or 5- or 6-phenylhexyloxy; etc.], naphthyl(lower)alkoxy [e.g. naphthylmethoxy, (1- or 2-&gt;napthylethoxy,<br>
1-naphthylpropoxy, 2-naphthyl-l-methylpropoxy, 3-naphthyl-2,2-dimetylpropoxy, (1- or 2- or 3- or 4-)naphthylbutoxy,<br><br>
(1- or 2- or 3- or 4- or 5-)naphthylpentyloxy, (1- or 2-or 3- or 4- or 5- or 6-)naphthylhexyloxy, etc], and the like,<br>
in which the preferred one may be naphthyl(C2-C4)alkoxy, and the more preferred one may be naphthylmethoxy.<br>
Suitable example of -(lower)alkanoyl- moiety in the term of -ar(lower)alkoxy(lower)alkanoyl which may have one or more suitable substituent(s)- can be referred to aforementioned -lower alkanoyl-,<br>
in which the preferred one may be (C’-C’)alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -suitable substituent(s)- in the term of -ar(lower)alkoxy(lower)alkanoyl which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl and higher alkyl, and the more preferred one may be higher alkoxy, and the much more preferred one may be (C7-C]_4) alkoxy, and the most preferred one may be heptyloxy.<br>
Suitable example of -arylamino- moiety in the term of -arylamino(lower)alkanoyl which may have one or more suitable substituent(s)- may include phenyl amino, mesitylamino, tolylamino, naphthylamino, anthrylamino and the like,<br>
in which the preferred one may be phenyl amino and naphthylamino.<br>
Suitable example of -lower alkanoyl- moiety in the term of -arylamino(lower)alkanoyl which may have one or more suitable substituent(s)- can be referred to aforementioned *-lower alkanoyl-,<br>
in which the preferred one may be (C’-C’)alkanoyl, and the more preferred one may be formyl.<br>
Suitable example of -suitable substituent (s)- in the<br><br>
term of -arylamino (lower) alkanoyl which may have one or more suitable substituent(s)- can be referred to aforementioned -suitable substituent(s)-,<br>
in which the preferred one may be lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, aryl which may have 1 to 3 lower alkoxy and aryl which may have 1 to 3 higher alkoxy, and the more preferred one may be (07-03’4) alkoxy, and phenyl which may have 1 to 3 (C7-C24) alkoxy, and the most preferred one may be heptyloxy and phenyl which may have heptyloxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy- can be referred to aforementioned -lower alkanoyl-, in which the preferred one may be   alkanoyl, and the most preferred one may be formyl.<br>
Suitable example of -lower alkyl- in the term of -lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy- can be referred to aforementioned -lower alkyl-, in which the preferred one may be  alkyl, and the most preferred one may be methyl.<br>
Suitable example of -aryl- in the term of -lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy- can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -higher alkoxy- in the term of -lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy- can be referred to aforementioned -higher alkoxy-, in which the preferred one may be   alkoxy, and the most preferred one may be octyloxy.<br>
Suitable example of -lower alkoxy(higher)alkanoyl- in<br><br>
the term of -lower alkoxy(higher)alkanoyl, in which higher alkanoyl may have one or more suitable substituent(s)- may be   alkoxy(C7-C2o) alkanoyl, in which the preferred one may be methoxyoctadecanoyl.<br>
Suitable example of -suitable substituent(s)- in the term of -lower alkoxy(higher)alkanoyl, in which higher alkanoyl may have one or more suitable substituent(s)- may be amino and aforementioned -protected amino-, in which the preferred one may be amino and<br>
ar(lower)alkoxycarbonylamino, and the most preferred one may be amino and benzyloxycarbonylamino.<br>
Suitable example of -aroyl- in the term of -aroyl substituted with aryl having heterocyclicoxy, in which heterocyclicoxy may have one or more suitable substituent (s)- can be referred to aforementioned -aroyl-, in which the preferred one may be benzoyl.<br>
Suitable example of -aryl- in the term of -aroyl substituted with aryl having heterocyclicoxy, in which heterocyclicoxy may have one or more suitable substituent (s)- can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -heterocyclic- moiety in the term of -aroyl substituted with aryl having heterocyclicoxy; in which heterocyclicoxy may have one or more suitable substituent(s)- can be referred to aforementioned -heterocyclic- moiety, in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), and the most preferred one may be pyridazinyl.<br>
Suitable example of -suitable substituent (s)- in the term of -aroyl’substituted with aryl having heterocyclicoxy, in which heterocyclicoxy may have one or more suitable substituent(s)- may be aryl, in which the preferred one may be phenyl.<br><br>
Suitable example of -aroyl- in the term of -aroyl substituted with cyclo(lower)alkyl having lower alkyl- can be referred to aforementioned -aroyl-, in which the preferred one may be benzoyl.<br>
Suitable example of -cyclo(lower)alkyl- in the term of -aroyl substituted with cyclo(lower)alkyl having lower alkyl- can be referred to aforementioned -cyclo(lower)alkyl-, in which the preferred one may be cyclohexyl.<br>
Suitable example of -lower alkyl- in the term of -aroyl substituted with cyclo(lower)alkyl having lower alkyl- can be referred to aforementioned -lower alkyl-, in which the preferred one may be pentyl.<br>
Suitable example of -higher alkyl- in the term of -indolylcarbonyl having higher alkyl- can be referred to aforementioned -higher alkyl-, in which the preferred one may be decyl.<br>
Suitable example of -lower alkyl- in the term of -naphthoyl having lower alkyl- can be referred to aforementioned -lower alkyl-, in which the preferred one may be hexyl.<br>
Suitable example of -higher alkyl- in the term of -naphthoyl having higher alkyl- can be referred to aforementioned -higher alkyl-, in which the preferred one may be heptyl.<br>
Suitable example of -lower alkoxy(higher)alkoxy- in. the term of -naphthoyl having lower alkoxy(higher)alkoxy- may be   alkoxy   alkoxy, in which the preferred one may be methoxyoctyloxy.<br>
Suitable example of -aroyl- in the term of -aroyl<br><br>
substituted with aryl having lower<br>
alkoxy(lower)alkoxy(higher)alkoxy-, -aroyl substituted with aryl having lower alkoxy(lower)alkoxy-, -aroyl substituted with aryl which has aryl having lower alkoxy-, -aroyl substituted with aryl which has aryl having lower alkoxy(lower)alkoxy-, -aroyl substituted with aryl having heterocyclicoxy(higher)alkoxy-, -aroyl substitued with aryl having aryloxy(lower)alkoxy- and -aroyl substituted with aryl having heterocycliccarbonyl(higher)alkoxy- can be referred to aforementioned -aroyl-, in which the preferred one may be benzoyl.<br>
Suitable example of -aryl- in abovementioned terms can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -lower alkoxy(lower)alkoxy-(higher)alkoxy- in the term of -aroyl substituted with aryl having lower alkoxy(lower)alkoxy(higher)alkoxy- may be  alkoxy(C’-C’)alkoxy(C7-C24)alkoxy, in which the preferred one may be ethoxy ethoxyoctyloxy.<br>
Suitable example of -lower alkoxy(lower)alkoxy- in the term of -aroyl substituted with aryl having lower alkoxy(lower)alkoxy- may be  alkoxy alkoxy, in which the preferred one may be propoxyhexyloxy.<br>
Suitable example of -lower alkoxy- in the term of -aroyl substituted with aryl which has phenyl having lower alkoxy- may be (C3-C6)alkoxy, in which the preferred one may be butoxy.<br>
Suitable example of -lower alkoxy(lower)alkoxy- in the term of -aroyl substituted with aryl which has phenyl having lower alkoxy(lower)alkoxy- may be  alkoxy-(C3-C6)alkoxy, in which the preferred one may be<br><br>
methoxy pentyloxy and methoxyhexyloxy.<br>
Suitable example of -heterocyclic- moiety in the term of -aroyl substituted with aryl having heterocyclicoxy(higher)alkoxy- can be referred to aforementioned -heterocyclic- moiety, in which the preferred one may be saturated 3 to 8-membered heteromonocyclic group containing an oxygen atom, and the most preferred one may be tetrahydropyranyl.<br>
Suitable example of -higher alkoxy- moiety in the term of -aroyl substituted with aryl having heterocyclicoxy(higher)alkoxy- may be (C7-C24)alkoxy, in which the preferred one may be octyloxy.<br>
Suitable example of -aryloxy(lower)alkoxy- in the term of -aroyl substituted with aryl having aryloxy(lower)alkoxy- may be phenoxy(C3-C6)alkoxy, in which the preferred one may be phenoxy pentyloxy.<br>
Suitable example of -heterocyclic- moiety in the term of -aroyl substituted with aryl having heterocycliccarbonyl(higher)alkoxy- can be referred to aforementioned -heterocyclic- moiety, in which the preferred one may be saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), and the most preferred one may be piperidyl.<br>
Suitable example of -higher alkoxy- moiety in the term of -aroyl substituted with aryl having heterocycliccarbonyl (higher)alkoxy- can be referred to aforementioned -higher alkoxy-, in which the preferred one may be (C7-C-1 4) alkoxy, and the most preferred one may be heptyloxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with oxazolyl which has aryl<br><br>
having higher alkoxy- can be referred to aforementioned -lower alkanoyl-, in which the preferred one may be  )alkanoyl, and the most preferred one may be formyl.<br>
Suitable example of -aryl- in the term of -lower alkanoyl substituted with oxazolyl which has aryl having higher alkoxy- can be referred to aforementioned -aryl-, in which the preferred one may he phenyl.<br>
Suitable example of -higher alkoxy- in the term of -lower alkanoyl substituted with oxazolyl which has aryl having higher alkoxy- can be referred to aforementioned -higher alkoxy-, in which the preferred one may be (C7-C24)alkoxy, and the most preferred one may be octyloxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with furyl which has aryl substituted with aryl having lower alkoxy- can be referred to aforementioned -lower alkanoyl-, in which the preferred one may be  )alkanoyl, and the most preferred one may be formyl.<br>
Suitable example of -aryl- in the term of -lower alkanoyl substituted with furyl which has aryl substituted with aryl having lower alkoxy- can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -lower alkoxy- in the term of -lower alkanoyl substituted with furyl which has aryl substituted with aryl having lower alkoxy- can be referred to aforementioned -lower alkoxy-, in which the preferred one may be    alkoxy, and the most preferred one may be butoxy.<br>
Suitable example of -lower alkanoyl- in the term of -lower alkanoyl substituted with triazolyl which has 0x0 and aryl having higher alkyl- can be referred to<br><br>
aforementioned -lower alkanoyl-, in which the preferred one may be (C-[_-C’) alkanoyl, and the most preferred one may be formyl.<br>
Suitable example of -higher alkyl- in the term of -lower alkanoyl substituted with triazolyl which has oxo and aryl having higher alkyl- can be referred to aforementioned -higher alkyl-, in which the preferred one may be   alkyl, and the most preferred one may be octyl.<br>
Suitable example of -aryl- in the term of -lower alkanoyl substituted with triazolyl which has oxo and aryl having higher alkyl- can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -higher alkanoyl- in the term of -higher alkanoyl having hydroxy- can be referred to aforementioned -higher alkanoyl-, in which the preferred one m.ay be (C7-C20) alkanoyl, and the most preferred one may be hexadecanoyl.<br>
Suitable example of -higher alkanoyl- in the term of -higher alkanoyl having ar(lower)alkyl and hydroxy- can be referred to aforementioned -higher alkanoyl-, in which the preferred one may be (C7-C20)’l’’’oyl, and the most preferred one  may be hexadecanoyl.<br>
Suitable example of -ar(lower)alkyl- in the term of -higher alkanoyl having ar(lower)alkyl and hydroxy- can be referred to aforementioned -ar(lower)alkyl-, in which the preferred one may be phenyl (C-i-C’) alkyl, and the most preferred one may be benzyl.<br>
Suitable example of - (C2-C6)alkanoyl- in the terms of -(C2-C6)alkanoyl substituted with aryl having higher alkoxy, in which (C2-C6)alkanoyl may have amino or protected amino- may include acetyl, propanoyl, butanoyl.<br><br>
pentanoyl, hexanoyl, and the like, in which the preferred one may be acetyl and propanoyl.<br>
Suitable example of -aryl- in the term of -(C2-C6)alkanoyl substituted with aryl having higher alkoxy, in which (C2-C6)alkanoyl may have amino or protected amino- can be referred to aforementioned -aryl-, in which the preferred one may be phenyl.<br>
Suitable example of -higher alkoxy- in the term of -(02-0’)alkanoyl substituted with aryl having higher alkoxy, in which (C2-C6)alkanoyl may have amino or protected amino- can be referred to aforementioned -higher alkoxy-, in which the preferred one may be (C7-C24)alkoxy, and the most preferred one may be octyloxy.<br>
Suitable example of -protected amino- in the term of -{C2-C6)alkanoyl substituted with aryl having higher alkoxy, in which (C2-C6)alkanoyl may have amino or protected amino- can be referred to aforementioned -protected amino-, in which the preferred one may be ar(lower)alkoxycarbonylamino, and the most preferred one may be benzyloxycarbonylamino.<br>
The process for preparing the object polypeptide compound [I] or a salt thereof of the present invention are explained in detail in the following.<br>
The object polypeptide compound [I] or a salt thereof can be prepared by reacting the compound [II] or its reactive derivative at the amino group or a salt thereof with the compound [III] or its reactive derivative at the carboxy group or a salt thereof.<br>
Suitable reactive derivative at the carboxy group of the compound [III] may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.  Suitable examples of the reactive derivatives may<br><br>
be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoryl acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g., methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g., acetic acid, propionic acid, butyric acid, isobutyric acid, pelagic acid, pentatonic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.]; or aromatic carboxylic acid [e.g., benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole, tetrazole or 1-hydroxy-lH-benzotriazole; or an activated ester [e.g., cyan methyl ester, methoxymethyl ester, dimethyliminomethyl [(CH3)2N=CH-] ester, vinyl ester, property ester,<br>
p-nitro phenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitro phenyl thioester, p-cresol thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, l-hydroxy-2-(IH)-pyridine, N-hydroxysuccinimide, N-hydroxyphthalimide, l-hydroxy-lH-benzotriazole, etc.], and the like.  These reactive derivatives can optionally be selected from them according to the mind of the compound [III] to be used.<br>
Suitable salts of the compound [III] and its reactive derivative can’ be referred to the ones as exemplified for the object polypeptide compound [I].<br>
The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g., methanol, ethanol.<br><br>
etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.  These conventional solvent may also be used in a mixture with water.<br>
In this reaction, when the compound [III] is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, N,N-'carbonyl is- (2-methylimidazole) ; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetyl; l-alkoxy-2-chloroethylene; thioalkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate   phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g., ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt;<br>
2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1- (p-chloro benzenesulfonyloxy)-6-chloro-lH-benzotriazole; so-called Voltmeter reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorous oxychloride, methanesulfonyl chloride, etc.; or the like.<br>
The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, alkali metal bicarbonate, tri(lower)alkylamino, pyridine, di(lower)alkylaminopyridine (e.g..<br><br>
4-dimethylaminopyridine, etc.), N-(lower)alkylmorpholine, N,N-di(lower)alkylphenylamine, or the like.<br>
The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.<br>
The starting compound [II] is a known compound.  It can be prepared by fermentation and synthetic processes disclosed in EP 0462531 A2.<br>
A culture of Coleophoma sp. F-11899, which is used in said fermentation process, has been deposited with National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (former name: Fermentation Research Institute Agency of Industrial Science and Technology) (1-3, Higashi 1-chome, Tsukuba-shi, IBARAKI 305, JAPAN) on October 26, 1989 under the number of PERM BP-2635.<br>
The compounds obtained by the above Process 1 can be isolated and purified by a conventional method such as pulverization, recrystallization, column-chromatography, high-performance liquid chromatography (HPLC), reprecipitation, or the like.<br>
The compounds obtained by the above Process ; may be obtained as its hydrate, and its hydrate is included within the scope of this invention.<br>
It is to be noted that each of the object compound (I) may include one or more stereoisomer such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s) and all such isomers and mixture thereof are included within the scope of this invention.<br><br>
Biological property of the polypeptide compound m of the present invention<br>
In order to show the usefulness of the polypeptide compound [I] of the present invention, the biological data of the representative compound is explained in the following.<br>
Test 1  (Antimicrobial activity) :<br>
In vitro antimicrobial activity of the compound of Example 17 disclosed later was determined by the two-fold agar-plate dilution method as described below.<br>
Test Method<br>
One lapful of an overnight culture of each test microorganism in Savored broth containing 2% Glucose (10’ viable cells per ml) was streaked on yeast nitrogen base dextrose agar (YNBDA) containing graded concentrations of the object polypeptide compound [I], and the minimal inhibitory concentration (MIC) was expressed in terms of pg/ml after incubation at SO’C for 24 hours.<br>
From the test result, it is realized that the object polypeptide compound [I] of the present invention has an antimicrobial activity (especially, antifungal activity).<br>
The pharmaceutical composition of the present<br><br>
invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid from, which contains the object polypeptide compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient in admixture with an organic or inorganic carrier or excipient which is suitable for rectal; pulmonary (nasal or buccal inhalation); ocular; external (topical); oral administration; parenteral (including subcutaneous, intravenous and intramuscularly) administrations; insufflations (including aerosols from metered dose inhalator); nebulizer; or dry powder inhalator.<br>
The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers in a solid form such as granules, tablets, dragees, pellets, troches, capsules, or suppositories; creams, ointments; aerosols; powders for insufflations; in a liquid form such as solutions, emulsions, or suspensions for injection; ingestion; eye drops; and any other form suitable for use.  And, if necessary, there may be included in the above preparation auxiliary substance such as stabilizing, thickening, wetting, emulsifying and coloring agents; perfumes or buffer; or any other commonly may be used as additives.<br>
The object polypeptide compound [I] or a pharmaceutically acceptable salt thereof is/are included in the pharmaceutical composition in an amount sufficient to produce the desired antimicrobial effect upon the process or condition of diseases.<br>
For applying the composition to human, it is preferable to apply it by intravenous, intramuscularly, pulmonary, oral administration, or insufflation.  While the dosage of therapeutically effective amount of the object polypeptide compound [I] varies from and also<br><br>
depends upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01-20 mg of the object polypeptide compound [I] per kg weight of human being in the case of intramuscularly administration, a daily dose of 0.1-20 mg of the object polypeptide compound [I] per kg weight of human being, in case of oral administration, a daily dose of 0.5-50 mg of the object polypeptide compound [I] per kg weight of human being is generally given for treating or preventing infectious diseases.<br>
Especially in case of the treatment of prevention of Pneumocystis carina infection, the followings are to be noted.<br>
For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized as powders which may be formulated and the powder compositions may be inhaled with the aid of an insufflation powder inhaler device.  The preferred delivery system for inhalation is a metered dose inhalation aerosol, which may be formulated as a suspension or solution of compound in suitable propellants such as fluorocarbons or hydrocarbons.<br>
Because of desirability to directly treat lung and bronchi, aerosol administration is a preferred method of administration.  Insufflation is also a desirable method, especially where infection may have spread to ears and other body cavities.<br>
Alternatively, parenteral administration may be employed using drip intravenous administration.<br>
The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.<br><br>
Preparation 1<br>
To a suspension of 1-(4-Hydroxyphenyl)-4-tert-butoxycarbonylpiperazine (3 g) and potassium carbonate (0.82 g) in N/N-dimethylformamide (15 ml) was added octyl bromide (1.87 ml).  The mixture was stirred for 10 hours at 70**C.  The reaction mixture was added to a mixture of water and ethyl acetate.  The organic layer was taken, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure.  The residue was subjected to column chromatography on silica gel, and eluted with (hexane : ethyl acetate = 9:1).  The fractions containing the object compound were combined, and evaporated under reduced pressure to give 1-(4-n-Octyloxyphenyl) - 4-tert-butoxycarbonylpiperazine (2.71 g) .<br>
IR (KBr) :  1687, 1513, 1241 cm-l<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.2Hz), 1.2-1.4<br>
(lOH, m), 1.48 (9H, s), 1.65-1.85 (2H, m), 3.00 (4H, t, J=5,2Hz), 3.57 (4H, t, J=5.2Hz), 3.90 (2H, t, J=6.5Hz), 6.83 (2H, dd, J=6.4 and 2.1Hz), 6.89 (2H, dd, J=6.4 and 2.1Hz)<br><br>
A solution of 1-(4-n-Octyloxyphenyl)-4-tert-butoxycarbonylpiperazine (2.61 g) in trifluoroacetic acid (20 ml) was stirred for 4 hours at ambient temperature. The reaction mixture was evaporated under reduced pressure, and to the residue was added a mixture of IN NaOH aqueous solution and ethyl acetate.  The organic layer was taken, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give l-(4-n-Octyloxyphenyl)piperazine (0.86 g).<br>
IR (KBr) :  2923, 1513, 1259, 831 cm-’<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.4Hz), 1.2-1.53<br><br>
(lOH, m), 1.65-1.85 (2K, m), 3.03 (4H, s), 3.90 (2H, t, J=6.5Hz), 6.83 (2H, dd, J=6.4 and 2.9Hz), 6.90 (2H, dd, J=6.4 and 2.9Hz) APCI-MASS :  m/z = 291 (M++1)<br>
Preparation 3<br>
To a suspension of 1-(4-n-0ctyloxyphenyl)piperazine (1 g) and potassium carbonate (0.476 g) in N,N-dimethyl-formamide (1 ml) was added p-fluoro benzonitrile (0.347 g), and stirred for 5 hours at 160'C.  The reaction mixture was added to a mixture of water and ethyl acetate.  The organic layer was taken, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-[4-(4-n-Octyloxyphenyl)piperazine-l-yl]benzonitrile (0.93 g).<br>
IR (KBr) :  2848, 2217, 1604, 1511, 1241 coml.<br>
NMR (CDCI3, 5) :  0.89 (3H, t, J=6.8Hz), 1.2-1.53 (lOH, m) , 1,65-1-85 (2H, m), 3.20 (4H, t, J=5.4Hz), 3,48 (4H, t, J=5.4Hz), 3.91 (2H, t, J=6.5Hz), 6.8-7,0 (6H, m), 7.52 (2H, d, J=8.9Hz)<br>
APCI-MASS :  m/z = 392 (M'‘+l)<br>
Preparation 4<br>
A mixture of 2,4-Dihydroxybenzaldehyde (5.52 g), potassium carbonate (6.08 g) and octyl bromide (7.73 g) in acetonitrile (55 ml) was stirred for 16 hours at 60°C. The solvent of reaction mixture was removed under reduced pressure, and the residue was dissolved in ethyl acetate, and washed with water and brine.  The separated organic layer was dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced*pressure.  The residue was subjected to column chromatography on silica gel and eluted with (hexane : ethyl acetate =9:1) to give 2-Hydroxy-4-octyloxybenzaldehyde (6.73 g).<br><br>
NMR (CDCI3, 5) :  0.89 (3H, t, J=8.8Hz), 1.2-1,5<br>
(lOH, m] ,   1,8-2.0 (2H, m) , 4.0-4.2 (2H, m), 6.42 (IH, s), 6.52 (IH, d, J=8.7Hz), 7.79 (IH, d, J=8.7Hz), 10.33 (IH, s)<br>
APCI-MASS :  m/z = 257 (M’+1)<br>
The following compound was obtained according to a similar manner to that of Preparation 4.<br><br>
Methyl 3,4-dipentyloxybenzoate<br>
NMR (CDCI3, 6) :  0.93 (6H, t, J=6.0 and 9,0H2), 1.3-2.0 {12H, m), 3.88 (3H, s),   4.04 (4H, m), 6.86(1H, d, J=8.4H2), 7.53 (IH, d, J=2-0H2), 7.63 (IH, dd, J=8.4 and 2.0Hz)<br>
APCI-MASS :  m/z = 309 (M++1)<br>
Preparation 6<br>
A mixture of 4-bromo-4'-pentylbiphenyl (5.04 g) , trimethylsilylacetylene (2.4 ml), tetrakis(triphenylphosphine)palladium (0.96 g) , triphenylphosphine (0.22 g) and cuprous iodide (95 mg) in piperidine (10 ml) was heated for an hour under atmospheric pressure of nitrogen at 90’*0.  The reaction mixture was poured into a mixture of cold water and ethyl acetate, and adjusted to about pH 1 with 6N hydrochloric acid.  The separated organic layer was washed with water and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give crude 2-[4-(4-pentylphenyDphenyl]-1-trimethylsilylacetylene, which was used for the next reaction without further purification. Crude mixture was dissolved in a mixture of dichloromethane (10 ml) and methanol (10 ml), and to the solution was added potassium carbonate (2.75 g) at O’'C.<br><br>
The mixture was allowed to warm to ambient temperature, and stirred for another 2 hours.  The reaction mixture was poured into a mixture of cold water and ethyl acetate, and the resultant precipitate was filtered off.  The filtrate was adjusted to about pH 7 with IN hydrochloric acid, and washed with brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give a crude powder, which was subjected to column chromatography on silica gel (300 ml), and eluted with a mixture of (n-hexane : ethyl acetate = 99:1 - 97:3, V/V) to give 4-(4-PentylphenyDphenylacetylene (2.09g) .<br>
IR (Nunol) :  3274, 1490 cm-l<br>
NMR {CDCI3, 5) :  0.90 (3H, t, J=6.4Hz), 1.30-1.50 (4H, m) , 1.50-1.80 (2H, m), 2.64 (2H, t, J=7.6H2), 7.20-7.30 (2H, m), 7.45-7.60 (6H, m)<br>
APCI-MASS :  m/z =281 (M++1 + MeOH)<br>
The following compound was obtained according to a similar manner to that of Preparation 6.<br>
-Preparation 7<br>
6-Heptyloxynaphthalen-2-yl-acetylene NMR (CDCI3, 5) :  0.90 (3H, t, J=6,5Hz), 1.20-1.60 (8H, m), 1.70-1.90 (2H, m), 3.10 (IK, s), 4.07 (2H, t, J=6.5Hz), 7.08 (IH, d, J=2.5Hz), 7.15 (IH, dd, J=2.5 and 8.9Hz), 7.47 (IH, dd, J=l.6 and 8.5Hz), 7.64 (IH, d, J=7.3Hz), 7.68 (IH, d, J=8.5Hz), 7.94 (IH, d, J=1.6Hz) APCI-MASS :  m/z = 267 (M++1)<br><br>
To a solution of 4-(4-Pentylphenyl)phenyl acetylene (2.09 g) in tetrahydrofuran (30 ml) was added dropwise a solution of lithium isobutyramide in a mixture of<br><br>
tetrahydrofuran and n-hexane (1.60 M, 5.6 ml) at -75'C, and the resultant mixture was stirred for an hour at -78°C.  To the mixture was added methyl chloroformate (0.72 ml), and the reaction mixture was allowed to warm to ambient temperature.  The solution was diluted with ethyl acetate, and washed in turn with water and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give a crude product, which was subjected to column chromatography on silica gel (150 ml), and eluted with a mixture of (n-hexane : ethyl acetate = 100:0 - 9:1, V/V) to give Methyl 3-[4-(4-pentylphenyl)phenyl]propionate (2.20 g) . IR (Nujol) :  2225, 1712 cm~l<br>
NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5Hz), 1.25-1.50 (4H, m), 1.52-1.80 (2H, m), 2.64 (2H, t, J=7.6Hz), 3.85 (3H, s), 7.20-7.35 (2H, m), 7.40-7.70 (6H, m) APCI-MASS :  m/z = 307 (M++1)<br>
The following compound was obtained according to a similar manner to that of Preparation 8.<br>
Preparation 9<br>
Methyl 3-(6-heptyloxynaphthalen-2-yl)propionate<br>
IR (Nujol) :  2219, 1704, 1621 cm~l<br>
NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5Hz), 1.20-1.60 (8H, m) , 1.70-2.00 (2H, m), 3.86 (3H, s), 4,08 (2H, t, J=6.5Hz), 7.10 (IH, d, J=2.5Hz), 7.17 (IH, dd, J=2.5 and 8.9Hz), 7.52 (IH, dd, J=1.6 and B.5HZ), 7.68 (IH, d, J=7.3Hz), 7.72 (IH, d, J=8.-5Hz), 8.06 (IH, d, J=1.6Hz)<br>
AFCI-MA.SS :  m/z = 325 (M-’+l)<br>
Preparation 10<br><br>
A mixture of 4-bromo-4'-pentylbiphenyl (5,0 g), methyl acrylate (2.2 ml), palladium acetate (0.11 g) and tris(o-tolyl)phospbine (0.60 g) in triethylamine (16 ml) was refluxed for 15 hours under nitrogen atmosphere.  The reaction mixture was poured into a mixture of cold water and ethyl acetate, and adjusted to about pH 1.5 with 6N hydrochloric acid.  The separated organic layer was washed in turn with water and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give a crude powder, which was subjected to column chromatography on silica gel (200 ml), and eluted with a mixture of (n-hexane : ethyl acetate = 100:0 - 94:6, V/V) to give Methyl 3-[4-(4-pentylphenyl)phenyl]acrylate (4.48 g). IR (Nujol) :  1718, 1637 cm~’<br>
NMR (CDCI3, 5) :  0.91 (3H, t, J=6.7Hz), 1.20-1.50 (4H, m) , 1.50-1.80 (2H, m), 2.65 (2H, t, J=7.4Hz), 3.82 (3H, s), 6.47 (IH, d, J=16.0Hz), 7.20-7.35 (2H, m) , 7.45-7.68 (6H, m), 7.73 (IH, d, J=16.0Hz) APCI-MASS :  m/z = 309 (M++1)<br>
The following compounds (Preparation? 11 to H) were obtained according to a similar manner to that of<br><br>
Preparation 11<br>
Methyl 3-(6-heptyloxynaphthalen-2-yl)acrylate<br>
IR (Nujol) :  1716, 1625, 1459 cm-l<br>
NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5H2), 1.20-1.65 (8H, m), 1.76-1.93 (2H, m), 3.82 {3H, s), 4.07 (2H/ t, J=6.5Hz), 6.49 (IH, d, J=16.0Hz), 7.05-7.20 (2H, m), 7.55-7.90 (5H, m)<br>
APCI-MS :  m/z = 327 (M++1)<br><br>
Preparation 12<br>
Methyl 3-- [4- (4-heptylphenyl) phenyl] acrylate NMR (CDCI3, 5) :  0.88 {3H, t, J=6.5H2), 1.15-1.50 (8H, m), 1.50-1.75 (2H, m), 2.64 {2H, t, J=7.6H2), 3.81 (3H, s), 6.46 (IH, d, J=16.0H2), 7.26 (2H, d, J=8.2H2), 7.52 (2H, d, J=8.2H2), 7.59 (6H, s), 7.73 (IH, d, J=16.0H2)<br>
APCI-MZISS :  m/2 = 337 (M'*'+l)<br>
Preparation 13<br>
Methyl 3-[4-(4-pentyloxyphenyl)phenyl]acrylate NMR (CDCI3, 6) :  0.94 (3H, t, J=7.0H2), 1.30-1.60 (4H, m) , 1.70-1.93 (2H, m), 3.82 (3H, s), 4.00 (2H, t, J=6.7H2), 6,45 (IH, d, J=16.0H2), 6.90-7.05 (2H, m), 7.48-8.65 (6H, m), 7,72 (IH, d, J=16.0H2) APCI-MASS :  m/2 = 325 {M++1)<br><br>
A mixture of 6-Heptyloxynaphthalen-2-carboxylic acid (1.00 g) and thionyl chloride (5 ml) was stirred for 18 hours at ambient temperature, and concentrated under reduced pressure to give crude 6-heptyloxy-2-naphthoyl chloride.  To a mixture of ethyl isonipecotinate (605 mg), triethylamine (425 mg) and N,N-dimethylaminopyridine (10 mg) in dichloromethane (10 ml) was added crude 6-heptyloxy-2-naphthoyl chloride, and the mixture was stirred for 2 hours at ambient temperature, and diluted with dichloromethane.  The mixture was washed with water, IN hydrochloric acid and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and filtrate was evaporated under reduced pressure.  The residue was subjected to column chromatography on silica gel, and eluted with (n-hexane : ethyl acetate = 3:1) to give 4-Ethoxycarbonyl-l-(6-heptyloxy-2-<br><br><br>
NMR (CDCI3, 5) :  0.90 (3H, t, J=6.6Hz), 1.2-2.0<br>
(19H, m), 2.5-2.7 (IH, m), 3.0-3.2 (2H, m), 4.1-4.3 (4H, m), 7.1-7.2 (2H, m), 7.44 (IH; dd, J=8.4 and 1.7H2), 7.72 (IH, d, J=3.9Hz), 7.77 (IH, d, J=3.9Hz), 7.82 (IH, s)<br>
APCI-MASS :  m/z = 426 (M'‘+1)<br>
To a mixture of Methyl 3,4-diaminoben2oate (1.91 g) and triethylamine (0.56 g) in N,N-dimethylformamide (20 ml) was added decanal chloride (2.31 g), and the mixture was stirred for an hour at O'‘C.  The reaction mixture was diluted with ethyl acetate, and washed with water and brine.  The separated organic layer was dried over magnesium sulfate.  The magnesium sulfate was filtered off, and filtrate was evaporated under reduced pressure. The residue was dissolved in methanol (20 ml), and cone, sulfuric acid (0.05 ml) was added, and the mixture was stirred for 6 hours at 60°C.  After cooling, the reaction mixture was evaporated under reduced pressure.  The residue was diluted with ethyl acetate, and washed with water and brine.  The separated organic layer was dried over magnesium sulfate.  The magnesium sulfate was filtered off, and filtrate was evaporated under reduced pressure.  Purification of the residue by column chromatography on silica gel eluted with (n-hexane : ethyl acetate = 3:1) gave 5-Methoxycarbonyl-2-nonylbenzimidazole (1.40 g).<br>
IR (KBr pelet) :  2923, 1718, 1623, 1544, 1438, 1413,<br>
1288, 1213, 1085, 750 cm'‘ NMR (DMSO-dg. 5) :  0.84 (3H, t, J=6.7H2), 1.1-1.4 (12K, m), 1.7-1.9 (2H, m), 2.83 (2H, t, J=7.4Hz), 7.56 (IH, d, J=8.4Hz), 7.78 (IH, d, J=8.4Hz), 8.07 (IH, s)<br><br>
APCI-MASS :  m/2 = 303 (M’ + 1)<br>
Preparation 16<br>
To a mixture of diethylmalonate (4 ml), 2-hydroxy-4 octyloxybenzaldehyde (2,50 g) and piperidine (0.1 ml) in methanol (10 ml) was added acetic acid (0.01 ml), and the mixture was stirred for 3 hours at 70°C.  The solvents were removed under reduced pressure, and the residue was dissolved in ethyl acetate, and washed with 0.5N hydrochloric acid, water and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and filtrate was evaporated under reduced pressure, and the precipitate was collected by filtration, and washed with n-hexane, and dried to give Methyl 7-octyloxycoumarin-3-Carboxylate (0.94 g).<br>
NMR (DMSO-dg, 6) :  0.86 (3H, m), 1.2-1.6 (lOH, m), 1.7-1.8 (2H, m), 3.81 (3H, s), 4.11 (2H, t, J=6.4Hz), 6.9-7.1 (2H, m), 7.83 (IH, d, J=9.0H2), 8.75 (IH, s) APCI-MASS :  m/z = 333 (M-’ + l)<br>
Preparation 17<br>
To a mixture of sodium hydride (423 mg) and 4-octylphenol (2.06 g) in tetrahydrofuran (16 ml) was added dropwise ethyl 2-chloroacetoacetate at ambient temperature.  The mixture was stirred for 6 hours at 70'C under nitrogen atmosphere, and poured into saturated ammonium chloride aqueous solution.  The solution was extracted with ethyl acetate, and the organic layer was washed with water and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure.  The residue was added to cone. H2SO4 (10 ml) at 0°C, and mixture was stirred for 10 minutes.  The reaction mixture was poured into ice-water, and adjusted to pH 7.0 with IN<br><br>
NaOH aqueous solution, and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure.  The residue was subjected to column-chromatography on silica gel, and eluted with (hexane : ethyl acetate = 95:5).  The fractions containing the object compound were combined, and evaporated under reduced pressure to give Ethyl 3-methyl 5-octylbenzo[b]furan-2-carboxylate (1.44 g).<br>
IR (Neat) :  2925, 2854, 1712, 1596, 1463, 1292,<br>
1149, 1089 cm~l NMR (CDCI3, 5) :  0.88 (3H, t, J=6.7Hz), 1.2-1.5<br>
(lOH, m), 1-44 (3H, t, J=7.1Hz), 1.6-1.8 (2H, m) , 2.58 (3H, s) , 2.71 (2H, t, J=8.0Hz), 4.45 (2H, t, J=7.1Hz), 7.2-7.5 (3H, m) APCI-MASS :  m/z = 317 (M-*' + l)<br>
Preparation 18<br>
To a solution of Ethyl 3-amino-4-hydroxybenzoate (1.81 g) and triethylamine (1.53 ml) in dichloromethane (20 ml) was dropwise added decanal chloride (2.01 ml) at 0°C.  The reaction mixture was stirred for 48 hours at ambient temperature, and washed with water, 0.5N hydrochloric acid, water and brine.  The separated organic layer was dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure.  To the residue dissolved in xylene (30 ml) was added p-tolune sulfonic acid monohydrate (0.5 g), and the mixture was stirred for 4 hours at 130*'C .  Ethyl acetate was added to the mixture, and washed with water and brine.  The separated organic layer was dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure.  Purification of the residue by<br><br>
colimm chromatography on silica gel eluted with (n-hexane : ethyl acetate = 9:1, V/V) gave Ethyl 2-nonyl benzo[b]oxa2ole-6-carboxylate (2.36 g) .<br>
IR (KBr pelet) :  2914, 1722, 1621, 1575, 1470, 1429, 1365, 1290, 1203, 1151, 1115, 1081, 1022 cm~l NMR (CDCI3, 5) : 0.88 (3H, t, J=6.7H2), 1.2-1.4 {12H, m), 1.42 (3H, t, J=7.2H2), 1.90 (2H, m), 2.95 (2H, t, J=7.4H2), 4.40 (2H, q, J=7.0Hz), 7.50 (IH, d, J=8.5H2), 8.06 (IH, d, J=8.5H2), 8.37 (IH, s) APCI-MASS :  m/2 = 318 (M++1)<br><br>
A mixture of Methyl 3,4-diaminoben2oate (1.84 g) and 4-hexyloxy benzaldehyde (2.30 g) in nitroben2ene {40  ml) was stirred for 48 hours at 145°C.  After cooling, the mixture was evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel eluted with (n-hexane : ethyl acetate = 2:1) gave 5-Methoxycarbonyl-2-(4-hexyloxyphenyl)benzimidazolyl d.l9 g) .<br>
NMR (CDCI3, 5) :  0.90 (3H, t, J=6.4Hz), 1.2-1.9 (8H, m) , 3.92 (3H, s), 3.90-4.1 (2H, m), 6.93 (2H, d, J=8.9Hz), 7.5-7.8 (IH, br), 7.94 (IH, dd, J=8.5 and 1.5Hz), 8.03 (IH, d, J=8.9Hz), 8.2-8.4 (IH, br) APCI-MASS :  m/z = 353 (M++1)<br>
Preparation 20<br>
A mixture of Methyl 3-[4-(4-pentylphenyl)phenyl]-acrylate (2.0 'g) and 10% palladium on carbon (50% wet, 0.2 g) in tetrahydrofuran (20 ml) was stirred for 8 hours under atmospheric pressure of hydrogen at ambient temparature.  The catalyst was filtered off, and the<br><br>
filtrate was evaporated under reduced pressure to give Methyl 3-[4-(4-pentylphenyl)phenyl]propionate (1.93 g). NMR {CDCI3, 6) :  0.90 (3H, t, J=6.8Hz), 1.25-1.50 {4H, m), 1.50-1.75 (2H, m),   2.55-2.75 (4H, m), 2.99 (2H, t, J=8.0H2), 3.68 (3H, s), 7.10-7.30 (4H, m), 7.40-7.60 {4H, m) APCI-MASS :  m/z = 311 (M++1)<br>
Preparation 21<br>
A mixture of Methyl 3-[4-(4-pentyloxyphenyl)phenyl]-acrylate (2.70 g) and platinum oxide (0.41 g) in tetrahydrofuran (40 ml) was stirred for 8 hours under 3 atom of hydrogen at ambient temperature.  The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give Methyl 3-[4-(4-pentyloxyphenyl)phenyl]propionate (2.70 g).<br>
NMR (CDCI3, 6) :  0.94 (3H, t, J=7.0H2), 1.28-1.60 (4H, m), 1.60-1.95 (2H, m), 2.55-2.78 (2H, m) , 2.98 (2H, t, J=7.8Hz), 3.98 (2H, t, J=6.5Hz), 6.85-7.05 (2H, m), 7.05-7.30 (2H, m) , 7.40-7.55 (4H, m) APCI-MASS :  m/z = 327 (M++1)<br>
The following compound was obtained according to a similar manner to that of Preparation 21.<br>
Preparation 22<br>
Methyl 3- (6-heptyloxynaphthalen-2-yl)propionate NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5H2), 1.20-1.70 (8H, m) , 1.70-1.93 (2H, m), 2.70 (2H, t, J=7.7Hz), 3.07 (2H, t, J=7.7H2), 3.67 (3H, s), 4.05' (2H, t, J=6.5Hz), 7.02-7.20 (2H, m) , 7.20-7.38 (2H, m), 7.55 (IH, s) , 7.66 (IH, dd, J=3.0 and 8.5H2) APCI-MASS :  m/2 = 329 (M++1)<br><br>
Preparation 23<br>
To a mixture of Methyl 3-[4-(4-pentylphenyl)phenyl]-acrylate (0.41 g) in tetrahydrofuran (5 ml) was added 3N NaOH aqueous solution (1.3 ml), and the resultant mixture was heated to 85°C for 10 hours.  The reaction mixture was poured into a mixture of cold water and ethyl acetate, and adjusted to about pH 2 with 6N hydrochloric acid.  The separated organic layer was washed in turn with water and brine, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 3-[4-(4-Pentylphenyl)phenyl]acrylic acid (0.41 g).<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=7.5Hz), 1.15-1.46 (4H, m) , 1.48-1.70 (2H, m), 2.61 (2H, t, J=7.4Hz), 6.56 (IH, d, J=16.0Hz), 7.29 (2H, d, J=8.2Hz), 7.60 (2H, d, J=4.0Hz), 7.66 (2H, d, J=4.0Hz), 7.68-7.85 (3H, m) APCI-MASS :  m/z = 295 (M++1)<br>
The following compounds (Preparations 24 to 31) were obtained according to a similar manner to that of Preparation 23.<br>
Preparation 24<br>
3-[4-(4-Pentyloxyphenyl)phenyl}propionic acid IR (Nujol) :  1697, 1606, 1500 cm-!<br>
NMR (CDCI3, 5) :  0.94 (3H, t, J=7.1Hz), 1.25-1.60 {4H, m) , 1.70-1.95 (2H, m), 2.72 (2H, t, J=7.5Hz), 3.00 (2H, t, J=7.5Hz), 3.99 (2H, t, J=6.5Hz), 6.95 (2H, dd, J=2.1 and 6.7Hz), 7.25 (2H, d, J=8.2Hz), 7.40-7.60 (4H, m) APCI-MASS :  m/z = 313 (M++1)<br>
Preparation 25<br>
3-[4-(4-Heptylphenyl)phenyl]propionic acid<br><br>
NMR (CDCI3, 6) :  0.88 (3H, t, J=6.8Hz), 1.15-1.50 (8H, in), 1.50-1.78 (2H, m) , 2.65 (2H, t, J=7.6Hz), 6.48 (IH, d, J=16.0Hz), 7.27 (2H, d, J=8.2Hz), 7.53 (2H, d, J=8.2Hz), 7.63 (4H, m), 7.83 (IH, d, J=16.0H2)<br>
APCI-MASS :  m/z = 323 (M++1)<br>
3-[4-{4-Pentylphenyl)phenyl]propionic acid NMR {CDCI3, 6) :  0.90 (3H, t, J=6.4Hz), 1.20-1.50 (4H, m) , 1.50-1.75 (2H, m) , 2.64 (2H, t, J=8.0Hz), 2.67 (2H, t, J=9.6Hz), 3.00 (2H, t, J=8.0Hz), 7.15-7.38 (4H, m), 7.38-7.60 (4H, m) APCI-MASS :  m/z = 297 (M++1)<br><br>
3-(6-Heptyloxynaphthalen-2-yl)propionic acid NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5Hz), 1.20-1.65 {8H, m), 1.75-2.00 (2H, m), 2.75 (2H, t, J=7.7Hz), 3.09 (2H, t, J=7.7Hz), 4.06 (2H, t, J=6.5Hz), 7.05-7.15 (2H, m), 7.15-7.35 (2H, m), 7.50-7.73 (2H, m) APCI-MASS :  m/z = 315 (M++1)<br>
Preparation 28<br>
3-(6-Heptyloxynaphthalen-2-yl)acrylic acid NMR (CDCI3, 5) :  0.90 {3H, t, J=6.5Hz), 1.15-1.60 (8H, m), 1.75-1.95 (2H, m), 4.09 (2H, t, J=6.5Hz), 6.51 (IH, d, J=16.0H2), 7.09-7.30 (2H, m), 7.65-8.00 (5H, m)<br>
Preparation 29 '<br>
3-[4-(4-Pentylphenyl)phenyl]propionic acid NMR (CDCI3, 6) :  0.91 (3H, t, J=6.5Hz), 1.23-1.50 (4H, m), 1.50-1.80 (2H, m), 2.65 (2H, t.<br><br>
J=7.6Hz), 7.27 (2H, d, J=8.2Hz), 7.51 (2H, d, J=8.2Hz), 7.58-7.80 (4H, m) APCI-MASS :  m/z = 325 (M++1 + MeOH)<br>
Preparation 30<br>
3-(6-Heptyloxynaphthalen-2-yl)propionic acid IR (Nujol) :  2645, 2198, 1670, 1627 cm-l NMR (DMSO-dg, 6) : 0.85 (3H, t, J=6.5Hz), 1.10-1.60 (8H, m) , 1.65-1.90 (2H, m), 4.10 (2H, t, J=6.5Hz), 7.24 (IH, dd, J=2.4 and 8.9Hz), 7.39 (IH, d, J=2.5Hz), 7.55 (IH, dd, J=1.6 and 8.5Hz), 7.8-8.0 (2H, m), 8.22 (IH, d, J=1.6Hz) APCI-MASS :  m/z = 343 (M++1 + MeOH)<br><br>
4-[5-(4-Pentyloxyphenyl)isoxazolyl-3-yl]benzoic acid IR (KBr) :  2939, 2867, 1681, 1614, 1429, 1255, 1178,<br>
821 cm--'-NMR (DMSO-dg, 5) :  0.91 (3H, t, J=7.1Hz), 1.3-1.5<br>
{4H,   m) ,   1.6-1.8    (2H,   m),   4.04   {2H,   t,   J=6.5Hz), 7.11    (2H,   d,   J=8.9Hz),   7.54   (IH,   s),   7.85   (2H, d,   J=8.9Hz),   7.98   (2H,   d,   J=8.6Hz),   8.11   (2H,   d, J=8.6Hz) APCI-MASS   :     la/z =  352   (M+H)’<br>
Preparation 32<br>
To a solution of Ethyl 3-inethyl-5-octylbenzo [b] furan-2-carboxylate (1.44 g) in ethanol (20 ml) was added 10% NaOH aqueous solution (2.2 ml), and stirred for 2 hours at ambient temperature, and evaporated under reduced press-are.  The residue was adjusted to pH 3.0 with IN hydrochloric a'cid, and extracted with ethyl acetate.  The organic layer was washed with brine, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to<br><br>
give 3-Methyl-5-octylbenzo[b]furan-2-carboxylic acid (1.00<br>
g).<br>
IR (KBr pelet) :  2923, 1689, 1664, 1581, 1456, 1319,<br>
1159, 933 cm~l<br>
NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.7Hz),<br>
1.2-1.5 (lOH, m), 1.5-1.8 (2H, m), 2.49 (3H, s), 2.69 (2H, t, J=7.9Hz), 7.32 (IH, dd, J=8.5 and 1.7Hz), 7.52 (IH, d, J=8.5Hz), 7.54 (IH, d, J=1.7Hz), 13.2-13.5 (IH, br)<br>
APCI-MASS :  m/z = 289 (M++1)<br>
The following compounds (Preparations 33 to 2R)   were obtained according to a similar manner to that of<br><br>
Preparation 33<br>
3, 4-Dipentyloxybenzoic acid<br>
NMR (DMSO-dg, 6) :  0.89 (6H, t, J=6.8Hz),<br>
1.2-1.5 (8H, m), 1.6-1.8 (4H, m), 3.9-4.1 (4H, m), 7.02 (IH, d, J=8.4Hz), 7.43 (IH, d, J=1.7Hz), 7.53 (IH, dd, J=8.4 and 1.7Hz) APCI-MASS :  m/z = 295 (M++1)<br>
Preparation 34<br>
1-(6-Heptyloxy-2-naphthoyl)piperidine-4-carboxylic acid<br>
NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.7Hz), 1.2-2.0 (14H, m), 2.5-2.6 (IH, m), 2.9-3.2 (2H, br), 3.25 (2H, s), 4.09 (2H, t, J=6.5Hz), 7.20 (IH, dd, J=8.9 and 2.4Hz), 7.36 (IH, d, J=2.3Hz), 7.43 (IH, dd, J=8.4 and 1.5Hz), 7,8-8.0 (3H, m), 12.3-0 (IH, br) APCI-MASS :  m/z = 398 (M’+1)<br><br>
Preparation 35<br>
7-Octyloxycoumarin-3-carboxylic acid<br>
IR (KBr) :  1748, 1625, 1558, 1467, 1430, 1386, 1360,<br>
1257, 1217, 1120 cm~l NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 4.11 (2H, t, J=6.4HZ), 6.9-7.1 (2H, m), 7.82 (IH, d, J=8.9Hz), 8.72 (IH, s), 12.98 (IH, br) APCI-MASS :  m/z =319 (M++1)<br>
Preparation 36<br>
4-(4-Pentyloxyphenyl)cinnamon acid<br>
IR (Nujol) :  2923, 1675, 1500, 1290, 1223, 985,<br>
821 cin~l NMR (DMSO-dg, 6) :  0.90 {3H, t, J=7.0Hz), 1.3-1.5<br>
(4H, m) , 1.6-1.8 (2H, m), 4.01 (2H, t, J=6.5Hz), 6.54 (IH, d, J=16.0Hz), 7.02 (2H, d, J=8.8Hz), 7.5-7.8 (7H, III) APCI-MASS :  m/z = 311 (M++1)<br>
Preparation 37<br>
2-Nonylbenzoxazole-6-carboxylic acid NMR (DMSO-dg, 5) :  0.84 (3H, t, J=6.7Hz), 1.2-1.5 (12H, m), 1.7-1.9 (2H, m), 2.96 (2H, t, J=7.4Hz), 7,76 (IH, d, J=8.4Hz), 7.98 (IH, d, J=8.4Hz), 8.19 (IH, s) APCI-MASS :  m/z =  290 (M++1)<br>
Preparation 38<br>
2-(4-Hexyloxyphenyl)benzimidazole-5-carboxylic acid NMR (DMSO-dg, 5) :  0.8-1.0 (3H, m), 1.3-1.6 (6H, m) , 1.7--1.8 (2H, m) , 4.06 (2H, t, J=6.4Hz), 7.12 (2H, d, J=8.8Hz), 7.6-7.9 (2H, m), 8.1-8.2 (3H, m), 13.00 (IH, br) APCI-MASS :  m/z = 339 (M++1)<br><br>
Preparation 39<br>
2-Nonylbenzimida2ole-5-carboxylic acid NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.7Hz), 1.1-1.4 (12H, m), 2.7-2.9 (2H, m), 2.96 (2H, t, J=7.6Hz), 3.6-5.2 (IH, br), 7.66 (IH, d, J=8,4Hz), 7.90 (IH, d, J=8.4H2), 8.15 (IH, s) APCI-MASS :  m/z = 289 (M++1)<br>
Preparation 40<br>
A solution of 4-[4-(4-0ctyloxyphenyl)piperazine-l-yl]benzonitrile (0.5 g) in 20% H2SO4 aqueous solution (30 ml) and acetic acid (20 ml) was refluxed for 9 hours.  The reaction mixture was pulverized with water.  The precipitate was collected by filtration, and added to a mixture of water, tetrahydrofuran and ethyl acetate, and adjusted to pH 2.5 with IN NaOH aqueous solution.  The organic layer was taken, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-[4-(4-Octyloxyphenyl)piperazin-l-yl]benzoic acid (388 mg). IR (KBr) :  2929, 1664, 1600, 1510, 1240 cm-l NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.6Hz), 1.2-1.5 (lOH, m), 1.5-1.8 (2H, m), 3.13 (4H, t, J=5.3Hz), 3.44 (4H, t, J=5.3Hz), 3.88 (2H, t, J=6.5Hz), 6.83 (2H, d, J=9.2Hz), 6.94 (2H, d, J=9.2Hz), 7.02 (2H, d, J=9.0H2), 7.79 (2H, d, J=9.0Hz) APCI-MASS :  m/z = 411 (M++1)<br>
Preparation 41<br>
To a suspension of sodium hydride (60% suspension in mineral oil) (0.296 g) in N,N-dimethylformamide (14 ml) was added 1,2,4-triazole (0.511 g) and 4-[4-(8-bromooctyloxy)phenyl]benzoic acid (1 g) , and was stirred for 5 hours at 120°C.  The reaction mixture was added to a<br><br>
mixture of water and ethyl acetate, and adjusted to pH 2.5 with cone, hydrochloric acid.  The organic layer was taken and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-[4-[8-(1, 2, 4-Triazol-l--yl)octyloxy]phenyl]benzoic acid (0.81 g).<br>
IR (KBr) :  2940, 1689, 1604, 1297, 1189 cm-l NMR (DMS0-d5, 5) :  1.1-1.53 (8H, m), 1.6-1.9 (4H, m), 4.00 (2H, t, J=6.3Hz), 4.16 (2H, t, J=7.0Hz), 7.03 (2H, d, J=8.7Hz), 7.67 (2H, d, J=8.7Hz), 7.75 (2H, d, J=8.4Hz), 7.95 (IH, s), 7.99 (2H, d, J=8.4Hz), 8.51 (IH, s), 12.9 (IH, s) APCI-MASS :  m/z = 394 (M'‘+1)<br>
Preparation 42<br>
A mixture of 2-Carbamoyl-5-methoxybenzo[b]thiophene (2.0 g), acetic acid (5 ml) and 48% hydrobromic acid (20 ml) was stirred for 16 hours at 110**C, and the mixture was poured into the ice-water.  The resulting precipitate was collected by filtration, and dried to give 5-Hydroxybenzo[b]thiophene-2-carboxylic acid (1.66 g) .<br>
NMR (DMSO-dg, 6) :  7.03 (IH, dd, J=8.8 and 0.6Hz), 7.31 (IH, d, J=0.6Hz), 7.81 (IH, d, J=8.8Hz), 7.96 (IH, s), 9.64 (IH, s), 13.32 (IH, s) APCI-MASS :  m/z = 195 (M++1)<br>
Preparation 43<br>
A solution of (S)-2-Tert-butoxycarbonyl-l,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid (1 g) in a mixture of 10% NaOH aqueous solution (2.73 ml) and dimethylsulfoxide (11 ml) was stirred for half an hour at 80'*C-  Then, octyl bromide (0.589 ml) was added thereto, and stirred for 4 hours at 60**C.  The reaction mixture was added to a mixture of water and ethyl acetate, and<br><br>
adjusted to pH 2,5 with cone, hydrochloric acid.  The organic layer was taken, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give (S)-2-Tert-butoxycarbonyl-1,2,3,4-tetrahydro-7-octyloxyisoquinoline-3-carboxylic acid (1.30 g).<br>
IR (Neat) :  2929, 1743, 1704, 1164 cm-l<br>
NMR (CDCI3, 5) :  0.89 (3H, t, J=6.1Hz), 1.1-1.6<br>
(lOH, m), 1.41 + 1.51 (9H, s, cis + trans), 1.75 (2H, quaint, J=6.5Hz), 3.10 (2H, m), 3.90 (2H, t, J=3.9Hz), 4.42 (IH, d, J=16.8Hz), 4.65 (IH, d, J=16.8Hz), 4.74 + 5.09 (IH, m, cis + trans), 6.5-6.8 (2H, m), 7.03 (IH, d, J=8.3Hz) APCI-MASS :  m/z = 306 (M++I-B0C)<br>
The following compounds (Preparations 44 to 4’) were obtained according to a similar manner to that of Preparation 43.<br>
Preparation 44<br>
5-Octyloxybenzo[b]thiophene-2-carboxylic acid<br>
IR (KBr) :  1673, 1666, 1600, 1517, 1409, 1267, 1214,<br>
1153, 865 cm~l<br>
NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m) , 1.7-1.9 (2H, m), 4.02 (2H, t, J=6.4Hz), 7.13 (IH, dd, J=8.9 and 0.6Hz), 7.51 (IH, d, J=0.6Hz), 7,90 (IH, d, J=9.0Hz), 7.99 (IH, s)<br>
APCI-MASS :  m/z =  307 (M++1)<br>
Preparation 45<br>
4-[4-(4-Hexyloxyphenyl)piperazine-l-yl]benzoic acid<br>
dihydrochloride<br>
IR (KBr) :  1668, 1600, 1510, 1228 cm~’<br>
NMR rnM.c;n-rt’. ?))   !  n.88 r'‘H. 1-. .7=6.9H7.). i.p-i.5<br><br>
(6H, m), 1.6-1.9 (2H, in), 3.0-3.2 (4H, m), 3.3-3.5 (4H, in), 3.88 (2H, t, J=6.3H2), 6.83 (2H, d, J=9H2), 6.9-7.1 (4H, m), 7.79 (2H, d, J=8.8H2), 12.32 (IH, s) APCI-MASS :  m/z = 383 (M+H-’)<br>
To a suspension of dimethyl terephthalate (1.94 g) and potassium t-butoxide (2.24 g) in tetrahydrofuran (30 ml) was added 4-pentyloxyacetophenone (1.59 g) in tetrahydrofuran (10 ml) at 70'C dropwise.  The mixture was refluxed for 30 minutes and poured into IN HCl (50 ml). The mixture was extracted with ethyl acetate (100 ml) and the organic layer was washed with H2O (100 ml), brine (100 ml) and evaporated under reduced pressure.  The residue was triturated with acetonitrile (20 ml), collected by filtration and dried under reduced pressure to give l-(4-Methoxycarbonylphenyl)-3-(4-pentyloxyphenyl)propane-1, 3-dione (2.41 g) as yellow solid.<br>
IR (KBr) :  3475, 2956, 2923, 1720, 1606, 1508, 1284,<br>
1176, 1108, 769 cm'l NMR (CDCI3, 5) :  0.95 (3H, t, J=7.0Hz), 1.3-1.5 (4H, m), 1.7-2.0 (2H, m), 3.96 (3H, s), 4.04 (2H, t, J=6.5H2), 6,82 (IH, s) , 6.96 (2H, d, J==8.9Hz), 8.0-8.1 (4H, m), 8.14 (2H, m, J=8.7H2), 12-13 (IH, br) APCI-MASS :  m/z = 369 (M+H-’)<br><br>
The solution of 1-(4-Methoxycarbonylphenyl)-3-(4-pentyloxyphenyl)propane-1,3-dione (1.00 g) and hydroxylamine hydrochloride (567 lag) in methanol (10 ml) was refluxed for 10 hours.  The reaction mixture was diluted with ethyl acetate (50 ml) and washed with water (50 ml x 2), brine (50 ml).  The organic layer was dried<br><br>
over magnesium sulfate and the solvents were removed under reduced pressure.  The residue was triturated with acetonitrile (10 ml), collected by filtration, and dried under reduced pressure to give Methyl 4-[5-(4-pentyloxyphenyl)isoxazol-3-yl]benzoate (0.74 g).<br>
IR (KBr) :  2942, 2873, 1716, 1616, 1508, 1280,<br>
1108 cm~’ NMR (CDCI3, 5) :  0.95 (3H, t, J=6.9Hz), 1.3-1.6 (4H, m), 1.8-2.0 (2H, m), 3.95 (3H, s), 4.02 (2H, t, J=6.5Hz), 6.74 (IH, s), 6.99 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.8Hz), 7.93 (2H, d, J=8.5H2), 8.14 (2H, d, J=8.5Hz) APCI-MASS :  m/z = 366 (M+H) -’<br>
Preparation 48<br>
A solution of 4-[4-(8-Bromooctyloxy)phenyl]benzoic acid (1 g) in a mixture of sodium methylate (28% solution in methanol) (10 ml) and N,N-dimethylformamide (5 ml) was refluxed for 5 hours.  The reaction mixture was added to a mixture of water and ethyl acetate and adjusted to pH 2.0 with cone. HCl.  The organic layer was taken and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-[4-(8-Methoxyoctyloxy)phenyl]-benzoic acid (0.77 g),<br>
IR (KBr) :  2935, 1685, 835, 773 cm-’ NMR (CDCI3, 5) :  1.27-1.7 (lOH, m), 1.7-1.95 (2H, m), 3.34 (3H, s), 3.38 (2H, t, J=6.4H2), 4.01 (2H, t, J=6.5Hz), 6.99 (2H, d, J=8.7Hz), 7.58 (2H, d, J=8.7Hz), 7.66 (2H, d, J=8.4Hz), 8.15 (2H, d, J=8.4Hz) APCI-MASS':  m/z = 339 (M’+H - H2O)<br>
Preparation 49<br>
To a suspension of l-Hydroxybenzotriazole (0,283 g)<br><br>
and 6-octyloxymethylpicolinic acid (0.505 g) in dichloroiuethane (15 ml) was added l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSCD-HCl) (0.473 g), and stirred for 3 hours at ambient temperature. The reaction mixture was poured into water.  The organic layer was taken, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give l-(6- OctyloxymethylpicolinoyDbenzotriazole 3-oxide (737 mg) . IR (Neat) :  1793, 1654, 1591, 1039 cm-l<br>
The following compounds [Preparations 50 to ££) were obtained according to a similar manner to that of Preparation 49.<br>
Preparation 50<br>
1-[4-(4-Octyloxyphenyl)piperazin-1-yl)benzoyl]-benzotriazole 3-oxide<br>
IR (KBr) :  1783, 1600, 1511, 1232, 1184 cm-l NMR (CDCI3, 6) :  0.89 (3H, t, J==6.6Hz), 1.2-1.65 (lOH, m), 1.65-1.9 (2H, m), 3.24 (4H, t, J=5.3Hz), 3.62 (4H, t, J=5.3Hz), 3.93 (2H, t, J=6.5Hz), 6.8-7.1 (6H, m), 7.35-7.63 (3H, m), 8.0-8.25 (3H, m)<br>
Preparation 51<br>
1-[4-[4- [8- (1,2,4-Triazol-l-yl)octyloxy]phenyl]-benzoyl]benzotriazole 3-oxide<br>
IR (KBr) :  1776, 1600, 1193, 983 cm~’<br>
NMR (CDCl’, 5) :  1.2-2.0 (12H, m), 4.03 (2H, t,<br>
J=6.4Hz), 4.18 (2H, t, J=7.1Hz), 7.02 (2H, d, J=8.7Hz), 7.4-7.63 (3H, m), 7.63 (2H, d, J=8.7Hz), 7.79 (2H, d, J=8.3Hz), 7.95 (IH, s), 8.06 (IH, s), 8.12 (IH, d, J=7.7Hz), 8.32 (2H, d, J=8.3Hz)<br><br>
APCI-M?ISS :  m/z = 511 {M++1)<br><br>
1-[2-Methyl-2-(4-octyloxyphenoxy)propionyl]-benzotriazole 3-oxide<br>
IR (Neat) :  2927, 1810, 1504, 1047 cm~l<br>
Preparation 53<br>
1-[2-(4-0ctyloxyphenoxy)propionyl]benzotriazole 3-oxide<br>
IR (KBr) :  2954, 1812, 1513, 1232 cm-l<br>
Preparation 54<br>
1-[(S)-2-tert-Butoxycarbonyl-l,2,3,4-tetrahydro-7-octyloxyisoquinolin-3-yl-carbonyl]benzotriazole 3-oxide<br>
IR (Neat) :  2929, 1816, 1739, 1704, 1392 cin-l<br>
Preparation 55<br>
Succinimide 4-(4-n-octyloxyphenyl)piperazine-l-carboxylate<br>
IR (KBr) :  2925, 1758, 1743, 1513, 1241   NMR (CDCI3, 5) :  0,89 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.65-1.85 (2H, m), 2.83 (4H, s), 3.0-3.2 (2H, m), 3.6-3.85 (2H, m), 3.91 (2H, t, J=6.5Hz), 6.84 (2H, dd, J=8.5 and 2.7Hz), 6.90 (2H, dd, J=8.5 and 2.7Hz) APCI-MASS :  m/z = 432 (M++1)<br>
Preparation 56<br>
(6-Heptyloxy-2  carbonate IR   (KBr)    :      1878,   1832,   1787,   1735,   1209   cin~l NMR   (CDCI3,   5)    :      0.90   (3H,   t,   J=6.2Hz),    1.2-1.6    (8H, m),    1.73-2.0   (2H,   m),   2.83   (4H,   s),   4.07   (2H,   t, J=6.5Hz),    5.44    (2H,   s),   7.13    (IH,   d,    J=2.4H2), 7.17    (IH,   dd,   J=8.8   and  2.4Hz),   7.44    (IH,   dd.<br><br>
J=8.4 and I.6H2), 7.67-7.85 (3H, m)<br>
Preparation 57<br>
1-(3,4-Dipentyloxybenzoyl)benzotria2ole 3-oxide<br>
IR (KBr) :  2952, 1774, 1594, 1515, 1430, 1272, 1147,<br>
1089 cni~l<br>
NMR (CDCI3, 5) :  0.9-1.1 (6H, m), 1.3-1.6 (8H, m), 1.8-2.1 (4H, m), 4.0-4.2 (4H, m), 6.99 (IH, d, J=8.5Hz), 7.4-7.6 (3H, m) , 7.68 (IH, d, J=2.0H2), 7,92 (IH, dd, J=8.5 and 2.OH2), 8.10 (IH, d, J=8.5Hz)<br>
APCI-MASS :  m/z = 412 (M++1)<br>
Preparation 58<br>
1-(7-Octyloxycoumarin-3-yl-carbonyl)benzotriazole 3-oxide<br>
IR (KBr) :  2925, 1754, 1716, 1610, 1548, 1282, 1199,<br>
1172, 1139, 1064, 781, 750 cm~l NMR (DMSO-dg, 5) :  0.86 (3H, t, J=7.8Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 4.11 (2H, t, J=6.5Hz), 6.9-7.1 (2H, m), 7.41 (IH, t, J=7.2Hz), 7.54 (IH, t, J=7.2Hz), 7.72 (IH, d, J=8.3Hz), 7.82 (IH, d, J=8.3Hz), 7.99 (IH, d, J=8.3Hz), 8.72 (IH, s) APCI-MASS :  ra/z = 436 (M++1)<br>
Preparation 59<br>
1-[4-(4-Pentyloxyphenyl)cineol]benzotriazole 3-oxide<br>
IR (Nujol) :  2854, 1778, 1708, 1620, 1597, 1494,<br>
1459, 1434, 1377, 1350, 1250, 1188, 1138, 1086, 97 8 cih-l<br>
Preparation 60<br>
1-(5-Octyloxybenzo[b]thiophen-2-yl-carbonyl)-<br><br>
benzotriazole 3-oxide<br>
IR (KBr) :  2950, 1776, 1517, 1342, 1211, 1151 cm~’ NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.7H2), 1.2-1.5 (lOH, m) ,   1.7-1.9 (2H, m) , 4.01 {2H, t, J=6.4H2), 7.13 (IH, dd, J=8.8 and 2.4Hz), 7.42 (IH, d, J=7.1Hz), 7.5-7.6 (3H, m), 7.72 (IH, d, J=8.4Hz), 7.89 (IH, d, J=8.8Hz), 7.9-8.1 {2H, m) APCI-MASS :  m/z = 424 (M++1)<br>
Preparation 61<br>
1-(3-Methyl-5-octylbenzo[b]furan-2-yl-carbonyl)-benzotriazole 3-oxide<br>
IR (KBr) :  1776, 1575, 1469, 1363, 1324, 1276, 1114,<br>
1027 cm'l NMR (CDCI3, 5) :  0.89 (3H, t, J=6.7Hz), 1.2-1.5<br>
(lOH, m), 2.6-2.8 (2H, m), 2.71 (3H, s), 2.76 (2H, t, J=7.4Hz), 7.4-7.6 (6H, m), 8.12 (IH, s) APCI-MASS :  m/z = 406 (M++1)<br>
Preparation 62<br>
1-(2-Nonylbenzoxazol-5-yl-carbonyl)benzotriazole 3-oxide<br>
IR (KBr) :  2980, 1783, 1623, 1573, 1276, 1151, 1091,<br>
989 cm~’ NMR (DMS0-d5, 6) : 0.84 (3H, t, J=6.8Hz), 1.1-1.4 (12H, m), 1.81 (2H, t, J=7.2Hz), 2.96 (3H, t, J=7.4Hz), 7.41 (IH, t, J=7.0Hz), 7.54 (IH, t, J=7.0Hz), 7.74 (2H, t, J=7.0Hz), 7.98 (2H, d, J=7.0Hz), 8.19 (IH, s) APCI-MASS :  m/z = 407 (M++1)<br>
Preparation 63 *<br>
1- [2- (4-Hexyloxyphenyl)benziniidazol-5-yl-carbonyl]-benzotriazole 3-oxide<br>
IR (KBr) :  3160, 2931, 2863, 1778, 1612, 1502, 1448,<br><br>
1388, 1294, 1247, 1174, 1097, 1010, 732 cm'‘ NMR (DMSO-dg, 5) :  0.89 {3H, t, J=6.7H2), 1.2-1.5<br>
(6H, m), 1.7-1.8 (2H, m), 4.08 (2H, t, J=6.4Hz),<br>
7.16 (2H, d, J=8.7H2), 7.6-8.4 (9H, m) , 8.3-8.6<br>
(IH, br) APCI-MASS :  m/z = 456 (M++1)<br>
Preparation 64<br>
1-[4-[4- (8-Methoxyoctyloxy)phenyl]benzoyl] -benzotria2ole-3-oxide<br>
IR (KBr) :  2931, 1793, 1770, 1600 cm~’ NMR (CDCI3, 5) :  1.2-1.7 (lOH, m), 1.7-1.93 (2H, m), 3.34 (3H, s), 3.38 (2H, t, J=6.4H2), 4.03 (2H, t, J=6.5Hz), 7.03 (2H, d, J=8.8Hz), 7.4-7.7 (3H, m) , 7.63 {2H, d, J=8.8H2), 7.79 (2H, d, J=8.6Hz), 8.12 (IH, d, J=8.2Hz), 8.32 (2H, d, J=8.6Hz)<br>
Preparation 65<br>
1-[4-[4-(4-Hexyloxyphenyl)piperazine-l-yl]benzoyl]benzotriazole 3-oxide<br>
IR (KBr) :  1770, 1604, 1510, 1232, 1186 cm-’ NMR (CDCI3, 5) :  0.91 (3H, t, J=6.6Hz), 1.2-1.6 (6H, m) , 1.6-1.9 (2H, m), 3.1-3.3 (4H, m), 3.5-3.7 (4H, m), 3.93 (2H, t, J=6.5Hz), 6.87 (2H, d, J=9.2Hz), 6.96 {2H, d, J=9.2Hz), 7.00 (2H, d, J=9.0Hz), 7.3-7.7 (3H, m), 8.10 (IH, d, J=8.2H2), 8.15 (2H, d, J=9.0Hz) APCI-MASS :  m/z = 500 (M+H-’)<br>
Preparation 66<br>
1-[4-[5-(4-Pentyloxyphenyl)isoxazol-3-yl]benzoyl]-benzotriazole 3-oxide<br>
IR (KBr) :  2950, 2837, 1774, 1616, 1508, 1452, 1251,<br>
1006 cm--<br><br>
NMR (CDCI3, 5) :  0,95 (3H, t,	J=7.1H2), 1.3-1.5 (4H,<br>
m), 1.8-2.0 (2H, m), 4.04	(2H, t, J=6.5H2), 6.81<br>
(IH, s), 7.0-7.1 (3H, m),	7.4-7.6 (3H, m), 7.80<br>
(2H, d, J=8.8Hz), 8.0-8.2	(3H, m), 8.40 (2H, d,<br>
J=8.4Hz)<br>
APCI-MASS :  m/z = 469 (M+H) - -<br>
Preparation 67<br>
To a suspension of 1-hydroxybenzotriazole (0.20 g) and 4-(4-pentylphenyl)cinnamon acid (0.40 g) in dichloromethane (12.0 ml) was added l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (0.33 g) (WSCD-HCl), and the mixture was stirred for 12 hours at ambient temperature.  The reaction mixture was diluted with dichloromethane, and washed with brine, and dried over magnesium sulfate.  After magnesium sulfate was filtered off, evaporation of the filtrate and trituration with acetonitrile gave l-[4-(4-<br>
Pentylphenyl)cinnamoyl]benzotriazole 3-oxide (0.24 g). NMR (CDCI3, 5) :  0.91 (3H, t, J=6.6H2), 1.20-1.50 (4H, m), 1.50-1.75 (2H, m), 2.66 (2H, t, J=8.0Hz), 7.20-8.25 (IIH, m), 8.55 (IH, d, J=8.4Hz) APCI-MASS :  m/z = 412 (M'‘+1)<br>
The following compounds (Preparations 68 to 21) were obtained according to a similar manner to that of Preparation 67.<br>
Preparation 68<br>
1-[3-[4-(4-Pentyloxyphenyl)phenyl]-2-propanoyl]-benzotriazole 3-oxide<br>
NMR (CDCI3, 6) :  0.90-1.05 (3H, m), 1.30-1.65 (4H, m), 1.70-1.95 (2H, m),   3.10-3.60 (4H, m) , 3.90-4.10 (2H, m), 6.88-7.08 (2H, m) ,<br><br>
7.20-8.50   (lOH,   m) APCI-MASS   :        =  430   (M++1)<br>
Preparation 69<br>
1-[4-(4-Heptylphenyl)cinnamoyljbenzotriazole 3-oxide NMR (CDCI3, 5) :  0.89 (3H, t, J=6.7Hz), 1.20-1.50 (8H, m), 1.50-1.80 {2H, m), 2.66 {2H, t, J=7.6Hz), 6.70-8.60 (12H, m) APCI-MASS :  m/z = 440 (M++1)<br>
Preparation 70<br>
1-[3-[4-(4-Pentylphenyl)phenyl]-2-propanoyl]-benzotriazole 3-oxide<br>
NMR (CDCI3, 6) :  0.90 (3H, t, J=6.8Hz), 1.20-1.50 (4H, m),   1.50-1.76 (2H, m),   2.63 (2H, t, J=7.4Hz), 3.21 (2H, t, J=7.3Hz), 3.51 (2H, t, J=7.3Hz), 7.20-7.45 (4H, m), 7.45-7.70 (5H, m), 7.78 (IH, dt, J=1.0 and 7.2Hz), 8.00 (IH, d, J=8.2Hz), 8.42 (IH, d, J=8.4Hz) APCI-MASS :  m/z = 414 (M'‘+l)<br>
Preparation 71<br>
1-[3-(6-Heptyloxynaphthalen-2-yl)propanoyl]-benzotriazole 3-oxide<br>
NMR (CDCI3, 6) :  0.80-1.10 (3H, m), 1.20-1.70 (8H, m), 1.70-2.00 (2H, m), 3.10-3.70 (4H, m), 4.00-4.18 (2H, m), 6.80-8.50 (lOH, m) APCI-MASS :  m/z = 432 (M++1)<br>
Preparation 72<br>
1-[3-(6-Heptyloxynaphthalen-2-yl)propenyl]-benzotriazole 3-oxide<br>
NMR (CDCI3, 6) :  0.90 (3H, t, J=6.5Hz), 1.20-1.65 (8H, m), 1.75-1.95 (2H, m), 4.10 (2K, d, J=6.5Hz), 6.75-8.62 (8H, m)<br><br>
APCI-MASS :  m/z = 430 (M++1)<br>
Preparation 73<br>
1-(4-Hexylphenylbenzoyl)benzotriazole 3-oxide NMR (CDCI3, 6) :  0.90 (3H, t, J=4.4Hz), 1.2-1.5 (6H, m), 1.6-1.8 (2H, m), 2.68 (2H, t, J=8.0Hz), 7.32 (2H, d, J=8.2Hz), 7.4-7.7 {5H, m) , 7.81 (2H, d, J=6.6Hz), 8.10 (2H, d, J=8.1Hz), 8.32 (2H, d, J=7.6Hz) APCI-MASS :  m/z = 400 (M++1)<br><br>
To a solution of 4-octyloxyphenol (1 g) in<br>
dimethylforinamide (10 ml) and pyridine (0.364 ml) was added N,N'-disuccinimidylcarbonate (1.16 g).  The mixture was stirred for 12 hours at ambient temperature.  The reaction mixture was added to a mixture of water and ethyl acetate. The organic layer was taken, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-Octyloxyphenylsuccinimidyl carbonate (0.59 g). IR (KBr) :  2927, 1876, 1832, 1735 cm~l NMR (CDCI3, 5) :  0.89 (3H, t, J=6.3Hz), 1.2-1.55<br>
(lOH, m), 1.67-1.87 (2H, m), 2.87 (4H, s), 3.94 (2H, t, J=6.5Hz), 6.89 (2H, d, J=9.2Hz), 7.17 (2H, d, J=9.2Hz) APCI-MASS :  m/z = 364 (M'‘+l)<br>
The following compounds (Preparations 75 to M) were obtained according to a similar manner to that of Preparation<br>
Preparation 75<br>
Methyl 4-[4-(6-phenylpyridazin-3-yl-oxy)phenyl]benzoate IR (KBr) :  1708, 1427, 1280, 1187, 1112 cm-l<br><br>
NMR {CDCI3, 5) :  3.95 (3H, s), 7.2-7.7 (lOH, m),<br>
7.92	(IH, d, J=9.2Hz), 8.0-8.2 (4H, m)<br>
APCI-MASS : m/z = 383 (M+H)’<br>
Preparation 76<br>
Methyl 4-[4-(5-bromopentyloxy)phenyl benzoate<br>
IR (KBr) :  2946, 2871, 1716, 1602, 1294, 1199, 1112,<br>
837 cm-’ NMR (CDCI3, 6) :  1.7-2.0 {6H, in), 3.45 (2H, t,<br>
J=6.7Hz), 3.93 (3H, s), 4.02 (2H, t, J=6.1Hz), 6.97 (2H, d, J=8.7Hz), 7.56 (2H, d, J=8.7Hz), 7.61 (2H, d, J=8.3Hz), 8.07 (2H, d, J=8.3Hz) APCI-MASS : m/z = 378 (M+H)’<br>
Preparation 77<br>
Methyl 4-[4-(5-phenoxypentyloxy)phenyl]benzoate IR (KBr) :  2944, 2931, 1720, 1600, 1492, 1197,<br>
1110 cm~’ NMR (CDCI3, 5) :  1.6-1.8 (2H, m) , 1.8-2.0 (4H, m),<br>
3.93	(3H, s), 4.00 (2H, t, J=6.3Hz), 4.04 (2H, t,<br>
J=6.3Hz), 6.9-7.1 (5H, m), 7.3-7.4 (2H, m), 7.56<br>
(2H, d, J=8.7Hz), 7.62 (2H, d, J=8.3Hz), 8.07 (2H,<br>
d, J=8.3Hz)<br>
APCI-MASS :  m/z = 391 (M+H)-’<br>
Preparation 78<br>
1-[2-(4-Cyclohexylphenylamino)ethyl]-2-oxazolidone hydrochloride<br>
IR (KBr) :  2923.6, 2852.2, 1747.2, 1683.6 cm-’ NMR (DMSO-dg, 5) :  1.1-1.5 (6H, m), 1.6-1.9 (4H, m), 2.3-2.6 (IH, m), 3.3-3.5 (4H, m), 3.58 (2H, dd, J=9.4 and 7.4Hz), 4,22 (2H, dd, J=9.4 and 7.4Hz), 7.1-7.4 (4H, m)<br>
Preparation 79<br><br>
Methyl 4-[4-(8-hydroxyoctyloxy)phenyl benzoate<br>
IR (KBr) :  3250, 2933, 2856, 1724, 1602, 1436, 1292,<br>
1199 cm--<br>
NMR (CDCI3, 5) :  1.3-1.9 (12H, m), 3.6-3.8 {2H, br),<br>
3.93 (3H, s), 4.00 (2H, t, J=6.7Hz), 4.82 (IH, s), 7.68 (2H, d, J=8.7Hz), 7.56 (2H, d, J=8.7Hz), 7.62 (2H, d, J=8.3Hz), 8.07 (2H, d, J=8.3Hz)<br>
APCI-MASS :  m/z = 357 (M+H-*-)<br>
Preparation 80<br>
Methyl 4- [4- (6-broinohexyloxy) phenyl benzoate<br>
IR (KBr) :  2937, 2861, 1724, 1602, 1529, 1436, 1292,<br>
1199, 1112 cm-’ NMR (CDCI3, 6) :  1.5-2.0 {8H, m), 3.43 (2H, t,<br>
J=6.8Hz), 3.93 {3H, s), 4.02 (2H, t, J=6.3Hz), 6.98 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.62 (2H, d, J=8.4Hz), 8.07 (2H, d, J=8.4Hz) APCI-MASS :  m/z = 391 (M+H-*-)<br>
Preparation 81<br>
4-[4-(5-Bromopentyloxy)phenyl]bromobenzene<br>
IR (KBr) :  2942, 2867, 1604, 1515, 1477, 1286 cm-’<br>
NMR (CDCI3, 6) :  1.5-2.0 (6H, m), 3.44 {2H, t,<br>
J=6.7Hz), 3.99 (2H, t, J=6.2Hz), 6.95 (2H, d,<br>
J=8.7Hz), 7.3-7.6 (6H, in) APCI-MASS :  m/z = 399 (M+H+)<br>
Preparation 82<br>
8-[4-(4-Methoxycarbonylphenyl)phenoxy3octanoyl piperidine<br>
IR (KBr) :  2935, 2852, 1720, 1639, 1604, 1438,<br>
1292 cm~’ NMR (CDCI3, 6) :  1.3-1.9 (16H, m), 2.34 {2H, d,<br>
J=7.6Hz), 3.4-3.6 (4H, m), 3.93 (3H, s), 3.99 (2H, t, J=6.4H2), 6.97 (2H, d, J=8.8Hz), 7.55 {2H, d.<br><br>
J=8.8Hz), 7.61 (2H, d, J=8.6Hz), 8.07 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 438 (M+H+)<br>
Preparation 83<br>
Methyl 6-[4-{4-n-heptyloxyphenyl)piperazine-l-yl]nictitate<br>
IR (KBr) :  2933, 2859, 1726, 1608, 1513, 1430,<br>
1280, 1245 cin~l NMR (CDCI3, 5) :  0.89 (3H, t, J=6.7H2), 1.2-1.8 (lOH, m), 3.17 (4H, t, J=4.9Hz), 3.8-4.0 (9H, m), 6.65 (IH, d, J=9.1Hz), 6.86 (2H, d, J=9.1Hz), 6.96 (2H, d, J=9.1Hz), 8.05 (IH, dd, J=9.1 and 2.3Hz), 8.82 (IH, d, J=2.3Hz) APCI-MASS :  m/z = 412 (M+H-’)<br>
Preparation 84<br>
Methyl 6-[4-[4-(8-bromooctyloxy)phenyl]piperazin-1-yl]nicotinate<br>
IR (KBr) :  2933, 2861, 1724, 1608, 1513, 1430,<br>
1280 cm-l NMR (CDCI3, 5) :  1.2-2.0 (12H, m), 3.17 (4H, t,<br>
J=5.0Hz), 3.40 (2H, t, J=6.8Hz), 3.8-4.0 (9H, m) , 6.64 (IH, d, J=9.0Hz), 6.85 (2H, d, J=9.1Hz), 6.96 (2H, d, J=9.1Hz), 8.05 (IH, dd, J=9.0 and 2.2Hz), 8.82 (IH, d, J=2.2Hz) APCI-MASS :  m/z = 504 (M+H-’)<br>
Preparation 85<br>
4-[4-(7-Bromoheptyloxy)phenyl]bromobenzene<br>
IR (KBr) :  2935.1, 2856.1, 1604.5 cm-’<br>
NMR (CDCI3, 6) : 1.18-1.65 (6H, m), 1.70-2.02 (4H, m), 3.41 (2H, t, J=6.8Hz), 3.99 (2H, t, J=6.4Hz), 6.95 (2H, d, J=8.6Hz), 7.40 (2H, d, J=8.6Hz), 7.46 (2H, d, J=8.6Hz), 7.52 (2H, d, J=8.6Hz)<br><br>
Preparation 86<br>
4-[4-(8-Bromooctyloxy)phenylJbromobenzene NMR (CDCI3, 5) :  1.22-1.65 (8H, m), 1.65-1.95 (4H, m), 3.41 (2H, t, J=6.8Hz), 3,99 (2H, t, J=6.4Hz), 6.95 (2H, d, J=8.6H2), 7.40 (2H, d, J=8.6Hz), 7.46 (2H, d, J=8.6H2), 7.52 (2H, d, J=8.6Hz)<br>
Preparation 87<br>
Methyl (E)-3-[4-[4-(5-hexenyloxy)phenyl]phenyl]acrylate NMR (CDCI3, 6) :  1.50-1.72 (2H, m), 1.72-1.95 {2H, m), 2.05-2.14 (2H, m), 3.82 (3H, s), 4.01 (2H, t, J=6.3Hz), 4.95-5.10 (2H, m), 5.70-5.93 (IH, m), 6.46 (IH, d, J=16Hz), 6.97 (2H, d, J=8.7Hz), 7.54 (2H, d, J=8.7Hz), 7.58 (4H, s), 7.72 (IH, d, J=16Hz) APCI-MASS :  m/z = 337 (M-’+l)<br>
Preparation 88<br>
4-Bromo-4'-{4-methylpentyloxy)biphenyl<br>
IR (KBr) :  2956.3, 2871.5, 1606.4 cm~’<br>
NMR (CDCI3, 6) :  0.93 {6H, d, J=6.6Hz), 1.25-1.45 (2H, m) , 1.62 (IH, sent, J=6.6Hz), 1.72-1.93 (2H, m), 3.98 (2H, t, J=6.6Hz), 6.95 (2H, d, J=8.6Hz), 7.30-7.60 (6H, m)<br>
APCI-MASS :  m/z = 332, 334  (M-’, M++2)<br>
The following compounds (Preparations 89 to 9£) were obtained according to a similar manner to that of Preparation 2.<br>
Preparation 89<br>
N-[4-[2-(4-Methylpentyl)-2,3-dihydro-4H-l,2,4-triazol-3-<br>
one-4-yl]phenylJpiperazine di trifluoroacetate<br>
IR (KBr) :  1668.1, 1519.6, 1203.4, 1176.4, 1130.1 cm~’ NMR (DMSO-dg, 5) :  0.86 (6H, d, J=6.6Hz), 1.1-1.3 (2H,<br><br>
m) , 1.4-1.8 (3H, m) ,   3.1-3.3 (4H, in), 3.3-3.5 (4H, m), 3.70 (2H, t, J=7.0Hz), 7.11 (2H, d, J=9.0H2), 7.53 (2H,d, J=9.0H2), 8.35 (IH, s), 8.90 (2H, s)<br>
Preparation 90<br>
1-(4-Phenylcyclohexyl)piperazine di trifluoroacetate<br>
IR (KBr) :  1677.8, 1197.6, 1133.9 cm~’<br>
NMR (DMSO-dg, 5) :  1.4-1.8 (4H, m) , 1.8-2.25 (4H, m),<br>
2.4-2.7 (IH, m),   3.2-3.7 (9H, m), 4.54 (2H, br s),<br>
7.0-7.4 (5H, m), 9.32 (IH, br s) APCI-MASS :  m/z = 245 (M-’+H)<br>
The following compounds (Preparations 91 to 103) were obtained according to a similar manner to that of Preparation<br>
3..<br>
Preparation 91<br>
Methyl 6-[4-(4-octyloxyphenyl)piperazin-1-yl]nicotinate IR (KBr) :  2923, 1726, 1608, 1515, 1278, 1116 cm~’ NMR (CDCI3, 5) :  0.88 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.7-1.8 (2H, m), 3.1-3.2 (4H, m) , 3.8-4.0 (9H, m), 6.64 (IH, d, J=9.0Hz), 6.8-7.0 (4H, m), 8.04 (IH, dd, J=9.0 and 2.4Hz), 8.81 (IH, d, J=2.4Hz) APCI-MASS :  m/z = 426 (M+H-’)<br>
Preparation 92<br>
4-[4-[4-[2-(4-Methylpentyl)-2,3-dihydro-4H-l,2,4-triazol-3-one-4-yl]phenyl]piperazin-1-yl]benzonitrile IR (KBr) :  2217.7, 1685.5 cm-’ NMR (CDCI3, 5) :  0.90 (6H, d, J=6.6Hz), 1.2-1.4 (2H,<br>
m), 1.5-2.0 (3H, m), 3.3-3.4 (4H, m), 3.4-3.6 (4H, m) , 3'.83 (2H, t, J=7.4H2), 6.92 (2H, d, J=9.GHz), 7.01 (2H, d, J=9.0Hz), 7.43 (2H, d, J=9.0Hz), 7.54 (2H, d, J=9.0Hz), 7.62 (IH, s)<br><br>
Preparation 93<br>
3-Fluoro-4-[4-(4-methoxyphenyl)piperazin-1-<br>
yl]benzonitrile<br>
IR (KBr) :  2225.5, 1510.0, 1240.0 cm~’ NMR (CDCI3, 5) :  3.1-3.55 (8H, m), 3.79 (3H, s) , 6.7-7.1 (6H, m), 7.3-7.5 (IH, m)<br>
Preparation 94<br>
3-Chloro-4-[4-(4-n-hexyloxyphenyl)piperazin-1-yl]benzonitrile<br>
IR (KBr) :  2223.5, 1592.9, 1510.0, 1490.7, 1236.1 cm-l NMR (CDCI3, 5) :  0.90 (3H, t, J=6.7Hz), 1.3-1.6 (6H,<br>
m), 1.7-1.9 (2H, m), 3.2-3.4 (8H, m), 3.92 (2H, t, J=6.6Hz), 6.85 (2H, d, J=9.3Hz), 6.94 (2H, d, J=9.3Hz), 7.08 (IH, d, J=8.4Hz), 7.53 (IH, dd, J=8.4 and 1.9Hz), 7.64 (IH, d, J=1.9Hz) APCI-MASS :  m/z = 398 (M++H)<br>
Preparation 95<br>
Ethyl 3-[4-(4-n-hexyloxyphenyl)piperazin-1-yl]-6-pyridazinecarboxylate<br>
IR (KBr) :  1729.8, 1587.1, 1511.9, 1245.8 cm-’<br>
NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5Hz), 1,2-1.4 (6H,<br>
ra) , 1.44 (3H, t, J=7.1Hz), 1.65-1.85 (2H, m) , 3.1-3.25 (4H, m), 3.8-4.0 (6H, m), 4.46 (2H, q, J=7.1Hz), 6.8-7.0 (5H, m), 7.91 (IH, d, J=9.6Hz)<br>
APCI-MASS :  m/z = 413 (M'‘+H) Preparation 96<br>
4-(4-Piperidinopiperidin-l-yl)benzonitrile<br>
IR (KBr) :  2217.7, 1602.6, 1511.9 cm~’<br>
NMR (CDCI3, 6) :  1.35-1.75 (8H, m), 1.92 (2H, d,<br>
J=12.'9Hz), 2.3-2.6 (5H, m) , 2.86 (2H, td, J=12.8 and 2.6Hz), 3.90 (2H, d, J=12.8Hz), 6.84 (2H, d, J=9.1Hz), 7.46 (2H, d, J=9.1Hz)<br>
APCI-MASS :  m/z = 270 (M++H)<br><br>
Preparation 97<br>
5-[4-(4-n-Hexyloxyphenyl)pipera2in-l-yl]picolinonitrile IR (KBr) :  2223.5, 1575.6, 1511.9, 1241.9 cm-’ NMR (CDCI3, 6) :  0.90 (3H, t, J=6.5Hz), 1.2-1.55 (6H, m) , 1.7-1.85 (2H, m), 3.22 (4H, t, J=5.1Hz), 3.52 (4H, t, J=5.1Hz), 3.92 (2H, t, J=6.5H2), 6.86 (2H, d, J=9.4Hz), 6.93 (2H, d, J=9.4Hz), 7.13 (IH, dd, J=8.8 and 3.GHz), 7.53 (IH, d, J=8.8Hz), 8.35 (IH, d, J=3.0Hz) APCI-MASS :  m/z = 365 (M'‘+H)<br><br>
4-[4-(4-Cyclohexylphenyl)pipera2in-l-yl]benzonitrile<br>
IR (KBr) :  2219.7, 1606.4, 1513.8, 1238.1 cm-’<br>
NMR (CDCI3, 6) :  1.1-1.5 (6H, m), 1.65-2.0 (4H, m) ,<br>
2.44 (IH, m), 3.30 (4H, t, J=5.1Hz), 3.46 (4H, t, J=5.1Hz), 6.90 (4H, d, J=8.9Hz), 7.14 (2H, d, J=8.9Hz), 7.52 (2H, d, J=8.9Hz) APCI-MASS :  m/z = 34 6 (M++H)<br>
Preparation 99<br>
4-[4-(4-n-Hexylphenyl)piperazine-l-yl]benzonitrile IR (KBr) :  2925.5, 2850.3, 2213.9, 1604.5, 1513.8,<br>
1234.2, 944.9 cm-’ NMR (CDCI3, 5) :  0.88 (3H, t, J=6.4Hz), 1.2-1.45 (6H, m), 1.45-1.7 (2H, m), 2.54 (2H, t, J=7.6Hz), 3.2-3.4 (4H, m), 3.4-3.6 (4H, m), 6.89 (2H, d, J=8.5Hz), 6.91 (2H, d, J=8.9Hz), 7.11 (2H, d, J=8.5Hz), 7.52 (2H, d, J=8.9H2)<br>
Preparation 100<br>
1-[2-(4-n-Hexylphenylamino)ethyl]-2-oxa2olidone<br>
hydrochloride<br>
IR (KBr) :  2925.5, 2852.2, 1753.0, 1729.8, 1267.0 cm-’ NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.5Hz), 1.1-1.4 (6H,<br><br>
m) , 1.45-1.7 (2H, m), 2.56 (2H, t, J=7.6Hz); 3.3-3.53 (4H, m), 3.57 (2H, t, J=7.9Hz), 4.24 {2H, t, J=7.9Hz), 7.24 (4H, s) APCI-MASS :  m/z = 291 (M’+H)<br>
Preparation 101<br>
4-[4-(4-Phenylcyclohexyl)piperazin-l-yl]benzonitrile IR (KBr) :  2212.0, 1602.6, 1513.8, 1249.6 cm~’ NMR (CDCI3, 5) :  1.3-1.8 (4H, m) , 1.9-2.2 (4H, m),<br>
2.3-2.6 (2H, m), 2.75 (4H, t, J=5.0Hz), 3.34 (4H, t,   J=5.0Hz), 6.86 (2H, d, J=8.9Hz), 7.1-7.4 (5H, m), 7.49 (2H, d, J=8.9Hz) APCI-MASS :  m/z = 34 6 (M'*-+H)<br>
Preparation 102<br>
Methyl 6-[4-(4-hydroxyphenyl)piperazin-l-yl]nicotinate IR (KBr) :  3411, 1691, 1602, 1510, 1432, 1249,<br>
1147 cm~’ NMR (DMSO-dg, 5) :  3.0-3.1 (4H, m) , 3.7-3.9 (7H, m),<br>
6.67 (2H, d, J=8.8Hz), 6.84 (2H, d, J=8.8Hz), 6.93 (IH, d, J=9.1Hz), 7.97 (IH, dd, J=2.4 and 9.1Hz), 8.66 (IH, d, J=2.4Hz), 8.88 (IH, s) APCI-MASS :  m/z = 314 (M+H)-’<br>
Preparation 103<br>
1-n-Decylindole-5-carboxylie acid<br>
IR (KBr) :  2921, 2854, 1679, 1612, 1427, 1313,<br>
1199 cm-’ NMR (DMSO-dg, 5) :  0.84 (3H, t, J=6.8Hz), 1.1-1.3<br>
(14H, m), 1.6-1.8 (2H, m) , 4.19 (2H, t, J=6.9Hz), 6.57 (IH, s), 7.4-7.8 (3H, m), 8.23 (IH, s), 12.40 (IH, -s) APCI-MASS :  m/z = 302 (M+H+)<br>
The following compounds (Preparations 104 to 111) were<br><br>
obtained according to a similar manner to that of Preparation<br>
Preparation 104<br>
(E)-Methyl 4- (4-n-butoxyphenyl)cinematic<br>
IR (KBr) :  2958, 2939, 2873, 1720, 1637, 1498, 1313,<br>
1195, 1170 cm~’ NMR (CDCI3, 6) :  0.98 (3H, t, J=7.3Hz), 1.4-1.8 (4H,<br>
m), 3.81 {3H, s), 4.00 (2H, t, J=6.4Hz), 6.45 (IH, d, J=16.0Hz), 6.97 (2H, d, J=8.7Hz), 7.5-7.7 (6H, m), 7.72 (IH, d, J=16.0Hz) APCI-MASS :  m/z = 311 (M+H’)<br>
Preparation 105<br>
Methyl (E)-3-[4-[4-(4-methylpentyloxy)phenyl]phenyl]-acrylate<br>
IR (KBr) :  2956.3, 2873.4, 1720.2, 1635.3, 1600.6 cm~’ NMR (CDCI3, 5) :  0.93 (6H, d, J=6.5Hz), 1.28-1.50 (2H, m), 1.50-1.95 (3H, m), 3.82 (3H, s), 3.99 (2H, t, J=6.6Hz), 6.44 (IH, d, J=16.0Hz), 6.97 (2H, d, J=8.7Hz), 7.49-7.65 (6H, m), 7.71 (IH, d, J=16Hz) APCI-MASS :  m/z = 339 (M-’+l)<br>
Preparation 106<br>
Methyl (E)-3-[4-[4-(6-fluorohexyloxy)phenyl]phenyl]-<br>
acrylate<br>
NMR (CDCI3, 6) :  1.23-2.00 (8H, m), 3.81 (3H, s), 4.01 (2H, t, J=6.4Hz), 4.47 (2H, dt, J=47.4 and 6.0Hz), 6.45 (IH, d, J=16.0Hz), 6.96 (2H, d, J=8.8Hz), 7.45-7.63 (6H, m), 7.72 (IH, d, J=16.0Hz)<br>
APCI-MASS ':  m/z = 357 (M’+1)<br>
Preparation 107<br>
Methyl (E)-3-[4-[4-(6-methoxyhexyloxy)phenyl]phenyl]-<br><br>
acrylate<br>
APCI-MASS :  m/z = 369 (M-’)<br>
Preparation 108<br>
Methyl (E)-3-[4-[4- (8-methoxyoctyloxy)phenyl]phenyl]-acrylate<br>
IR (KBr) :  2935.1, 2858.0, 1722.1, 1637.3, 1602.6 cm~’ NMR (CDCI3, 5) :  1.30-1.70 (lOH, m), 1.70-1.92 (2H,<br>
m) , 3.33 (3H, s), 3.37 (2H, t, J=6.5Hz), 3.81 (3H, s), 4.00 (2H, t, J=6.5Hz), 6.45 (IH, d, J=16.0Hz), 6.97 (2H, d, J=8.8Hz), 7.46-7.78 (6H, m), 7.72 (IH, d, J=16.0Hz) APCI-MASS :  m/z = 397 (M++1)<br>
Preparation 109<br>
Methyl (E)-3-[4-(4-hydroxyphenyl)phenyl]acrylate<br>
IR (KBr) :  3409.5, 1695.1 cm~’<br>
NMR (DMSO-dg, 5) :  3.73 (3H, s), 6.64 (IH, d, J=16Hz),<br>
6.85 (2H, d, J=8.6Hz), 7.50-7.83 (5H, m) APCI-MASS :  m/z = 255 (M'‘+l)<br>
Preparation 110<br>
Methyl (E)-3-[4-[4-(7-methoxyheptyloxy)phenyl]phenyl]-acrylate<br>
NMR (CDCI3, 5) :  1.32-1.70 (8H, m), 1.70-1.92 (2H, m), 3.34 (3H, s), 3.38 (2H, t, J=6.4Hz), 3.81 (3H, s), 4.00 (2H, t, J=6.5Hz), 6.45 (IH, d, J=16.0Hz), 6.97 (2H, d, J=8.8Hz), 7.47-7.65 (6H, m) , 7.70 (IH, d, J=16Hz) APCI-MASS :  m/z = 383 (M++1)<br>
Preparation 111<br>
Methyl (E)-3-[4’[4- (7-fluoroheptyloxy)phenyl]phenyl]-acrylate<br>
IR (KBr) :  2937.1, 2861.8, 1722.1, 1637,3, 1600.6 cm-’<br><br>
The following compound was obtained according to a similar manner to that of Preparation 20.<br>
Preparation 112<br>
Methyl 3-[4-(4-heptylphenyl)phenylJpropanoate NMR (CDCI3, 5) :  0.88 (3H, t, J=6.5Hz), 1.15-1.50 (8H, m), 1.50-1.77 (2H, m), 2.52-2.73 (4H, m), 2.99 (2H, t, J=7.8Hz), 3.68 (3H, s), 7.18-7.35 (4H, m), 7.40-7.58 (4H, m) APCI-MASS :  m/z = 339 (M++1)<br>
The following compounds (Preparation 113 to 164) were obtained according to a similar manner to that of Preparation<br>
32..<br>
Preparation 113<br>
4-(4-Octylphenyl)-2,4-dihydro-3H-l,2,4-triazol-3-one-2-yl-acetic acid<br>
IR (KBr) :  2923.6, 1704.8, 1224.6 cm~’<br>
NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.7Hz), 1.1-1.4<br>
(lOH, m), 1.4-1.7 (2H, m), 2.60 (2H, t, J=7.2Hz), 4.38 (2H, s), 7.32 (2H, d, J=8.5Hz), 7.58 (2H, d, J=8.5Hz), 8.43 (IH, s)<br>
Preparation 114<br>
1-Kepty1-4-(4-carboxyphenyl)pyrazole<br>
IR (KBr) :  3106, 2917, 1687, 1612, 1425, 1295, 1184,<br>
952, 860, 773 cm-’ NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.8Hz), 1.1-1.4 (8H, m), 1.7-1.9 (2H, m), 4.11 (2H, t, J=7.0Hz), 7.69 (2K, d, J=8.5Hz), 7.91 (2H, d, J=8.5Hz), 7.98 (IH, s), 8-.32 (IH, s), 12.82 (IH, br) APCI-MASS :  m/z = 287 (M+H-’)<br>
Preparation 115<br><br>
6-[4-(4-0ctyloxyphenyl)piperazin-l-yl]nicotinic acid IR (KBr pelet) :  2919, 2854, 1697, 1608, 1515, 1429,<br>
1263, 1245, 1228 cm'‘ NMR (DMSO-dg, 5) : 0.86 (3H, t, J=6.7Hz), 1.1-1.5 (lOH, m), 1.6-1.8 (2H, m), 3.0-3.2 (4H, m), 3.7-3.9 (4H, m) , 3.88 (2H, t, J=6.4Hz), 6.7-7.0 (5H, m), 7.95 (IH, dd, J=9.0 and l.lHz), 8.64 (IH, d, J=l.lHz) APCI-MASS :  m/z = 412 (M+H-*-)<br>
Preparation 116<br>
2-(4-Hexyloxyphenyl)benzoxazole-5-carboxylic acid<br>
IR (KBr) :  2952, 1689, 1677, 1619, 1500, 1415, 1299,<br>
1172, 1024 cm-l NMR (DMSO-dg, 5) :  0.89 (3H, t, J=6.7Hz), 1.2-1.5 (6H, in), 1.7-1.9 (2H, m) , 4.09 (2H, t, J=6.5H2), 7.16 (2H, d, J=8.8Hz), 7.84 (IH, d, J=8.5Hz), 8.01 (IH, dd, J=8.5 and 1.5Hz), 8.15 (2H, d, J=8.8Hz), 8.26 (IH, d, J=1.5Hz) APCI-MASS :  m/z = 340 (M+H-’)<br>
Preparation 117<br>
4-[4-(4-n-Butyloxyphenyl)phenyl]benzoic acid<br>
IR (KBr) :  2958, 2873, 1689, 1600, 1537, 1396 cm-’<br>
Preparation 118<br>
6-(4-Heptyloxyphenyl)nicotinic acid<br>
IR (KBr) :  2858, 1699, 1674, 1589, 1425, 1180, 1016,<br>
781 cin~l<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.7Hz), 1.2-1.5 (8H, m), 1.6-1.8 (2H, m), 4.04 (2H, t, J=6.4Hz), 7.06 (2H, d, J=8.9Hz), 8.03 (IH, d, J=8.2Hz), 8.13 (2H, d, J=8.9Hz), 8.27 (IH, dd, J=8.2 and 2.2Hz), 9.09 (IH, d, J=2.2Hz), 13.31 (IH, br)<br>
APCI-MASS :  m/z = 314 (M+K-’)<br><br>
Preparation 119<br>
5-(4-Octyloxyphenyl)isoxazole-3-carboxylic acid<br>
IR (KBr pelet) :  2923, 2852, 1704, 1612, 1440, 1272,<br>
1178 cm~’ NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.8Hz), 1.2-1.6<br>
(lOH, m), 1.6-1.9 (2H, m), 4.03 (2H, t, J=6.5Hz), 7.08 {2H, d, J=8.9Hz), 7.25 (IH, s), 7.86 (2H, d, J=8.9Hz) APCI-MASS :  m/z = 318 (M+H’)<br><br>
2-(2-Octyloxypyridin-5-yl)benzoxazole-5-carboxylic acid<br>
IR (KBr) :  2954, 2923, 2854, 1697, 1683, 1625, 1488,<br>
1290 cm~-<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=7.6Hz), 1.2-1.5<br>
(lOH, m) , 1.7-1.8 (2H, m), 4.36 (2H, t, J=6.6Hz), 7.04 (IH, d, J=8.7Hz), 7.88 (IH, d, J=8.5Hz), 8.04 (IH, dd, J=8.5 and 1.6Hz), 8.29 (IH, d, J=1.6Hz), 8.43 (IH, dd, J=8.7 and 2.4Hz), 8.99 (IH, d, J=2.4Hz), 13.0-13.2 (IH, br)<br>
APCI-MASS :  m/z = 369 (M+H+)<br>
Preparation 121<br>
2-[4-(4-Hexylphenyl)phenyl]benzoxazole-5-carboxylic acid IR (KBr) :  2923, 2854, 1683, 1411, 1299, 1054   APCI-MASS :  m/z = 4 00 (M+H**-)<br>
Preparation 122<br>
6-[4-(4-n-Butyloxyphenyl)phenyl]nicotinic acid IR (KBr) :  3406, 2958, 1691, 1591, 1394, 1284,<br>
1253      (DMSO-dg,   5)    :      0.94    (3H,   t,   J=7.3Hz),   1.4-1.8    (4H, m),   4.01   (2H,   t,   J=6.4Hz),   7.02   (2H,   d,   J=8.7Hz), 7.57   (2H,   d,   J=8.7Hz),   7.61    (2H,   d,   J=8.2Hz),   7.83 (2H,   d,   J=8.2Hz),    8.05    (IH,   d,   J=8.5Hz),    8.22    (IH,<br><br>
dd, J=8.5 and 1.6Hz), 9.14 (IH, d, J=1.6Hz) APCI-MASS :  m/z = 348 (M+H’)<br>
Preparation 123<br>
4-[4-(5-Phenoxypentyloxy)phenyl]benzoic acid<br>
NMR (DMSO-dg, 6) :  1.5-1.7 (2H, m), 1.7-1.9 (4H, m) ,<br>
3.98 (2H, t, J=6.3Hz), 4.05 (2H, t, J=6.1Hz), 6.8-7.0 (3H, m), 7.05 (2H, d, J=8.6Hz), 7.25 (2H, t, J=8.2Hz), 7.68 (2H, d, J=8.5Hz), 7.75 (2H, d, J=8.2Hz), 7.98 (2H, d, J=8.2Hz), 12.8-13.0 (IH, br s) APCI-MASS :  m/z = 375 (M-H)~<br>
Preparation 124<br>
4-[5-(4-n-Hexyloxyphenyl)-1,3, 4-oxadiazol-2-yl]benzoic acid<br>
IR (KBr) :  2935, 2854, 1685, 1612, 1495, 1425, 1286,<br>
1251 cm-’ NMR (DMSO-dg, 5) :  0.89 (3H, t, J=6.7Hz), 1,2-1.5 (6H, m), 1.6-1.9 (3H, m), 4.12 (2H, t, J=6.4Hz), 7.19 (2H, d, J=8.7Hz), 8.08 {2H, d, J=8.7Hz), 8.18 (2H, d, J=8.4Hz), 8.24 (2H, d, J=8,4Hz) APCI-MASS :  m/z = 367 (M+H) -’<br>
Preparation 125<br>
4-[5-(4-n-Hexyloxyphenyl)-1,3,4-thiadiazol-2-yl]benzoic acid<br>
IR (KBr) :  2952, 2586, 1699, 1604, 1517, 1432, 1251,<br>
1174 cm'l NMR (DMSO-dg, 5) :  0.89 (3H, t, J=6.7Hz), 1.3-1.9 (8H, m), 4.04 (2H, t, J=6.3Hz), 7.13 (2H, d, J=8.8Hz), 7.97 '(2H, d, J=8.8Hz), 8.11 (4H, s) APCI-MASS :  m/z = 383 (M+H) -’<br>
Preparation 126<br><br>
5- {4-Octyloxyphenyl)-l-inethylpyrazole-3-carboxylic acid<br>
IR (KBr pelet) :  2950, 2923, 1695, 1450, 1282, 1251,<br>
956 cm-’<br>
NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.8Hz), 1.2-1.5<br>
(lOH, m), 1.6-1.8 (2H, m), 3.98 (2H, t, J=6.5Hz), 4.10 (3H, s), 6,95 (IH, d, J=8.8Hz), 7.18 (IH, s), 7.73 (2H, d, J=8.8Hz), 13.37 (IH, br)<br>
APCI-MASS :  m/z = 331 (M+H’)<br>
Preparation 127<br>
4-[3-(4-n-Pentyloxyphenyl)pyrazol-5-yl]benzoic acid IR (KBr) :  3224, 2956, 1692, 1614, 1506, 1251 cm-’ NMR (DMSO-dg, 5) :  0.91 (3H, t, J=6.9Hz), 1.3-1.5 (4H, m), 1.6-1.8 (2H, m) , 4.00 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.8Hz), 7.19 (IH, s), 7.75 (2H, d, J=8.8Hz), 7.95 (2H, d, J=8.7Hz), 8.02 (2H, d, J=8.7Hz), 12.8-13.3 (2H, br) APCI-MASS :  m/z = 351 (M+H-*-)<br>
Preparation 128<br>
5-[4-(4-n-Butoxyphenyl)phenyl]furan-2-carboxylic acid IR (KBr) :  2958, 2873, 1679, 1487, 1253, 1166 cm~’ NMR (DMSO-dg, 6) :  0.95 (3H, t, J=7.3Hz), 1.3-1.8 (4H, m), 4.02 (2H, t, J=6.3Hz), 7.03 (2H, d, J=8.6Hz), 7.17 (IH, d, J=3.6Hz), 7.33 (IH, d, J=3.6Hz), 7.66 (2H, d, J=8.6Hz), 7.74 (2H, d, J=8.4Hz), 7.86 (2H, d, J=8.4Hz), 13.1 (IH, br s) APCI-MASS :  m/z = 337 (M+H)+<br>
Preparation 129<br>
3-(S)-Hydroxyhexadecanoic acid IR (KBr) :-  1679.7, 1467.6, 1224.6 cm-’<br>
NMR (CDCI3, 6) : 0.88 (3H, t, J=6.4Hz), 1.1-1.7 (24H, m), 2.35-2.65 (2H, m), 4.03 (IH, m), 5.41 (IH, br s)<br><br>
Preparation 130<br>
6-[4-(4-n-Hexyloxyphenyl)piperazin-l-yl]pyridazine-3-carboxylic acid<br>
IR (KBr) :  1697.1, 1589.1, 1515.8, 1448.3 cin-’ NMR (DMSO-dg, 5) :   0.87 (3H, t, J=6.4H2), 1.2-1.5<br>
(6H, m), 1.6-1.8 (2H, m) , 3.0-3.2 (4H, m) , 3.7-4.0 (6H, m), 6.83 (2H, d, J=9.0Hz), 6.95 (2H, d, J=9.0Hz), 7.36 (IH, d, J=9.6Hz), 7.86 (IH, d, J=9.6Hz), 11.68 (IH, s)<br>
Preparation 131<br>
4-[4-[1-(4-n-Hexyloxyphenyl)piperidin-4-yl]piperazin-l-yl]benzoic acid hydrochloride<br>
IR (KBr) :  1699.0, 1608.3, 1513.8 cm~’<br>
NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.5Hz), 1.2-1.5 (6H, m), 1.6-1.8 (2H, m), 2.0-2.45 (3H, m) , 3.2-3.8 (12H, m) , 3.94 (2H, t, J=6.4H2), 4.03 (2H,, d, J=llHz), 6.95 (2H, d, J=8.7Hz), 7.07 (2H, d, J=8.9Hz), 7.32 (2H, br s), 7.83 (2H, d, J=8.9Hz) APCI-MASS :  ra/z = 466 (M-’+H)<br>
Preparation 132<br>
6-(8-Methoxyoctyloxy)-2-naphthoic acid IR (KBr) :  2937.1, 2854.1, 1677.8, 1211.1 cm'‘ NMR (DMSO-dg, 5) :  1.2-1.6 (lOH, m), 1.7-1.9 (2H, m), 3.20 (3H, s), 3.29 (2H, t, J=6.5Hz), 4.11 (2H, t, J=6.4Hz), 7.23 (IH, dd, J=9.0 and 2.3Hz), 7.39 (IH, d, J=2.3Hz), 7.85 (IH, d, J=8.7Hz), 7.93 (IH, d, J=8.7Hz), 7.99 (IH, d, J=9.0Hz), 8.51 (IH, s), 12.9 (IH, s)<br>
Preparation 133'<br>
Mixture of (E) and (Z)-3-[4-(4-Heptylphenyl)phenyl]-2-butenoic acid<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.6Hz), 1.15-1.50 (8H,<br><br>
m), 1.52-1.75 {2H, m), 2.63 and 3.62 (total 3H, each s), 2.53-2.75 (2H, m), 6.24 and 5,68 (total IH, each s), 7.19-7.35 (2H, m), 7.47-7.70 (6H, m) APCI-MASS :  m/z = 337 (M'‘+1), 351 (methyl ester’+1)<br>
Preparation 134<br>
3-[4-(4-Heptylphenyl)phenyl]propionic acid NMR (CDCI3, 6) :  0.88 (3H, t, J=6.6Hz), 1.13-1.48 (8H, m), 1.48-1.75 (2H, m), 2.52-2.83 (4H, m), 3.00 (2H, t, J=7.8Hz), 7.15-7.35 (4H, m) , 7.40-7.60 (4H, m) APCI-MASS :  m/z = 323 (M-'--l)<br>
Preparation 135<br>
4-(4-n-Heptylphenyl)benzoyl-carboxylic acid NMR (CDCI3, 6) :  0.88 (3H, t, J=6.6Hz), 1.13-1.50 (8H, m), 1.50-1.75 (2H, m), 2.66 (2H, t, J=7.7Hz), 7.20-7.40 (2H, m), 7.50-7.66 (2H, m), 7.66-7.84 (2H, m), 8.40-8.60 (2H, m) APCI-MASS :  m/z = 323 (M+-1)<br>
Preparation 136<br>
6-Hexylnaphthalene-2-carboxylic acid<br>
NMR (CDCI3, 5) :  0.89 (3H, t, J=6.8Hz), 1.15-1.53 (6H, m), 1.55-1.84 (2H, m), 2.80 (2H, t, J=7.6Hz), 7.42 (IH, dd, J=1.7 and 8.4Hz), 7.67 (IH, s), 7.84 (IH, d, J=8.6Hz), 7.90 (IH, d, J=8.4Hz), 8.09 (IH, dd, J=1.7 and 8.6Hz), 8.68 (IH, s) APCI-MASS :  m/z = 257 (M-’+l), 271 (methyl ester'‘ + l)<br>
Preparation 137<br>
3-(E)-[4-[4-(7-Methoxyheptyloxy)phenyl]phenyl]acrylic acid<br>
NMR (DMSO-dg, 5) :  1.20-1.60 (8H, m), 1.60-1.83 (2H, m) , 3.21 (3H, s), 3.25-3.60 (2H, m) , 4.01 (2H, t, J=6.4Hz), 6.54 (IH, d, J=16.0Hz), 7.02 (2H, d.<br><br>
J=8.8Hz), 7.55-7.80 (7H,. its) APCI-MASS :  m/z = 369 (M'‘+l)<br>
Preparation 138<br>
3-(E)-[4-[4-(8-Methoxyoctyloxy)phenyl]phenyl]acrylic acid<br>
IR (KBr) :  3037.3, 2933.2, 2858.0, 2551.4, 1706.7,<br>
1677.8, 1629.6, 1602.6 cm-’ NMR (DMSO-dg, 6) :  1.18-1.55 (lOH, m), 1.65-1.83 (2H, m), 3.18-3.45 (5H, m), 4.01 (2H, t, J=6.5Hz), 6.53 (IH, d, J=16.0Hz), 7.02 (2H, d, J=8.8Hz), 7.50-8.80 (7H, m) APCI-MASS :  m/z = 383 (M’+1)<br>
Preparation 139<br>
3-(E)-[4-[4-(5-Hexenyloxy)phenyl]phenyl]acrylic acid NMR (DMSO-dg, 6) :  1.42-1.63 (2H, m), 1.63-1.85 (2H,<br>
m), 2.00-2.20	{2H, m), 4.03 (2H, t, J=6.3Hz), 4.90-<br>
5.15 (2H, m),	5.68-5.97 (IH, m), 6.54 (IH, d,<br>
J=16Hz), 7.02	(2H, d, J=8.7Hz), 7.50-7.80 (7H, m)<br>
APCI-MASS :  m/z =	323 (M’+1)<br>
Preparation 140<br>
3-(E)-[4-[4-(4-Methylpentyloxy)phenyl]phenyl]acrylic acid<br>
IR (KBr) :  2956.3, 2869.6, 2713.4, 2599.6, 1689.3,<br>
1627.6, 1602.6 cm~’ NMR (DMSO-dg, 5) :  0.89 (6H, d, J=6.5Hz), 1.15-1.43<br>
(2H, m), 1.48-1.90 (3H, m) , 4.00 (2H, t, J=6.7Hz), 6.54 (IH, d, J=16Hz), 7.02 (2H, d, J=8.7Hz), 7.50-7.90 (7H, m) APCI-MASS :  m/z = 325 (M++1)<br>
Preparation 141<br>
3-(E)-[4-[4-(6-Fluorohexyloxy)phenyl]phenyl]acrylic acid<br><br>
NMR (CDCI3, 6) :  1.39-2.00 (8H, m), 4.01 (2H, t,<br>
J=6.5Hz), 4.47 (2H, dt, J=47.3 and 6.0Hz), 6.49 (IH, d, J=15.9Hz), 6.98 (2H, d, J=8.7Hz), 7.40-7.70 (6H, m), 7.81 (IH, d, J=15.9Hz)<br>
APCI-MASS :  m/z = 343 (M'‘ + 1)<br>
Preparation 142<br>
3-(E)-[4-[4-(6-Methoxyhexyloxy)phenyl]phenyl]acrylic acid<br>
NMR (DMSO-dg, 5) :  1.22-1.63 (6H, m), 1.63-1.88 (2H, m), 3.21 (3H, s), 3.22-3.40 (2H, m), 4.00 (2H, t, J=6.5Hz), 6.54 (IH, d, J=15.8Hz), 7.02 (2H, d, J=8.7Hz), 7.50-7.84 (7H, m) APCI-MASS :  m/z = 369 (methyl ester, M-*-+l)<br>
Preparation 143<br>
4-[4-[8-(Tetrahydropyran-2-yl-oxy)octyloxy]phenyl]benzoic acid<br>
IR (KBr) :  2935, 1697, 1683, 1604, 1303, 1290,<br>
1197 cm~’ NMR (DMSO-dg, 5) :  1.2-1.8 (18H, m), 3.3-3.9 (4H, m), 4.01 (2H, t, J=6.3Hz), 4.5-4.6 (IH, m), 7.03 (2H, d, J=8.7H2), 7.67 (2K, d, J=8.7Hz), 7.74 (2H, d, J=8.3Hz), 7.98 (2H, d, J=B.3Hz) APCI-MASS :  m/z = 425 (M-H-*-)<br>
Preparation 144<br>
4-[3-(4-n-Hexyloxyphenyl)pyrazol-5-yl]benzoic acid IR (KBr) :  2956, 2935, 1693, 1614, 1508, 1432, 1251,<br>
1178 cm~l I’R (DMSO-dg, 5) :  0.89 (3H, t, J=6.4H2), 1.2-1.5 (6H, m), 1.6-1.8 (2H, m), 4.00 (2H, t, J=6.4Hz), 7.02 (2H, d, J=8.7Hz), 7.12 (IH, s), 7.74 (2H, d, J=8.7Hz), 7.95 (2H, d, J=8.8Hz), 8.01 (2H, d, J=8.8Hz), 13.17 (IH, s)<br><br>
APCI-MASS :  m/z = 365 (M+H'*')<br>
Preparation 145<br>
4-[4-[4-{6-Methoxyhexyloxy)phenyl]phenyl]benzoic acid IR (KBr) :  2939, 2861, 1685, 1602, 1430, 1286,<br>
1128 cm-’ NMR (DMSO-dg, 6) :  1.3-1.8 (8H, m), 3.21 (3H, s),<br>
3.3-3.4 (2H, m), 4.01 (2H, t, J=6.5Hz), 7.04 (2H, d, J=8.6Hz), 7.66 (2H, d, J=8.6Hz), 7.7-7.9 (6H, m), 8.03 (2H, d, J=8.2Hz) APCI-MASS :  m/z = 405 (M+H+)<br><br>
4-[5-[4-(8-Methoxyoctyloxy)phenyl]-1,3,4-thiadia2ol-2-<br>
yl]benzoic acid<br>
IR (KBr) :  2931, 2854, 1691, 1602, 1251 cm~l<br>
NMR (DMSO-dg, 6) :  1.2-2.0 (12H, in), 3.20 (3H, s) ,<br>
3.29 (2H, t, J=6.4Hz), 4.04 (2H, t, J=6.4Hz), 7.13 (2H, t, J=8.8Hz), 7.9-8.2 (6H, m) , 13.95 (IH, br) APCI-MASS :  m/z = 441 (M+H-’)<br>
Preparation 147<br>
4-(4-n-Butoxyphenyl)cinnamon acid<br>
IR (KBr) :  2958, 2871, 1695, 1625, 1498, 1249 cm~’<br>
NMR (DMSO-dg, 5) :  0.94 (3H, t, J=7.3Hz), 1.44 (2H, to, J=7.0 and 7.3Hz), 1.71 (2H, tt, J=7.0 and 6.4Hz), 4.01 (2H, t, J=6.4Hz), 6.54 (IH, d, J=16.0Hz), 7.02 (2H, d, J=8.7Hz), 7.6-7.9 (7H, m)<br>
APCI-MASS   :     m/z  =   297   (M+H-’)<br>
Preparation   148<br>
4-[5-(4-Cyclohexylphenyl)-1,3,4-thiadiazol-2-yl]benzoic<br>
acid<br>
IR (KBr) :  2925, 2850, 1683, 1429, 1292 cm~’<br>
NMR (DMSO-dg, 5) :  1.1-1.5 (5H, m), 1.6-2.0 (5H, m) ,<br><br>
2.4-2.6 (IH, m), 7.45 (2H, d, J=8.3Hz), 7.96 (2H, d, J=8.3Hz), 8.13 (4H, s) APCI-MASS :  m/z = 365 (M+H)-’<br>
Preparation 149<br>
4-[5-[4-(Piperidin-1-yl)phenyl]-1,3,4-thiadiazol-2-yl]-benzoic acid<br>
IR (KBr) :  2931, 2854, 1685, 1604, 1415, 1238 cm~’ NMR (DMSO-dg, 6) :  1.61 (6H, s), 3.31 (4H, s), 7.05<br>
(2H, d, J=9.0Hz), 7.83 (2H, d, J=9.0Hz), 8.10 (4H, s) APCI-MASS :  m/z = 366 (M+H)-’<br>
Preparation 150<br>
4-[5-[4-[4-n-Propyloxyphenyl)phenyl]-1,3,4-oxadiazol-2-yl]benzoic acid<br>
IR (KBr) :  2939, 1689, 1606, 1488, 1429, 1290 cm-’ NMR (DMSO-dg, 5) :  1.00 (3H, t, J=7.3Hz), 1.76 (2H,<br>
tq, J=6.5 and 7.3Hz), 4.00 (2H, t, J=6.5Hz), 7.07 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.5Hz), 7.78 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.5Hz), 8.0-8.4 (4H, m) APCI-MASS :  m/z = 401 (M+H)+<br>
Preparation 151<br>
4-(5-n-Nonyl-l,3,4-oxadiazol-2-yl)benzoic acid<br>
IR (KBr) :  2919, 2852, 1685, 1565, 1430, 1284 cm-l<br>
NMR (DMSO-dg, 5) :  0.84 (3H, t, J=6.5Hz), 1.2-1.5<br>
(12H, m), 1.7-1.9 (2H, m), 2.94 (2H, t, J=7.4Hz), 8.0-8.2 (4H, m), 13.35 (IH, s) APCI-MASS :  m/z = 317 (M+H-*-)<br>
Preparation 152<br>
4-[3-(4-n-Hexyloxyphenyl)-1,2,4-oxadiazol-5-yl]benzoic acid<br>
IR (KBr) :  2942, 2869, 1695, 1421, 1251 cm~l<br><br>
NMR (DMSO-dg, 6) :  0.89 (3H, t, LJ=b.bH2), 1.2-1.8 (8H, m), 4.06 (2H, t, J=6.5H2), 7.13 (2H, d, J=8.9H2), 8.03 (2H, d, J=8.9H2), 8.17 (2H, d, J=8.5Hz), 8.28 (2H, d, J=8.5Hz)<br>
APCI-MASS :  m/z = 367 (M+H) -’<br><br>
A-[A-[A-(5-Methoxypentyloxy)phenyl]phenyl]phenylacetic acid<br>
IR (KBr) :  2939, 2861, 1699, 1253, 1182, 1124 cm-l NMR (DMSO-dg, 6) :  1.4-1.9 (6H, m), 3.22 (3H, s), 3.39 (2H, t, J=6.2H2), 3.61 (2H, s), 4.01 (2H, t, J=6.4Hz), 7.02 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 7.6-7.8 (8H, m) APCI-MASS :  m/z = 405 (M+H-’)<br>
Preparation 154<br>
4-[5-(4-n-Octyloxyphenyl)-1,3,4-thiadiazol-2-yl]benzoic acid<br>
IR (KBr) :  2921, 2856, 1691, 1432, 1251 cm~-<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.7Hz), 1.2-1.5<br>
(lOH, m), 1.7-1.9 (2H, m), 4.07 (2H, t, J=6.5Hz), 7.13 (2H, d, J=8.9Hz), 7.97 {2H, d, J=8.9Hz), 8.12 (4H, s) APCI-MASS :  m/z = 411 (M+H-*-)<br>
Preparation 155<br>
4-[5-(4-Trans-n-pentylcyclohexyl)-1,3,4-thiadiazol-2-yljbenzoic acid<br>
IR (KBr) :  2919, 2848, 1677, 1430, 1294 cm~-<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.9Hz), 1.0-1.4<br>
(HH; m) , 1.5-1.6 (2H, m) , 1.8-2.0 (2H, m) , 2.1-2.3 (2H, m), 3.1-3.3 (IH, m), 8.07 (4H, s) APCI-MASS :  m/z = 359 (M+H-’)<br><br>
Preparation 156<br>
4-[3-(4-n-Pentyloxyphenyl)isoxazol-5-yl]benzoic acid<br>
IR (KBr) :  2925, 2869, 1699, 1687, 1612, 1432, 1251,<br>
1178 cm-’<br>
NMR (DMSO-dg, 5) :  0.91 (3H, t, J=6.9Hz), 1.2-1.5 (4H, m), 1.7-1.9 (2H, m), 4.04 (2H, t, J=6.5Hz), 7.09 (2H, d, J=8.8Hz), 7.69 (IH, s), 7.85 (2H, d, J=8.8Hz), 8.01 (2H, d, J=8.5Hz), 8.11 (2H, d, J=8.5Hz)<br>
APCI-MASS :  m/z = 352 (M+H-’)<br>
Preparation 157<br>
4-[5-[4-(8-Methoxyoctyloxy)phenyl]-l, 3, 4-oxadiazol-2-yl]benzoic acid<br>
IR (KBr) :  2967, 2937, 2877, 1687, 1290 cni-’ NMR (DMSO-dg, 5) :  1.2-1.6 (lOH, m), 1.7-1.9 (2H, m), 3.20 (3H, s), 3.29 (2H, t, J=6.4Hz), 4.08 (2H, t, J=6.5Hz), 7.17 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.9Hz), 8.15 (2H, d, J=8.6Hz), 8.24 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 425 (M+H) -’<br>
Preparation 158<br>
4-[4-(6-Phenylpyridazin-3-yl-oxy)phenyl]benzoic acid IR (KBr) :  1700, 1687, 1608, 1427, 1284, 1186 cm~’ NMR (DMSO-dg, 5) :  7.40 (2H, d, J=8,6Hz), 7.5-7.7 (4H, m), 7.7-7.9 (4H, m), 7.9-8.1 (4H, m), 8.35 (IH, d, J=9.2Hz), 12.99 (IH, br s) APCI-MASS :  m/z = 369 (M+H)+<br>
Preparation 159<br>
4-[5-(4-n-Octyloxyphenyl)-1,3,4-oxadiazol-2-yl]benzoic acid<br>
IR (KBr) :  2921, 2852, 1685, 1612, 1496, 1425, 1288,<br>
1251 cm--<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Preparation 254<br>
1-[4-[5-[4-(4-n-Propyloxyphenyl)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]benzotriazole 3-oxide IR (KBr) :  1774, 1600, 1234, 985 cm~’<br>
NMR (CDCI3, 5) :  1.07 (3H, t, J=7.3Hz), 1.85 (2H, tq, J=6.5 and 7.3Hz), 3.99 (2H, t, J=6.5Hz), 7.01 (2H, d, J=8.7Hz), 7.4-7.7 (5H, m), 7.72 (2H, d, J=8.7Hz), 8.1-8.2 (2H, m), 8.28 (2H, d, J=8.6Hz), 8.44 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 534 (M+H)-’<br>
The following compounds (Preparations 255 to 256) were obtained according to a similar manner to that of Preparation<br>
32.<br><br>
6-Heptylnaphthalene-2-carboxylic acid<br>
NMR (CDCI3, 6) :  0.88 (3H, t, J=6.6Hz), 1.15-1.53 (8H, m) , 1.58-1.88 (2H, m), 2.80 (2H, t, J=7.6Hz), 7.42 (IH, dd, J=1.7 and 8.4Hz), 7.67 (IH, s), 7.84 (IH, d, J=8.6Hz), 7.90 (IH, d, J=8.4Hz), 8.09 (IH, dd, J=1.7 and 8.6Hz), 8.68 (IH, s)<br>
APCI-MASS :  m/z = 271 (M'‘+l) , 285 (methyl ester+-l)<br>
Preparation 256<br>
3- (E)-[4-[4-(7-Fluoroheptyloxy)phenyl]phenyl]acrylic acid<br>
IR (KBr) :  3037.3, 2935.1, 2861.8, 1679.7, 1633.4,<br>
1600.6 cm--NMR (DMSO-dg, 5) :  1.30-1.85 (lOH, m), 4.01 (2H, t, J=6.4Hz), 4.44 (2H, dt, J=47.6 and 6.1Hz), 6.54 (IH,-d, J=15.9Hz), 7.02 (2H, d, J=8.7Hz), 7.53-7.80 (7H, m)<br>
Preparation 257<br><br>
To a solution of 4-methylpentanol (3.0 ml) in pyridine (20 ml) were added in turn with p-toluenesulfonic chloride (4.6 g) and 4-N,N-dimethylaminopyridine (1.5 g) at ambient Temperature.  After stirring at ambient temperature, the reaction mixture was taken up into a mixture of ethyl acetate (100 ml) and water (100 ml).  The separated organic layer was washed in turn with hydrochloric acid(IN), water, aqueous sodium hydrogencarbonate, and brine, and dried over magnesium sulfate.  Evaporation gave 1-p-Toluenesulfonyloxy-4-methylpentane (5.30 g).<br>
NMR (CDCI3, 5) :  0.83 (6H, d, J=6.6Hz), 1.48 (IH,<br>
step, J=6.6Hz), 1.50-1.70 (2H, m), 2.45 (3H, s), 4.00 (2H, t, J=6.6H2), 7.34 (2H, d, J=8.1H2), 7.79 (2H, d, J=8.1Hz) APCI-MASS :  m/z = 257 (M’+1)<br>
Preparation 258<br>
To a solution of 4-bromo-4'-n-butyloxybiphenyl (3.05 g) in tetrahydrofuran (60 ml) was added 1.55M n-butyl lithium in n-hexane (7.74 ml) at -60°C over a period of 10 minutes.  The solution was stirred at -30’*0 for 1.5 hours and cooled to -60°C-  To the solution was added triisopropylborate (3.46 ml) over a period of 5 minutes, and the mixture was stirred for 1.5 hours without cooling.  To the solution was added IN hydrochloric acid (20 ml) and the solution was stirred for 30 minutes and extracted with ethyl acetate.  The organic layer was separated and washed with water, brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure and the residue was triturated with n-hexane.  The solid was collected by filtration and dried under reduced pressure to give 4-(4-n-Butyloxyphenyl)phenylboronic acid (2.31 g).<br>
IR (KBr) :  3398, 2956, 2919, 2871, 1604, 1531, 1392,<br>
1257 cm-l<br>
NMR (DMSO-dg, 5) :  0.94 (3H, t, J=7.3Hz), 1.4-1.8 (4H,<br><br>
m) , 4.01 (2H, t, J=6.3H2), 7.01 (2H, d, J=8.7Hz), 7.58 (2H, d, J=7.9Hz), 7.62 (2H, d, J=8.7Hz), 7.84 (2H, d, J=7.9Hz), 8.03 {2H, s)<br>
The following compounds (Preparations 259 to 260) were obtained according to a similar manner to that of Preparation 258.<br>
Preparation 259<br>
4-[4-{6-Methoxyhexyloxy)phenyl]phenylboronic acid<br>
IR (KBr) :  3448, 3392, 2937, 2861, 1606, 1529, 1346,<br>
1288 cm~’ NMR (DMSO-dg, 6) :  1.3-1.8 (8H, m), 3.21 (3H, s), 3.31 (2H, t, J=6.3Hz), 3.99 {2H, t, J=6.4H2), 7.00 (2H, d, J=8.7H2), 7.5-7.7 {4H, m), 7.84 (2H, d, J=8.1Hz), 8.03 (2H, s) APCI-MASS :  m/z = 329 (M+H+)<br>
Preparation 260<br>
4-[4-(5-Methoxypentyloxy)phenyl]phenylboronic acid IR (KBr) :  3473, 3369, 3330, 2935, 2863, 1604, 1531,<br>
1338, 1251 cm~’ NMR (DMSO-dg, 5) :  1.4-1.8 (6H, m), 3.22 (3H, s), 3.3-3.4 (2H, m), 3.99 (2H, ,t, J=6.4H2), 7.00 (2H, d, J=8.7Hz), 7.58 (2H, d, J=8.0Hz), 7.61 (2H, d, J=8.7Hz), 7.84 (2H, d, J=8.0Hz), 8.04 (2H, s) APCI-MASS :  m/z = 315 (M+H-’)<br><br>
To a suspension of 4-Methoxycarbonylphenyl boronic acid (648 mg) and 4-iodo-l-heptylpyrazole (876 mg) and Pd(PPh3)4 (173 mg) in 1,2-dimethoxyethane (10 ml) was added 2M Na2C03 aq. (3.6 ml).  The reaction mixture was stirred at 80°C for 2 hours under N2 atmosphere, and poured into ice-water and extracted with ethyl acetate.  The organic layer was washed<br><br>
with brine, and dried over MgSO’.  The solvent was removed under pressure.  The residue was subjected to cilium-chromatography on silica gel 60 (Merk) and eluted with n-hexane/ethyl acetate (80:20).  The fractions containing the object compound were combined and evaporated under reduced<br>
pressure to give l-heptyl-4-(4-methoxycarbonylphenyl)pyra2ole (0.20 g).<br>
IR (KBr pelet) :  2952, 2920, 2848, 1712, 1610, 1288,<br>
1114, 769 cm~l NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.7Hz), 1.1-1.4 (8H, m), 1.7-1.9 {2H, m), 3.85 (3H, s), 4.11 (2H, t, J=7.0H2), 7.72 (2H, d, J=8.5H2), 7.93 (2H, d, J=8.5Hz), 7.99 (IH, s), 8.34 (IH, s) APCI-MASS :  m/z = 301 (M+H-’)<br>
The following compounds (Preparations 2 62 to 2 68) were obtained according to a similar manner to that of Preparation 261.<br>
Preparation 262<br>
Ethyl 4-[4- (4-n-butyloxyphenyl)phenyl]benzoate<br>
IR (KBr) :  2958, 2935, 2871, 1714, 1602, 1396, 1280,<br>
1108 cm~l<br>
NMR (CDCI3, 5) :  0.99 (3H, t, J=7.3Hz), 1.4-2.0 (7H, m), 4.02 (2H, t, J=6.4Hz), 4.40 (2H, q, J=7.1Hz), 6.98 (2H, d, J=6.8Hz), 7.56 (2H, d, J=6.8Hz), 7.66 (4H, s), 7.68 (2H, d, J=8.4Hz), 8.12 (2H, d, J=8.4Hz)<br>
APCI-MASS :  m/z = 375 (M+H)-’<br>
Preparation 263<br>
Methyl 6- (-4-heptyloxyphenyl) nicotinate<br>
IR (KBr) :  2954, 2859, 1724, 1597, 1288, 1251, 1116,<br>
783 cm~’ NMR (CDCI3, 5) :  0.90 (3H, t, J=6.6Hz), 1.2-1.5 (8H,<br><br>
m), 1.7-1.9 (2H, m), 3.96 {3H, s), 4.03 (2H, t, J=6.5H2), 7.00 (2H, d, J=8.8Hz), 7.75 (IH, d, J=8.4H2), 8.02 (IH, d, J=8.8Hz), 8.30 (IH, dd, J=8.4 and 2.2H2), 9.23 (IH, d, J=2.2H2) APCI-MASS :  m/z = 328 (M+H+)<br>
Preparation 264<br>
Methyl 6-[4-(4-n-butyloxyphenyl)phenyl]nicotinate<br>
IR (KBr) :  2956, 2933, 2871, 1724, 1598, 1282,<br>
1118 cm~’<br>
NMR (CDCI3, 5) :  1.00 (3H, t, J=7.3H2), 1.4-1.9 (4H,<br>
m), 3.98 (3H, s), 4.02 (2H, t, J=6.4Hz), 7.00 (2H, d, J=8.8H2), 7.59 (2H, d, J=8.8H2), 7.70 (2H, d, J=8.5H2), 7.86 (IH, d, J=8.8H2), 8.13 (2H, d, J=8.5Hz), 8.37 (IH, dd, J=8.8 and 1.6Hz), 9.30 (IH, d, J=1.6H2)<br>
APCI-MASS :  m/z = 362 (M+H+)<br>
Preparation 265<br>
Methyl 5-[4-(4-n-butyloxyphenyl)phenyl]furan 2-carboxylate<br>
IR (KBr) :  2958, 2933, 2873, 1716, 1483, 1303,<br>
1139 cm-’ NMR (CDCI3, 5) : 0.99 (3H, t, J=7.3Hz), 1.5-1.9 (4H,<br>
m), 3.93 (3H, s), 4.01 (2H, t, J=6.4Hz), 6.75 (IH, d, J=3.6Hz), 6.98 (2H, d, J=8.7H2), 7.26 (IH, d, J=3.6Hz), 7.56 (2H, d, J=8.4Hz), 7.61 (2H, d, J=8.7Hz), 7.83 (2H, d, J=8.4Hz) APCI-MASS :  m/z = 351 (M+H)+<br>
Preparation 266<br>
Ethyl 4-[4-[4-(6-methoxyhexyloxy)phenyl]phenyl]ben2oate IR (KBr) :  2937, 2863, 1712, 1602, 1396, 1278,<br>
1108 cm-’ MMR (CDCI3, 5) :  1.4-2.0 (IIH, m) , 3.34 (3H, s), 3.39<br><br>
(2H, t, J=6.4H2),	4.01 (2H, t,   J=6.4Hz), 4.41 (2H,<br>
q, J=7.1Hz), 6.98	(2H, d, J=8.7H2), 7.56 {2H, d,<br>
J=8.7Hz), 7.6-7.8	(6H, m), 8.12 (2H, d, J=8.4H2)<br>
APCI-MASS :  m/z = 433	(M+H-’)<br><br>
4-[4-[4-(5-Methoxypentyloxy)phenyl]phenyl]benzoic acid IR (KBr) :  2939, 2859, 1679, 1587, 1396, 1321, 1292,<br>
112 6 cm-’ NMR (DMSO-dg, 5) :  1.3-1.8 (6H, m), 3.21 (3H, s), 3.2-3.4 (2H, m), 4.01 (2H, t, J=6.5Hz), 7.04 (2H, d, J=8.6Hz), 7.66 (2H, d, J=8.6Hz), 7.7-7.9 (6H, m), 8.03 (2H, d, J=8.2Hz) APCI-MASS :  m/z = 391 (M+H’)<br>
Preparation 268<br>
Methyl 4-[4-[4-{5-methoxypentyloxy)phenyl]phenyl]phenyl acetate<br>
IR (KBr) : 2937, 2863, 1739, 1604, 1492, 1255 cm-’ NMR (CDCI3, 5) :  1.5-2.0 (6H, m), 3.34 (3H, s), 3.42<br>
(2H, t, J=6.3Hz), 3.68 (2H, s), 3.72 (3H, s), 4.02 (2H, t, J=6.4Hz), 6.97 (2H, d, J=8.7Hz), 7.36 (2H, d, J=8.2H2), 7.5-7.7 (8H, m) APCI-MASS :  m/z = 419 (M+H’)<br>
Preparation 269<br>
A solution of 3-[2-(4-Hexylphenylamino)ethyl]-2-0x0-oxazolidine hydrochloride (2.131 g) in 25% hydrobromic acid in acetic acid (13.04 ml) was stirred for 96 hours at ambient temperature.  The reaction mixture was pulverized with isopropyl ether.  The precipitate was collected by filtration and added to ethanol (15 ml).  The solution was refluxed for 5 hours and pulverized with isopropyl ether. The precipitate was collected by filtration to give l-(4-n-Hexylphenyl)piperazine di hydrobromide (2.413 g).<br><br>
IR {KBr) :  2921.6, 2711.4, 2485.8, 1452.1, 1012.4 cm-’ NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.6H2), 1.1-1.4 (6H, m), 1.4-1.6 (2H, m), 2.49 (2H, t, J=8.4H2), 3.1-3.4 (8H, m), 6.54 {2H, s), 6.90 (2H, d, J=8.7Hz), 7.08 (2H, d, J=8.7Hz), 8.78 (IH, s) APCI-MASS :  m/z = 247 (M'‘+H)<br>
The following compounds (Preparations 270 to 274) were obtained according to a similar manner to that of Preparation 269.<br><br>
4-[4-(4-n-Hexylphenyl)pipera2in-l-yl]benzoic acid di hydrobromide<br>
IR (KBr) :  2956.3, 1691.3, 1664.3, 1602.6, 1232.3 cm~’<br>
NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.5H2), 1.2-1.4<br>
(lOH, m), 1.4-1.6 (2H, m), 2.51 (2H, t, J=7.4Hz), 3.2-3.6 (8H, m), 7.0-7.2 (6H, m), 7.81 (2H, d, J=8.8Hz)<br>
APCI-MASS :  m/z = 367 (M-'-+H)<br>
Preparation 271<br>
1-(4-Cyclohexylphenyl)piperazine di hydrobromide<br>
IR (KBr) :  2927,4, 1510.0, 1452.1 cm-’<br>
NMR (DMSO-dg, 5) :  1.1-1.5 (6H, m), 1.6-1.9 (4H, m), 2.41 (IH, m), 3.1-3.4 (8H, m), 6.91 (2H, d, J=8.7Hz), 7.11 (2H, d, J=8.7Hz), 8.78 (IH, s)<br>
APCI-MASS :  m/z = 245 (M-’+H)<br>
Preparation 272<br>
4-[4-(4-Cyclohexylphenyl)piperazin-l-yl]benzoic acid di hydrobromide<br>
IR (KBr) :  1668.1, 1602.6, 1230.4, 1189.9 cm-’<br>
APCI-MASS :  m/z = 365 (M'‘+H)<br><br>
Preparation  273<br>
3-Fluoro-4-[4-(4-hydroxyphenyl)piperazin-l-  acid di hydrobromide<br>
IR   (KBr)    :      1708.6,   1610.3  cm-’<br>
NMR   (DMSO-dg,   6)    :      3.2-3.6   (8H,   m),   6.81   (2H,   d,<br>
J=8.6Hz), 7.0-7.4 (3H, m) , 7.4-7.8 (2H, m) APCI-MASS :  m/z = 317 (M-’+H)<br>
Preparation 274<br>
4-[4-(4-Hydroxyphenyl)piperazin-1-ylJbenzoic acid di hydrobromide<br>
IR (KBr) :  1670.1, 1604,5, 1226.5, 775.2 cm-’<br>
NMR (DMSO-dg, 5) :  3.0-3.2 (4H, m), 3.3-3.5 (4H, m) ,<br>
6.68 (2H, d, J=8.8Hz), 6.85 (2H, d, J=8.8Hz), 7.02 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.8Hz), 8.86 (IH, s), 12.29 (IH, s) APCI-MASS :  m/z = 299 (M+H+)<br>
Preparation 275<br>
A mixture of 4-n-hexyloxyaniline (10 g), ethyl acrylate (56.1 ml), glacial acetic acid (19.25 ml), and cuprous chloride (1.02 g) was heated under reflux with stirring under nitrogen for 26 hours.  A solution of the cold product in ether was shaken with water and then with aqueous ammonia. The organic layer was taken and dried over magnesium sulfate. The magnesium sulfate was filtered off, and filtrate was evaporated under reduced pressure.  The residue was subjected to column chromatography on silica gel and eluted with hexane - ethyl acetate (9:1).  The fractions containing the object compound were combined and evaporated under reduced pressure to give Ethyl 3-[N’(2-ethoxycarbonylethyl)-N-(4-hexyloxyphenyD'amino]propionate (15.756 g).<br>
IR (Neat) :  1733.7, 1513.8, 1241.9, 1182.2 cm-’ NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5Hz), 1.2-1.55 (6H, m) , 1.24 (6H, t, J=7,lHz), 1.65-1.85 {2H, m), 2.51<br><br>
(4H, t, J=7.2Hz), 3.53 (4H, t, J=7.2H2), 3,89 (2H, t,   J=6.5H2), 4*12 (4H, q, J=7.1H2), 6.72 (2H, d, J=9.3H2), 6.83 (2H, d, J=9.3H2) APCI-MASS :  m/z = 394 (M'‘+H)<br><br>
A suspension of methyl 4-formylben2oate (4.92 g),<br>
hydroxylamine hydrochloride (5.21 g) and sodium acetate (6.15 g) in ethanol (50 ml) was refluxed for 2 hours.  The mixture was poured into water and extracted with ethyl acetate and the separated organic layer was washed with brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure to give 4-methoxycarbonyl-benzaldehyde oxime (5.28 g).<br>
IR (KBr) :  3291, 1727, 1438, 1284, 1112 cm-’ NMR (CDCI3, 5) :  3.93 (3H, s), 7.65 (2H, d, J=8.3Hz), 8.10 (2H, d, J=8.3Hz), 8.18 (IH, s),.8.27 (IH, s) APCI-MASS :  m/z = 180<br>
The following compound was obtained according to a similar manner to that of Preparation 276.<br>
Preparation 277<br>
N-Hydroxy-4-n-hexyloxybenzamidine<br>
IR (KBr) :  3446, 3349, 2937, 2865, 1650, 1610, 1519,<br>
1392, 1253 cm-’ NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.4Hz), 1.2-1.8 (8H, m) , 3.97 (2H, t, J=6.5H2), 5.70 (2H, s), 6,90 (2H, d, J=8.4Hz), 7.58 (2H, d, J=8,4Hz), 9.43 (IH, s) APCI-MASS :  m/z = 237 (M+H)’<br>
Preparation 278 '<br>
To a solution of 4-methoxycarbonylbenzaldehyde oxime (896 mg) in N,N-dimethylformamide (10 ml) was added 4N-hydrochloride acid in 1,4-dioxane (1.38 ml) and Oxone ‘ (1.69<br><br>
g).  The suspension was stirred at ambient temperature for 16 hours and poured into ice-water.  The object compound was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate.  The solvents were removed under reduced pressure to give 4-Methoxycarbonylbenzaldehyde oxime chloride (1.05 g).<br>
IR (KBr) :  3390, 1710, 1436, 1405, 1284, 1232, 1116,<br>
1016 cRNA-’<br>
NMR (CDCI3, 5) :  3.95 (3H, s), 8.93 (2H, d, J=8.3Hz), 8.10 (2H, d, J=8.7Hz), 8.39 (IH, s)<br>
APCI-MASS :  m/z = 176 (M-H’-HCl)<br>
Preparation 279<br>
A solution of Ethyl 4-oxo-l-(4-n-hexyloxyphenyl)piperidine-3-carboxylate (1.437 g) in 20% hydrochloric acid (7.2 ml) was refluxed for 2 hours, cooled, basified with 60% aqueous sodium hydroxide, and extracted with ethyl acetate.  The organic layer was taken and dried over magnesium sulfate.  The magnesitim sulfate was filtered off, and filtrate was evaporated under reduced pressure to give 1-(4-n-Hexyloxyphenyl)-4-piperidone (0.959 g) .<br>
IR (Neat) :  2931.3, 1716.3, 1511.9, 1243.9, 825.4 cm~’<br>
NMR (CDCI3, 5) :  0.90 (3H, t, J-6.5Hz), 1.2-1.6 (6H,<br>
m), 1.65-1.85 (2H, m), 2.57 (4H, t, J=6.1Hz), 3.46 (4H, t, J=6.1Hz), 3.92 (2H, t, J=6.5Hz), 6.85 {2H, d, J=9,3Hz), 6.95 (2H, d, J=9.3Hz)<br>
APCI-MASS :  m/z = 276 (M'‘+H)<br>
Preparation 280<br>
A solution of 4-[4-(7-Bromoheptyloxy)phenyl]bromobenzene (0.25 g) in a solution of tetra n-butyl ammonium fluoride (tetrahydrofuran solution, IM, 2.9 ml) was heated to 50°C for 2 hours.  After cooling to ambient temperature, the solution was taken up into a mixture of ethyl acetate (20 ml) and water (20 ml).  The separated organic layer was washed with<br><br>
- /<br>
v-.. . ‘   L_<br>
-.zinc  of 4- [4- (8-Bromooctyloxy) phenyl] bromobenzene :; a mixture of sodium methoxide (4.9M in methanol, ,K-dimethylformamide (20 ml) and tetrahydrofuran (8 ea-ed ro BO'‘C for 3 hours.  The reaction mixture was inn’s a mixture of ethyl acetate (200 ml) and water<br>
The separated organic layer was washed in turn r, brine, dried over magnesium sulfate.  Evaporation .value which was subjected to column chromatography e: , 20'0 ml) eluting with n-hexane to give 4-[4-(8-ry’oxyjphenyl]bromobenzene (2.73 g). K2tr;  :  2935.1, 2858.0, 1604.5 cm-’ :2:2:'., 6) :  1.25-1.70 (lOH, m) , 1.70-1.95 (2H,<br><br>
m), 3.33 (3H, s),   3.37 (2H, t, J=6.5Hz), 3.99 (2H, t, J=6.5Hz), 6.95 (2H, d, J=8.8Hz), 7.35-7.66 (6H, m) APCI-MASS :  m/z = 391 (M’)<br>
The following compounds (Preparations 283 to 284) were obtained according to a similar manner to that of Preparation<br>
282.<br>
Preparation 283<br>
4-[4-(6-Methoxyhexyloxy)phenyl]bromobenzene NMR (CDCI3, 6) :  1.50-1.70 (6H, m), 1.70-1.95 {2H, m), 3.34 (3H, s), 3.40 (2H, t, J=6.2Hz), 3.99 (2H, t, J=6.5Hz), 6.95 (2H, d, J=8.7Hz), 7.30-7.60 (6H, m) APCI-MASS :  m/z = 365 (M'‘+2)<br>
Preparation 284<br>
4-[4-(7-Methoxyheptyloxy)phenyl]bromobenzene<br>
IR (KBr) :  2935.1, 2854.1, 1604.5 cm~l<br>
NMR (CDCI3, 5) :  1.25-1.70 (8H, m), 1.70.1.95 (2H, m), 3.33 (3H, s), 3.37 (2H, t, J=6.4Hz), 3.98 (2H, t, J=6.5Hz), 6.95 (2H, d, J=8.8Hz), 7.35-7.56 (6H, m)<br>
APCI-MASS :  m/z = 37 9 (M-’ + 2)<br>
Preparation 285<br>
N-(4-octylphenyl)-N'-amino urea, Formamide acetate<br>
(12.76 g) and N-carbazoyl-4-octylaniline (6.458 g) in N,N-dimethylformamide (19.4 ml) were stirred at 150°C for 6 hours.  The reaction mixture was pulverized with water.  The precipitate was collected by filtration and washed with water to give 4-(4-Octylphenyl)-2,3-dihydro-4H-l, 2, 4-triazol-3-one<br>
(4.27 g).<br>
IR (KBr) :  3214.8, 3085.5, 1704.8 cm-’<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m), 1.5-1.8 (2H, m), 2.64 (2H, t, J=7.9Hz), 7.29<br><br>
(2H, d, J=8.5H2), 7.43 {2H, d, J=8.5H2), 7.67 (IH, d, J=1.3Hz), 10.31 (IH, s) APCI-MASS :  m/z = 274  (M+H’)<br>
The following compound (Preparation 286) was obtained according to a similar manner to that of Preparation 285.<br>
Preparation 286<br>
4-[4-(4-tert-Butoxycarbonylpipera2in-l-yl)phenyl]-2,3-dihydro-4H-l;2,4-tria2ol-3-One<br>
IR (KBr) :  3200, 1699.0, 918.0 cm-’<br>
NMR (CDCI3, 5) :  1.49 (9H, s), 3.17 (4H, t, J=4.9H2), 3.60 (4H, t, J=4.9Hz), 7.00 (2H, d, J=9.0Hz), 7.40 (2H, d, J=9.0Hz), 7.63 (IH, s), 10.4 (IH, s) APCI-MASS :  m/z = 346 (M+H-’)<br>
Preparation 287<br>
A mixture of Methyl 6-(1-heptynyl)naphthalene-2-carboxylate (4.51 g) and platinum oxide (0.4 g) in tetrahydrofuran was stirred under 3.5 atm pressure of hydrogen for 5 hours.  The catalyst was filtered off and the filtrate was evaporated to give Methyl 6-heptylnaphthalene-2-carboxylate (4.40 g).<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.6Hz) , 1.16-1.50 (8H, m), 1.50-1.80 (2H, m), 2.78 (2H, t, J=7.6Hz), 3.97 (3H, s), 7,39 (IK, dd, J==17 and 8.4Hz), 7.64 (IH, s),   7.79 (IH, d, J=8.6Hz), 7.86 (IH, d, J=8.4H2), 8.02 (IH, dd, J=1.7 and 8.6Hz), 8.57 (IH, s) APCI-MASS :  m/z = 285 (M'*'+l)<br>
The following compound (Preparation 288) was obtained according to a 'similar manner to that of Preparation 287.<br>
Preparation 288<br>
Methyl 6-hexylnaphthalene~2-carboxylate<br><br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.BH2), 1.17-1.53 (6H, m), 1.60-1.82 (2H, m), 2.79 (2H, t, J=7.7H2), 3.97 (3H, s), 7.39 (IH, dd, J=1.7 and 8.4H2), 7.64 (IH, s), 7.80 (IH, d, J=8.6Hz), 7.86 (IH, d, J=8.4Hz); 8.03 (IH, dd, J=1.7 and 8.6Hz), 8.57 (IH, s)<br>
APCI-MASS :  m/z = 271 (M+1)<br>
Preparation 289<br>
To a stirred solution of Methyl 6-hydroxynaphthalene-2-carboxylate (3,0 g) in dichloromethane (40 ml) were added in turn diisopropylethylamine (3.9 ml) and triflic anhydride (3-0 ml) at -40**C.  After stirring at -40-C for 20 minutes, the mixture was taken up into a mixture of ethyl acetate and cold water.  The organic layer was separated, washed with brine, dried over magnesium sulfate, and dried in vacuo.  The residue was taken up into piperidine (20 ml) and to the solution were added 1-heptyne (4.0 ml) and tetrakis(triphenylphosphine)palladium(O) (0.5 g).  After heating to 85'C for 1 hour under nitrogen atmosphere, the reaction mixture was evaporated in vacuo.  The residue was diluted with ethyl acetate, and the solution was washed in turn with hydrochloric acid and brine, dried over magnesium sulfate and evaporated in vacuo.  The residue was chromatographed on silica gel (200 ml) eluting with a mixture of n-hexane and ethyl acetate (9:1, V/V) to give Methyl 5-(1-heptynyl)naphthalene-2-carboxylate (4.01 g).<br>
NMR (CDCI3, 5) :  0.94 (3H, t, J=7.1Hz), 1.30-1.70 (6H, m), 2.46 (2H, t, J=7.0Hz), 3.97 (3H, s), 7.50 (IH, dd, J=1.7 and 8.6Hz), 7.80 (IH, d, J=8.6Hz), 7.86 (IH, d, J=8.6Hz), 8.04 (IH, dd, J=1.7 and 8.6Hz), 8.55 (IH, s) APCI-MASS':  m/z = 281 (M’ + 1)<br>
The following compound was obtained according to a similar manner to that of Preparation 289.<br><br>
Preparation 290<br>
Methyl 6-(1-hexynyl)naphthalene-2-carboxylate NMR (CDCI3, 5) :  0.97 (3H, t, J=7.1Hz), 1.40-1.71 (4H, m), 2.47 (2H, t, J=6.8H2), 3.98 (3H, s), 7.50 (IH, dd, J=1.5 and Sash), 7.79 (IH, d, J=8.6H2), 7.85 (IH, d, J=8.5Hz), 7.92 (IH, s), 8.04 (IH, dd, J=1.7 and 8.6Hz), 8.55 (IH, s) APCI-MASS :  m/z = 267 (M'‘+1)<br>
Preparation 291<br>
To a solution of 4-octylaniline (5 ml) in a mixture of pyridine (12.5 ml) and chloroform (40 ml) was added phenyl chloroformate (2.95 ml) and stirred for 1.5 hours at ambient temperature.  The reaction mixture was added to a mixture of water and ethyl acetate.  The organic layer was taken and dried over magnesitim sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-Octyl-N-phenoxycarbonylaniline (4.51 g)<br>
IR (KBr) : 3318.9, 1714.4, 1234.2 cm~’<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.2Hz), 1.2-1.4 (lOH, m), 1.5-1.7 (2H, m), 2.57 (2H, t, J=7.3Hz), 6.88 (IH, s), 7.1-7.5 (9H, m)<br>
The following compounds (Preparations 292 to 299) were obtained according to a similar manner to that of Preparation<br>
291 .<br>
Preparation 292<br>
4-(4-tert-Butoxycarbonylpiperazin-l-yl)-N-phenoxycarbonylaniline<br>
IR (KBr) :  3309.2, 1743.3, 1658.5, 1197.6 cm~’ NMR (CDCI3, 5) :  1.48 {9H, s), 3.08 (4H, t, J=5.3Hz), 3.58 (4H, t, J=5.3Hz), 6.87 (IH, s), 6.91 (2H, d, J=9Hz), 7.1-7.5 (7H, m) APCI-MASS :  m/z = 398 (M+H-*-)<br><br>
reparation 2 93<br>
: -(‘-Cyclohexylbenzoyl)-2-(4-methoxycarbonylbenzoyl)-V':: r a:: 1 n e<br>
IR (KBr) :  3236, 2925, 2852, 1726, 1679, 1637, 1278,<br>
1110 cm~l NKR   (DMSO-dg, 6) :  1.1-1.5 (5H, m) , 1.6-2.0 (5H, m) ,<br>
2.60 (IH, m), 3.90 (3H, s), 7.37 (2H, d, J=8.0Hz), 7.85 (2H, d, J=8.0Hz), 8.0-8.2 {4H, m), 10.48 (IH, s), 10.68 (IH, s) APCI-MASS :  m/z = 381 (M+H)-'-<br><br>
1-[4-(Piperidin-1-yl)benzoyl]-2- (4-:r;vcxycarbonylbenzoyl] hydrazine<br>
IR (KBr) :  3500, 3286, 2941, 2854, 1712, 1689, 1650,<br>
1606, 1286, 1242 cm~’ :IV-:R (DMSO-dg, 5) :  1.59 (6H, s), 3.33 (4H, s) , 3.90 {3K, s), 6.97 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.8Hz), 8.02 (2H, d, J=8.4Hz), 8.09 (2H, d, J=8.4Hz), 10.23 (IH, s), 10.57 (IH, s) .RPCI-M.ASS :  m/z = 382 (M+H) +<br>
•:;..’ration 295<br>
:. - [ 4- (4-n-Propyloxyphenyl)benzoyl] -2- (4-r::Cxycarbonylbenzoyl] hydrazine<br>
IR    ;K3r)    :      3230,    1724,    1679,    1654,    1280,    1108   cm-’ MIR    (DMSO-dg,    5)    :      1.00   3H,   d,    J=7.5Hz),    1.76    (2H,    tq, J=6.5   and  7.5Hz),   3.91    (3H,    s),   7.05   (2H,   d, J=8.7H2),    7.71    (2H,    d,    J=8.7Hz),    7.79    (2H,   d, J-8.5HZ),    8.00    (2H,    d,    J=8.5Hz),    8.05    (2H,    d, J=6.6Hz),    8.11    (2H,    d,    J=8.5Hz),    10.60    (IH,    s), 10.72-   (IH,    s) ARCI-f-IASs    :      m/z   =   433    (M+H) -’<br><br><br>
1-(4-Methoxycarbonylbenzoyl)-2-decanoylhydrazine<br>
IP, (K3r) :  3220, 2919, 2850, 1724, 1643, 1600, 1567,<br>
1479, 1284 cin-l<br>
I’R (DMSO-dg, 6) :  0.86 (3H, t, J=6.8Hz), 1.2-1.7<br>
(14K, m), 2.18 (2H, t, J=7.4Hz), 3.89 (3H, s), 7.97 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.5Hz), 9.15 (IH, s), 10.49 (IH, s)<br>
APCI-MASS   :     m/z   =   349    (M+H-')<br>
Preparation   2 97<br>
1-(4-Methoxycarbonylben2oyl)-2-{trans-4-n-pentylcyclohexylcarbonyl)hydrazine<br>
IR   (K3r)    :      3201,   2923,   2852,   1727,    1600,   1567,   1479,<br>
1282   cm-’ IxIMR   (DMSO-dg,    5)    :      0.86    (3H,   t,    J=6.9Hz),    0.9-1.0    (2H, m),    1.1-1.5   (IIH,   m),   1.7-1.9   (4H,   m),   2.20   (IH, m),    3.88    (3H,   s),   7.97    (2H,   d,   J=8.6Hz),   8.06   (2H, d,    J=8.6Hz),    9.85    (IH,    s),    10.46    (IH,    s) APCI-IIASS   :     m/z  =  375   (M+H-’)<br><br><br><br>
ion 298<br><br><br><br><br><br>
1~ [4~ (8-Methoxyoctyloxy)benzoyl]-2-(4-<br>
xycarbonylbenzoyl)hydrazine<br>
:?, (K3r) :  3213, 2935, 2856, 1718, 1600, 1567, 1465,<br>
1282 cin-l<br>
w u<br>
(DMSO-dg, 6) :  1.2-1.8 (12H, m), 3.21 (3H, s), 3.29 (2H, t, J=6.4Hz), 3.90 (3H, s), 4.04 (2H, t, J=6.5Hz), 7.04 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.8Hz), 8.04 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz), 10.41 (IH, s), 10.64 (IH, s)<br>
-Mesas :  m/z = 457 (M+H-’)<br><br>
rara-ion 299<br>
- 4-Ocryloxybenzoyl)-2-(4-methoxycarbonylbenzoyl)-<br>
TT (=.<br><br><br><br>
IR (KBr) :  3224, 2923, 2854, 1724, 1681, 1643, 1502,<br>
1434, 1282, 1253, 1106 cm~’ NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.8H2), 1.2-1.5<br>
(lOH, m) , 1.6-1.8 (2H, m), 3.89 (3H, s), 4.04 (2H, t, J=6.3H2), 7.04 (2H, d, J=8.7H2), 7.90 (2H, d, J=8.7Hz), 8.03 (2H, d, J=8.6H2), 8.10 (2H, d, J=8.6Hz), 10.42 (IH, s), 10.64 (IH, s) APCI-MASS :  m/z = 427 (M+H-’)<br>
anon 300<br><br><br>
solution of Methyl 4-n-hexyloxyben2oate (2,00 g) and hydrazine hydrate (4.24 g) in ethanol (10 ml) was refluxed for 6 hours.  After cooling, the reaction mixture was poured into vaster.  The precipitate was collected by filtration,   water and dried over P2O5 under reduced pressure ::c give N-(4-n-hexyloxybenzoyl) hydrazine (1.96 g) . :R (P3r) :  3311, 2954, 2869, 1623, 1253 cm-l   (DMSO-dg, 5) :  0.87 (3H, t, J=6.8H2), 1.2-1.5 (6H, rrO , 1.6-1.8 (2H, m) , 4.00 (2H, t, J=6.5Hz), 4.40 (2H, s), 6.95 (2H, d, J=8.6Hz), 7.77 (2H, d, J=8.6H2), 9.59 (IH, s) A?CI-MZi.SS :  m/z = 237 (M+H)-’<br><br><br>
Preparation  302<br>
N-[4-(4-tert-Butoxycarbonylpiperazin-l-yl)phenyl]-N'-amino urea<br>
IR   (KBr)    :      3237.9,   1695.1,   1670.1,   1540.8,   1230.4   cm~’ NMR   (DMSO-dg,   6)    :      1.42   (9H,   s),   2.97    (4H,   t,<br>
J=4.9Hz),   3.44    (4H,   t,   J=4.9Hz),   4.30   (2H,   s) ,    6.85 (2H,   d,   J=9.0Hz),   7.26   (IH,   s),   7.36   (2H,   d, J=9.0Hz),   8.41   (IH,   s)<br>
Preparation 303<br>
4-Cyclohexylben2oylhydrazine<br>
IR (KBr) :  3318, 2925, 2852, 1625, 1606, 1527,<br>
1326 cm~l NMR (DMSO-dg, 6) :  1.1-1.5 (5H, m) , 1.6-2.0 (5H, m), 2.4-2.6 (IH, m), 4.44 (2H, s), 7.27 (2H, d, J=8.2Hz), 7.73 (2H, d, J=8.2Hz), 9.66 (IH, s) APCI-MASS :  m/z = 219 (M+H)+<br>
Preparation 304<br>
4-(Piperidin-1-yl)benzoylhydrazine<br>
IR (KBr) :  3263, 2852, 1612, 1504, 1245, 1124 cm-’ NMR (DMSO-dg, 5) :  1.57 (6H, s), 3.25 (4H, s), 4.35 (2H, s), 6.90 (2H, d, J=9.0Hz), 7.68 (2H, d, J=9.0Hz), 9.44 (IH, s) APCI-MASS :  m/z = 220 (M+H) +<br>
Preparation 305<br>
4-(4-n-Propyloxyphenyl)benzoylhydrazine<br>
IR (KBr) :  3350, 3276, 1610, 1494, 1288, 978 cm~’<br>
NMR (DMS0-d3, 5) :  0.99 (3H, t, J=7.5Hz), 1.75 (2H,<br>
tq, J=6.5 and 7.5Hz), 3.98 (2H, t, J=6.5Hz), 4.50 (2H, 's), 7.03 (2H, d, J=8.8Hz), 7.65 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.4Hz), 7.88 (2H, d, J=8.4Hz), 9.79 (IH, s) APCI-MASS :  m/z = 271 (M+H-’)<br><br>
Preparation 306<br>
4-Methoxycarbonylbenzoylhydrazine<br>
IR (KBr) :  3322, 3250, 3018, 1727, 1658, 1621, 1565,<br>
1432, 1280, 1110 cm~’ NMR (DMSO-dg, 6) :  3.87 (3H, s), 4.58 (2H, s) , 7.93<br>
(2H, dd, J=8.6 and 3.1Hz), 7.02 (2H, dd, J=8.6 and 3.1Hz), 9.97 (IH, s) APCI-MASS :  m/z = 195 (M+H-*-)<br>
Preparation 307<br>
Trans-4-n-pentylcyclohexylcarbonylhydrazine<br>
IR (KBr) :  3303, 3199, 2954, 2925, 2850, 1639, 1619,<br>
1533, 1457 cm-l NMR (DMSO-dg, 5) :  0.8-1.0 (6H, m), 1.1-1.5 (lOH, m),<br>
1.6-2.2 (5H, m), 4.10 (2H, s), 8.85 (IH, s) APCI-MASS :  m/z = 213 (M+H+)<br>
Preparation 308<br>
4-(8-Methoxyoctyloxy)benzoylhydrazine<br>
IR (KBr) :  3309, 2937, 2852, 1606, 1494, 1253 cm-’<br>
NMR (DMSO-dg, 6) :  1.2-1.8 (12H, m), 3.20 (3H, s),<br>
3.25 (2H, t, J=6.5Hz), 3.99 (2H, t, J=6.5Hz), 4.39 (2H, s), 6.95 (2H, d, J=8.8Hz), 7.77 (2H, d, J=8.8Hz), 9.58 (IH, s) APCI-MASS :  m/z = 295 (M+H)+<br>
Preparation 309<br>
To a stirred solution of 4-bromo-4'-n-heptylbiphenyl (2.71 g) in tetrahydrofuran (100 ml) was added dropwise a solution of n-butyl lithium in a mixture of diethyl ether and n-hexane (1.6M, 5.1 ml) at -78'C.  After stirring at -78°C for 30 minutes, the resultant mixture was added to a solution of diethyl oxalate (3.4 ml) in tetrahydrofuran (50 ml) at -78°C.  The resultant mixture was allowed to warm to 0°C for about 1 hour, and to the mixture was added acetic acid (0.5<br><br>
ml).  Evaporation gave a residue which was taken up into a mixture of water and ethyl acetate.  The organic layer was separated, washed with brine, dried over magnesium sulfate. Evaporation gave a residue which was chromatographed on silica gel (200 ml) eluting with a mixture of n-hexane and ethyl acetate (10:0-95:5, V/V) to give l-Ethyl-2-(4-n heptylphenyl)ethanedione (2.23 g) .<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.6H2), 1.10-1,50 (8H, m), 1.44 {3H, t, J=7.1H2), 1.50-1.80 (2H, m), 2.66 (2H, t, J=7.7H2), 4.47 (2H, q, J=7.1Hz), 7.20-7.40 (2H, m), 7.50-7.64 (2H, m), 7.64-7.85 (2H, m), 8.00-8.20 (2H, m) APCI-MASS :  m/z = 353 (M-**+l)<br>
Preparation 310<br>
To a suspension of sodium hydride (60% in oil, 0.37 g) in tetrahydrofuran (40 ml) was added by portions 4-acetyl-4'-n-heptylbiphenyl (2,50 g) at ambient temperature,  After stirring at ambient temperature for 1 hour, to the solution was added triethyl phosphonoacetate (1.9 ml) and the mixture was heated to reflux for 5 hours.  After cooling to ambient temperature, to the mixture was added acetic acid (0.53 ml) and evaporated.  The residue was taken up into a mixture of water and ethyl acetate.  The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated.  The residue was chromatographed on silica gel (200 ml) eluting with mixture of n-hexane and isopropyl ether (99:1-20:1, V/V) to give Ethyl (E)-3-[4-(4-heptylphenyl)phenyl]-2-butenoate (2.19 g) .<br>
NMR (CDCI3, 5) :  0.88 (3H, t, J=6.6Hz), 1.13-1.48 (8H, m), 1.48-1-78 (2H, m), 2.61 (3H, s), 2.65 (2H, t, J=7.4Hz), 4.22 (2K, q, J=7.1H2), 6.20 (IK, t, J=2,7H2), 7.23-7.28 (2H, m), 7.50-7.63 (6H, m) APCI-MASS :  m/z = 365 (M’+1)<br><br>
Preparation 311<br>
To a solution of 4-bromo-4'-n-heptylbiphenyl (5.1 g) in tetrahydrofuran (60 ml) was added a solution of n’ butyl lithium in a mixture of n-hexane and diethyl ether (1.6M; 9.7 ml) at -60-C.  After stirring at -  for 30 minutes, to the mixture was added N,N-dimethylacetamide (4.3 ml) and the reaction mixture was allowed to warm to CC.  The reaction mixture was taken up into a mixture, of cold water and ethyl acetate, and the pH was adjusted to around 1 with IN hydrochloric acid.  The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated.  The residue was chromatographed on silica gel (150 ml) eluting with a mixture of n-hexane and ethyl acetate (20:1, V/V) to give 4-Acetyl-4'-n-heptylbiphenyl (1.60 g).<br>
NMR (CDCI3, 5) :  0.89 (3H, t, J=6.6Hz), 1.05-1.48 (8H, m), 1.48-1.75 (2H, m), 2.65 (2H, t, J=7.6Hz), 2.63 (3H, s), 7,20-7.31 (2H, m), 7.52-7.58 (2H, m), 7.65-7.70 (2H, m), 7.97-8.05 (2H, m) APCI-MASS :  m/z = 295 (M+1)<br><br>
To a solution of Methyl 4-[4-(8-hydroxyoctyloxy)phenyl]-benzoate (500 mg) and dihydropyrane (141 mg) in dichloromethane (15 ml) was added p-toluenesulfonic acid (5 ml) .  The mixture was stirred at ambient temperature for 10 minutes and diluted with dichloromethane and washed with water and brine.  The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure to give Methyl 4-[4-(8-tetrahydropyran-2-yl-oxyoctyloxy)phenyl]-benzoate (616 mg).<br>
IR (KBr) :  2935, 2856, 1722, 1602, 1438, 1290, '  1199 cm~’<br>
NMR (CDCI3, 5) :  1.3-2.0 (18H, m), 3.3-3.9 (4H, m) ,<br>
3.93 (3H, s), 4.00 (2H, t, J=6.5Hz), 4.5-4.6 (IH, m), 6.98 (2H, d, J=8.7Hz), 7.56 (2H, d, J=8.7Hz),<br><br>
7.62 (2H, d, J=8.3H2), 8.07 (2H, d, J=8.3H2)<br>
Preparation 313<br>
To a solution of titanium(IV) chloride (11.6 g) in dichloromethane (100 ml) was added 4-n-Pentyloxyacetophenone (10.3 g) and Methyl 4-formylben2oate (8.21 g) in dichloromethane (50 ml) dropwise at 0**C.  To the mixture was added triethylamine (11.15 ml) in dichloromethane (30 ml). The mixture was stirred at 0**C for 30 minutes and diluted with n-hexane.  The organic layer was washed with water (four times), brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure and the residue was triturated with iso-propyl ether.  The solid was collected by filtration and dried to give 1-(4-Methoxycarbonylphenyl)-3-(4-n-pentyloxyphenyl) -l--propen-3-one (4 .02 g) .<br>
IR (KBr) :  2950, 2910, 2863, 1718, 1654, 1606, 1274,<br>
1176 cm-l NMR (CDCI3, 5) :  0.94 (3H, t, J=6.9Hz), 1.3-1.6 (4H, m), 1.8-2.0 (2H, m), 3.93 (3H, s), 4.04 (2H, t, J-6.5HZ), 6.97 (2H, d, J=8.8Hz), 7.60 (IH, d, J=15.7Hz), 7.68 (2H, d, J==8.4Hz), 7.80 (IH, d, J=15.7Hz), 8.0-8.2 (4H, m) APCI-MASS :  m/z = 353 (M+H’)<br>
Preparation 314<br>
To a solution of titanium(IV) chloride (13.88 g) in dichloromethane (100 ml) was added Ethyl 4-acetylbenzoate<br>
(11.53 g) and 4-n-pentyloxybenzaldehyde (12.69 g) in dichloromethane (50 ml) was added dropwise at 0°C.  To the mixture was added triethylamine (12.44 ml) in dichloromethane<br>
(30 ml) .  The mixture was stirred at CC  for 30 minutes and diluted with ethyl acetate.  The organic layer was washed with water (four times) and brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure and the residue was triturated with n-hexane.  The solid was<br><br>
)<br><br>
collected by filtration and dried to give l-(4-n-Pentyloxyphenyl)-3- (4-ethoxycarbonylphenyl)-l-propen-3-one (13.45 g).<br>
IR (KBr) :  2956, 2929, 2861, 1718, 1656, 1594, 1510,<br>
1272 cm~l NMR (CDCI3, 6) :  0.94 (3H, t, J=7.1Hz), 1.3-1.9 (9H, m), 4.01 (2H, t, J=6.5H2), 4.42 (2H, q, J=7.1Hz), 6.93 (IH, d, J=8.7Hz), 7.37 (IH, d, J=15.6Hz), 7.60 (2H, d, J=8.7Hz), 7.81 (IH, d, J=15.6H2), 8.03 (2H, d, J=8.5Hz), 8.16 (2H, d, J=8.5Hz) APCI-MASS :  m/z = 367 (M+H-')<br>
The following compound was obtained according to a similar manner to that of Preparation 314.<br>
Preparation 315<br>
Ethyl 4-0x0-1-(4-n-hexyloxyphenyl)piperidine-3-carboxylate<br>
IR (Neat) :  1664.3, 1511.9, 1243.9, 1216.9 cm~’<br>
NMR (CDCI3, 6) :  0.90 (3H, t, J=6.5Hz), 1.2-1.5 (6H,<br>
m), 1.32 (3H, t, J=7.1Hz), 1.65-1.85 (2H, m), 2.51 (2H, t, J=5.8Hz), 3.31 (2H, t, J=5.8Hz), 3.76 (2H, s), 3.91 (2H, t, J=6.5Hz), 4.26 (2H, q, J=7.1Hz), 6.84 (2H, d, J=9.2Hz), 6.94 (2H, d, J=9.2H2), 12.06 (IH, s) APCI-MASS :  m/z =34 8 (M’+H)<br>
Preparation 316<br>
To a solution of 4-n-Hexyloxybenzoylhydrazine (1.96 g) and pyridine (0.74 ml) in tetrahvdrofuran (20 ml) was added a solution of terephthalic acid monomethyl ester chloride (1.56 g) in tetrahydrofuran (15 ml) dropwise at 0°C.  The reaction mixture was stirred at room temperature for 2 hours, and poured into water.  The precipitate was collected by filtration and washed with acetonitrile.  The residue was<br><br>
dried under reduced pressure to give 1-(4-n-Hexyloxyben2oyl)-2-(4-methoxycarbonylben2oyl)hydrazine (2.99 g).<br>
IR (KBr) :  3230, 3023, 2954, 2858, 1724, 1681, 1643,<br>
1280, 1251, 1105 cm-’ NMR (DMSO-dg, 6) :  0.88 (3H, t, J=6.6Hz), 1.2-1.5 (6H, m), 1.6*1.8 (2H, m), 3.90 (3H, s), 4.04 (2H, t, J=6.4Hz), 7.04 (2H, d, J=8.7Hz), 7.90 (2H, d, J=8.7Hz), 8.03 (2H, d, J=8.4H2), 8.10 (2H, d, J=8.4Hz), 10.42 (IH, s), 10.65 (IH, s) APCI-MASS :  m/z = 399 (M+H)’<br><br>
A mixture of 1-(4-n-Hexyloxyphenyl)-4-piperidone (0.823 g) , 1-(4-Ethoxycarbonylphenyl)piperazine (0.7 g), and titanium(IV) isopropoxide (1.11 ml) was stirred at room temperature.  After 1 hour, the IR spectrum of the mixture showed no ketone band, and the viscous solution was diluted with absolute ethanol (3 ml).  Sodium cyano borohydride (0.121 g) was added, and the solution was stirred for 3 hours. Water (3 ml) was added with stirring, and the resulting in organic precipitate was filtered and washed with ethanol. The filtrate was extracted with ethyl acetate.  The organic layer was taken and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and filtrate was evaporated under reduced pressure to give Ethyl 4-[4-[1-(4-n-hexyloxyphenyl)piperidin-4-yl]piperazin-l-yl]benzoate (331 mg) .<br>
IR (KBr) :  1708.6, 1606.4, 1511.9, 1284.4, 1236.1 cm-' NMR (CDCI3, 5) :  0.90 (3H, t, J=6.5Hz), 1.2-1.55 (6H, m) , 1.37 (3H, t, J=7.1Hz), 1.6-1.85 (4H, m), 1.95 (2H, d, J==12Hz), 2.41 (IH, m) , 2.62 (2H, d, J=llHz), 2.75 (4H, t, J=5.0Hz), 3.35 (4H, t, J=5.0Hz), 3.58 (2H, d, J=llHz), 3.90 (2H, t, J=6.5Hz), 4.32 (2H, q, J=7.1Hz), 6.7-7.0 (6H, m), 7.92 (2H, d, J=9.0Kz)<br><br>
APCI-MASS :  m/z = 494 (M'*'+H)<br>
The following compound was obtained according to a similar manner to that of Preparation 317.<br>
Preparation 318<br>
l-tert-Butoxycarbonyl-4-(4-phenylcyclohexyl)piperazine IR (KBr) :  1697.1, 1245.8, 1170.6, 1124.3, 700 cm-’ NMR (CDCI3, 5) :  1.2-1.65 (17H, m), 1.9-2.1 (4H, m),<br>
2.3-2.6 (2H, m), 2.55 (4H, t, J=5.0Hz), 3.44 (4H,<br>
t, J=5.0Hz), 7.1-7.4 (5H, m) APCI-MASS :  m/z = 345 (M’+H)<br>
Preparation 319<br>
To a suspension of 1-(N,N-dimethylamino)-2-(4-ethoxycarbonylbenzoyl)ethylene (0.742 g) and 4-n-hexyloxybenzamidine hydrochloride (0.847 g) in methanol (10 ml) was added 28% sodium methoxide in methanol (0.64 ml). The suspension was refluxed for 6 hours, and partitioned with ethyl acetate and water.  The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure.  The residue was triturated with acetonitrile, collected by filtration and dried under reduced pressure to give Methyl 4-[2-(4-n-hexyloxyphenyl)pyrimidin-6-yl]benzoate (0.61 g).<br>
IR (KBr) :  2931, 2861, 1722, 1606, 1558, 1251 cm~’ NMR (CDCI3, 6) :  0.95 (3H, t, J=6.7Hz), 1.2-1.6 (6H, m), 1.8-2.0 (2H, m), 3.97 (3H, s), 4.05 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.8Hz), 7.56 (IH, d, J=5.2Hz), 8.18 (2H, d, J=8.6Hz), 8.28 (2H, d, J=8.6Hz), 8.52 (2H, d, J=8.8Hz), 8.83 (IH, d, J=5.2Hz) APCI-MASS :  m/z = 391 (M+H+)<br>
Preparation 320<br><br>
A solution of 1-(4-Methoxycarbonylphenyl)-3-(4-n-pentyloxyphenyl)-l-propen-3-one (4.0 g) and hydroxyamino hydrochloride (3.93 g) in ethanol (40 ml) was refluxed for 4 hours-  The mixture was diluted with ethyl acetate, and the organic layer was washed with water (x 2), brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure to give crude oxime.  To a solution of crude oxime in 1,2-dichloroethane (20 ml) was added activated-manganese (IV) oxide (10.0 g).  The reaction mixture was refluxed for 2 hours and filtered.  The residue was washed with dichloromethane.  The solvents were removed under reduced pressure and the residue was triturated with acetonitrile.  The solid was collected by filtration and dried to give Methyl 4-[3-(4-n-pentyloxyphenyl)isoxazol-5-yljbenzoate (0.98 g).<br>
IR (KBr) :  2940, 2871, 1720, 1612, 1278, 1249, 1178,<br>
1108 cm-l NMR (DMSO-dg, 5) :  0.94 (3H, t, J=7.2Hz), 1.2-1.6 (4H, m), 1.7-1.9 (2H, m), 3,95 (3H, s), 4.01 (2H, t, J=6.5Hz), 6.87 (IH, s), 6.98 (2H, d, J=8.9Hz), 7.79 (2H, d, J=8.9Hz), 7.89 (2H, d, J=8.6Hz), 8.15 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 366 (M+H’)<br><br>
To a solution of 4-Methoxycarbonylphenylhydroxyimino’ methyl chloride (16.98 g) and 4-n-pentyloxyphenylacetylene (18-96 g) in tetrahydrofuran (170 ml) was added triethylamine (14,4 ml) in tetrahydrofuran (140 ml) over a period of 2 hours at 40°C and the mixture was stirred at 40'*C for 30 minutes-  The mixture was diluted with dichloromethane and washed with water and brine.  The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure.  The residue was triturated with acetonitrile-  The precipitate was collected by filtration and dried to give<br><br>
Methyl 4-[5-(4-n-pentyloxyphenyl)isoxazol-3-yl]benzoate (24.56 g) .<br>
IR (KBr) :  2942, 2873, 1716, 1616, 1508, 1280,<br>
1108 cm-’ NMR (CDCI3, 5) :  0.95 (3H, t, J=6.9Hz), 1.3-1.6 (4H, m), 1.8-2.0 (2H, m), 3.95 (3H, s), 4.02 (2H, t, J=6.5Hz), 6.74 (IH, s), 6.99 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.8Hz), 7.93 (2H, d, J=8.5Hz), 8.14 {2H, d, J=8.5Hz) APCI-MASS :  m/z = 366 (M+H+)<br>
Preparation 322<br>
To a solution of N-Hydroxy-4-octyloxybenzamidine (1.89 g) in pyridine (10 ml) was added terephthalic acid monomethyl ester chloride (1.67 g) in tetrahydrofuran (15 ml) dropwise at 0°C.  The mixture was stirred at room temperature for 15 minutes, and poured into water.  The precipitate was collected by filtration, dried and dissolved in pyridine (10 ml).  The solution was refluxed for 1 hour.  The reaction mixture was diluted with ethyl acetate and washed with IN HCl, water and brine.  The separated organic layer was dried over magnesium sulfate and the solvents were removed under reduced pressure.  The residue was triturated with acetonitrile and collected by filtration.  The solid was dried to give Methyl 4-[3-(4-n-hexyloxyphenyl)-1,2,4-oxadiazol-5-yl]benzoate (2.27 g),<br>
IR (KBr) :  2950, 2925, 2863, 1720, 1280, 1255 cm~’ NMR (CDCI3, 5) :  0.92 (3H, t, J=6.6Hz), 1.2-1.9 (8H,<br>
m) , 3.97 (3H, s), 4.03 (2H, d, J=6.5Hz), 7.00 (2H, d, J=8.9Hz), 8.09 (2H, d, J=8.9Hz), 8.20 (2H, d, J=6.6Hz), 8.28 (2H, d, J=6.6Hz) APCI-MASS *:  m/z = 381 (M+H)’<br>
Preparation 323<br>
A suspension of 1-(4-n-Hexyloxybenzoyl)-2-(4-<br><br>
methoxycarbonyl benzoyl)hydrazine (1.00 g) in phosphorus oxychloride (5 ml) was refluxed for 1 hour.  After cooling, the solution was concentrated under reduced pressure.  The residue was poured into ice-water and extracted with dichloromethane.  The organic layer was washed with water, brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure.  The residue was triturated with acetonitrile, collected by filtration and dried under reduced pressure to give Methyl 4-[5-(4-n-hexyloxyphenyl)-1, 3, 4-oxadiazole-2-yl]benzoate (761 mg).<br>
IR (KBr) :  2954, 2854, 1724, 1612, 1494, 1280,<br>
1249 cm~’ NMR (CDCI3, 6) :  0.91 (3H, t, J=6.6Hz), 1.3-1.6 (6H, m) , 1.7-1.9 (2H, m), 3.96 (3H, s), 4.04 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.6Hz), 8.07 (2H, d, J=8.6Hz), 8.19 (4H, m) APCI-MASS :  m/z = 381 (M+H)+<br>
The following compounds (Preparations 324 to 327) were obtained according to a similar manner to that of Preparation 323.<br>
Preparation 324<br>
Methyl 4-[5-[4-(4-n-propyloxyphenyl)phenyl]-1,3,4-oxadiazol-2-yl]benzoate<br>
IR (KBr) :  1720, 1614, 1496, 1280, 1103 cm-’ NMR (CDCI3, 5) :  1.07 (3H, d, J=7.5Hz), 1.84 (2H, tq, J=6.5 and 7.5Hz), 3.98 (3H, s), 3.99 (2H, t, J=6.5Hz), 7.01 (2H, d, J=8.8Hz), 7.60 (2H, d, J=8.8Hz), 7.73 (2H, d, J=8.5Hz), 8.19 (2H, d, J=8.5Hz), 8.22 (4H, s) APCI-MASS-:  m/z = 415 (M+H-’)<br>
Preparation 325<br>
Methyl 4-[5-(n-nonyl)-1,3,4-oxadiazol-2-yl]benzoate<br><br>
IR (KBr) :  2915, 2848, 1724, 1569, 1436, 1413,<br>
1278 cm-’ NMR (CDCI3, 5) :  0.88 (3H, t, J=6.4H2), 1.2-1.6 (12H, m) , 1.8-2.0 (2H, m), 2.94 (2H, t, J=7.6Hz), 3.96 (3H, s), 8.11 (2H, d, J=8.8Hz), 8.17 (2H, d, J=8.8Hz) APCI-MASS :  m/z = 331 (M+H) +<br>
Preparation 326<br>
Methyl 4-[5-[4- (8-methoxyoctyloxy)phenyl]-1, 3, 4-oxadiazol-2-yl]benzoate<br>
IR (KBr) :  2925, 2858, 1722, 1614, 1280, 1259 cm~’ NMR (CDCI3, 6) :  1.3-1.9 (12H, iti) , 3.36 {3H, s) , 3.37 (2H, t, J=6.4Hz), 3.97 (3H, s), 4.04 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.9Hz), 8.20 (4H, s) APCI-MASS :  la/z = 439 (M+H+)<br>
Preparation 327<br>
Methyl 4-[5-(4-n-octyloxyphenyl)-1,3,4-oxadiazol-2-yljbenzoate<br>
IR (KBr) :  2923, 2856, 1722, 1614, 1496, 1282,<br>
1103 cni~l NMR (CDCI3, 6) :  0.89 (3H, t, J=6.8Hz), 1.2-1.6 (lOH, m), 1.7-1.9 (2H, m), 3.97 (3K, s), 4.04 (2H, t, J=6.5Hz), 7.03 (2H, d, J=8.7Hz), 8.07 (2H, d, J=8.7Hz), 8.19 (4H, m) APCI-MASS :  m/z = 409 (M+H-’)<br>
Preparation 328<br>
A suspension of 1-(4-Hexyloxybenzoyl)-2-(4-methoxycarbonylbenzoyl)hydrazine (1.0 g) and di-phosphorus pent sulfide (1.28 g) in tetrahydrofuran (15 ml) was stirred at room temperature for 3 hours.  The mixture was diluted with water (30 ml), stirred for 30 minutes and extracted with<br><br>
dichloroinethane.  The organic layer was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure.  The residue was triturated with acetonitrile.  The solid was collected by filtration and dried under reduced pressure to give Methyl 4-[5-(4-n-hexyloxyphenyl)-1,3,4-thiadiazol-2-yl]benzoate (816 mg).<br>
IR (KBr) :  2925, 2871, 1722, 1608, 1436, 1276,<br>
1106 cm-’ NMR (CDCI3, 5) :  0.92 (3H, t, J=6.6Hz), 1.3-2.0 (8H,<br>
m), 3.96 (3H, s), 4.03 (2H, t, J=6.5Hz), 6.99 (2H, d, J=8.6Hz), 7.95 (2H, d, J=8.4Hz), 8.16 (2H, d, J=8.4Hz) APCI-MASS :  m/z = 397 (M+H)+<br>
The following compounds (Preparations 329 to 334) were obtained according to a similar manner to that of Preparation 328.<br>
Preparation 329<br>
Methyl 4-[5-[4-(8-methoxyoctyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoate<br>
IR (KBr) :  3210, 2935, 2856, 1718, 1600, 1465, 1280,<br>
1110 cm-’ NMR (CDCI3, 6) :  1.3-1.6 (lOH, m), 1.7-1.9 (2H, m),<br>
3.33 (3H, s), 3.37 (2H, d, J=6.4Hz), 3.96 (3H, s), 4.03 (2H, t, J=6.5Hz), 6.99 (2H, d, J=8.9Hz), 7.94 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.6Hz), 8.16 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 455 (M+H’)<br>
Preparation 330<br>
Methyl 4-[5-(4-cyclohexylphenyl)-1,3, 4-thiadiazol-2-<br>
yljbenzoate<br>
IR (KBr) :  2925, 2850, 1716, 1432, 1274, 1108, 997 cm~’ NMR (CDCI3, 5) :  1.2-1.6 (5H, m), 1.7-2.0 (5H, m) ,<br><br>
2.58 (IH, m), 3.96 (3H, s), 7.34 (2H, d, J=8.2Hz), 7.93 (2H, d, J=8.2Hz), 8.07 (2H, ,d, J=8.6Hz), 8.16 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 379 (M+H-’)<br>
Preparation 331<br>
Methyl 4-[5-[4-(piperidin-1-yl)phenyl]-1,3,4-thiadiazol-2-yl]benzoate<br>
IR (KBr) :  2940, 2848, 1720, 1602, 1436, 1415, 1276,<br>
1108 cm-’ NMR {CDCI3, 6) :  1.68 (6H, br), 3.34 (4H, br), 3.96 (3H, s), 6.95 (2H, d, J=8.7Hz), 7.88 (2H, d, J=8.7Hz), 8.05 (2H, d, J=8.6Hz), 8.16 (2H, d, J=8.6Hz) APCI-MASS :  m/z = 380 (M+H-*-)<br>
Preparation 332<br>
Methyl 4-[5-(4-n-octyloxyphenyl)-1,3, 4-thiadiazol-2-yljbenzoate<br>
IR (KBr) :  2927, 2858, 1720, 1606, 1434, 1276,<br>
1106 cm~’ NMR (CDCI3, 5) :  0.89 (3H, t, J=6.8Hz), 1.2-1.6 (lOH, m), 1.7-1.9 (2H, m), 3.96 (3H, s) , 4.03 (2H, t, J=6.5Hz), 7.00 (2H, d, J=8.9Hz), 7.95 (2H, d, J=8.9Hz), 8.06 (2H, d, J=8.4Hz), 8.16 (2H, d, J=8.4Hz)<br>
APCI-MASS :  m/z = 425 (M+H+)<br><br>
Methyl 4-[5-(4-trans-n-pentylcyclohexyl)-1,3,4-thiadiazol-2-yi]benzoate<br>
IR (KBr) :  2923, 2850, 1722, 1440, 1276, 1110 cm~-NMR (CDCI3, 6) :  0.89 (3H, t, J=6.9Hz), 1.0-1.8 (13H,<br>
m), 1.92 (2H, d, J=13.4Hz), 2.24 (2H, d, J=12.2Hz), 3.15 (IH, tt, J=12.2 and 3.5Hz), 3.95 (3H, s) , 8.01<br><br>
(2H, dd, J=8.6 and 2.0Hz), 8.13 (2H, dd, J=8.6 and 2.0H2) APCI-MASS :  m/z = 373 (M+H’)<br>
Preparation 334<br>
Methyl 4- [5- [4-- (4-n-propyloxyphenyl)phenyl] -1, 3, 4-thiadiazol-2-yl]benzoate<br>
IR (KBr) :  1720, 1540, 1508, 1282 cm-’ NMR (CDCI3, 6) :  1-07 (3H, t, J=7.5Hz), 1.85 (2H, m) , 3.9-4.1 (5H, m), 7.01 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.4H2), 8.07 (2H, d, J=8.4Hz), 8.1-8.2 (4H, m) APCI-MASS :  m/z = 431 (M+H)-’<br>
Preparation 335<br>
To a suspension of 4-hexyloxyben2oic acid in oxalyl chloride (10 ml) and dichloromethane (10 ml) was added N,N-dimethylformamide (0.1 ml).  The mixture was stirred at room temperature for 2 hours.  The solvent was removed under reduced pressure to give crude 4-hexyloxybenzoyl chloride. To a suspension of Ethyl 3-amino-4-hydroxybenzoate (733 mg) and triethylamine (1,38 ml) and 4-dimethylaminopyridine (DMAP, 10 mg) in methylene chloride (10 ml) was added the solution of 4-hexyloxybenzoyl chloride obtained above in dichloromethane (5 ml) dropwise at 10°C.  The reaction mixture was stirred at IC'C for 1.5 hours and diluted with dichloromethane (20 ml).  The solution was washed with H2O (20 ml), IN HCl aq. (20 ml x 2), H2O (20 ml) and brine (20 ml) successively-  The organic layer was dried over MgSO’ and the solvent was removed under reduced pressure.  To the residue was added toluene (15 ml) and p-toluenesulfonic acid (10 mg).  The mixture was refluxed for 6 hours and the solvent was removed under reduced pressure.  The residue was triturated with acetonitrile, and precipitate was collected with filtration and dried over PO5 to give 2-(4-<br><br>
Hexyloxyphenyl)-5-ethoxycarbonylbenzoxazole (0.60 g). IR (KBr) :  2952, 2871, 1712, 1623, 1500, 1294,<br>
1255 cm~l NMR (CDCI3, 5) :  0.92 (3H, t, J=6.6Hz), 1.3-1.6 (9H, in), 1.7-1.9 (2H, m) , 4.05 (2H, t, J=6.5Hz), 4.42 (2H, q, J=7.1Hz), 7.03 (2H, d, J=6.9Hz), 7.57 (IH, d, J=8.6Hz), 8.08 (IH, dd, J=8.6 and 1.7Hz), 8.18 (2H, d, J=6.9Hz), 8.43 (IH, d, J=1.7Hz) APCI-MASS :  m/z = 368 (M+H+)<br>
The following compounds (Preparations 336 to 337) were obtained according to a similar manner to that of Preparation 335.<br>
Preparation 336<br>
5-Ethoxycarbonyl-2-(2-octyloxypyridin-5-yl)benzoxazole<br>
IR (KBr) :  2933, 2858, 1716, 1623, 1604, 1577, 1467,<br>
1290, 1213, 1083 cm~’<br>
NMR (CDCI3, 5) :  0.89 (3H, t, J=6.7Hz), 1.2-1.5 (lOH,<br>
m), 1.43 (3H, t, J=7.1Hz), 1.7-1.9 (2H, m) , 4.3-4.5 (4H, m), 6.87 (IH, d, J=8.7Hz), 7.60 (IH, d, J=8.6Hz), 8.11 (IH, dd, J=8.6 and 1.6Hz), 8.37 (IH, dd, J=8.8 and2.4Hz), 8.45 (IH, d, J=1.6Hz), 9.03 (IH, d, J=2.4Hz)<br>
APCI-MASS :  m/z = 397 (M+H’)<br>
Preparation 337<br>
2-[4-(4-Hexylphenyl)phenyl]-5-ethoxycarbonylbenzoxazole IR (KBr) :  2952, 2871, 1712, 1623, 1500, 1294, 1255,<br>
1024 cm~-NMR (CDCI3, 6) :  0.90 (3K, t, J=6.6Hz), 1.2-1.5 (6H, m) , r.44 (3H, t, J=7.1Hz), 1.6-1.8 (2H, m), 2.67 (2H, t, J=7.3Hz), 4.43 (2H, q, J=7.1Hz), 7.27 (IH, d, J=3.7Hz), 7,32 (IK, s) , 7.5-7.7 (3H, m), 7.77 (2H, d, J=8.6Hz), 8.12 (IH, dd, J=8.6 and 1.7Hz),<br><br>
8.32 (2H, d, J=8.5H2), 8.48 (IH, d, J=1.2H2) APCI-MASS :  m/z = 428 (M+H’)<br>
P;rgp’;rgt3-QP 338<br>
A suspension of 4-[4-(8-bromooctyloxy)phenyl]ben2oic acid (1 g) in 2, 6-diinethylinorpholine (3.06 ml) was refluxed for 30 minutes.  The reaction mixture was added to a mixture of water and ethyl acetate and adjusted to pH 2.0 with cone. HCl.  The organic layer was taken and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-[4-[8-(2, 6-dimethylmorpholin-4-yl)octyloxy]phenyl]benzoic acid hydrochloride (0.95 g).<br>
IR (KBr) :  2939.0, 1704.8, 1606.4, 1189.9 cm-’ NMR (DMSO-dg, 5) :  1.12 (6H, d, J=6.3Hz), 1.2-1.6<br>
(lOH, m) , 1.6-1.9 (4H, m), 2.4-2.7 (2H, m) , 2.9-3.1 (2H, m), 3.8-4.0 (2H, m), 4.02 (2H, t, J=6,3Hz), 7.04 (2H, d, J=8.8Hz), 7.68 (2H, d, J-8.8Hz), 7.75 (2H, d, J=8.4Hz), 7.99 (2H, d, J=8.4Hz) APCI-MASS :  m/z = 440 (M+H-’)<br>
Preparation 339<br>
Sodium hydride (60% suspension in mineral oil, 108 mg) was added to ethoxyethanol (10 ml), and the solution was stirred at 60**C for 20 minutes.  To the solution was added Methyl 4-[4-(8-bromooctyloxy)phenyl benzoate (1,26 g), and the reaction mixture was stirred at 70 for 2 hours.  To the reaction mixture was added 10% sodium hydroxide aqueous solution (2.4 ml), and the solution was stirred at 70'C for 1 hour.  After cooling, the solution was adjusted to pH 2.0 with IN hydrochloric acid.  The precipitate was collected by filtration, and dried to give 4-[4-[8-(2-Ethoxyethoxy)octyloxy]phenyl]benzoic acid (1.13 g).<br>
IR (KBr) :  2933, 2858, 1685, 1604, 1434, 1294,<br>
1132 cm--<br><br>
NMR (DMSO-dg, 5) :  1.09 (3H, t, J=7.0Hz), 1.2-1.9<br>
(14H, m), 3.2-3.6 (6H, m), 4.01 (2H, d, J=6.3Hz), 7.04 (2H, d, J=8.8H2), 7.67 (2H, d, J=8.8H2), 7.74 {2H, d, J=8.5Hz), 7.98 (2H, d, J=8.5H2)<br>
APCI-MASS :  m/z = 415 (M+H+)<br>
The following compound was obtained according to a similar manner to that of Preparation 300.<br>
Preparation 340<br>
4-n-Pentyloxybenzoylhydra2ine<br>
IR (KBr) :  3182, 2937, 2869, 1645, 1618, 1571,<br>
1251 cm~’ NMR (DMSO-dg, 6) :  0.89 (3H, d, J=7.1Hz), 1.2-1.8 (6H, m) , 4.00 (2H, t, J=6.5Hz), 4.41 (2H, s), 6.96 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.8Hz), 9.59 (IH, s) APCI-MASS :  m/z = 223 (M+H-’)<br>
The following compound was obtained according to a similar manner to that of Preparation 291.<br>
Preparation 341<br>
1-(4-Methoxycarbonylbenzoyl)-2-(4-n-pentyloxybenzoyl)-hydrazine<br>
IR (KBr) :  3234, 2956, 2931, 1724, 1683, 1643, 1610,<br>
1284, 1253 cm-’ NMR (DMSO-dg, 5) :  0.90 (3H, t, J=6.9Hz), 1.2-1.5 (4H, m), 1.6-1.8 (2H, m), 3.90 (3H, s), 4.04 (2H, t, J=6.5Hz), 7.04 (2H, d, J=8.8Hz), 7,90 (2H, d, J=8.8Hz), 8.03 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz),, 10.42 (IH, s) , 10.64 (IH, s) APCI-MASS :  m/z = 385 (M+H’)<br>
The following compound was obtained according to a similar manner to that of Preparation 328.<br><br>
Preparation 342<br>
Methyl 4-[5-(4-n-pentyloxyphenyl)thiadiazol-2-yljbenzoate<br>
IR (KBr) : 2940, 2871, 1720, 1606, 1438, 1280 can-’<br>
NMR (CDCI3, 5) :  0.95 (3H, t, J=7.1Kz), 1.3-1.6 (4K, m), 1.8-2.0 (2H, m), 3.96 (3H, s), 4.03 (2H, t, J=6.5Hz), 6.99 (2H, d, J=8.8Hz), 7.94 (2H, d, J=8.8Hz), 8.06 (2H, d', J=8.7Hz), 8.16 (2H, d, J=8.7Hz)<br>
APCI-MASS :  m/z .= 383 (M+H’)<br>
The following compound was obtained according to a similar manner to that of Preparation 32<br>
Preparation 343<br>
4-[5-(4-n-Pentyloxyphenyl)thiadiazol-2-yl]benzoic acid IR (KBr) :  2954, 2867, 1687, 1602, 1432, 1294,<br>
1255 cm~’ NMR (DMSO-dg, 5) :  0.91 {3H, t, J=7.0Hz), 1.3-1.5 (4H, m), 1.7-1.9 (2H, m), 4.07 (2K, t, J=6,7Hz), 7.13 (2H, d, J=8.8Hz), 7.97 (2H, d, J=8.8Hz), 8.07 (4H, s) APCI-MASS :  m/z = 369 (M+H+)<br>
The following compound was obtained according to a similar manner to that of Preparation 49.<br>
Preparation 344<br>
1-[4-[5-{4-n-Pentyloxyphenyl)thiadiazol-2-yl]benzoyl]-benzotriazole 3-oxide<br>
IR (KBr) :  2948, 2873, 177G, 1602, 1257, 1232 cm~’ NMR (CDCl'-5, 5) :  0.95 (3K, z,   J=7.1Hz), 1.3-1.6 (4H, m), 1.8-2.0 (2H, m), 4.04 (2H, u, J=6.5Kz), 7.01 (2K, d, J=8.1Kz), 7.4-7.7 (3H, m) , 7.97 (2H, d, J=8.1Hz), 8.12 (IH, d, J=8.2Hz), 8.24 (2K, d,<br><br>
J=8.0H2),   8.40   (2H,   d,   J=8.0Hz) APCI-MASS   :     lu/z  =  486   (M+H-’)<br>
Preparation 345<br>
To a solution of 4-broinobenzaldehyde oxime chloride (647 mg) and 4-n-pentyloxy-phenylacetylene (650 mg) in tetrahydrofuran (7 ml) was added triethylamine (0.5 ml) in tetrahydrofuran (5 ml) dropwise at 40*0.  The solution was stirred at 40**C for 30 minutes, poured into water and extracted with ethyl acetate.  The organic layer was washed with H2O, brine and dried over magnesium sulfate.  The solvents were removed under reduced pressure and the residue was triturated with acetonitrile.  The precipitate was collected by filtration and dried to give 4-[5-(4- n-pentyloxyphenyl)isoxazol-3-yl]bromoben2ene (0.59 g).<br>
IR (KBr) :  2948, 2867, 1612, 1430, 1255 cm-’<br>
NMR (CDCI3, 5) :  0.95 (3H, t, J=6.9Hz), 1.3-1.6 (4H, m), 1.7-1.9 (2H, m), 4.01 (2H, t, J=6.5Hz), 6.66 (IH, s),   6.98 (2H, d, J=8.8H2), 7.60 (2H, d, J=8.6Hz), 1.1-1.9   (4H, m)<br>
APCI-MASS :  m/z = 388 (M+H*’)<br>
Preparation 346<br>
To a suspension of 4-[5-(4-n-pentyloxyphenyl)isoxazol-3-yljbromobenzene (386 mg) in tetrahydrofuran (5 ml) was added 1.55M n-butyl lithium in hexane (0.84 ml) at -40'C under N2 stream and the solution was stirred for 1 hour at '40'C.  To the solution was added crushed dry ice (1 g) and the suspension was stirred for 1 hour at -40°C.  The suspension was diluted with H2O, and acidified with IN-hydrochloric acid.  The precipitate was collected by filtration and dried to give 4-[5-(4-n-pentyloxyphenyl)isoxazol-3-yl]benzoic acid (312 mg).<br>
IR (KBr) :  2939, 2867, 1681, 1614, 1429, 1255, 1178,<br>
821 cm-l<br><br>
NMR (DMSO-dg, 5) :  0.91 (3H, t, J=7.1H2), 1.3-1.5 (4H, m), 1.6-1.8 (2H, m), 4.04 (2H, t, J=6.5H2), 7.11 (2H, d, J=8.9Hz), 7.54 (IH, s), 7.85 (2H, d, J=8.9H2), 7.98 (2H, d, J=8.6Hz), 8.11 (2H, d, J=8.6Hz)<br>
APCI-MASS :  m/z = 352 (M+H-’)<br>
The Starting Compound in the following Examples 1 to 117 and The Object Compounds (1) to (122) and (124) in the following Examples 1 to 12Z  and 124 are illustrated by chemical formulae as below.<br>
The Starting Compound (the same in Examples 1 to 117)<br><br><br>
The Object Compounds (1) to (122) and (124)<br><br>
In the following Examples,  The Object Compound (X) [e.g. The Object Compound (1)] means the object compound of Example fX) [e.g. Example (1)].<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Example I<br>
To a solution of The Starting Compound (1 g) and 1-<br>
(6-octyl-oxymethylpicolinoyl)benzotriazole 3-oxide (0.399<br>
g) in N,N-dimethylformamide (10 ml) was added 4-(N,N-<br>
dimethylamino)pyridine (0,140 g) , and stirred for 12 hours<br>
at ancient temperature.  The reaction mixture was<br>
pulverized with ethyl acetate.  The precipitate was<br>
collected by filtration, and dried under reduced pressure.<br>
The powder was dissolved in water, and subjected to column<br>
chromatography on ion exchange resin (DOWEX-50WX4<br>
(Trademark :  prepared by Dow Chemical)) eluting with<br>
water.  The fractions containing the object compound were<br>
combined, and subjected to column chromatography on ODS<br>
(YMC-gel-ODS-AM'S-50) (Trademark :  prepared by Yamamura<br>
Chemical Lab.) eluting with 50% methanol aqueous solution.<br>
The fractions containing the object compound were<br>
combined, and evaporated under reduced pressure to remove<br>
methanol.  The residue was lyophilized to give The Object<br>
Compound (1).<br>
IR (KBr) :  3347, 1664, 1629, 1517 cm’’<br>
NMR (DMSO-dg, 5) :  0.8 6 (3H, t, J=6.7Hz), 0.98 (3H,<br>
d, J=6.7Hz), 1.09 (3H, d, J=6.0Hz), 1.2-1.47<br>
(lOH, m), 1.47-1.67 (2H, m), 1.67-2.06 (3H, m),<br>
2.06-2.5 (4H, m), 3.19 (IH, m), 3,53 (2H, t,<br>
J=6.4Hz), 3.5-3.85 (2H, m), 3.85-4.7 (13H, m),<br>
5.35 (IIH, m), 5.56 (IK, d, J=5.7Hz), 6.73 (IH,<br>
d, J=8.3Hz), 6.83 (IH, d, J=8,3Hz), 6.89 (IH,<br>
s), 7,05 (IH, s), 7.11 (IH, s), 7.32 (IH, m),<br>
7.43 (IH, d, J=8.5Hz), 7.63 (IH, d, J=7.3Hz),<br>
7.85-8.13 (4H, m), 8.66 (IH, d, J=7.8Hz), 8.84<br>
(IH, s)<br>
FAB-MASS.:  m/z = 1228 (M++Na)<br>
Elemental Analysis Clad. for C5oH72Ng022SNa'6H20 :<br>
C 45.49, H 6.44, N 9.59 Found :  C 45.89, H 6.52, N 9.69<br><br>
The Object Compounds (2) to (25) were obtained according to a similar manner to that of Example 1.<br>
Example 2<br>
IR (KBr) :  3353, 1666, 1510, 1236 cm~’ NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.8Hz), 1.2-1.5 (lOH, m), 1.55-2.05 (5H, m), 2.11-2.7 (4H, m), 3.0-3.3 (5H, m), 3.3-3.5 (4H, m), 3.6-4.5 (15H, m), 4.6-5.6 (12H, m), 6.6-7.2 (lOH, m), 7.2-7.5 (3H, m), 7.81 (2H, d, J=8.8Hz), 8.05 (IH, d, J=8.7Hz), 8.28 (IH, d, J=8.7Hz), 8.41 (IH, d, J=6.7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1373 (M++Na)<br>
Elemental T’alysis Calcd. for C6oHe3Nio022SN’-’’2'‘ •<br>
C 50.63, H 6.44, N 9.84 Found :  C 50.59, H 6.59, N 9.79<br>
Example 3<br>
IR (KBr) :  3350, 1664, 1627, 1047 cm~l<br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.6Hz), 1.08 (3K, d, J=5.7Hz), 1.15-1.53 (8H, m), 1.55-2.1 (9H, m) , 2.1-2.45 (3H, m), 2.5-2.7 (IH, m), 3.18 (IH, m) , 3.6-3.83 (2H, m), 3.83-4.6 (17H, m), 4.7-5.4 (IIH, m), 5.51 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.85 (IH, s), 7.03 (2H, d, J=8.4Hz), 7.05 (IH, s), 7.30 (IH, s), 7.2-7.5 (2H, m), 7.67 (2H, d, J=8.4Hz), 7,71 (2H, d, J=7.4Hz), 7.94 (IH, s), 7.96 (2H, d, J=7.4Hz), 8.06 (IH, d, J=8.0Hz), 8.25 (IH, d, J=6.7Hz), 8.50 (IH, s), 8.74 (IH, d, J=6.7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1356 (M++Na)<br>
Elemental Analysis Calcd. for C58H7gN]_-L022SNa-4H20 :<br>
C 49.53, H 6.02, N 10.95<br><br>
Found :  C 49.26, H 6.22, N 10.77<br>
Example 4<br>
IR (KBr) :  3350, 1660, 1631, 1047 cm-’ NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.9H2), 0.97 (3K, d, J=6.6Hz), 1.09 (3H, d, J=5.3Hz), 1.2-1.5 (lOH, m), 1.37 (6H, s), 1.55-2.0 (5H, m), 2.1-2.6 (4H, m), 3.16 (IH, m) , 3.73 (2H, m), 3.89 (2H, t, J=6.3Hz), 3.95-4.49 (IIH, m) , 4.68-5.21 (lOH, m) , 5.25 (IH, d, J=4.1Hz), 5.53 (IH, d, J=5.7Hz), 6.73 (IH, d, J=8.2Hz), 6.75-6.85 {4H, m), 6.91 (IH, d, J=8.2Hz), 7.05 (IH, s), 7.15 (IH, s), 7.3-7.5 (2H, m), 7.9-8.2 (3H, m), 8.84 (IH, s) FAB-MASS :  m/z = 1271 (M++Na)<br>
Elemental Analysis Calcd. For C53H77NgO23SNa-4H20 :<br>
C 48.18, K 6.48, N 8.48 Found :  C 48.04, K 6.51, N 8.38<br>
Example 5<br>
IR (KBr) :  1666, 1629, 1222 cm~l<br>
NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.6H2), 0.9-1.12 (6H, m) , 1.12-1.52 (13H, m), 1.52-1.93 (5H, m) , 2.08-2.55 (4H, m) , 3.1'6 (IH, m) , 3.6-5.3 (26H, m), 5.49 + 5.54 (IH, d, J=5.8Hz, mixture of diastereomer), 6.60-7.1 (7H, m), 7.04 (IH, s), 7.1 (IH, m), 7.2-7.5 (2H, m), 7.9-8.43 (3H, m) , 8.83 (IH, s) FAB-MASS :  m/z = 1257 (M++Na) Elemental Analysis Calcd. for C52H75Ng023SNa-3H20 :<br>
C 48.44, H 6.33, N 8.69 Found :  C 48.16, H 6.51, N 8.53<br>
Example 6<br>
IR (KBr) :  3349, 1666, 1629, 1259 cm~l<br><br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.7Hz), 0.9 (3H, d, J=5.7Hz), 0.96 (3H, d, J=6.7H2), 1.1-1.55 (19H, m), 1.55-2.0 (5H, m), 2.0-2.47 (4H, m) , 2.65-3.25 (3H, m), 3.5-5.13 (27H, m), 5.17 (IH, d, J=3.2Hz), 5.24 (IH, d, J=4.5Hz), 5.38 (IH, d, J=5.9Hz), 6.5-6.9 (5H, m), 6.9-7.1 (3H, m), 7.2-7.46 (2H, m), 7.7-8.1 (3H, m), 8.83 (IH, s) FAB-MASS :  m/z = 1368 (M++Na) Elemental Analysis Calcd. for C58H84N9024SNa-5H20 :<br>
C 48.50, N 6.60, N 8.78 Found :  C 48.47, H 6.83, N 8.78<br>
Example 7<br>
IR (KBr) :  3350, 1666, 1502, 1199 cm~l<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.6H2), 0.97 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.7Hz), 1.2-1.5 (lOH, m), 1.55-2.0 (5H, m), 2.1-2.6 (4H, m), 3.17 (IH, m), 3.7-4.5 (15H, m), 4.7-5.22 (lOH, m), 5.24 (IH, d, J=4.4Hz), 5.60 (IH, d, J=5.9Hz), 6.68-7.03 (8H, m), 7.04 (IH, s), 7.2-7.42 (2H, m), 7.85-8.1 (3H, m), 8.83 (IH, s)<br>
FAB-MASS :  m/z = 1229 (M++Na)<br>
Elemental Analysis Calcd. for C5oH7]_N8023SNa-5H20 :<br>
C 46.29, H 6.29, N 8.64 Found :  C 46.39, H 6.05, N 8.72<br>
Example 8<br>
IR (KBr) :  3350, 1666, 1631, 1513 cm~-NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.2Hz), 0.97 (3H, d, J=6.7Hz), 1.04 (3H, d, J=5.7Hz), 1.2-1.58 (8H, m), 1.58-2.0 (5H, m), 2.0-2.6 (4H, m), 3.17 (lH,'m), 3.6-4.5 (i5H, m) , 4.63-5.33 (13H, m), 5.53 (IH, d, J=5.9H2), 6.73 (IH, d, J=8.2Hz), 6.82 (IH, d, J=8.2Hz), 6.84 (IH, s), 6.95-7.52 (7H, m), 7.66 (IH, d, J=7.6Hz), 7.7-7.9 (3H, m),<br><br>
8.05 (IH, d, J=9.1H2), 8.15 (IH, d, J=7.6H2), 8.85 (IH, s) FAB-MASS :  m/z = 1279 (M++Na) Elemental Analysis Calcd. for C54H73Ng023SNa-5H20 :<br>
C 48.14, H 6.21, N 8.32 Found :  C 48.43, H 6.28, N 8.30<br>
Example 9<br>
IR (KBr) :  3347, 2956, 1664, 1633, 1508, 1444, 1268,<br>
1047 cm~l NMR (DMSO-dg, 5) :  0.9-1.1 (9H, m), 1.06 (3H, d,<br>
J=5.9Hz), 1.3-1.5 (8H, m), 1.6-2.0 (7H, m), 2.1-2.4 (3H, m), 2.5-2.6 (IH, m), 3.1-3.3 (IH, m) , 3.6-4.4 (17H, m), 4.7-5.0 (8H, m) , 5.09 (IH, d, J=5.5Hz), 5.16 (IH, d, J=3.1Hz), 5.24 (IH, d, J=4.5Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (2H, m), 6.98 (IH, d, J=8.3Hz), 7.05 (IH, d, i       J=1.7Hz), 7.3-7.6 (5H, m), 8.08 (IH, d,<br>
J=8,9Hz), 8.25 (IH, d, J=8.4Hz), 8.54 (IH, d, J=7.5Hz), 8.83 (IH, s) FAB-MASS :  m/z = 1257 (M++Na) Elemental Analysis Calcd. for C52H75Ng023SNa-4H20 :<br>
C 47.78, H 6.40, N 8.57 Found :  C 47.88, H 6.71, N 8.53<br>
Example 10<br>
IR (KBr) :  3350, 2931, 1664, 1625, 1529, 1440, 1276,<br>
1226, 1047 cm~-NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.8Hz), 0.97 (3H, d, J=6.7Hz), 1.12 (3K, d, J=5.9Hz), 1.2-1.5 (lOH, m), 1.6-2.1 (5H, m), 2.1-2.4 (4H, m), 3.1-3.3 (IH, m), 3.5-4.6 (15H, m), 4.7-5.0 (3H, m) , 5.0-5.2 (7H, m), 5.27 (IH, d, J=4.4Hz), 5.55 (IH, d, J=5.7Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m), 7.0-7.2 (4H, m), 7.3-7.6 (2H, m), 7.90<br><br>
(IH, d, J=8.8Hz), 8.0-8.2 (2H, m), 8.8-8.9 (2H, m), 9.06 (IH, d, J=7.2Hz) FAB-MASS :  m/z = 1281 (M++Na) Elemental Analysis Calcd. for C53H72N8024SNa-5H20 :<br>
C 47.18, H 6.05, N 8.30 Found :  C 46.97, H 6.27, N 8.22<br>
Example 11<br>
NMR (DMSO-dg, 5) :  0.87-1.05 (6H, m) , 1.10 (3H, d,<br>
J=5.7Hz), 1.3-1.5 (4H, m), 1.6-1.9 (5H, m), 2.2-2.5 (3H, m), 2.6 (IH, m) , 3.1-3.2 (IH, m), 3.7-4.5 (15H, m), 4.8-5.1 (8H, m) , 5.09 (IH, d, J=5.64Hz), 5.16 (IH, d, J=3.2Hz), 5.26 (IH, d, J=4.2Hz), 5.52 (IH, d, J=6.0Hz), 6.73 (2H, d, J=8.4Hz), 6.8-6.9 (2H, m), 7.0-7.1 (3H, m), 7.2-7.4 (4H, m), 7.6-7.8 (6H, m) , 8.11 (IH, d, J=8.4Hz), 8.29 (IH, d, J=8.4Hz), 8.51 (IH, d, J=7.7Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1273 (M++Na)<br>
Elemental Analysis Calcd. for C55H72N8022SNa-4H20 :<br>
C 49.92, H 6.02, N 8.47 Found :  C 49.79, H 6.14, N 8.45<br>
Example 12<br>
IR (KBr) :  3330, 2929, 1670, 1629, 1533, 1440, 1280,<br>
1226, 1045, 804 cm-l NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.9Hz), 1.2-1.6 (lOH, m), 1.6-2.0 (5H, m) , 2.1-2.5 (4H, m), 3.1-3.3 (IH, m), 3.6-4.5 (15H, m), 4.8-5.1 (9H, m) , 5.17 (IH, d, J=3.0Hz), 5.25 (IH, d, J=4.5Hz), 5.56 (IH, d, J=5.6Hz)., 6.73 (IH, d, J=8.2Hz),<br>
6.83	(IH, d, J=6.8Hz), 7.1-7.2 (3H, m) , 7.3-7.5 (3H, m), 7.85 (IH, d, J=8.8Hz), 8.0-8.2 (3H, m) ,<br>
8.83	(IH, s), 8.96 (IH, d, J=7.2Hz)<br><br>
FAB-MASS :  la/z = 1269 (M++Na)<br>
Elemental Analysis Calcd. for C52H7]_N8022S2Na-4H20 :<br>
C 47.34, H 6.04, N 8.49 Found :  C 47.21, H 5.96, N 8.41<br>
Example 3-3<br>
IR (KBr) :  3345, 2927, 1664, 1629, 1515, 1442,<br>
1274, 1047 cin~l NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.9H2), 1.2-1.4 (lOH, m), 1.5-2.5 (8H, m), 2.46 (3H, s), 2.69 (2H, t, J=7.7Hz), 3.1-3.4 (2H, m), 3.6-4.5 (17H, m) , 4.8-5.2 (8H, iti) , 6.7-7.0 (3H, m) , 7.05 (IH, d, J=1.7Hz), 7.14 (IH, s), 7.3-7.6 (5H, m), 8.0-8.2 (2H, m), 8.47 (IH, d, J=7.0Hz), 8.84 (IH, s) FAB-MASS :  iti/z = 1251 (M++Na) Elemental Analysis Calcd. for C53H73N8022SNa-3H20 :<br>
C 49.61, H 6.21, N 8.73 Found :  C 49.88, H 6.44, N 8.74<br>
Example 14<br>
IR (KBr) :  3340, 1672, 1627, 1542, 1513, 1440, 1268,<br>
1045 cm-l<br>
NMR (DMSO-dg, 6) :  0.84 (3H, t, J=6.7Hz), 0.94 (3H,<br>
d, J=6.7Hz), 1.07 (3H, d, J=6.0Hz), 1.2-1.4<br>
(12H, m) , 1.6-2.0 (5H, m), 2.1-2.4 (3H, m), 2.6<br>
(IH, m), 2.96 (2H, t, J=7.4Hz), 3.1-3.3 (IH, m) ,<br>
3.6-4.5 (13H, m), 4.7-5.2 (IIH, m), 5.50 (IH, d,<br>
J=5.7Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (2H,<br>
m), 7.04 (IH, s), 7.2-7.5 (3H, m), 7.72 (IH, d,<br>
J=8.5Hz), 7.91 (IH, d, J=8.4Hz), 8.05 (IH, d,<br>
J=8.'4Hz), 8.2-8.4 (IH, m) , 8.80 (IH, d,<br>
J=7.7Hz), 8.83 (IH, s)<br>
FAB-MASS :  m/z = 1252 (M'‘+Na)<br>
Elemental Analysis Calcd. for C52H72Ng022SNa-6H20 :<br><br>
C 46.67, H 6.33, N 9.42 Found :  C 46.72, H 6.53, N 9.45<br>
Example 15<br>
IR (KBr) :  3350, 2935, 1664, 1627, 1517, 1446, 1251,<br>
1045 cm~l<br>
NMR (DMSO-dg, 5) :  0.90-1.1 (6H, m), 1.10 (3H, d,<br>
J=5.9Hz), 1.2-1.4 (6H, m), 1.6-2.4 (8H, m), 2.6-2.7 (IH, m), 3.1-3.3 (IH, m), 3.7-4.5 (16H, m), 4.7-5.4 (IIH, m), 5.51 (IH, d, J=5.6Hz), 6.7-7.0 (3H, m), 7.0-7.6 (7H, m), 7.74 (IH, d, J=8.6Hz), 8.0-8.4 (5H, m) , 8.7-8.8 (IH, m) , 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1301 (M++Na)<br>
Elemental Analysis Calcd. for C55H7iNio022'‘‘‘-’’2'  <br>
C 47.62, H 6.03, N 10.01 Found :  C 47.65, H 6.03, N 10.03<br>
Example 16<br>
IR (Nujol) :  3353, 1668, 1627, 1540, 1515, 1500 cm~l<br>
NMR (DMSO-dg, 6) :  0.80-1.00 (6H, m) , 1.06 (3H, d, J=5.9Hz), 1.20-1.53 (4H, m), 1.60-1.95 (5H, m) , 2.00-2.65 (8H, m), 2.80 (2H, t, J=7.5Hz), 3.05-3.45 (IH, m), 3.50-3.85 (2H, m), 3.90-4.48 (IIH, m), 4.65-5.38 (IIH, m), 5.47 (IH, d, J=6.0Hz), 6.65-6.90 (2H, m), 6.90-7.10 (2H, m), 7.10-7.65 (UK, m) , 7.90-8.25 (2H, m) , 8.30 (IK, d, J’7.8Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1275.3 (M++Na)<br>
Elemental Analysis Calcd. for C55H73Ng022SNa-3H20 :<br>
C 50.53, H 6.09, N 8.57 Found :  C 50.48, K 6.39, N 8.57<br>
Example 17<br>
IR (Nujol) :  3351, 1656, 1623, 1538, 1515 cm~-<br>
NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.7Hz), 0.96 (3H,<br><br>
d, J=6.7H2), 1.08 (3H, d, J=5.8Hz), 1.15-1.40 (8H, m), 1.50-2.00 (5H, m), 2.10-2.48 (4H, m), 2.52-2.70 (2H, m), 3.05-3.28 (IH, m) , 3.60-4.50 (13H, m) , 4.70-5.20 (9H, iti) , 5.25 (IH, d, J=4.6Hz), 5.52 (IH, d, J=6.0Hz), 6.68-6.92 (4H, m),'7.04 (IH, d, J=1.0Hz), 7.22-7.50 (5H, m), 7.55-7.82 (7H, m), 8.14 (IH, d, J=8.4Hz), 8.31 (IH, d, J=8.4Hz), 8.54 (IH, d, J=7.7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1285 (M’+Na)<br>
Example 18<br>
IR (Nujol) :  3351, 1668, 1627, 1540, 1515 cm <br>
NMR (DMSO-dg, 6) :  0.87 (3H, t, J=6.8Hz), 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.8Hz), 1.17-1.48 (4H, m), 1.50-1.95 (5H, m), 2.05-2.70 (8H, m), 2.70-2.95 (2H, m), 3.05-3.30 (IH, m) , 3.60-3.90 (2H, m), 3.90-4.50 (IIH, m), 4.65-5.10 (9H, m), 5.15 (IH, d, J=3.2Hz), 5.23 (IH, d, J=4.2Hz), 5.48 (IH, d, J=6.0Hz), 6.67-6.90 (3H, m), 7.03 (IH, d, J=1.5Hz), 7.15-7.80 (IIH, m), 8.00-8.20 (2H, m), 8.29 (IH, d, J=7.8Hz), 8.84 (IK, s)<br>
FAB-MASS :  m/z = 1259 (M++Na)<br>
Elemental Analysis Calcd. for C55H73N802iSNa-6H20 :<br>
C 50.30, H 6.52, N 8.53 Found :  C 50.42, H 6.50, N 8.4 5<br>
Example 19<br>
IR (Nujol) :  3351, 1668, 1652, 1623, 1540 cm'‘ NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=6.0Hz), 1.25-1.45 (4H,'m), 1.50-2.00 (5H, m) , 2.05-2.48 (4H, m) , 2.50-2.75 (2H, m), 3.60-4.50 (13H, m), 4.68-5.25 (lOH, m), 5.27 (IH, d, J=4.5Hz), 5.53 (IH, d, J=6.0Hz), 6.67-6.98 (4H, m), 7.05 (IH, d.<br><br>
J=1.0Hz), 7.22-7.58 (5H, m) , 7.58-7.90 (7H, m) , 8.16 (IH, d, J=9.0K2), 8.34 (IH, d, J=8.4Hz), 8.57 (IH, d, J=7.7Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1258 (M++Na) Elemental Analysis Calcd. for C55H7]_N802iSNa-5H20 :<br>
C 49.84, H 6.15, N 8.45 Found :  C 49.77, H 6.27, N 8.39<br>
Example 20<br>
IR (Nujol) :  3353, 1670, 1629, 1540, 1508 cm-l<br>
NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.5Hz), 0.97 (3H, d, J=6.8Hz), 1.04 (3H, d, J=5.9Hz), 1.20-1.58 (8H, m) , 1.60-1.96 (5H, m), 2.08-2.60 (6H, m) , 2.70-3.00 (2H, m) , 3.00-3.40 (IH, m) , 3.60-3.85 (2H, m) , 3.85-4.50 (13H, m), 4.50-5.60 (12H, m), 6.65-6.90 (3H, m) , 7.00-7.15 (3H, m) , 7.18-7.50 (4H, m), 7.59 (IH, s), 7.62-7.78 (2H, m), 7.95-8.20 (2H, m), 8.30 (IH, d, J=7.7Kz), 8.83 (IH, s)<br>
FAB-MASS :  m/z = 1277 (M++Na)<br>
Elemental Analysis Calcd. for C55K75NgO22SNa-4H20 :<br>
C 49.77, H 6.30, N 8.44 Found :  C 49.67, H 6.31, N 8.40<br>
Example 21<br>
IR (Nujol) :  3351, 1654, 1623, 1538, 1515 cm~l NMR (DMS0-d5, 5) :  0.87 (3H, t, J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.9Hz), 1.20-1.58<br>
(8H, m), 1.66-1.95 (5H, m), 2.10-2.60 (4H, m) , 3.09-3.30 (IH, m) , 3.58-4.60 (15H, m) , 4.69-5.20<br>
(lOH, m), 5.24 (IH, d, J=4.5Hz), 5.51 (IH, d, J=6'.0Hz), 6.68-6.95 (4H, m) , 7.04 (IK, d, J=1.0Hz), 7.10-7.73 (7H, m), 7.73-7.90 (2H, m) , 7.98 (IH, d, J=1.9Hz), 8.10 (IH, d, J=8.4Hz), 8.32 (IH, d, J=8.4H2), 8.50 (IH, d, J=7.7Hz),<br><br>
8.84 (IH, s) FAB-MASS :  m/z = 127 5 (M++Na) Elemental Analysis Calcd. for C55H73N8022SNa-5H20 :<br>
C 50.38, H 6.38, N 8.55 Found :  C 49.98, H 6.37, N 8.41<br>
Example 2Z<br>
IR (KBr) :  3340, 2931, 1664, 1627, 1531, 1444, 1278,<br>
1047 cm-1<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.8Hz), 1.08 (3H, d, J=5.9H2), 1.2-1.4 (6H, m), 1.5-1.7 (2H, m) , 1.7-2.1 (3H, m) , 2.2-2.4 (3H, m), 2.6-2.7 (3H, m), 3.1-3.2 (IH, m), 3.7-4.6 (13H, m), 4.78 (IK, d, J=6.0H2), 4.8-5.1 (IH, m), 5.09 (IH, d, J=5.6Hz), 5.16 {IH, d, J=3.2H2), 5.24 (IH, d, J=4.4Hz), 5.52 (IH, d, J=6.0Hz), 6.73 (IH, d, J=8.2Hz), 6.83 (2H, d, J=8.3Hz), 7.05 (IH, s) , 7.3-7.5 (5H, iti) , 7.65 (2H, d, J=8.2H2), 7.74 (2H, d, J=8.4Hz), 7.98 (2H, d, J=8.4Hz), 8.11 (IH, d, J=8.4Hz), 8.31 (IH, d, J=8.4Hz), 8.79 (IH, d, J=7.7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1245 (M++Na)<br>
Elemental Analysis Calcd. for C54H73’N802iSNa-4H20 :<br>
C 50.07, H 6.15, N 8.65 Found :  C 50.26, H 6.44, N 8.67<br>
Example 23<br>
NMR (DMSO-dg, 5) :  0.91 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.8Hz), 1.05 (3H, d, J=5.6Hz), 1.2-1.5 (6H, m), 1.6-2.1 (5H, m) , 2.1-2.7 (4H, m) , 3.0-3.5 (9H,'m), 3.6-4.5 (15H, m) , 4.6-5.6 (IIH, m) , 6.73 (IH, d, J=8.2Kz), 6.8-6.9 (4H, m), 6.95 (2H, d, J=8.6Hz), 7.02 (2H, d, J=9.2Hz), 7.04 (IH, s), 7.2-7.5 (3H, m), 7.82 (2H, d, J=8.6Hz),<br><br>
8.06 (IH, d, J=8Hz), 8.25 (IH, d, J=6.7Hz), 8.43<br>
(IH, d, J=6.7Hz), 8.85 (IH, s) IR (KBr) :  3350, 1668, 1629, 1510 cm-! FA3-MASS :  m/z = 1345 (M+Na)<br>
Elemental Analysis Calcd. for  <br>
C 48.67, H 6.41, N 9.78 Found ;  C 48.80, H 6.4 6, N 9.82<br>
Example 24 Major product<br>
IR (KBr) :  3350, 1668, 1631, 1047 cm'‘ NMR (DMSO-dg, 5) :  0.96 (3H, d, J*=6.7Hz), 1.08 (3H, d, J=5.7Hz), 1.2-1.6 (lOH, m), 1.6-2.4 (8H, m) , 2.5-2.7 (IH, m), 3.18 (IH, m), 3.21 (3H, s), 3.29 (2H, t, J=6.4H2), 3.6-3.83 (2H, m), 3.83-4.6 (13H, m), 4.7-5.4 (IIH, m), 5.51 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.85 (IH, s), 7.04 (2H, d, J=8.4Hz), 7.06 (IH, s), 7.31 (IH, s), 7.2-7.5 (2H, m), 7.67 (2H, d, J=B.4H2), 7.71 (2H, d, J=8.4H2), 7.96 (2H, d, J=8.4Hz), 8.06 (IH, d, J=8Hz), 8.25 (IH, d, J=6.7Hz), 8.74 (IH, d, J=6.7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1319 (M+Na) Elemental Analysis Calcd. for C57H-7-7Ng023SNa-4H20 :<br>
C 49.99, H 6.26, N 8.18 Found :  C 49.74, H 5.27, N 8.06<br>
Minor product<br>
IR (KBr) :  3350, 1668, 1631 cm <br>
NMR (DMSO-dg, 6) :  0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.7Kz), 1.2-1.6 (6H, m) , 1.6-2.1 (7H, m) , 2.1-2.5 (3H, m), 2.5-2.7 (IH, m), 3.18 (IH, m), 3.6-3.8 (2H, m), 3.8-4.6 (13H, m), 4.6-5.2 (12H, m) , 5.26 (IH, d, J=4.6H2), 5.53 (IH, d.<br><br>
J=5.8Hz), 5.6-6.0 (IH, m) , 6.73 (IH, d, J=8.2H2), 6.83 (IH, d, J=8.3H2), 6.85 (IH, s), 7.04 (2H, d, J=8.5H2), 7.06 (IH, s), 7.30 (IH, s), 7.2-7.5 (2H, m), 7.68 (2H, d, J=8.5Hz), 7.72 {2H, d, J=8.5H2), 7.96 (2H, d, J=8.5Hz), 8.06 {IH, d, J=8Hz), 8.25 (IH, d, J=6.7H2), 8.74 (IH, d, J=6.7Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1287 (M+Na)<br>
Elemental Analysis Calcd. for C5gH-73NgNa022S-7H20 :<br>
C 48.34, H 6.30, N 8.05 Found :  C 48.19, H 6.19, N 7.99<br><br>
IR (KBr) :  3350, 2935, 2873, 1668, 1629, 1538, 1506,<br>
1438, 1257, 1049 cin~-NMR (DMSO-dg, 5) :  0.9-1.0 (6H, m), 1.08 (3H, d,<br>
J=5.7Hz), 1.2-1.6 (4H, m), 1.6-2.0 (5H, m), 2.1-2.4 (3H, m) , 2.5-2.6 (IH, in), 3.1-3.2 (IH, m) , 3.6-4.6 (15H, m), 4.7-5.2 (lOH, m), 5.26 (IH, d J=4.5H2), 5.55 (IH, d, J=5.9Hz), 6.7-6.9 (3H, m), 7.0-7.6 (7H, m), 7.85 (2H, d, J=8.6Hz), 7.9-8.2 (4H, m), 8.26 (IH, d, J=7.7H2), 8.8-9.0 (2H, m) FAB-MASS :  n/z = 1314.3 (M+Na)’ Elemental Analysis Calcd. for C5gK-7QNg023NaS-7H20 :<br>
C 47.42, H 5.97, N 8.89 Found :  C 47.33, H 5.85, N 8.73<br><br>
To a solution of The Starting Compound (1 g) and succinimide 4-(4-octyloxyphenyl)piperazine-1-carboxylate (0.45 g) in N,N-dimethylformamide (10 ml) was added 4-dimethylaminopyridine (0.141 g), and stirred for 5 days at 50°C.  The reaction mixture was pulverized with ethyl acetate.  The precipitate was collected by filtration, and<br><br>
dried under reduced pressure,  one power was missive m water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4) eluting with water.  The fractions containing the object compound were combined, and subjected to colimm chromatography on ODS (YMC-gel-ODS-AM-S-50) eluting with 50% acetonitrile aqueous solution.  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile.  The residue was lyophilized to give crude The Object Compound (23).  The powder of crude The Object Compound (23) was purified by preparative HPLC utilizing a Cog    Bandana resin (Waters Associates, Inc.) which was eluted with a solvent system comprised of (acetonitrile-pH 3 phosphate buffer = 40:60) at a flow rate of 80 ml/minute using a Shimadzu LC-8A pump.  The column was monitored by a UV detector set at 240 um.  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile.  The residue was subjected to column chromatography on ion exchange resin (DOWEX-50WX4) eluting with water.  The fractions containing the object compound were combined, and subjected to colimm chromatography on ODS (YMC-gel-ODS-AM-S-50) eluting with 50% acetonitrile aqueous solution.  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile.  The residue was lyophilized to give The Object Compound (23) (60 mg). IR (KBr) :  3347, 1629, 1511, 1245 cm-’ NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.7Hz), 0.95 (3H, d, J=6.8Hz), 1.06 {3H, d, J=5.9Hz), 1.2-1.5 (lOH, m), 1.55-1.92 (5H, m), 2.0-2.65 (4H, m) , 2.8-3.05 (5H, m), 3.2-4.47 (17H, m), 4.6-5.6 (12H, m), 6.6-7.0 (7H, m), 7.03 (IH, s), 7.2-7.5 (3K, m) , 7.9-8.3 (3H, m), 8.84 (IH, s) FAB-MASS :  m/z = 1297 (M'‘+Na)<br><br>
Elemental Analysis Calcd. for C54H79NT_Q022SNa-6H20-CH3CN:<br>
C 47.22, H 6.65, N 10.82 Found :  C 47.58, H 7.05, N 10.85<br>
EHftP\Pl€ 27<br>
To a suspension of l-hydroxybenzotriazole (0.53 g) and 2-(4-octyloxyphenoxy)acetic acid (1 g) in dichloromethane (30 ml) was added l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSCD-HCl) (0.886 g), and stirred for 3 hours at ambient temperature. The reaction mixture was added to water.  The organic layer was taken, and dried over magnesium sulfate.  The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give l-[2-(4-octyloxyphenoxy)acetyljbenzotriazole 3-oxide (892 mg).  To a solution of The Starting Compound (1.79 g) and l-[2-(4-octyloxyphenoxy)acetyljbenzotriazole 3-oxide (892 mg) in N,N-dimethylformamide (18 ml) was added 4-(N,N-dimethylamino)pyridine (0.297 g), and stirred for 12 hours at ambient temperature.  The reaction mixture was pulverized with ethyl acetate.  The precipitate was collected by filtration, and dried under reduced pressure. The powder was added to water, and subjected to ion-exchange column chromatography on DOWEX-50WX4, and eluted with water.  The fractions containing the object compound were combined, and subjected to colimm chromatograph on ODS (YMC-gel-ODS-AM-S-50) , and eluted with 50% methanol aqueous solution.  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove methanol.  The residue was lyophilized to give The Object Compound (24) (1.75 g).<br>
IR (KBr) ':  3350, 1666, 1629, 1228 cm--NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.9Hz), 0.95 (3H, d, J=6,7Hz), 1.04 (3H, d, J=5.7Hz), 1.15-1.5 (lOH, m), i.55-2.0 (5H, m) , 2.05-2.5 (4H, m),<br><br>
3.16 (IK, m), 3.72 (2H, m) , 3.88 (3H, t, J=6.3Hz), 4.41 (2H, s), 3.93-4.6 (IIH, m), 4.69-5.25 (lOH, m),   5.28 (IH, d, J=4.3H2), 5.57 (IH, d, J=5.7Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (5H, m), 7.04 (IH, s),   7.09 (IH, s), 7.3-7.4 (2H, m), 7.92-8.17 (2H, iti) , 8.29 (IH, d, J=7.5Hz), 8.84 (IH, s)<br>
FAB-M?ISS :  m/z = 1243 (M++Na)<br>
Elemental Analysis Calcd. for C5iH73Ng023SNa-4H20 :<br>
C 47.36, H 6.31, N 8.66 Found :  C 47.22, H 6.44, N 8.37<br>
The Object Compounds (28) to (31) were obtained according to a similar manner to that of Example 27.<br>
Example 28<br>
IR (KBr) :  3350, 2933, 1664, 1628, 1446, 1205,<br>
1045 cm-l NMR (DMSO-dg, 6) :  0.8-1.1 (9H, m), 1.2-2.0 (19H, m),<br>
2.1-2.3 (3H, m), 3.6-3.8 (4H, m), 3.9-4.4 (13H, m), 4.6-5.0 (8H, m), 5.07 (IH, d, J=5.6Hz), 5.14 (IH, d, J=3.2Hz), 5.23 (IH, d, J=4.3Hz), 5.46 (IH, d, J=6.7Hz), 6.7-6.9 (3H, m), 7.04 (IH, s), 7.2-7.5 (6H, m), 7.8-8.0 (3H, m), 8.05 (IH, d, J=8.4Hz), 8.2-8.4 (2H, m), 8.83 (IH, s) FAB-MASS :  m/z = 1360 (M-’+Na) Elemental Analysis Calcd. for C59H8oN9023SNa-6H20 :<br>
C 48.99, H 6.41, N 8.72 Found :  C 48.92, H 6.37, N 8 . 64<br>
Example 29<br>
IR (KBr) •:  3350, 2927, 1668, 1627, 1535, 1515, 1452,<br>
1440, 1286, 1045 cm~’ NMR (DMSO-dg, 5) :  0.83 (3H, t, J=6,7Hz), 0.95 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.2-1.4<br><br>
(12H, m) , 1.6-2.0 (5H, m) , 2.1-2.4 (3H, iti) , 2.6 (IH, m), 2.82 (2H, t, J=7.4H2), 3.1-3.2 (IH, m), 3.6-4.5 (13H, m), 4.7-5.2 (IIH, m), 5.4-5.6 (IH, m) , 6.72 (IH, d, J=8.2Hz), 6.82 (2H, d, J=8.1Hz), 7.03 (IH, s), 7.2-7.4 (3H, m), 7.47 (IH, d, J=8.5Hz), 7.69 (IH, d, J=8.5Hz), 8.1-8.2 (2H, m), 8.23 (IH, d, J=8.4K2), 8.62 (IH, d, J=7.8Hz), 8.83 (IH, s) FAB-MASS :  m/z = 1251 (M++Na) Elemental Analysis Calcd. for C52H73N2o02iSNa-5H20 :<br>
C 47.34, H 6.34, N 10.61 Found :  C 47.30, H 6.45, N 10.45<br>
Example 30<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.8Hz), 0.96 (3H, t, J=6.7Hz), 1.05 (3H, t, J=5.8Hz), 1.2-1.5 (lOH, m), 1.6-2.0 (5H, m), 2.2-2.4 (3H, m), 2.5-2.6   (IH, m), 3.1-3.2 (IH, m), 3.7-4.5 (15H, m), 4.7-5.0 (8H, m), 5.10 (IH, d, J=5.6H2), 5.17 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.5Hz), 5.52 (IH, d, J=5.8Hz) 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (3H, m), 7.04 (IH, s), 7.2-7.4 (3H, m) , 8.0-8.3 (3H, m), 8.68 (IH, d, J=2.3Hz), 8.7-8.8 (IH, m), 8.85 (IH, m)<br>
FAB-MASS :  m/z = 1214 (M’+Na)<br>
Elemental Analysis Calcd. for C49H7oN9022SNa-4H20 :<br>
C 4 6.55, H 6.22, N 9.97 Found :  C 46.29, H 6.18, N 9.71<br>
Example 31<br>
IR (Nujol) :  3342, 2210, 1668, 1623 cm~l NMR (DMSd-dg, 5) :  0.88 (3H, t, J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 1.08 (3H, d, J=6.7Hz), 1.20-1.60 (8H, m), 1.60-2.00 (5H, m) , 2.05-2.50 (4H, m) , 3.05-3.30 (IH, m), 3.60-4.60 (15H, m) , 4.65-5.18<br><br>
(lOH, m), 5.24 (IH, d, J=4.5Hz), 5.58 (IH, d, J=6.0Hz), 6,68-7.10 (4H, m) , 7.15-7.65 (5H, m) , 7.80-8.30 (6H, m), 8.84 (IH, s), 9.18 (IH, d, J’7.7Hz) FAB-MASS :  m/z = 1273.5 (M++Na)<br><br>
To a solution of 6-heptyloxy-2-naphthoic acid (0.358 g) and triethylamine (0.174 ml) in N,N-dimethylformamide (10 ml) was added diphenylphosphoryl azide (0.4 ml), and stirred for an hour at ambient temperature.  Then, the reaction mixture was stirred for an hour at 100’*0. After cooling, to the reaction mixture was added The Starting Compound (1 g) and 4-(N,N-dimethylamino)pyridine (0.140 g) , and stirred for 10 hours at ambient temperature.  The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration, and dried under reduced pressure.  The powder was dissolved in water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4) eluting with water.  The fractions containing the object compound were combined, and subjected to column chromatography on ODS (YMC-gel-ODS-AM-S-50) eluting with 50% acetonitrile aqueous solution.  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile.  The residue was lyophilized to give The Object Compound (29) (0.832 g).<br>
IR (KBr) :  3350, 1664, 1629, 1546, 1240 cm-’ NMR (DMSO-dg, 6) :  0.88 (3H, t, J=&amp;.6Hz), 0.97 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.9Hz), 1.2-1.55 (8H, m) , 1.55-2.0 (5H, m), 2.1-2.5 (4K, m) , 3.18' (IH, m) , 3,6-3.8 {3H, m), 3.9-4.5 (13H, m), 4.7-4.95 (3H, m), 5,0-5.3 (7H, m) , 5.59 (IH, d, J=5,8Hz), 6.52 (IH, d, J=8.1Hz), 6.73 (IH, d, J=8,2Hz), 6.83 (IH, d, J=8.2Hz), 6.90 (IH, s),<br><br>
7.0-7.15 (3H, m), 7.20 (IK, s), 7.27-7.4 (3K, IT.) , 7.6-7.7 (2H, m), 7.87 (IH, s) , 7.95-8.2 (2K, m) , 8.69 (IH, s), 8.85 (IH, s) FAB-MS :  m/z = 1264 (M++Na) Elemental Analysis Calcd. for C53H72N9022SNa-5H20 :<br>
C 47.78, H 6.20, N 9.46 Found :  C 47.65, H 6.42, N 9.34<br>
The Object Compound (33) was obtained according to a similar manner to that of Example 32.<br>
Example 33<br>
IR (KBr) :  3350, 1666, 1629, 1537, 1240 cm-l<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.7Hz), 0.97 (3H, d, J=6.7H2), 1.09 (3H, d, J=5.8Hz), 1.2-1.55 (8H, m) , 1.55-2.0 (5H, m), 2.07-2.6 (4H, m) , 3.18 (IH, m), 3.6-3.85 (3H, m), 3.9-4.5 (13H, m) , 4.7-4.98 (3H, m), 5.0-5.3 (7H, m), 5.57 (IH, d, J=5.9Hz), 6.50 (IK, d, J=8.1Hz), 6.73 (IH, d, J=8.2Hz), 6.82 (IH, dd, J=8.2 and 1.7Hz), 6.87 (IH, s), 6.97 (2H, d, J=8.8Hz), 7.05 (IH, d, J=1.7Hz), 7.10 (IH, s), 7.23-7.43 (2H, m), 7.38 (2H, d, J=8.8Hz), 7.50 (2H, d, J=8.8Hz), 7.52 (2H, d, J=8.8Hz), 8.0-8.15 (2K, m), 8.65 (IK, s), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1290 (M++Na)<br>
Elemental Analysis Calcd. for C55H74N9022SNa-7H20 :<br>
C 47.38, H 6.36, N 9.04 Found :  C 47 . 67, H 6. 53, N 9. 03<br>
Example 34<br>
A solution of The Starting Compound (2.45 g), 3-[4-(4-pentylphenyl)phenyl]propionic acid (0.90 g),   l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSCD-KCl) (0.59 g) and triethylamine (0.43 ml) in N,N-<br><br>
dimethylformamide (50 ml) was stirred for 15 hours at ambient temperature.  The reaction mixture was diluted with ethyl acetate, and the resultant precipitate was collected by filtration, and washed in turn with ethyl acetate and isopropyl ether, and dried under reduced pressure.  The powder was dissolved in water, and was subjected to column chromatography on ion exchange resin (DOWEX-50WX4 (Na form, 50 ml)) eluting with water.  The fractions containing the object compound were combined, and subjected to reversed phase chromatography on ODS (YMC-gel-ODS-AM-S-SO, 50 ml) eluting with (water : acetonitrile = 10:0 -  7:3, V/V).  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile.  The residue was lyophilized to give The Object Compound (31) (1.53 g). IR (Nujol) :  3351, 2212, 1668, 1627 cm-’ NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.5Hz), 0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.8Hz), 1.20-1.50 (4H, m), 1.50-2.00 (5H, m), 2.03-2,55 (4H, m) , 2.62 (2H, t, J=7.5Hz), 3.17 (IH, t, J=8.4Hz), 3.55-4.57 (15H, m), 4.65-5,13 (9H, m), 5.16 (IH, d, J=3.2H2), 5.24 (IH, d, J=4.5Hz), 5.58 (IH, d, J=5.8Hz), 6.67-6.90 (3H, m), 6.93-7.10 (2H, m) , 7.15-7.50 (4H, m), 7.50-7.90 (6H, m), 8.06 (IH, d, J=8.4Hz), 8.15 (IH, d, J=7.7H2), 8.84 (IH, s), 9.19 (IH, d, J=‘7,lHz) FAB-MASS :  m/z = 1255 (M’+Na) Elemental Analysis Calcd. for C55Kg9N802iSNa-4H20 :<br>
C 50.61, H 5.95, N 8.58 Found :  C 50,47, H 6.00, N 8.54<br>
Example 35<br>
To a suspension of 1-hydroxybenzotriazole (501 mg) and 4-(4-heptylphenyl)benzoic acid (1 g) in dichloromethane (30 ml) was added 1-ethyl-3-(3'-<br><br>
dimethylamino propyl)carbodiimide hydrochloride (WSCD-HCl) (839 mg), and stirred for 3 hours at ambient temperature. The reaction mixture was added to water.  The organic layer was separated, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give l-[4-(4-heptylphenyl)benzoyl benzotriazole 3-oxide.  To a solution of The Starting Compound (2.49 g) and l-[4-(4-heptylphenyl)benzoyl]benzotriazole S-oxide in N,N-dimethylformamide (25 ml) was added 4-(N,N-dimethylamino)pyridine (381 mg), and stirred for 12 hours at ambient temperature.  The reaction mixture was pulverized with ethyl acetate-  The precipitate was collected by filtration, and dried under reduced pressure. The residue was dissolved in water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4) eluting with water.  The fraction containing the object compound were combined, and subjected to column chromatography on CDS (YMC-gel-ODS-AM-S-50) eluting with 30% acetonitrile aqueous solution.  The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give The Object Compound (32) (1.99 g).<br>
IR (Nujol) :  3350, 2852, 1749, 1621, 1457, 1376,<br>
1045 cm-l NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.9Hz), 1.5-1.7 (2H, m), 1.7-2.2 (3H, m) , 2.2-2.5 (3H, m) , 2.6-2.8 (3H, m) , 3,1-3.2 (IH, m), 3.7-4.6 (13H, m), 4.7-5.2 (8H, m), 5.12 (IH, d, J=5.5Hz), 5.18 (IH, 'd, J=2.9Hz), 5.27 (IH, d, J=4.4Hz), 5.54 (IH, d, J=5.8Hz), 6.7-6.9 (3H, m), 7.05 (IK, s), 7.2-7.4 (5H, m), 7.65 (2H, d, J=8.0H2), 7,74 (2H, d, J=8.3Hz), 7.98 (2H, d, J=8,3Hz), 8.11<br><br>
(IH, d, J=8.7Hz), 8.28 (IH, d, J=8.4Hz), 8.78 (IH, d, J=7.3H2), 8.85 (IH, s)' FAB-MASS :  m/z = 1259 (M++Na) Elemental Analysis Calcd. for C55H73N802iSNa-5H20 :<br>
C 49.77, H 6.30, N 8.44 Found :  C 49.98, H 6.44, N 8.41<br>
The Object Compounds (36) to (107) were obtained according to a similar manner to that of Example 1.<br><br>
IR (KBr) :  3350, 1675.8, 1629.6, 1515.8 cm~-<br>
NMR (DMSO-dg, 5) :  0.86 (6H, d, J=6.6H2), 0.96 (3H, d, J=6.6H2), 1.06 (3H, d, J=5.7Hz), 1.1-1.3 (2H, m) , 1.4-2.0 (6H, m) , 2.0-2.7 (4H, m) , 3.1-3.5 (9H, m), 3.66 (2H, t, J=7.3Hz), 3.6-4.5 (13H, m), 4.7-5.6 (12H, m), 6.73 (IH, d, J=8.3Hz), 6.82 (IH, d, J=8.3Hz), 6.8-6.9 (IH, m), 7.02 (2H, d, J=9.0Hz), 7.04 (IH, s), 7.11 (2H, d, J=9.0Hz), 7.2-7.6 (3H, m), 7.50 (2H, d, J=9.0H2), 7.82 (2H, d, J=9.0Hz), 8.1 (IH, d, J=8.5Hz), 8.28 (IH, d, J=8.5Hz), 8.33 (IH, s), 8.45 (IH, d, J=7.0Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1412 (M+Na)<br>
Elemental Analysis Calcd. for C6QHgoN2_3022SNa-9H20 :<br>
C 46.42, H 6.36, N 11.73 Found :  C 46.64, H 6.43, N 11.62<br>
Example 37<br>
IR (KBr) :  3350, 1668.1, 1629.6, 1268.9 cm~’ NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.2-1.4 (lOH, m), 1.4-2-. 0 (5H, m) , 2.0-2.5 (4H, m) , 2.61 (2H, t, J=7.2Hz), 3.1-3.3 (IH, m), 3.6-4.5 (13H, m), 4.40 (2H, s), 4.6-5.3 (IIH, m), 5.60 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8,2Hz), 6.82 (IH, d, J=8,2Hz), 6.6-<br><br>
6.9 (IH, m), 7.04 (IH, s), 7.0-7.1 (IH, m), 7.32 (2H, d, J=8.5H2), 7.2-7.5 (2K, m), 7.58 (2H, d, J=8.5H2), 7.93 (IH, d, J=7Hz), 8.04 (IH, d, J=9.4Hz), 8.41 (IH, s), 8.44 (IH, d, J=9.4Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1294 (M+Na)<br>
Elemental Analysis Calcd.  <br>
C 45.52, H 6.34, N 11.02 Found :  C 45.47, H 6.27, N 10.93<br>
Example 38 Major product<br>
IR (KBr) :  3349.7, 1670.1, 1627.6, 1508.1 cm~’ NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.6Hz), 1.06 (3H, d, J=5.7Hz), 1.2-1.6 (8H, m), 1.6-2.1 (5H, m) , 2.1-2.7 (4H, m), 3.0-3.2 (5H, m), 3.21 (3H, s), 3.30 (2H, t, J=6.5Hz), 3.3-3.5 (4H, m), 3.6-4.5 (15H, m), 4.7-5.3 (IIH, m), 5.49 (IK, d, J=5.9Hz), 6.73 (IH, d, J=8.3Hz), 6.8-6.9 (4H, m), 6.95 (2H, d, J=9.2Hz), 7.01 (2H, d, J=8.5Hz), 7.04 (IH, s), 7.20 (IH, s), 7.2-7.5 (2H, m), 7.81 (2H, d, J=8.5Hz), 8.09 (IH, d, J=8.7Hz), 8.28 (IH, d, J=8.7Hz), 8.45 (IK, d, J=6.7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1389 (M+Na) Elemental Analysis Calcd. for C6QH33N2’Q023SNa-8H20 :<br>
C 47.68, H 6.60, N 9.27 Found :  C 47.83, H 6.72, N 9.27<br>
Minor product<br>
IR (KBr) : 3338.2, 1646.9, 1511.9 cm~-<br>
NMR (DMSO-dg, 6) :  0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.'7Hz), 1.3-1.6 (4H, m) , 1.6-2.7 (IIH, m) , 3.0-3.2 (5H, m), 3.3-3.5 (4H, m), 3.6-4.5 (15H, m) , 4.7-5.3 (13H, m), 5.48 (IH, d, J=5.9Hz), 5.7-6.0 (IH, m), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (4H, m) ,<br><br>
6.94 (2H, d, J=9.3Hz), 7.01 (2H, d, J=8.6Hz), 7.04 (IH, s), 7.2-7.5 (3H, m), 7.81 (2H, d, J=8.6Hz), 8.06 (IH, d, J=8.7Hz), 8.25 (IH, d, J=8.7Hz), 8.42 (IH, d, J=6.7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1357 (M+Na)<br>
Elemental Analysis Calcd. for C5gH7gN2o022’’’-’’2'‘ *<br>
C 47.32, H 6.53, N 9.35 Found :  C 47.08, H 6.66, N 9.25<br><br>
IR (KBr) :  3350, 1670.1, 1631.5, 1510.0, 1234.2 cin~l<br>
NMR (DMSO-dg, 6) :  0.87 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.6Hz), 1.2-1.5 (8H, m) , 1.6-2.1 (5H, m) , 2.1-2.7 (4H, m) , 3.0-3.3 (5H, xn) , 3.3-3.5 (4H, m), 3.6-3.8 (2H, m), 3.88 (2H, d, J=6.4Hz), 3.8-4.5 (IIH, m),4.7-5.1 (8H, m), 5.10 ■ (IH, d, J=5.6Hz), 5.16 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5Hz), 5.48 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.2Hz), 6.8-5.9 (4H, m), 6.94 (2H, d, J=9.3Hz), 7.01 (2H, d, J=8.7Hz), 7.04 (IH, s), 7.2-7.5 (3H, m), 7.81 (2H, d, J=8.7Hz), 8.06 (IH, d, J=8H2), 8.25 (IH, d, J=6.7Hz), 8.43 (IH, d, J=6.7Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z =  1359 (M+Na)<br>
Elemental Analysis Calcd. for C59H33_N-j’o029SNa-5H20 :<br>
C 49.64, H 6.43, N 9.81 Found :  C 49.49, H 6.54, N 9.72<br>
Example 4 0<br>
IR (KBr) :  3355.5, 1670.1, 1627.6, 1510.0 1236.1 cm~’ NMR (DMSO-dg, 5) :  0.8 9 (6H, d, J=6.5Hz), 0.96 {3H, d, J=6.-7Hz), 1.05 (3K, d, J=5.7Hz), 1.2-1.4 (2H, m) , 1.5-2.1 (6H, m) , 2.1-2.7 (4H, m) , 3.0-3.6 (9H, m) , 3.6-4.5 (15H, m), 4,5-5.4 (12H, m), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (4H, m), 6.96 (2H, d, J=9.6Hz),<br><br>
7.02 (2H, d, J=8,7Hz), 7.05 (IH, s),   7.2-7.5 (3H, m), 7.82 (2K, d, J=8.7Hz), 8.08 (IH, d, J=8Hz), 8,27 (IH, d, J=6.7Hz), 8.46 (IH, d, J=6.7Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1345 (M+Na) Elemental Analysis Calcd. for C5gK-7 9N-j’Q022SNa-8H20 :<br>
C 47.47, H 6.52, N 9.54 Found :  C 47.47, H 6.54, N 9.51<br>
Example 41<br>
IR (KBr) :  3347.8, 1668.1, 1629.6, 1510.0, 1234.2 cm~’<br>
NMR (DMSO-dg, 5) :  0.89 (3H, t, J=7.0Hz), 0.96 (3H, d, J=6.7Hz), 1.05 (3H, d, J=5.8Hz), 1.2-1.5 (4H, m), 1.6-2.1 (5H, m) , 2.1-2.7 (4H, m) , 3.0-3.6 (9H, m) , 3.6-3.8 (2H, m) , 3.8-4.5 (13H, m), 4.7-5.6 (12H, m), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (4H, m), 6.96 (2H, d, J=8.7Hz), 7.02 (2H, d, J=9.0Hz), 7.04 (IH, s), 7.2-7.5-(3H, m), 7.82 (2H, d, J=8.7Hz), 8.07 (IH, d, J=8Hz), 8.27 (IH, d, J=6.7Kz), 8.45 (IH, d, J=6.7Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1331 (M+Na)<br>
Elemental Analysis Calcd. for C57H7-7N-|_o022SNa-6H20 :<br>
C 48.30, H 6.33, N 9.88 Found :  C 48.20, H 6.58, N10.03<br>
Example 42 Mixture product<br>
IR (KBr) ;  3344, 1670.1, 1631.5 cm~'<br>
NMR (DMSO-dg, 5) :  0.96 (3K, d, J=6.7Hz), 1.08 (3H, d, J=5.9Hz), 1.2-1.5 (8H, m), 1.6-2.1 (7H, m) , 2.1-2.7 (4H, m), 3.1-3.3 (IH, m), 3.6-4.5 (15H, m) , 4.45 and 4.70 (2H,t, J=7.1Hz), 4.6-5.3 (IIH, m), 5.52 (IH, d, J=5.9Hz), 6.73 (IK, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.85 (IH, s), 7.03 (2H, d, J=8.6Hz), 7.05 (IH, s), 7.2-7.5 (3H, m), 7.68 (2H, d.<br><br>
J=8.6Hz), 7.71 (2H, d, J=8.4Hz), 7.96 (2H, d, J=8.4Hz), 8.12 (IH, d, J=8.5Hz), 8.30 (IH, d, J=7.0Hz) FAB-MASS :  m/z = 1357 (M+Na)<br>
Elemental Analysis Calcd. for Cc,'jH'j’Ni2'‘22’’’'‘‘2'‘   '<br>
C 48.64, H 5.94, N 11.94 Found :  C 48.91, H 5.88, N 11.86<br>
Example 43<br>
IR (KBr) : 3350, 1666.2, 1651.5 cm~’<br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.7Hz), 1.05 (6H, d, J=6.3Hz), 1.06 (3H, d, J=5.7Hz), 1.2-1.6 (lOH, m), 1.6-2.1 (7H, m), 2.1-2.7 (6H, m), 2.8-3.0 (2H, m) , 3.0-3.2 (IH, m) , 3.4-3.7 (2H, m), 3.6-3.8 (2H, m), 3.8-4.5 (13H, m), 4.7-5.6 (12H, m), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m), 7.03 (2H, d, J=8.7Hz), 7.06 (IH, s), 7.2-7.5 (3H, m), 7.67 (2H, d, J=8.7Hz), 7.71 (2H, d, J=8.4Hz), 7.96 (2K, d, J=8.4Hz), 8.04 (IH, d, J=8.5Hz), 8.31 (IH, d, J=8.5Hz), 8.73 (IH, d, J=7.0Hz), 8.90 (IH, s)<br>
FAB-MASS :  m/z = 1402 (M+Na)<br>
Example 44<br>
IR (KBr pelet) : 3350, 2929, 2856, 1670, 1631, 1510,<br>
1243, 1045 cm--NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.8Hz), 0.96 (3H, d, J=6.7H2), 1.06 (3H, d, J=5.7Hz), 1.6-2.0 (5H, m) , 2.2-2.5 (5H, m), 2.6-2.7 (IH, m), 3.0-3.3 (5H, m), 3.6-4.5 (19H, m), 4.77 (2H, d, J=5.9Hz), 4.8-5.1 (6H, m), 5.10 (IH, d, J=5.6Hz), 5.17 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5Hz), 5.50 (IH, d, J=5.-8Hz), 6.7-7.0 (8H, m) , 7.04 (IH, s) , 7.2-7.4 (3H, m), 8.0-8.2 (2H, m), 8.26 (IH, d, J=8.0H2), 8.55 (IH, d, J=7.3Hz), 8.67 (IH, d, J=1.2Hz), 8.85 (IH, s)<br><br>
FAB-MASS :  m/z = 1374.3 (M+Na-’)<br>
Elemental Analysis Calcd. for C5gHg2N-[_T 022NaS-5.5H2O :<br>
C 48.82, H 6.46, N 10.61 Found :  C 48.89, H 6.74, N 10.50<br>
Example 4 5<br>
IR (KBr) : 3350, 2935, 1668, 1623, 1538, 1257, 1174,<br>
1047  cm-’ NMR (DMSO-dg, 6) :  0.8-1.1 (6H, m), 1.09 (3H, d,<br>
J=5.7Hz), 1.2-1.6 (6H, m), 1.7-2.1 (5H, m) , 2.2-2.4 (3H, m), 2.5-2.6 (IH, m), 3.6-3.8 {2H, m), 3.8-4.6 (14H, m), 4.8-5.2 (7H, m), 5.18 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.5Hz), 5,54 (IH, d, J=5.8Hz), 6.7-7.5 (9H, in), 7.82 (IH, d, J=8.5Hz), 7.96 (IH, d, J=8.7Hz), 8.1-8.4 (5H, m) , 8.8-9.0 (2H, m) FAB-MASS :  ra/z = 1302.6 (M+Na-*-) Elemental Analysis Calcd. for C55H7QNg023SNa-6H20 :<br>
C 47.58, H 5.95, N 9,08 Found :  C 47.46, H 6.04, N 9,05<br>
Example 4 6<br>
IR (KBr) :  3355, 2958, 1670, 1627, 1521, 1247,<br>
104 7 cm~-<br>
NMR (DMSO-dg, 6) :  0.9-1.0 (6H, m), 1.08 (3H, d,<br>
J=5.6Hz), 1.4-1.6 (2H, m), 1,7-2.1 (5H, m) , 2.1-2,4 (3K, m) , 2.5-2.6 (IH, m), 3.1-3.3 (IH, m) , 3.7-3,8 (2H, m), 3.9-4,6 (13H, m), 4.8-5.1 (8H, m), 5.11 (IH, d, J=5.6Hz), 5,17 (IH, d, J=3,1H2), 5,26 (IH, d, J=4,5H2), 5,54 (IH, d, J=5,9Hz), 6,7-6,9 (3H, m), 7.0-7.2 (3H, m), 7.3-7.5 (3H, m), 7.7-7.9 (8K, m), 8,02 (2H, d, J=8.4Hz), 8.08 (IH, d, J=8.4Hz), 8.32 '(IK, d, J=7,7HZ), 8,81 (IH, d, J=7.0Hz), 8,85 (IK, s)<br>
FAB-MASS :  m/z = 1309.3 (M+Na) -’<br>
Elemental Analysis Calcd. for C5gK72Ng022NaS-6H20 :<br><br>
C 49.92, H 6.00, N 8.03 Found :  C 49.92, H 5.97, N 8.03<br>
Example 47<br>
IR (KBr) :  3350, 2933, 1668, 1629, 1517, 1249,<br>
1045 cm~’ NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.7H2), 0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.8Hz), 1.7-2.7 (8H, m) , 3.1-3.3 (IH, m) , 3.6-4.5 (16H, m), 4.7-5.2 (8H, m) , 5.18 (IH, d, J=3.1Hz), 5.27 (IH, d, J=4.5Hz), 5.56 (IH, d, J=5.8Hz), 6.7-7.0 (3H, m) , 7.0-7.2 (3H, m) , 7.2-7.5 (3H, m) , 8.0-8.4 (6H, m), 8.85 (IH, s), 8.96 (IH, d, J=7.0Hz), 9.07 (IH, s) FAB-MASS :  m/z = 127 6.6 (M+Na’) Elemental Analysis Calcd. for C54H-72Ng022NaS-5H20 :<br>
C 48.25, H 6.15, N 9.38 Found :  C 48.10, H 6.14, N 9.30 Example 4 8<br>
IR (KBr) : 3350, 2931, 1668, 1629, 1537, 1049 cm-’ NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.9Hz), 0.9-1.5<br>
(16H, m) , 1.6-2.4 (8H, m), 2.5-2.7 (IH, m) , 3.1-3.3 (IH, m), 3.5-5.6 (25H, m), 6.6-7.4 (8H, m), 7.8-8.4 (6H, m), 8.7-9.0 (2H, m), 9.00 (IH, d, J=2.4Hz) FAB-MASS :  m/z =  1331.4 (M+Na’) Elemental Analysis Calcd. for C5gK73N]_Q023NaS-8H20 :<br>
C 46.28, H 6.17, N 9.64 Found :  C 46.50, H 6.27, N 9.65<br>
Example 4 9<br>
IR (KBr pelet) :  3300, 2931,	1668, 1650, 1629, 1538,<br>
1515, 1268,	1049 cm-’<br>
NMR (DMSO-dg, 5) :  0.87 (3H,	t, J=6.6Hz), 0.97 (3H, d,<br>
J=6.7Hz), 1.10 (3H, d, J=5.6Hz), 1.2-1.4 (6H, m) ,<br>
1.5-1.7 (2H, m) , 1.7-2.1	(3K, m), 2.1-2.4 (3H, m) ,<br>
2.6-2.7 {3H, m) , 3.1-3.2	(IH, m), 3.7-3.9 (2H, m) ,<br><br>
3.9-4.5 (12H, m), 4.8-5.1 (7H, m), 5.11 (IH, d, J=5.5Hz), 5.18 (IH, d, J=3.1Hz), 5.27 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.8Hz), 6.7-7.0 (3H, m), 7.06 (IH, s), 7.3-7.5 (5H, m), 7.72 (2H, d, J=8.2Hz), 7.9-8.2 (5H, m), 8.3-8.4 (4H, m), 8.9-9.0 (2H, m)<br>
FAB-MASS :  m/z = 12 60.5 (M+Na-*-)<br>
Elemental Analysis Calcd. for C62.K74Ng022SNa-6H20 :<br>
C 50.58, H 5.98, N 8.70 Found :  C 50.34, H 6.16, N 8.55<br>
Example 50<br>
IR (KBr) :  3369, 2958, 2935, 1670, 1629, 1525, 1473,<br>
1247, 1047 cm-’ NMR (DMSO-dg, 5) :  0.95 (3H, t, J=7.3Hz), 0.97 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.7Hz), 1.3-1.6 (2H, m), 1.7-2.1 (5H, m) , 2.1-2.4 (3H, m), 2.5-2.6 (IH, m), 3.1-3.3 (IH, m), 3.7-4.6 (15H, m), 4.7-5.1 (8H, m), 5.10 (IH, d, J=5.6Hz), 5.18 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.4Hz), 5.56 (IH, d, J=5.7Hz), 6.7-7.0 (3H, m), 7.1-7.2 (3H, m) , 7.2-7.4 (3H, m), 7.70 (2H, d, J=8.6Hz), 7.78 (2H, d, J=8.4Hz), 8.1-8.4 (6H, m), 8.85 (IH, s), 8.99 (IH, d, J=7.0Hz), 9.13 (IH, d, J=1.6Hz) FAB-MASS :  m/z = 1310.1  (M+Na)’ Elemental Analysis Calcd. for C57H7QNg022NaS-7H20 :<br>
C 47.20, H 6.12, N 8.69 Found :  C 47.42, H 6.19, N 8.92<br>
Example 51<br>
IR (KBr) :  3351, 2937, 2875, 1670, 1627, 1533, 1245,<br>
1047 cm-’ NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.7Hz), 1.08 (3H,<br>
d, J=5.7Hz), 1.5-1.7 (2H, ra) , 1.7-2.1 (7H, m), 2.1-2.4 (3H, m), 2.5-2.6 (IH, m) , 3.1-3.2 (IH, m), 3.7-<br><br>
3.8 (2H, m), 3.9-4.6 (15H, m), 4.7-4.9 (3H, m), 5.0-5.1 (5H, m), 5.10 (IH, d, J=5.6H2), 5.17 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.5H2), 5.52 (IE, d, J=5.9Hz), 6.7-7.1 (9H, m), 7.2-7.5 (5H, m), 7.68 (2H, d, J=8.2Hz), 7.72 (2H, d, J=6.7Hz), 7.96 (2H, d, J=8.2H2), 8.06 (IH, d, J=8.4H2), 8.28 (IH, d, J=7.7Hz), 8.76 (IH, d, J=7.0Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1339.5 (M+Na-’)<br>
Elemental Analysis Calcd. for C59H73Ng023NaS-7H20 :<br>
C 49.09, H 6.08, N 7.76 Found :  C 49.04, H 6.08, N 7.82<br>
gx&amp;’\pl$ 52<br>
IR (KBr) : 3350, 2954, 2937, 1670, 1631, 1440, 1257,<br>
1047 cm~l NMR (DMSO-dg, 6) :  0.89 (3H, t, J=6.8Hz), 0.97 (3H, d, J=6.7Hz), 1.09 (2H, d, J=5.8Hz), 1.2-1.5 (6H, m), 1.7-2.1 (5H, m) , 2.1-2.4 (3H, m), 2.5-2.6 (IH, m), 3.1-3.2 (IH, m) , 3.7-4.6 (15H, m), 4.7-5.3 (IIH, m), 5.5-5.6 (IH, m), 6.7-6.9 (IH, m), 7.0-7.5 (6H, m), 8.0-8.4 (8H, m), 8.85 (IH, s), 8.96 (IH, d, J=7.0H2) APCI-MASS :  m/z = 1329.0 (M+Na)-’ Elemental Analysis Calcd. for C5gH-7]_N2o023NaS-6H20 :<br>
C 47.52, K 5.91, N 9.90 Found :  C 47.42, H 6.05, N 9.90<br>
Example 53<br>
IR (KBr) : 3350, 2952, 1666, 1629, 1537, 1519,<br>
1255  cm-’ NMR (DMSO-dg, 5) :  0.89 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.4Hz), 1.08 (3H, d, J=5.6Hz), 1.7-2.4 (8H, m) , 2.5-2.6 (IH, m), 3.7-4.5 (15H, m), 4.7-5.1 (8H, m) , 5.11 (IH, d, J=5.5H2), 5.17 (IH, d, J=3.1Hz), 5.26 (IH, d, J=3.1H2), 5.56 (IH, d, J=5.7Hz), 6.73 (IH,<br><br>
d, J=8.2Hz), 6.7-7.0 (2H, m) ,   7.05 (IH, s), 7.13 (2H, d, J=8.7Hz), 7.2-7.5 (3H, m), 7.97 (2H, d, J=8.7H2), 8.1-8.4 (6H, m), 8.85 (IH, s), 8.92 (IH, d, J=7.0Hz)<br>
FAB-MASS :  m/z = 1345.3 (M+Na) +<br>
Elemental Analysis Calcd. for<br>
C 45.84, H 5.98, N 9.55 Found :  C 45.87, H 6.07, N 9.55<br>
E&gt;‘ajnp3.g 54<br>
IR (KBr pelet) :  3350, 2931, 1670, 1652, 1628, 1442,<br>
1247, 1047 cm-l NMR (DMSO-dg, 6) : 0.86 (3H, t, J=6.6Hz), 0.97 (3H, d, J=6.8Hz), 1.12 (3H, d, J=6.8Hz), 1.2-1.5 (lOH, m), 1.7-2.0 (5H, m), 2.2-2.4 (3H, m), 2.5-2.6 (IK, m), 3.1-3.2 (IH, m), 3.72 (2H, br), 3.8-4.5 (17H, m), 4.7-5.2 (9H, m), 5.26 (IH, d, J=4.6Hz), 5.57 (IH, d, J=5.7Hz), 6.7-7.1 (7H, m), 7.3-7.5 (3H, m), 7.66 (2H, d, J=8.7Hz), 8.10 (IH, d, J=7.6Hz), 8.17 (IH, d, J=7.6Hz), 8.76 (IH, d, J=7.0Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1293 (M+Na’) Elemental Analysis Calcd. for C54H75NT Q022NaS-7H20 :<br>
C 46.41, H 6.42, N 10.02 Found :  C 46.51, H 6.43, N  9.95<br>
Example<br>
IR (KBr) :  3345, 2937, 1650, 1511, 1249, 1047 cm-’ NMR (DMSO-dg, 6) :  0.91 (3H, t, J=7.0H2), 0.96 (3H, t, J=7.8Hz), 1.09 (3H, d, J=6.8Hz), 1.3-1.5 (4H, m) , 1.6-2.1 (5H, m) , 2.1-2.5 (3H, m), 2.5-2.6 (IH, m) , 3.1-3.3 (IH, m) , 3.7-3.9 (2H, m), 3.9-4.6 (13H, m), 4.79 (2H, d, J=5.9Hz), 4.8-4.9 (IH, m) , 4.9-5.2 (5H, m), 5.10 (IH, d, J=5.9Hz), 5.17 (IH, d, J=3.1H2), 5.25 (IH, d, J=4.6Hz), 5.53 (IH, d.<br><br>
J=5.9Hz), e.1-1.0   (3H, m), 7.0-7.2 (3H, m), 7.19 (IH, s), 7.3-7.5 (3H, m), 7.7-8.1 (6H, m), 8.08 (IH, d, J=10.0H2), 8.26 (IH, d, J=8.8Hz), 8.77 (IH, m) , 8.85 (IH, s), 13.32 (IH, s) FAB-MASS :  m/z = 1314.0 (M+Na)’<br>
Elemental Analysis Calcd. for C’’lii-j-’’-’Q022’'‘‘'‘'‘2’   •<br>
C 46.86, H 6.11, N 9.76 Found :  C 46.93, H 5.87, N 9.74<br><br>
IR (KBr) :  3350, 2958, 2935, 2873, 1666, 1629, 1247,<br>
1045 cm~’ NMR (DMSO-dg, 5) :  0.9-1.1 (6H, m), 1.08 (3H, d,<br>
J=6.0Hz), 1.4-1.6 (2H, m), 1.6-2.1 (5H, m) , 2.1-2.4 (3H, m), 2.5-2.6 (IH, m), 3.1-3.3 (IH, m) , 3.6-4.5 (15H, m) , 4.7-5.1 (8H, m), 5.10 (IH, d, J=5.5Hz), 5.17 (IH, d, J=2.9Hz), 5.25 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.7Hz), 6.7-6.9 (3H, m), 7.0-7.5 (8H, m), 7.68 (2H, d, J=8.9Hz), 7.73 (2H, d, J=8.3Hz), 8.01 (2H, d, J=8.3H2), 8.10 (IH, d, J=8.4Hz), 8.26 (IH, d, J=7.7Hz), 8.8-9.0 (2H, m) FAB-MASS :  m/z = 1299.5 (M+Na)-’ Elemental Analysis Calcd. for C5gH59N3023NaS-6H2O :<br>
C 48.55, H 5.89, N 8.09 Found :  C 48.52, H 5.94, N 8.07<br>
Example 57<br>
IR (KBr) :  3355.5, 1662.3, 1629.6, 1267.0 cm-’ NMR (DMSO-dg, 5) :  0.88 (3K, t, J=6.8Hz), 0.93 (3H, d, J=8.4Hz), 0.97 (3H, d, J=6.7Hz), 1.2-1.5 (4H, m) , 1.5-1.95 (5H, m), 2.1-2.45 (4H, m), 2.5-2.7 (4H, m), 3.17 (IH, m), 3.55-4.45 (14H, m), 4.6-5.3 (13H, m), 5.56 (IK, d, J=5.6Hz), 6.72 (IH, d, J=8.1Hz), 6.75 (IH, s), 6.77 (IH, d, J=8.1Hz), 7.04 (IH, s), 7.10 (IH, s), 7.2-7.45 (lOH, m), 7.53 (4H, d.<br><br>
J=6.6Hz), 7.85 (IH, d, J=7Hz), 7.92 (IH, d, J=7Hz), 8.05 (IH, d, J=7Hz), 8.22 (IH, d, J=7H2), 8.84 (IH, s) FAB-MASS :  m/z = 1408 (M+Na)<br>
IR (KBr) :  3347.8, 1664.3, 1631.5, 1245.8 cm-’<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.6Hz), 1.04  (3H, d, J=5.7Hz), 1.15-2.6 (21H, m), 3.16 (IH, m), 3.5-4.5 (16H, m), 4.6-5.4 (13H, m), 5.47 (IH, d, J=5.7Hz), 6.73 (IH, d, J=8.2Hz) 6.78-6.85 (4H, m), 7.05 (IH, s), 7.10 (IH, s), 7.18 (2H, d, J=8.6Hz), 7.25-7.45 (6H, m), 7.72 (IH, d, J=7Hz), 7.91 (IH, d, J=7H2), 8.05 (IH, d, J=9.3Hz), 8.20 (IH, d, J=7Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1390 (M+Na)<br>
Elemental Analysis Calcd. for C6QHg2Ng024SNa-5H20 :<br>
C 49.41, H 6.36, N 8.64 Found :  C 49.77, H 6.71, N 8.71<br>
Example 59<br>
IR (KBr) :  3353.6, 1670.1, 1627.6, 1247.7 cm-’ NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.5Hz), 0.97 (3H, d, J=6.8Hz), 1.01 (3H, d, J=5.4H2), 1.1-1.55 (12H, m), 1.55-1.95 (5H, m), 2.05-4.7 (4H, m), 3.16 (IH, m), 3.5-4.5 (16H, m), 4.6-5.3 (13H, m), 5.55 (IH, d, J=5.6H2), 6.7-6.9 (5H, m), 7.05 (IH, s), 7.1 (IH, s), 7.15 (IH, d, J=8.5H2), 7.25-7.5 (6H, m), 7.73 (IH, d, J=8.4Hz), 7.92 (IH, d, J=7H2), 8.08 (IH, d, J=8.4H2), 8.18 (IH, d, J=7Hz), 8.84 (IH, s) FAB-MASS :  m/z =  1390 (M+Na)<br>
Example 60<br>
NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.6Hz), 1.05 (3H, d, J=5.6H2), 1.1-1.5 (22H, m),<br><br>
1.5-2.5 (9H, m), 2.5-3.5 (4H, m), 3.5-4.45 (14H, m) , 4.45-5.45 (12H, m), 6.72 (IH, d, J=8.2Hz), 6.79 (IH, s), 6.81 (IH, d, J=8.2Hz), 7.04 (IH, s), 7.05-7.5 (8H, m), 7.9-8.3 (3H, m), 8.84 (IH, s) FAB-MASS :  m/z =  1325 (M+Na) Elemental Analysis Calcd. for C5gH89Ng022SNa-6H20 :<br>
C 49.35, H 7.14, N 7.94 Found :  C 49.33, H 7.04, N 7.87<br><br>
IR (KBr) :  3400, 1668.1, 1629.6, 1270.9 cm-’<br>
NMR (DMSO-dg, 6) :  0.96 (3H, d, J=6.8Hz), 1.06 (3H, d, J=5.7Hz), 1.1-2.0 (33H, m), 2.1-2.5 (4H, m), 3.20 (3H, s), 3.28 (2H, t, J=6.5H2), 3.1-3.3 (IH, m) , 3.6-4.45 (14H, m), 4.6-5.3 (13H, m), 5.49 (IH, d, J=6.1Hz), 6.70 (IH, s), 6.72 (IH, d, J=8.2Hz), 6.80 (IH, d, J=8.2Hz), 7.03 (IH, s), 7.0-7.1 (IH, m) , 7.15 (IH, s), 7.2-7.45 (6H, m), 8.0-8.3 (3H, m), 8.83 (IH, s)<br>
FAB-MASS :  m/z = 142 6 (M+Na)<br>
Elemental Analysis Calcd. for C62Kg4N9024SNa-5H20 :<br>
C 49.82, H 7.01, N 8.43 Found :  C 49.86, H 7.31, N 8.40<br>
Example 62<br>
IR (KBr) :  3355.5, 1668.1, 1629.6, 1274.7 cm~l<br>
NMR (DMSO-dg, 5) : 0.85 (3H, t, J=6.5Hz), 0.96 (3H, d, J=6.7Hz), 1.04 (3H, d, J=5.9Hz), 1.1-2.6 (34H, m), 3.2 (IH, m) , 3.6-4.55 (14H, m), 4.7-5.3 (IIH, m), 5.47 (IH, d, J=5.9Hz), 6.72 (IH, d, J=8.1Hz), 6.79 (IH, s), 6.81 (IH, d, J=8.1H2), 7.05 (IH, s), 7.11 (lH,'s), 7.2-7.5 (2H, m), 8.0-8.15 (2H, m), 8.20 (IH, d, J=8.0Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1235 (M+Na)<br>
Elemental Analysis Calcd. for C5THg-|_N8022SNa-7H20 :<br><br>
C 45.73, H 7.15, N 8.37 Found :  C 45.55, H 7.24, N 8.23<br>
Example 63<br>
IR (KBr) :   3353.6, 1664.3, 1627.6 cm-’ NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.6Hz), 0.95 (3H, d, J=6.7Hz), 1.04 (3H, d, J=5.7Hz), 1.2-2.7 (30H, m), 3.16 (IH, m), 3.6-4.5 (13H, m), 4.7-5.3 (IIH, m), 5.51 (IH, d, J=6.0Hz), 5.74 (IH, s) , 6.72 (IH, d, J=8.2Hz), 6.75 (IH, s), 6.77 (IH, d, J=8.2Hz), 7.05 (IH, s), 7.2-7.5 (3H, m) , 8.0-8.3 (3H, lu) , 8.85 (IH, s) FAB-MASS :  m/z =  1204 (M+Na) Elemental Analysis Calcd. for C5QH-77Ng02iSNa-5H20 :<br>
C 47.24, H 6.90, N 8.81 Found :  C 4 6.98, H 7.12, N 8.72<br>
Example 6A Major product<br>
IR (KBr) :  3400, 1675.8, 1631.5, 1511.9, 1234.2 cm~’ NMR (DMSO-dg, 6) :  0.96 (3H, d, J=6.6Hz), 1.05 (3H, d, J=5.8Hz), 1.2-1.6 (lOH, m), 1.6-2.1 (5H, m), 2.1-2.7 (4H, m), 3.05-3.2 (4K, m), 3.20 (3H, s), 3.29 (2H, t, J=6.4Hz), 3.3-3.5 (5H, m), 3.6-4.5 (15H, m), 4.7-5.3 (IIH, m), 5.50 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.1 (9H, m), 7.2-7.5 (3H, m), 7.81 (2K, d, J=8.6Hz), 8.08 (IH, d, J=8.2Hz), 8.24 (IH, d, J=7Hz), 8.44 (IK, d, J=7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1403 (M+Na)<br>
Elemental Analysis Calcd. for C6’’gsNi o023'‘‘‘'‘‘2’ '<br>
C 47.47, H 6.73, N 9.07<br>
Found :  C 47.43, H 7,06, N 9.03<br>
Minor product<br>
IR (KBr) :  3350, 1668.1, 1631.5, 1511.9, 1234.2 cm~’<br><br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.6Hz), 1.07 (3H, d, J=5.8Hz), 1.2-1.5 (6H, m),   1.55-2.1 (7H, m), 2.1-2.65 (4H, ID), 3.0-3.6 (9H, m) , 3.7-4.5 (15H, m) , 4.7-5.6 (14H, m), 5.7-6.0 (IH, m), 6.72 (IH, d, J=8.0Hz), 6.75-7.1 (9H, m), 7.25-7.5 (3H, m), 7.81 (2H, d, J=8.3H2), 8.08 (IH, d, J=8.2Hz), 8.25 (IH, d, J=7Hz), 8.45 (IH, d, J=7Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1371 (M+Na)<br>
Elemental Analysis Calcd. for C6QHg2N2’o'‘22’’’-’’2'‘ '<br>
C 48.25, H 6.55, N 9.38 Found :  C 48.10, H 6.81, N 9.40<br>
Example 65<br>
IR (KBr) :  3450, 1668.1, 1635.3 cm-’<br>
NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.5Hz), 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=6Hz), 1.2-1.5 (6H, m), 1.6-2.1 (5H, m) , 2.1-2.7 (4H, m), 3.1-3.4 (9H, m) , 3.6-4.5 (15H, m) , 4.7-5.3 (IIH, m) , 5.49 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m) , 6.83 (2H, d, J=9.0Hz), 6.94 (2H, d, J=9.0Hz),. 7.04 (IH, s), 7.12 (IH, t, J=8.4Hz), 7.2-7.5 (3H, m) , 7.65-7.8 (2H, m), 8.09 (IH, d, J=8.4Hz), 8.25 (IH, d, J=7Hz), 8.63 (IH, d, J=7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z =  1363 (M+Na)<br>
Elemental Analysis Calcd. for C5gH7gFN2o022SNa-5H20 :<br>
C 48.67, H 6.20, N 9.79 Found :  C 48.83, H 6.15, N 9.74<br>
Example 66<br>
IR (KBr) :  3400, 1668.1, 1635.3, 1510.0, 1240.0 cm--NMR (DMSO-dg, 5) :  0.88 (3H, z,   J=6.6Hz), 1.2-1.5 (6H, m), i.5-2.05 (5H, m), 2.1-2.65 (4H, m) , 3.1-3.3 (9H, m) , 3.6-4.5 (15H, m) , 4.7-5.3 (UK, m) , 5.51 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 i4E,   m), 6.94 (2H, d, J=9.2Hz), 7.04 (IH, s), 7.24<br><br>
(IH, d, J=8.5Hz), 7.15-7.5 (3H, m), 7.86 (IH, dd, .J=8.6 and 2.1Hz), 8,02 (IH, d, J«=2.1Hz), 8.04 (IH, d, J=8.4Hz), 8.23 (IH, d, J=7H2), 8.70 (IH, d, J=7Hz), 8.84 (IH, s) FAB-MASS :  iti/z = 1379 (M+Na)<br>
Elemental Analysis Calcd. for C58H78ClN2o022SNa-6H20 :<br>
C 47.52, H 6,19, N 9.55 Found :  C 47.78, K 6.23, N 9.55<br>
Example 67<br>
IR (KBr) :  3400, 1670 cm'‘<br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.7Hz), 1.05 (3H, d, J=5.7Hz), 1.4-2.65 (17H, m), 2.65-3.6 (8H, m), 3.6-4.5 (15H, m), 4.6-5.3 (IIH, m), 5.44 (IH, d, J=6.0Hz), 6.73 (IH, d, J=8.2Hz), 6.81 (IH, s), 6.83 (IH, d, J=8.2Hz), 6.98 (2H, d, J=8.9H2), 7.05 (IH, s), 7.2-7.5 (3H, m), 7.80 (2H, d, J=8.9Hz), 8.05 (IH, d, J=8.4Hz), 8.26 (IH, d, J=7Hz), 8.39 (IH, d, J=7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1229 (M+Na)<br>
Elemental Analysis Calcd. for C52K-7’N-]_o021’-’’2'‘ '<br>
C 48.14, H 6.53, N 10.80 Found :  C 48.29, H 6,33, N 10.95<br>
Example 68<br>
IR (KBr) :  3400, 1652.7, 1635.3, 1511.9, 1241.9 cm-’ NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.6H2), 0.97 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.7Hz), 1.2-1.5 (6H, m) , 1.6-2.0 (5H, m) , 2.1-2.6 (4H, m), 3.0-3.3 (5K, m) , 3.6-4.6 (19K, m), 4.7-5.3 (IIH, m) , 5.53 (IH, d, J=5.6H2), 6.73 (IH, d, J=8.2Hz), 6.75-7.0 (2H, m) , 6.83 ■(2H, d, J=9.2Hz), 6.95 (2H, d,. J=9.2Hz), 7.05 (IH, s), 7.12 (IH, s), 7.25-7.5 (2H, m), 7.42 (IH, d, J=9.5Hz), 7.84 (IH, d, J=9.5Hz), 7.9-8.1 (2H, m) , 8.71 (IH, d, J=7H2), 8.84 (IH, s)<br><br>
FAB-MASS :  m/z = 134 7 (M+Na)<br>
Elemental Analysis Calcd. for C5gH77N22022SNa-7H20 :<br>
C 46.34, H 6.32, N 11.58 Found :  C 46.38, H 6.18, N 11.36<br>
Example 69<br>
NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.6Hz), 0.97 (3H, d, J=6.7Hz), 1.08 (3K, d, J=5.8Hz), 1.2-1.5 (6H, m) , 1.6-2.05 (5H, m), 2.1-2.6 {4H, m), 3.0-3.3 (5H, m) , 3.4-3.55 (4H, m), 3.7-4.6 (15H, m), 4.7-5.3 (IIH, m), 5.52 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.1Hz), 6.8-6.95 (2H, m), 6.83 (2H, d, J=9.3Hz), 6.95 (2H, d, J=9.3Hz) 7,05 (IH, s), 7.14 (IH, s), 7.3-7.6 (3H, m), 7.84 (IH, d, J=8.6Hz), 7.95-8.1 (2H, m) , 8.40 (IH, s), 8.42 (IH, d, J=7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 134 6 (M+Na)<br>
Elemental Analysis Calcd. for C57H7gN2i022SNa-5H20 :<br>
C 48.40, H 6.27, N 10.89 Found :  C 48.32, H 6.44, N 10.86<br>
Example 70<br>
IR (KBr) : 3400, 1668.1, 1629.6, 1511.9 cm-’<br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.7Hz), 1.15-1.5 (6H, m), 1.6-2.0 (7H, m), 2.1-2.65 (5H, m), 3.1-3.5 (9H, m), 3.6-4.5 (13H, m), 4.7-5.3 (IIH, m), 5.46 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.2Hz), 6.81 (IH, s), 6.84 (IH, d, J=8.2Hz), 6.91 (2H, d, J=8.7Hz), 6.95-7.05 (3H, m), 7.09 (2H, d, J=8.7Hz), 7.25-7.5' (3H, m) , 7.81 (2H, d, J=8.8Hz), 8.09 (IH, d, J=7Hz), 8.25 (IH, d, J=7Hz), 8.04 (IK, d, J=7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1327 (M+Na)<br>
Elemental Analysis Calcd. for C5gH77N-j_Q02]_SNa-5H20 :<br>
C 49.92, H 6.28, N 10.03 Found :  C 49.75, K 6.41, N 10.25<br><br>
Example 71<br>
IR (KBr) :   3350, 1668.1, 1629.6, 1511.9, 1232.3 cm-’<br>
NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.5Hz), 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=6.0Hz), 1.2-1.4 (6H, m), 1.4-1.6 {2H, m), 1.7-2.1 (3H, m), 2.1-2.7 (6H, m), 3.1-3.5 (9H, m), 3.72 (2H, m), 3.8-4.5 (IIH, m), 4.7-5.3 (IIH, m), 5.47 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (2H, m), 6.91 (2H, d, J=8.6Hz), 6.95-7.15 (5H, m), 7.25-7.5 (3H, m), 7.81 (2H, d, J=8.8Hz), 8.09 (IH, d, J=8.4Hz), 8.26 (IH, d, J=7HZ), 8.40 (IH, d, J=7Hz), 8.84 (IH, s)<br>
FAB-MASS :  iti/z =  1329 (M+Na)<br>
Elemental Analysis Calcd. for C38H79N-]_QNa022S-6H20 :<br>
C 49.22, H 6.48, N 9.90 Found :  C 49.33, H 6.67, N 9.89<br>
Example 72<br>
IR (KBr) : 3450, 1668.1, 1631.5, 1240.0 cm~’ NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.6Hz), 1.05 (3H, d, J=5.6Hz), 1.3-1.7 (4H, m), 1.7-2.1 (7H, m), 2.1-2.73 (6H, m), 2.75-3.05 (4H, m), 3.05-4.5 (18H, m), 4.7-5.5 (12H, m), 6.72 (IH, d, J=8.3Hz), 6.77-6.9 (2H, m), 6.96 (2H, d, J=8.6Hz), 7.05 (IH, s), 7.1-7.5 (8H, m), 7.80 (2H, d, J=8.6Hz), 8.06 (IH, d, J=8.4Hz), 8.28 (IH, d, J=7Hz), 8.41 (IH, d, J=7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1305 (M+Na)<br>
Elemental Analysis Calcd. for C58H78N2 0*’21’-’-’2'‘ -<br>
C 48.80, H 6.64, N 9.81 Found :  C 48.88, H 6.50, N 9.81<br>
*<br>
Example 73<br>
IR (KBr) :  1673.9,	1646.9, 1510.0 1238.1 cm~’<br>
NMR (DMSO-dg, 5) :	0.87 (3H, t, J=6.4Hz), 0.96 (3K, d,<br>
J=6.6Hz), 1.05	(3H, d, J=5.6Hz), 1.2-1.5 (6H, m) ,<br><br>
1.5-2.0 (9H, m), 2.1-2.8 (llH, m), 3.1-3.4 (5H, m) , 3.4-4.5 (17H, m), 4.6-5.5 (12H, m), 6.6-7.0 {9H, m), 7.04 (IH, s), 7.2-7.5 (3H, m),   7.78 (2H, d, J=8.7Hz), 8.05 (IH, d, J=8.4Hz), 8.24 (IH, d, J=7Hz), 8.39 (IH, d, J=7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1326 (M-’-S03+Na) Elemental Analysis Calcd. for C63Kg9N2i022S-9H20 :<br>
C 48.92, H 6.97, N 9.96 Found :  C 48.77, H 6.73, N 9.94<br><br>
IR (KBr) :  3450, 1670.1, 1631.5, 1280.5 cm~’<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=7.0Hz), 0.96 (3H, t, J=6.8Hz), 1.05 (3H, d, J=5.6Hz), 1.1-1.65 (13H, m), 1.65-2.1 (7H, m), 2.1-2.65 (5H, m), 3.17 (IH, m), 3.6-4.5 (13H, m), 4.7-5.3 (IIH, m), 5.49 (IH, d, J=5.9Hz), 6.72 (IH, d, J=8.2Hz), 6.82 (IH, d, J=8.2Hz), 6.84 (IH, s), 7.04 (IH, s), 7.29 (2H, d, J=8.3Hz), 7.2-7.5 (3H, m), 7.80 (2H, d, J=8.3Hz), 8.10 (IH, d, J=8.4Hz), 8.26 (IH, d, J=7Hz), 8.65 (IK, d, J=7Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1237 (M+Na)<br>
Elemental Analysis Calcd. for C53H75Ng02]_SNa-6H20 :<br>
C 48.10, H 6.63, N 8.47 Found :  C 48.2 6, H 6.62, N 8.46<br>
le 75<br>
IR (KBr) :  3400, 1670.1, 1627.6, 1272.8 cm--NMR (DMSO-dg, o) :  0.96 (3H, d, J=3.3Hz), 1.08 (3H, d, J=5.7Hz), 1.2-1.6 (lOH, m), 1.6-2.1 (5K, m), 2.1-2.7 (4H, m), 3.0-3.3 (IH, m), 3.20 (3H, s), 3.29 (2H,-t, J=6.4Hz), 3.73 (2H, m), 3.9-4.6 (13H, m), 4.7-5.3 (IIH, m), 5.53 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.3Hz), 6.83 (IH, d, J=8.3Hz), 6.91 (IH, s), 7.05 (IH, s), 7.23 (IH, dd, J=9.0 and 2.3Hz), 7.3-<br><br>
7.5 (4H, m), 7.8-8.0 (3H, m), 8.09 (IH, d, J=8.4Hz), 8.33 (IH, d, J=7H2), 8.44 (IE, s), 8.80 (IH, d, J=7Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1293 (M+Na) Elemental Analysis Calcd. for C55H-y5Ng023SNa-6H20 :<br>
C 47.89, H 6.36, N 8.12 Found :  C 47.81, H 6.26, N 8.05<br>
Example 7 6<br>
IR (KBr) :  3361.3, 1668.1, 1635.3, 1627.6 cm-’<br>
NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.7H2), 0.96 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.8Hz), 1.19-1.25 (8H, m) , 1.25-2.00 (5H, m), 2.02-2.53 (4H, m), 2.44 (3H, s), 2.61 (2H, t, J=7.6Hz), 3.05-3.27 (IH, m) , 3.55-4.50 (13H, m), 4.65-5.65 (12H, m), 6.42 (IH, s), 6.65-6.95 (3H, m), 7.05 (IH, d, J=0.4Hz), 7.13-7.50 (5H, m), 7.50-7.88 (6H, m), 8.10 (IH, d, J=9.0H2), 8.25 (IH, d, J=8.4H2), 8.40 (IH, d, J=7.0H2), 8.85 (IH, s)<br>
FAB-MASS :  m/2 = 1299.3 (M+Na-1)<br>
Elemental Analysis Calcd. for C5gH77NgNa02iS-5H20 :<br>
C 50.94, H 6.41, N 8.19 Found :  C 50.99, H 6.40, N 8.15<br>
Example 77<br>
IR (Nujol) :  3351.7, 1670.1, 1652.7, 1623.8 cm~’ NMR (DMSO-dg, 6) :  0,86 (3H, t, J=6.7H2), 0.96 (3H, d, J=6.7H2), 1.06 (3H, d, J=5.8Hz), 1.13-1.45 (8H, m) , 1.47-1.96 (5H, m), 2.06-2.66 (8H, m), 2.81 (2H, t, J=7.6H2), 3.04-3.30 (IH, m), 3.53-4.50 (13H, m) , 4.53-5.70 (12H, m), 6.64-6.88 (3H, m), 7.04 (IH, d, J=0.4H2), 7.13-7.60 (IIH, m), 8.10 (IH, d, J=9.0H2), 8.18 (IH, d, J=8.4H2), 8.30 (IH, d, J=7.0H2), 8.85 (IH, s) FAB-MASS :  m/2 = 1287.4 (M+Na-1)<br><br>
Elemental Analysis Calcd. for C57H77NgNa022S-5H20 :<br>
C 50.51, K 6.46, N 8.27 Found :  C 50.84, H 6.60, N 8.33<br>
Example 78<br>
IR (KBr) :  3361.3, 1683.6, 1670.1, 1662.3, 1652.7,<br>
1646.9, 1635.3, 1627.6, 1623.8 cm~l NMR (DMSO-dg, 5) :  0.97 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.6Hz), 1.28-2.00 (13H, m), 2.08-2.60 (4H, m), 3.07-3.30 (IH, m) , 3.60-4.66 (17H, m), 4.66-5.12 (9H, m), 5.11 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.6Hz), 5.52 (IH, d, J=6.0Hz), 6.62-6.95 (4H, m), 6.95-7.15 (3H, m) , 7.20-7,50 (3H, m) , 7.50-7,85 (7H, m), 8.12 (IH, d, J=8.4Hz), 8.35 (IH, d, J=7.7H2), 8.53 (IH, d, J=7.0Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1319.7 (M+Na-1) Elemental Analysis Calcd. for C57H7’NgNa022SF-8H20 :<br>
C 47.49, H 6.29, N 7.77 Found :  C 47.79, H 6.16, N 7.93<br>
Example 7 9<br>
IR (KBr) :  3354.9, 1668.1, 1662.3, 1654.6, 1646.9,<br>
1627.6 cm~l NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.7Hz), 0.90-1.10 (6H, m), 1.10-1.40 (8H, m), 1.48-1.95 (5H, m) , 2.05-2.46 (4H, m), 2.60 (2K, t, J=7.6Hz), 3.07-3.23 (IH, m), 3.55-4.45 (14H, m), 4.67-5.32 (IIH, m), 5.48-5.63 (IH, m), 6.22 (IH, , J=5.3Hz), 6.65-6.89 (3H, m), 6.97-7.15 (2H, m), 7.20-7.68 (lOH, m), 7.85-8.20 (3H, m), 8.84 (IH, s) FAB-MASS :  m/z = 1289.4 (M+Na-1) Elemental Analysis Calcd. for C5gH75NgNa022S-3H20 :<br>
C 50.90, H 6.18, N 8.48 Found :  C 50.80, H 6.44, N 8 .29<br><br>
Example 80<br>
IR (KBr) :  3361.3, 1664.3, 1631.5, 1600.6 cm~’<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.7Hz), 0.98 (3H, d, J=6.7Hz), 1.16 (3H, t, J=5.9Hz), 1.20-1.45 (8H, ra) , 1.50-1.70 (2H, m), 1.70-2.05 (3H, m), 2.10-2.57 (4H, m) , 2.63 (2H, t, J=7.6H2), 3.10-3.30 (IH, m) , 3.68-4.50 (13H, m), 4.78-5.32 (IIH, m), 5.66 (IH, d, J=5.7H2), 6.68-7.02 (3H, m), 7.04 (IH, d, J=0.4Hz), 7.25-7.48 (4H, m) , 7.60-8.08 (7H, m) , 8.10 (IH, d, J=8.4Hz), 8.28 (IH, d, J=7.7H2), 8.85 (IH, s), 9.30 (IH, d, J=7.1Hz)<br>
FAB-MASS :  m/z = 1287.5 (M+Na-1)<br>
Elemental Analysis Calcd. for C55H-73N3Na022S-3H20 :<br>
C 50.53, H 6.09, N 8.57 Found :  C 50.66, H 6.01, N 8.22<br>
Example 81<br>
IR (KBr) :  3349.7, 1668.1, 1627.6 cm~-<br>
NMR (DMSO-dg, 6) :  0.85 (3H, t, J=6.7H2), 0.96 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.8Hz), 1.18-1.48 (8H, m) , 1.50-2.10 (5H, m), 2.10-2.45 (3H, m), 2.50-2.65 (IH, m), 2.77 (2H, t, J=7.6Hz), 3.05-3.25 (IH, m) , 3.60-4.65 (13H, m), 4.67-5.60 (12H, m), 6.65-6.97 (3H, m), 7.05 (IH, d, J=0.4Hz), 7.21-7.43 (4H, m) , 7.76 (IH, s), 7.83-8.05 (3H, m) , 8.10 (IH, d, J=9.0Hz), 8.29 (IH, d, J=8.4Hz), 8.48 (IH, s), 8.64-9.03 (2H, m)<br>
FAB-MASS :  m/z = 1233.0 (M+Na-1)<br>
Elemental Analysis Calcd. for C53H7TNgNa02oS-3H20 :<br>
C 50.96, H 6.22, N 8.96 Found :  C 50.62, H 6.4 0, N 8.92<br>
Example 82<br>
IR (KBr) :  3361.3, 1670.1, 1627.6 cm-’<br>
NMR (DMSO-dg, 5) :  0.88 (3H, t, J=6.7Hz), 0.96 (3H, d.<br><br>
J=6.7HZ), 1.09 (JJH, a, J=5.yH2), 1.18-1.43 (6H, m) , 1.50-2.10 (5H, m), 2.10-2.69 (4H, m), 2.77 (2H, t, J=7.6Hz), 3.07-3.29 (IH, m), 3.60-4.62 (13H, m), 4.69-5.23 (lOH, m),   5.27 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.9H2), 6.68-7.00 (3H, m), 7.05 (IH, d, J=0.4Hz), 7.25-7.53 (4H, m) , 7.76 (IH, s), 7.84-8.05 (3H, m), 8.13 (IH, d, J=8.4H2), 8.33 (IH, d, J=7.7Hz), 8.48 (IH, s), 8.73-9.00 (2H, m)<br>
FAB-MASS :  m/z = 1219.4 (M+Na-1)<br>
Elemental Analysis Calcd. for C52H69NgNa022S-5H20 :<br>
C 48.51, H 6.19, N 8.71 Found :  C 48.67, H 6.34, N 8.74<br>
g?c»iftP]-g   83<br>
IR   (KBr)    :     3357.5,   1668.1,   1627.6  cm-’<br>
NMR   (DMSO-dg,   5)    :      0.97   (3H,   d,   J=6.7Hz),   1.07    (3H,   d, J=6.0Hz),    1.20-1.62   (lOH,   m),   1.62-2.00   (5H,   m) , 2.10-2.65   (4H,   m),   3.20   (3H,   s),   3.08-3.45    (IH,   m) , 3.28   (2H,   t,   J=6.5Hz),   3.53-4.50   (15H,   m),    4.68-5.13   (9H,   m),   5.17    (IH,   d,   J=3.1Hz),   5.25   (IH,   d, J=4.4H2),   5.53   (IH,   d,   J=6.0Hz),    6.68-6.95    (4H,   m) , 6.95-7.11    (3H,   m),   7.20-7.52   (3H,   m),   7.55-7.95 (7H,   m),    8.13    (IH,   d,    J=8.4Hz),    8.30    (IH,   d, J=7.7Hz),    8.52   (IH,   d,   J=7.0Hz),   8.85   (IH,   s)<br>
FAB-MASS :  m/z = 1345.2 (M+Na-1)<br>
Elemental Analysis Calcd. for C5gH79NgNa023S-8H20 :<br>
C 48.29, K 6.53, N 7.64 Found :  C 48.44, H 6.58, N 7.75<br>
Example 84<br>
IR (KBr) :  3353.6, 1662.3, 1627.6 cm--<br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.5Hz), 1.40-1.65 (2H, m),   1.65-2.00 (5H, m), 2.00-2.67 (6H, m), 3.08-3.30 (IH, m), 3.50-4.50 (15H, m), 4.68-5.13 (IIH, m), 5.18 (IH, d.<br><br>
J=3.1H2), 5.26 (IH, d, J=4.5Hz), 5.53 (IH, d, J=6.0Hz), 5.70-6.00 (IH, m), 6.63-6.95 (4H, m), 6.95-7.13 (3H, m), 7,20-7.52 (3H, m) ,   7.52-7.95 (7H, m), 8.12 (IH, d, J=8.4Hz), 8.31 (IH, d, J=7.7H2), 8.53 (IH, d, J=7.0Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1285.4 (M+Na-1) Elemental Analysis Calcd. for C55H-7-[‘N8022SNa-8H20 :<br>
C 47.79, H 6.23, N 7.96 Found :  C 47.59, H 6.32, N 8.06<br>
IR (KBr) :  3363.2, 1670.1, 1627.6 cm-’<br>
NMR (DMSO-dg, 6) :  0.89 (6H, d, J=6.5Hz), 0.96 (3H,<br>
d, J=6.7Hz), 1.07 (3H, d, J=5.7Hz), 1.22-1.41 (2H, m), 1.50-1.97 (6H, m), 2.11-2.65 (4H, m) , 3.10-3.30 (IH, m) , 3.60-4.50 (15H, m), 4.70-5.08 (8H, m) , 5.10 (IH, d, J=5.6Hz), 5.16 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5Hz), 5.50 (IH, d, J=5.9Hz), 6.65-6.92 (4H, m), 6.92-7.12 (3H, m), 7.21-7.50 (3H, m), 7.52-7.90 (7H, m), 8.12 (IH, d, J=8.4Hz), 8.30 (IH, d, J=7.7Hz), 8.56 (IH, d, J=7.0Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1287.6 (M+Na-1)<br>
Elemental Analysis Calcd. for C55H73NgNa022S-6.5H2O :<br>
C 48.66, H 6.27, N 8.11 Found :  C 48.67, H 6.32, N 8.20<br>
Example 8 6<br>
IR (KBr) :  3351.3, 1683.6, 1670.1, 1654.6, 1635.3,<br>
1623.8 cm-l NMR (DMSO-dg, 6) :  0.97 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.6Hz), 1.30-2.00 (IIH, m), 2.10-2.70 (4H, m), 3.05-S.15 (IH, m), 3.55-4.70 (17H, m), 4.70-5.11 (9H, m) , 5.16 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5Hz), 5.52 (IH, d, J=6.0Hz), 6.65-6.95 (4H, m) , 6.95-7.10 (3H, m), 7.10-7.50 (3H, m), 7.50-7.85<br><br>
(7H, m), 8.12 (IK, d, J=8.4H2), 8.30 (IH, d, J=8.3Hz), 8.52 (IH, d, Js=7.0H2), 8.85 (IH, s) FAB-MASS :  m/z = 1305.2 (M+Na-1) Elemental Analysis Calcd. for C5gH72N8Na022SF-6H90 :<br>
C 48.34, H 6.09, N 8.05 Found :  C 48.47, H 6.29, N 7.95<br>
Example 87<br>
IR (KBr) :  3359.4, 1668.1, 1654.6, 1625.7 cm-’<br>
NMR (DMSO-dg, 5) :  0.97 (3H, d, J=6.7Hz), 1.07 (3H, d, J=6.0Hz), 1.22-1.62 (6H, m), 1.62-2.00 (5H, m), 2.10-2.65 (4H, m), 3.20 (3H, s), 3.05-3.40 (IK, m) , 3.31 (2H, t, J=6.5Hz), 3.60-4.55 (15H, m), 4,65-5.13 (9H, m), 5.16 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.4Hz), 5.53 (IH, d, J=6.0H2), 6.68-6.95 (4H, m) , 6.95-7.20 (3H, m), 7.20-7.58 (3H, m) , 7.58-7.90 (7H, m), 8.13 (IH, d, J=8.4H2), 8.32 (IH, d, J=7.7Hz), 8.53 (IH, d, J=7.0Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1317.6 (M+Na-1)<br>
Elemental Analysis Calcd. for C57H-75NgNa023S-7H90 :<br>
C 48.16, H 6.31, N 7.88 Found :  C 48.21, H 6.60, N 7.78<br>
Example 88<br>
IR (KBr) :  3350, 2954, 1668, 1629, 1538, 1511, 1454,<br>
1249 cm-l<br>
NMR (DMSO-dg, 5) :  0.88 (3K, t, J=7.1Hz), 0.96 (3H, d, J=7.5Hz), 1.08 (2H, d, J=5.7Hz), 1.2-1.5 (6K, m), 1.6-2.4 (8H, m), 2.6-2.7 (IH, m), 3.1-3.3 (IH, m), 3.6-4.5 (19H, m), 4.7-5.3 (8K, m) , 6.73 (IH, d, J=B.2Hz), 6.8-7.1 (5H, m), 7.19 (IH, s), 7.3-7.5 (3H, m), 7.75 (2H, d, J=8.7Hz), 7.8-8.0 (4H, m), 8.08 (IH, d, J=8.9H2), 8.30 (IH, d, J=7.7Hz), 8,7-9.0 (3H, m)<br>
FAB-MASS :  m/z = 1327 (M+Na-’)<br><br>
Elemental Analysis Calcd. for C57H73N2o022’’’'‘‘2 <br>
C 46.65, H 6.25, N 9.54 Found :  C 46.95, H 6.22, N 9.55<br>
Example 8 9<br>
IR (KBr) :  3376, 2931, 2858, 1662, 1631, 1521, 1444,<br>
1245, 1047 cm~’ NMR (DMSO-dg, 6) :  0.97 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.9Hz), 1.3-1.6 (6H, m), 1.7-2.1 (5H, m) , 2.2-2.4 (3H, m), 2.5-2.6 (IH, m), 3.21 (3H, s), 3.2-3.4 (3H, m), 3.6-4.5 (16H, m) , 4.79 {2H, d, J=6.0Hz), 4.9-5.2 (5H, m), 5.10 (IH, d, J=3.6Hz), 5.18 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.5Hz), 5.53 (IH, d, J=6.0Hz), 6.73 (IH, d, J=8.2H2), 6.8-7.0 (2H, m) , 7.0-7.2 (3H, m), 7.3-7.5 (3H, m), 7.6-7.9 (8H, m), 8.01 (2H, d, J=8.4Hz), 8.12 (IH, d, J=8.4Hz), 8.31 (IH, d, J=7.7Hz), 8.79 (IH, d, J=7.0Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1367 (M+Na-’)<br>
Elemental Analysis Calcd. for C6-]_H77Ng023NaS-6.5H2O :<br>
C 50.10, H 6.20, N 7.66 Found :  C 50.09, H 6.17, N 7.62<br>
Example 90<br>
IR (KBr) : 3363, 2937, 2869, 1646, 1444, 1255 cm-’<br>
NMR (DMSO-dg, 5) :  0.97 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.7Hz), 1.2-1.6 (lOH, m), 1.7-2.1 (5H, m), 2.1-2.4 (3H, m), 2.5-2.7 (IH, m), 3.20 (3H, s), 3.2-3.4 (IH, m), 3.6-4.6 (16K, m) , 4.7-5.2 (8H, m), 5.16 (IH, d, J=3.1Hz), 5.24 (IH, d, J=4.5Hz), 5.54 (IH, d, J=5.8Hz), 6.73 (IH, d, J=6.2Hz), 6.8-7.0 (2H, m), 7.1-7.4 (6H, m), 7.97 (2H, d, J=8.8Hz), 8.0-8.4 (6H, m), 8.84 (IH, s), 8.92 (IH, d, J=7.0Hz)<br>
FAB-MASS :  m/z = 14 03.6 (M+Na-’)<br>
Elemental Analysis Calcd. for C5gH77N-[_Q023NaS2-6H20 :<br><br>
C 47.58, H 6.02, N 9.40 Found :  C 47.72, H 6.12, N 9.42<br>
Example 91<br>
IR (KBr) :  3350, 1668, 1654, 1625, 1537, 1521, 1245,<br>
1047 cm-’ NMR (DMSO-dg, 6) :  0.9-1.1 (6H, m), 1.07 (3H, d,<br>
J=5.7H2), 1.4-2.0 (7H, m), 2.2-2.5 (3H, m), 2.5-2.6 (IH, m), 3.1-3.3 (IH, m), 3.6-4.5 (16H, m), 4.7-5.1 (7H, m), 5.09 (IH, d, J=5.6Hz), 5.16 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.4Hz), 5.53 (IH, d, J=6.0Hz), 6.73 (IH, d, J=8.4Hz), 6.8-7.2 (6H, m) 7.2-7.5 (4H, m) , 7.5-7.8 (6H, m), 8.11 (IH, d, J=8.4Hz), 8.32 (IH, d, J=7.7Hz), 8.54 (IH, d, J=7.0Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1259 (M+Na-’) Elemental Analysis Calcd. for C54HggNg022NaS-8H20 :<br>
C 46.95, H 6.20, N 8.11 Found :  C 47.20, K 6.23, N 8.28<br>
Example 92<br>
IR (KBr) :  3359, 2929, 2852, 1668, 1650, 1631, 1538,<br>
1515 cm~l<br>
NMR (DMSO-dg, 6) :  0.96 (3H, d, J=6.7H2), 1.09 (3K, d, J=6.1Hz), 1.2-1.6 (5H, m), 1.6-2.5 (lOH, m), 2.5-2.6 (IH, m), 3.18 (IH, m), 3.7-4.5 (15H, m), 4.8-5.2 (8H, m), 5.17 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.1Hz), 6.81 (IH, s), 6.85 (IH, s),7.05 (IH, s), 7.2-7.4 (3H, m), 7.45 (2H, d, J=8.2Hz), 7.96 (2H, d, J=8.2Hz), 8.0-8.2 (4H, s), 8.2-8.3 (IH, m), 8.85 (lH,'s), 8.9-9.0 (IH, d, J=7.0Hz)<br>
FA3-MASS :  m/z = 1327.5 (M+Na)’<br>
Elemental Analysis Calcd. for C5gHggN2o02iS2Na-6H20 :<br>
C 47.59, K 5.78, N 9.91<br><br>
Found :  C 47.89, H 5.76, N 9.93<br>
Example 93<br>
IR (KBr) :  3350, 1654, 1629, 1517, 1249, 1047 cm~l NMR (DMSO-dg, 5) :  0.9-1.1 (6H, m), 1.11 (3H, d,<br>
J=5.9Hz), 1.6-2.0 (5H, s), 2.1-2.4 (3H, s), 2.6-2.7 (IH, m), 3.1-3.3 (IH, m), 3.6-4.5 (16H, m), 4.7-5.2 (7H, m), 5.10 (IH, d, J=5.6Hz), 5.17 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5H2), 5.55 (IH, d, J=5.7H2), 6.7-6.9 (3H, m), 7.0-7.5 (6H, m), 7.74 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.5Hz), 8.1-8.4 (8H, m), 8.84 (IH, s), 8.97 (IH, d, J=7,0Hz) FAB-MASS :  m/z = 1363.5 (M+Na) + Elemental Analysis Calcd. for C59HggN-j’Q023SNa-5H20 :<br>
C 49,51, H 5.56, N 9.79 Found :  C 49.39, H 5.63, N 9.77<br>
Example 94<br>
IR (KBr) :  3355, 2929, 2856, 1664, 1631, 1519, 1440,<br>
1282 cm~-NMR (DMSO-dg, 6) :  0.84 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.07 (3H, t, J=5.8H2), 1.2-1.5 (12H, m), 1.7-2.0 (5H, m), 2.2-2.4 (3H, m) , 2.5-2.7 (IH, m), 2.94 (2H, t, J=7.4Hz), 3.1-3.3 (IH, m), 3.6-4.6 (14H, m), 4.8-5.2 (7H, m) , 5.10 (IH, d, J=3.6Hz), 5.17 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.9H2), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m) , 7.0-7.,5 (4H, m) , 8.0-8.2 (5H, m) , 8.27 (IH, d, J=7.7Hz), 8.85 (IH, s), 8.93 (IH, d, J=7.0Hz) FAB-MASS :  m/z = 1279 (M+Na’)<br>
Elemental- Analysis Calcd. for C53H-73N-]_Q022SNa-5. 5H2O :<br>
C 46.93, K 6.24, N 10.33 Found :  C 46.93, H 6.46, N 10.31<br><br>
Example 95<br>
IR (KBr) :  3363, 1673, 1648, 1538, 1253 cm~’<br>
NMR (DMSO-dg, 6) :  0.92 (3H, t, J=6.8H2), 0.97 (3H, d, J=6.8H2), 1.10 {3H, d, J=5.8Hz), 1.2-1.5 (6H, m), 1.7-2.1 (5H, m) , 2.1-2.4 (3H, m) , 2.5-2.5 (IH, m), 3.1-3.3 (IH, m) , 3.6-4.5 (16H, m), 4.7-5.1 (9H, m) , 5.16 (IH, d, J=3.1Hz), 5.24 (IH, d, J=4.5Hz), 5.54 (IH, d, J=5.8H2), 6.73 (IH, d, J=8.2Hz), 6.8-7.4 (8H, m), 8.04 (2H, d, J=8.8Hz), 8.13 (2H, d, J=8.6H2), 8.2-8.4 (4H, m), 8.84 (IH, s), 8.98 (IH, d, J=7.0Hz)<br>
FAB-MASS :  m/z = 1329.6 (M+Na)-’<br>
Elemental Analysis Calcd. for C5gH-7-,N-|_Q023SNa-7H20 :<br>
C 4 6.92, H 5.97, N 9.77 Found :  C 4 6.86, H 5.99, N 9.77<br>
Example 96<br>
IR (KBr) :  3355, 2929, 1666, 1648, 1631, 1515, 1442,<br>
1047 /cm-l NMR (DMSO-dg, 6) :  0.87 (3H, t, J=6.7H2), 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.8Hz), 1.2-1.5 (lOH, m), 1.7-2.1 (5H, m) , 2.1-2.4 (3H, m) , 2.5-2.6 (IH, m) , 3.1-3.3 (IH, m), 3.6-4.6 (16H, m), 4.79 (2H, d, J=5.9Hz), 4.8-5.2 (5H, m) , 5.09 (IH, d, J=5.5Hz), 5.16 (IH, d, J=3.1Hz), 5.23 (IH, d, J=4.5Hz), 5.53 (IH, d, J=5.9H2), 6.73 (IH, d, J=8.0K2), 6.8-6.9 (2H, m) , 7.0-7.5 (6H, m), 7.97 (2H, d, J=8.8Hz), 8.0-8.3 (6H, m), 8.83 (IK, s) , 8.88 (IH, d, J=7.0H2) Fib-MASS :  m./z = 1373.5 (M+Na)’<br>
Elemental Analysis Calcd. for C5gH-75N-]_Q022S2Na-6H20 :<br>
C 47.73, H 6.01, N 9.60 Found :  C 47.57, H 5.92, N 9.53<br>
Example 97<br><br>
IR (KBr) :  3361, 2925, 2852, 1668, 1650, 1631, 1538,<br>
1452, 1049 cm~-<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.9Hz), 0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.7Hz), 1.2-1.4 (IIH, in), 1.4-1.6 (2H, m), 1.7-2.1 (5H, m) , 2.1-2.5 (5H, m), 2.5-2.6 (IH, m) , 3.1-3.3 (2H, m), 3.7-4.5 (14H, m), 4.7-5.0 (7H, m), 5.09 (IH, d, J=5.6Hz), 5.16 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5Hz), 5.54 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, d) , 7.04 (IH, s), 7.2-7.5 (3H, m), 8.03 (4H, s), 8.0-8.3 (2H, m), 8.84 (IH, s), 8.95 (IH, d, J=7.0Hz)<br>
FAB-MASS :  m/z = 1321.9 (M+Na)-’<br>
Elemental Analysis Calcd. for C55H75N2o021’2’’'‘‘2'-' •<br>
C 47.54, H 6.17, N 10.08 Found :  C 47.38, H 6.12, N  9.98<br>
Example 98<br>
IR (KBr) :  3374, 2937, 2875, 1658, 1629, 1531, 1436,<br>
1255, 1047 cm~’ NMR (DMSO-dg, 5) :  0.9-1.11 (6H, m), 1.09 (3H, d,<br>
J=5.7Hz), 1.2-1.5 (4H, m), 1.7-2.1 (5H, m), 2.2-2.5 (3H, m), 2.6-2.7 (IH, m), 3.2-3.3 (IH, m) , 3.6-4.5 (16H, m), 4.80 (2H, d, J=5.8Hz), 4.8-5.2 (5H, m) , 5.10 (IH, d, J=5.5Hz), 5.17 (IH, d, J=3.0Hz), 5.24 (IH, d, J=4.5Hz), 5.53 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m), 7.06 (IH, s), 7.10 (2H, d, J=8.9Hz), 7.2-7.5 (3K, m), 7.68 (IH, s), 7.86 (2H, d, J=8.8HZ), 8.0-8.4 (6H, m), 8.84 (IH, S), 8.90 (IH, d, J=7.0Hz) FAB-MASS :  m/z = 1314 (M+Na’) Elemental Analysis Calcd. for C5gH7QN9023NaS-6H2O :<br>
C 48.03, H 5.90, N 9.00 Found :  C 47.92, H 5.83, N 8.88<br>
Example 99<br><br>
IR (KBr) :  3345, 1646, 1633, 1531, 1257 cm~’ NMR (DMSO-dg, 5) :  0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.2-1.6 (lOH, m), 1.7-2.5 (8H, m), 2.6-.2.7 (IH, m), 3.21 (3H, s), 3.3-3.4 (IH, m), 3.7-4.6 (16H, m), 4.8-5.2 (8H, m), 5.16 (IH, d, J=3.1Hz), 5.24 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.7Hz), 6.7-6.9 (3H, iti), 7.0-7.5 (6H, m) ,   8.0-8.3 (8H, m) , 8.84 (IH, s), 8.96 (IH, d, J=7.0Hz) FAB-MASS :  m/z = 1387.7 (M+Na-’)<br>
Elemental Analysis Calcd. for C5gH77N2o024’’’'‘‘2'‘ •<br>
C 48.09, H 6.09, N 9.51 Found :  C 47.81, H 5.83, N 9.38<br>
Example 100<br>
IR (KBr) :  3357, 1668, 1631, 1429, 1284, 1047 cm-’<br>
NMR (DMSO-dg, 5) :  0.97 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.8Hz), 1.8-2.4 (6H, m), 2.5-2.6 (IH, m), 3.1-3.2 (IH, m), 3.7-4.6 (14H, m), 4.7-5.2 (7H, m), 5.10 (IH, d, J=5.5Hz), 5.17 (IH, d, J=3.1Hz), 5.24 (IH, d, J=5.5Hz), 5.53 (IH, d, J=5.8Hz), 6.75 (IH, d, J=8.2Hz), 6.8-6.9 (2H, m), 7,05 (IH, s), 7.3-7.6 (9H, m), 7.8-7.9 (4H, m), 8.0-8.2 (5H, m) , 8.2-8.3 (IH, m), 8.34 (IH, d, J=9.3Hz), 8.7-8,8 (IH, m) , 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1332.7 (M+Na’)<br>
Elemental Analysis Calcd. for C5gHg5N-[‘Q022SNa-8H20 :<br>
C 47.93, H 5.62, N 9.64 Found :  C 47.83, H 5.53, N 9.56<br>
Example 101<br>
IR (KBr) :  3353, 2929, 2856, 1666, 1631, 1612, 1496,<br>
1440, 1259 cm~’ NMR (DMSO-dg, 5) :  0.87 (3H, t, J=6.6Hz), 0.97 (3H, d, J=6.5Hz), 1.09 (3H, d, J=5.9Hz), 1.2-1.5 (lOH, m), 1.7-2.1 (5H, m) , 2.2-2.5 (3H, m), 2.6-2,7 (IH, m) ,<br><br>
3.1-3.2 (IH, m) , 3.6-4.5 (16H, m),   4.7-5.0 (3H, m), 5.0-5.2 (5H, m), 5.10 (IH, d, J=3.1H2), 5.26 (IH, d, J=4.2Hz), 5.56 (IK, d, J=5.5H2), 6.73 (IH, d, J=8.1H2), 6.8-7.0 (2H, m), 7.05 (IH, s), 7.1-7.5 (5H, m), 8.0-84 (8H, m), 8.85 (IH, s), 8.95 (IH, d, J=7.0Hz)<br>
FAB-MASS :  m/z = 1357.3 (M+Na-’)<br>
Elemental Dialysis Calcd. for C5gH75N2o023NaS-7H20 :<br>
C 47.67, H 6.14, N 9.58 Found :  C 47.63, H 6.42, N 9.52<br>
Example 102<br>
IR (KBr) :  3361, 1670, 1648, 1633, 1540, 1519,<br>
1249 cm~’ NMR (DMSO-dg, 5) :  0.89 (3H, t, J=7.0Hz), 0.97 (3H, d, J=6.8H2), 1.10 (3H, d, J=5.7Hz), 1.2-1.5 (6H, m), 1.6-2.4 (8H, m), 2.5-2.7 (IH, m) , 3.1-3.3 (IH, m) , 3.6-4.5 (16H, m), 4.80 (2H, d, J=5.8Hz), 4.8-5.2 (5H, m), 5.10 (IK, d, J=5.4Hz), 5.18 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.3Hz), 5.55 (IH, d, J=5.7Hz), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m), 7.0-7.5 (6H, m), 8.02 (IH, d, J=5.3Hz), 8.0-8.4 (4H, m), 8.42 (2H, d, J=8.4Hz), 8.48 (2H, d, J=8.9Hz), 8.8-9.0 (3H, m) FAB-MA.SS :  m/z = 1339.3 (M+Na’) Elemental Analysis Calcd. for C5gH73N2g022SNa-6H20 :<br>
C 48.87, H 6.01, N 9.83 Found :  C 49.16, H 5.92, N 9.86<br>
Example 103<br>
IR (KBr) : 3350, 2971, 2859, 1672, 1629, 1537, 1442,<br>
1’47, 1047 cm~-NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.8Hz), 1.0-1.2 (6H, m), 1.2-1.6 (12H, m), 1.7-2.5 (8K, m), 2.5-2.6 (IH, m), 3.2-3.6 (7H, m), 3.7-4.5 (16K, m), 4.76 (2H, d.<br><br>
J=5.6Hz), 4.8-5.1 (5H, m), 5.09 (IH, d, J=5.5Hz), 5.16 (IH, d, J=3.1Hz), 5.23 (IH, d, J=5.5Hz), 5.51 (IH, d, J=5.9Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (2H, m) , 7.0-7.1 (3H, m), 7.3-7.5 (3H, m), 7.67 (2H, d, J=6.9Hz), 7.71 (2H, d, J=6.9Hz-), 7.95 {2H, d, J=8.4Hz), 8.05 (IH, d, J=7.0Hz), 8.23 (IH, d, J=7.7Hz), 8.70 (IH, d, J=7.0Hz), 8.84 (IH, s)<br>
FAB-MASS :  m/z = 1377.1 (M+Na-’)<br>
Elemental Analysis Calcd. for C6oH83N8024NaS'5H20 :<br>
C 49.86, H 6.49, N 7.75 Found :  C 49.74, H 6.73, N 7.68<br>
Example 104<br>
IR (KBr) :  3349, 2937, 2858, 1672, 1629, 1537, 1444,<br>
1249, 1047 cm~’ NMR (DMSO-dg, 6) :  0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.6Hz), 1.2-1.7 (14H, m), 1.7-2.1 (5H, m), 2.1-2.4 (5H, m), 2.5-2.6 (IH, m), 3.1-3.2 (IH, m), 3.4-3.6 (4H, m), 3.7-4.5 (16H, m), 4.77 (2H, d, J=5.7Hz), 4.8-5.2 (5H, m), 5.09 (IH, d, J=5.6Hz), 5.16 (IH, d, J=3.1Hz), 5.24 (IH, d, J=4.5Hz), 5.51 (IH, d, J=5.8Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (2H, m) , 7.0-7.1 (3H, m), 7.3-7.5 (3H, m), 7.6-7.8 (4H, m), 7.96 (2H, d, J=8.4Hz), 8.10 (IH, d, J=8.4Hz), 8.24 (IH, d, J=7.7Hz), 8.71 (IH, d, J=7.0Hz), 8.89 (IH, s) FAB-MASS :  m/z = 138 6.5 (M+Na+) Elemental Analysis Calcd. for C5-i_H82N9023NaS-6H20 :<br>
C 49.76, H 6.43, N 8.56 Found :  C 49.99, H 6.39, N 8.52<br>
Example 105<br>
IR (KBr) :  3350, 2933, 2856, 1664, 1631, 1604, 1511,<br>
1450, 1243, 1045 cm~’ NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.7Hz), 0.96 (3H, d.<br><br>
J=6.5H2), 1.05 (3H, d, J=5.7H2), 1.2-1.5 (8H, m), 1.6-2.0 {5H, m), 2.1-2.4 {3H, m) , 2.5-2.6 (IH, m), 3.0-3.3 (5H, m), 3.6-4.4 (20H, m), 4.7-5.1 (7H, m) , 5.10 (IH, d, J=5.5Hz), 5.16 (IK, d, J=3.1Hz), 5.27 (IH, d, J=4.5Hz), 5.51 (IH, d, J=6.0H2), 6.7-7.1 (9H, m) , 7.2-7.5 (3H, m) , 8.0-8.2 (2H, m), 8.2-8.4 (IH, m) , 8.4-8.6 (IH, m), 8.66 (IH, d, J=2.2Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1360 (M+Na-’)<br>
Elemental Analysis Calcd. for C5gHgQN2’20222’’'‘‘2’ •<br>
C 48.16, H 6.41, N 10.65 Found :  C 47.91, H 6.31, N 10.56<br>
Example 106<br>
IR (Kerr) :  3369, 3345, 2935, 1672, 1629, 1511, 1245,<br>
1047 cm~l NMR (DMSO-dg, 5) : 0.96   (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.8H2), 1.3-1.6 (lOH, m), 1.6-2.0 (5H, m), 2.1-2.4 (3H, m), 2.5-2.6 (IH, m), 3.20 (3H, s), 3.28 (2H, t, J=6.4H2), 3.1-3.4 (5H, m) , 3.7-4.5 (20H, m), 4.7-5.1 (7H, m), 5.08 (IH, d, J=5.5Hz), 5.15 (IH, d, J=3.1Hz), 5.23 (IH, d, J=4.5Hz), 5.48 (IH, d, J=5.8H2), 6.73 (IH, d, J=8.2Hz), 6.82 (2H, d, J=9.1H2), 6.94 (2H, d, J=9.1H2), 6.9-7.0 (IH, m), 7.04 (IH, s), 7.3-7.5 (3H, m), 8.0-8.1 (2H, m), 8.27 (IH, d, J=7.7Hz), 8.49 (IH, d, J=7.0Hz), 8.66 (IH, d, J=2.2H2), 8.84 (IH, s) FAB-MASS :  m/z = 14 04 (M+Na’)<br>
Example 107-<br>
IR (KBr) :  3357, 1647, 1631, 1537, 1444, 1249,<br>
'  1049 cm-l NMR (DMSO-dg, 5) :  0.9-1.1 (6H, m), 1.09 (3H, d,<br>
J=5.9H2), 1.6-2.4 (8H, m), 2.4-2.5 (IH, m), 3.1-3.3 (IH, m) , 3.6-4.5 (16H, m), 4.8-5.2 (7H, m), 5.10<br><br>
(IH,   d,   J=5.6H2),   5.17   (IH,   d,   J=3.1Hz),   5.25   (IH, d,   J=4.5Hz),   5.55   (IH,   d,   J=5.9H2),    6.73    (IH,   d, J=8.2Hz),   6.8-7.0   (2H,   m),   7.0-7.6   (6H,   m),   7.73 (2H,   d,   J=8.7Hz),   7.86   (2H,   d,   J=8.5Hz),   8.0-8.3 (8H,   m),   8.84   (IH,   s),   8.9-9.0   (IH,   m) FAB-MASS   :     iti/z  =  1379.4    (M+Na)’<br>
Elemental Analysis Calcd.   for C59Hg9N2o022’2’’'‘‘2’    <br>
C   48.36,   H  5.57,   N  9.56 Found   :       48.18,   H  5.60,   N 9.36<br>
The Object Compounds (108) to (117) were obtained according to a similar manner to that of Example 27.<br>
Example 108<br>
IR (KBr) :  3350, 2933, 1670, 1527, 1521, 1436, 1272,<br>
1047 cm~’ NMR (DMSO-dg, 5) :  0.85 (3H, t, J=6.7Hz), 0.92 (3H, d, J=6.7Hz), 1.1-1.4 (IIH, m), 1.7-2.4 (9H, m), 3.1-3.2 (IH, m), 3.5-5.4 (27H, m), 6,6-7.2 (8H, m) , 7.5-7.8 (3H, m) , 7.8-8.0 (3H, m), 8.1-8.8 (3H, m) FAB-MASS :  m/z = 1249.4 (M+Na+)<br>
Elemental Analysis Calcd. for Ccj2’1l'‘lo'‘21’’’'‘‘2’  •<br>
C 46.15, H 6.33, N 10.35 Found :  C 46.12, H 6.35, N 10.24<br>
Example 109<br>
IR (Kbr pelet) :  3361, 2933, 2856, 1670, 1652, 1616,<br>
1540, 1508, 1448, 1261, 1047 cm-’<br>
NMR (DMSO-dg, 5) :  0.86 (3H, t, J=6.6H2), 0.97 (3H, d, J=6.8Hz), 1.12 (3H, d, J=6.8Hz), 1.2-1.5 (lOH, m), 1.7-2.0 (5H, m) , 2.2-2.6 (4H, m), 3.1-3.2 (IH, m) , 3.7-4-.4 (16H, m) , 4.8-5.3 (lOH, m) , 5.59 (IH, d, J=6.0Hz), 6.7-6.9 (3H, m) , 7.0-7.4 (7H, m) , 7.8-8.2 (4H, m), 8.8-9.0 (2H, m)<br>
FAB-MASS :  m/z = 1280.3 (M+Na-*-)<br><br>
Elemental Analysis Calcd. for C54H72Ng023NaS-7H20 :<br>
C 46.45, H 6.21, N 9.03 Found :  C 46.68, H 6.44, N 9.03<br>
Example 110<br>
IR (KBr) : 3350, 2931, 1670, 1627, 1540, 1436, 1276,<br>
1047 cm-’ NMR (DMSO-dg, 6) :  0.87 (3H, t, J=6.8Hz), 0.93 (2H, d, J=8.8Hz), 1.08 (2H, d, J=5.9H2), 1.2-1.4 (4H, m) , 1.5-1.7 (2H, m), 1.7-2.1 (3H, m) , 2.1-2.4 (3H, m) , 2.6-2.7 (3H, m), 3.1-3.3 (IH, m), 3.6-4.5 (17H, m), 4.7-5.4 (8H, m), 6.73 (IH, d, J=8.2Hz), 6.83 (2H, d, J=8.2Hz), 7.0-7.1 (IH, m), 7.2-7,5 (5H, m), 7.65 (2H, d, J=8.2Hz), 7.74 (2H, d, J=8.4Hz), 7.98 (2H, d, J=8.4Hz), 8.08 (IH, d, J=8.5Hz), 8.25 (IH, d, J=8.5Hz), 8.74 (IH, d, J=7.6Hz), 8.7-9.0 tlH, br) FAB-MASS :  m/z = 1231.2 (M+Na-’) Elemental Analysis Calcd. for C53HggNg02]_NaS-3H20 :<br>
C 50.39, H 5.98, N 8.87 Found :  C 50.34, H 6.25, N 8.90<br>
Example 111<br>
IR (KBr) :  3353.6, 1670.1, 1652.7, 1623.8 cm~’<br>
NMR (DMSO-dg, 5) :  0.96 (3H, d, J=6.7Hz), 1.07 (3K, d, J=5.6Hz), 1.20-1.62 (8H, m), 1.62-2.00 (5H, m), 2.10-2.65 (4H, m), 3.20 (3H, s) , 3.08-3.40 (IH, m) , 3.30 (2H, t, J=6.5Hz), 3.53-4.50 (15H, m), 4.68-5.13 (9H, m), 5.16 (IH, d, J=2.9Hz), 5.26 (IH, d, J=4.5Hz), 5.53 (IH, d, J=5.9Hz), 6.68-6.95 (4H, m) , 6.95-7.11 (3H, m) , 7.20-7.52 (3H, m), 7.55-7.95 (7H, m), 8.13 (IH, d, J=8.4Hz), 8.31 (IH, d, J=7.VHZ), 8.53 (IH, d, J=7.0Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1331.5 (M+Na-1)<br>
Elemental Analysis Calcd. for C5gH-77NgNa023S-6H20 :<br>
C 49.15, H 6.33, N 7.91<br><br>
Found :  C 49.07, H 6.53, N 7.84<br>
Example 112<br>
IR (KBr) :  3350, 2937, 1673, 1646, 1631, 1538, 1519,<br>
1456, 1247, 1049 cm-’ NMR (DMSO-dg, 5) :  0.97 (3H, d, J=6.6Hz), 1.07 (3H, d, J=5.7Hz), 1.3-2.4 (25H, m), 2.5-2.6 (IH, m), 3.2-3.4 (IH, m), 3.5-4.6 (20H, m), 4.8-5.7 (IIH, m), 6.73 (IH, d, J=8.0Hz), 6.9-7.0 (2H, m) , 7.0-7.2 (3H, m), 7.3-7.6 (3H, m), 7.74 (2H, d, J=8.5Hz), 7.77 (2H, d, J=8.3Hz), 8.02 (2H, d, J=8.3Hz), 8.13 (IH, d, J=8.4Hz), 8.30 (IH, d, J=7.7Hz), 8.77 (IH, d, J=7.0Hz), 8.85 (IH, s) FAB-MASS :  m/z = 1389 (M+Na’) Elemental Analysis Calcd. for C62’Hg3Ng024NaS-7H20 :<br>
C 49.06, H 6.55, N 7.50 Found :  C 49.03, H 6.54, N 7.56<br>
Example 113<br>
NMR (DMSO-dg, 6) :  0.84 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.1-1.3 (14H, m) , 1.7-2.1 (5H, m), 2.2-2.5 (3H, m), 2.6-2.7 (IH, m), 3.1-3.3 (IH, m) , 3.7-4.5 (16H, m), 4.7-5.1 (7H, m), 5.10 (IH, d, J=5.5Hz), 5.16 (IH, d, J=3.1Hz), 5.25 (IH, d, J=4.5Hz), 5.49 (IH, d, J=5.7Hz), 6,53 (IH, d, J=3.1Hz), 6.73 (IH, d, J=8.2Hz), 6.8-6.9 (2H, m), 7.05 (IH, m), 7.31 (IH, d, J=8.1Hz), 7.4-7.6 (4H, m), 7.70 (IH, d, J=6.7Hz), 8.08 (IH, d, J=8.4Hz), 8.18 (IH, s), 8.31 (IH, d, J=7.7Hz), 8.57 (IH, d, J=7.0Hz), 8.85 (IK, s)<br>
FAB-MASS :  m/z = 12 64 (M+Na- -)<br>
Elemental- Analysis Calcd. for C54H-ygNg02iNaS-6H20 :<br>
C 48.03, H 6.57, N 9.34 Found :  C 48.02, H 6.61, N 9.28<br><br>
IR (KBr) : 3350, 2937, 1668, 1631, 1537, 1247, 1047 cm~’<br>
NMR (DMSO-dg, 5) :  0.85 (3H, t, J=7.4Hz), 0.96 (3H, d, J=6.5Hz), 1.07 (3H, d, J=5.7Hz), 1.3-1.7 (7H, m) , 1.7-2.1 (5H, m), 2.2-2.4 (3H, m), 2.6-2.7 (IH, m), 3.0-3.8 (16H, m) , 3.8-4.6 (IIH, lu) , 4.7-5.3 (6H, m), 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m) , 7.0-7.2 (3H, m), 7.3-7.5 (3H, m), 7.6-7.8 (4H, m), 7.96 {2H, d, J=8.3Hz), 8.11 (IH, d, J=8.2Hz), 8.26 (IH, d, J=7.6Hz), 8.6-9.0 (2H, m)<br>
FAB-MASS :  m/z = 1319.4 (M+Na-’)<br>
Elemental Analysis Calcd. for C57H-7-7Ng023NaS-8H20 :<br>
C 47.50, H 6.50, N 7.77 Found :  C 47.72, H 6.85, N 7.85<br>
Example 115<br>
IR (KBr) :  3350, 1666, 1631, 1546, 1276, 1247 cm-’<br>
NMR (DMSO-dg, 6) :  0.97 (3H, d, J=7.5Hz), 1.08 (3H, d, J=5.7H2), 1.4-1.6 (4H, m), 1.6-2.1 (5H, m) , 2.1-2.4 (3H, m), 2.5-2.6 (IH, m), 3.1-3.3 (IH, m), 3.23 (3H, s), 3.3-3.5 (2H, m), 3.7-4.5 (16H, m), 4.79 (2H, d, J=6.2Hz), 4.8-5.1 (5H, m), 5.11 (IH, d, J=5.6Hz), 5.18 (IH, d, J=3.1Hz), 5.26 (IH, d, J=4.4Hz), 5.54 (IH, d, J=5.7Hz), 6.73 (IH, d, J=8.1Hz), 6.8-7.0 (2H, m), 7.0-7.1 (3H, m) , 7.3-7.5 (3H, m), 7.6-7.9 (8H, m), 8.01 (2H, d, J=8.4Hz), 8.08 (IH, d, J=8.4Hz), 8.32 (IH, d, J=7.7Hz), 8.80 (IH, d, J=7.0Hz), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1353.9 (M+Na-’)<br>
Elemental Analysis Calcd. for C6QH-7 5Ng023NaS-9.5H2O :<br>
C 47.96, H 6.31, N 7.46 Found :  C 47.97, H 6.25, N 7.41<br>
Example 116<br>
IR (KBr) :  3450, 2935, 1675, 1650, 1540, 1513, 1454,<br><br>
1047 cm'l NMR (DMSO-dg, 6) :  0.97 (3H, d, J=6.7Hz), 1.09 (3H, d,<br>
J=5.9Hz), 1.60 (6H, s), 1.7-2.4 (6H, m), 2.5-2.6<br>
(IH, m), 3.1-3.6 (5H, m), 3.7-4.5 (14H, m), 4.7-5.0<br>
(3K, m), 5.0-5.2 (4H, m), 5.11 (IH, d, J=5.5Hz),<br>
5.18 (IH, d, J=3.1H2), 5.26 (IH, d, J=4.5H2), 5.56<br>
(IH, d, J=6.0Hz), 6.8-7.5 (9H, m), 7.84 (2H, d,<br>
J=8.8Hz), 8.0-8.4 (6H, m),   8.85 (IH, s) , 8.91 (IH,<br>
d, J=7.0Hz)<br>
FAB-MASS :  m/z = 1328 (M+Na)-’<br>
Elemental Analysis Calcd. for C55HggN2i02]_S2Na-8H20 :<br>
C 45.55, H 5.84, N 10.62 Found :  C 45.62, H 5.70, N 10.54<br>
Example 117<br>
IR (KBr) :  3350, 2939, 1664, 1627, 1531, 1446, 1249,<br>
1049 cm~’ NMR (DMSO-dg, 5) :  0.8-1.0 (6H, m), 1.4-1.9 (9H, m) , 2.0-2.5 (4H, m), 3.1-3.2 (IH, m), 3.22 (3H, s), 3.3-3.4 (2H, m), 3.51 (2H, s), 3.6-4.4 (16H, m), 4.7-5.2 (7H, m), 5.07 (IH, d, J=5.6Hz), 5.17 (IH, d, J=3.1Hz), 5.23 (IH, d, J=4.5Hz), 5.54 (IH, d, J=5.9Hz), 6.7-6.8 (3K, m), 7.0-7.4 (8H, m) , 7.5-7.7 (4H, m), 7.70 (4H, s), 8.1-8.2 (2H, m), 8.51 (IH, d, J=7.0Hz), 8.83 (IH, s) FAB-MASS :  m/z = 1367.6  (M+Na’)<br>
Elemental Analysis Calcd. for C62H77N3023SNa-6.5H2O :<br>
C 50.01, H 6.20, N 7.66 Found :  C 50.30, K 6.50, N 7.75<br>
Example 118<br>
To a solution of The Object Compound (61) (0.25 g) in methanol (50 ml) was added dry 10% palladium on carbon (0.2 g) and stirred for 6 hours under hydrogen atmosphere.  The palladium on carbon was filtered off, and the filtrate was<br><br>
evaporated under reduced pressure to give Object Compound 118 (179 mg) .<br>
IR (KBr) :  3400, 1668.1, 1627.6 cin-’<br>
NMR (DMSO-dg, 6) :  0.92 (3H, d, J=6.7H2), 1.1-2.45<br>
(40H, m), 3.20 (3H, s), 3.28 (2H, t, J=6.5Hz), 3.0-3.4 (IH, m), 3.5-4.7 (14H, m), 4.95-5.5 (12H, m) , 6.55 (IH, d, J=8.4Hz), 6.84 (IH, s),   6.86 (IH, d, J=8.4Hz), 7.0-7.3 (4H, m) , 7.9-8.3 (4H, m) FAB-MASS :  m/z = 1292 (M+Na) Elemental Analysis Calcd. for C54HggN9022SNa-5H20 :<br>
C 47.67, H 7.26, N 9.26 Found :  C 47.72, H 7.35, N 8.95<br>
The Object Compounds (119) to (121) were obtained according to a similar manner to that of Example 118.<br>
Example 119<br>
NMR (DMSO-dg, 6) :  0.87 (3H, t, J=6.6Hz), 1.00 (3H, d, J=7.3Hz), 1.03 (3H, d, J=6.0Hz), 1.2-1.5 (4H, m) , 1.5-2.0 (5H, m), 2.1-2.7 (8H, m) , 3.17 (IH, m), 3.6-4.5 (14H, m), 4.65-5.7 (12H, m), 6.72 (IH, d, J=8.1Hz), 6.75 (IH, s), 6.80 (IH, d, J=8.1Hz), 7.05 (IH, s), 7.1-7.7 (15H, m), 8.0-8.6 (4H, m), 8.85 (IH, s) FAB-MASS :  m/z = 1274 (M+Na) Elemental Analysis Calcd. for C55H74Ng02iSNa-7H20 :<br>
C 47.93, N 6.43, N 9.15 Found :  C 48.12, N 6.56, N 9.03<br>
Example-120<br>
IR (KBr) :  3355.5, 1672.0 1629.6 cm~’<br>
NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.6H2), 0.98 (3H, d, J=6.5Hz), 1.03 (3H, d, J=6.0Hz), 1.2-2.6 (21H, m), 3.18 (IH, m), 3.6-4.5 (16H, m), 4.65-5.55 (12H, m) , 6.6-7.5 (lOH, m), 8.0-8.6 (4H, m), 8.89 (IH, s)<br><br>
FAB-MASS :  m/z = 1256 (M+Na)<br>
 , <br>
IR (KBr) :  3357.5, 1660.4, 1629.6, 1249.6 cm~l NMR (DMSO-dg, 6) :  0.86 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.8Hz), 1.03 {3H, d, J=6.0Hz), 1.1-1.5 (12H, m), 1.6-2.0 (5H, m), 2.0-2.5 (4H, m) , 3.07 (IH, m), 3.5-4.5 (16H, m) , 4.6-5.6 (12H, m), 6.72 (IH, d, J=8.1Hz), 6.7-6.9 (4H, m), 7.04 (IH, s), 7.16 (IH, s), 7.1-7.5 (2H, m), 7.25 (2H, d, J=8.6Hz), 8.0-8.2 {3H, m), 8.46 (IH, d, J=7Hz), 8.84 (IH, s) FAB-MASS :  m/z = 1256 (M+Na) Elemental Analysis Calcd. for C52H7gN9022SNa'7H20 :<br>
C 45.91, H 6.67, N 9.27 Found :  C 45.98, H 6.67, N 9.10<br>
Example 122<br>
A solution of Object Compound (11) (795 mg) in water (16 ml) was left for 240 hours.  The solution was subjected to column chromatography on ODS (YMC-gel ODS-AMS50) and eluted with 25% CH3CN/H2O.  The fractions containing Object Compound were combined and the acetonitrile was removed under reduced pressure.  The residue was lyophilized to give Object Compound (123) (38 mg).<br>
IR (KBr) : 3361, 2956, 2875, 1668, 1627, 1521, 1249,<br>
1047 cm'-NMR (DMSO-dg, 5) :  0.8-1.5 (19H, m), 1.6-2.4 (13H, m), 3.1-3.2 (IH, m), 3.5-4.1 (12H, m), 4.1-4.7 (lOH, m.) , 4.9-5.6 (5H, m) , 5.98 (IH, d, J=10.6Hz), 6.36 (IH, d, J=10.6Hz), 6.7-7.3 (12H, m), 7.4-8.0 (7H, m) FAB-MASS :  m/z = 1273.1 (M+Na’) Elemental Analysis Calcd. for C55H72N8022NaS-llH20 :<br>
C 45.58, H 6.47, N 7.73 Found :  C 45.83, H 6.26, N 7.75<br><br>
The Object Compound (123) was obtained according to a similar manner to that of Example 118.<br>
IR (KBr) :  3349.7, 1670.1, 1627.6 cm-’<br>
NMR (DMSO-dg, 5) :  0.87 (3H, t, J=7.2Hz), 0.96 (3H, d, J=6.7H2), 1.13 (3H, d, J=5.7Hz), 1.18-1.55 (lOH, m), 1.58-2.08 (5H, m), 2.08-2.90 (4H, m) , 2.90-3.30 (2H, m), 3.60-4.50 (17H, m), 4.70-5.70 (12H, m), 6.65-7.60 (IIH, m), 7.80 (2H, br s), 7.95-8.23 (2H, m) , 8.75 (IH, d, J=7.0H2), 8.85 (IH, s)<br>
FAB-MASS :  m/z = 1114-4  (M-SO4-2)<br>
Elemental Analysis Calcd. for C52H77N902xS-6H20 :<br>
C 47.88, H 6.88, N 9.66 Found :  C 47.60, H 6.74, N 9.53<br>
The following compound (124) was obtained according to a similar manner to that of Example 1.<br>
Example 124<br>
IR (KBr) :  3324, 2937, 2873, 1664, 1629, 1442,<br>
1257 cm~’<br>
NMR (DMSO-dg, 6) :  0.91 (3H, t, J=7.1H2), 0.96 (3H, d, J=6.7Hz),. 1.09 (3H, d, J=5.7Hz), 1.3-1.5 (4H, m) , 1.7-2.6 (9H, m) , 3.1-3.3 (IH, m) , 3.7-4.6 (16H, m), 4.7-5.1 (7H, m), 5.11 (IH, d, J=5.6Hz), 5.17 (IH, d, J=3.lHz), 5.26 (IH, d, J=4.5Hz), 5.55 (IH, d, J=5.8Hz), 6.7-6.9 (3H, m) , 7.0-7.6 (6H, m), 7.97 (2H, d, J=8.8Hz), 8.0-8.4 (6H, m), 8.85 (IH, s), 8.92 (IH, d, J=7.0Hz)<br>
FAB-MASS :  m/z = 1331 (M+Na+)<br>
Elemental- Analysis Calcd. for C55HggN2o022’’’2 '<br>
C 45.45, H 5.89, N 9.64 Found :  C 45.71, H 5.68, N 9.60<br><br><br><br><br><br><br>
WE CLAIM:<br>
1,	A polypeptide compound of the following general formula (l):<br><br>
wherein Ri is<br>
(C1-C6) alkanoyl substituted with pyrazolyl which<br>
has (C1-C6) alkyl and phenyl having (C7-C2o) alkoxy<br>
(C1-C6) alkoxy  alkanoyl, in which (C7-C2o) alkanoyl may have amino<br>
or protected amino <br>
benzoyl substituted with cycle (C4-C6) alkyl having (C1-C6) alkyl;<br>
indenylcarbonyl having (C7'C2o) alkyl;<br>
naphthoyl having (C1-C6) alkyl;<br>
naphthoyl having (C7-C20) alkyl;<br>
benzoyl substituted with phenyl having (C1-C6) alkoxy (C1-C6) alkoxy (C7-C2o)<br>
alkoxy;<br><br>
which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 2 or more nitrogen atomls) which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with saturated 3 to 8 meandered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substituent (s);<br>
 alkenoyl substituted with aryl which may have one or more suitable substituent(s);<br>
naphthyl(lower)alkenoyl which may have one or more higher alkoxy;<br>
‘‘Ower alkynyl shish may have one or more suitable substituent(s);<br>
(C1-C6) alkanoyl "substituted with naphthyl having higher alkoxy;<br>
ar(02-05)alkanoyl substituted with aryl having one or more suitable substituent (s), in which ar{C1-C6)-alkanoyl may have one or more suitable substituent(s);<br>
aroyl substituted with heterocyclic group which may have one or more suitable substiruent(s), in which aroyl may have one or more suitable substituent (s);<br>
aroyl substituted with aryl having heterocyclic(higher)alkoxy/ in which heterocyclic group may have one or more suitable substituents);<br><br>
aroyl substituted with aryl having lower alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkenyl(lower)alkoxy;<br>
aroyl substituted with 2 lower alkoxy;<br>
aroyl substituted with aryl having lower alkyl;<br>
aroyl substituted with aryl having higher alkyl;<br>
aryloxy(lower)alkanoyl which may have one or more suitable substituent(s);<br>
ar (lower)alkoxy(lower)alkanoyl which may have one or more suitable substituent(s);<br>
arylamino(lower)alkanoyl which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy;<br>
lower alkoxy(higher)alkanoyl, in which higher alkanoyl may have one or more suitable substituent(s);<br>
aroyl substituted with aryl having heterocyclicoxy/ in which heterocyclicoxy may have one or more suitable substituent(s); aroyl substituted with cyclo(lower)alkyl having lower alkyl; indenylcarbonyl having higher alkyl; naphthoyl having lower alkyl; naphthoyl having higher alkyl; naphthoyl having lower alkoxy(higher)alkoxy;<br><br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy(higher)-alkoxy;<br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy;<br>
aroyl substituted with aryl which has aryl having lower alkoxy;<br>
aroyl substituted with aryl which has aryl having lower alkoxy(lower)alkoxy;<br>
aroyl substituted with 'aryl having heterocyclicoxy(higher)alkoxy;<br>
aroyl substituted with aryl having aryloxy(lower)alkoxy;<br>
aroyl substituted with aryl having heterocycliccarbonyl(higher)alkoxy;<br>
lower alkanoyl substituted with oxazolyl which has aryl having higher  <br>
lower alkanoyl substituted with furyl which has aryl substituted with aryl having lower alkoxy;<br>
lower alkanoyl substituted with triazolyl which has oxo and aryl having higher alkyl;<br>
higher alkanoyl having hydroxy; higher alkanoyl having ar(lower)alkyl and hydroxy;<br>
3-inethyl-tridecenoyl; or (C2-C6)alkanoyl substituted with aryl having higher alkoxy, in which - (C2-C6)-alkanoyl ivy have amino or protected amino, and a pharmaceutically acceptable salt thereof.<br>
2. A, compound of careering<br><br>
R1 is lower alkanoyl substituted with unsaturated<br>
e-membered heteromonocyclic group containing at least one nitrogen atom which may have 1 to 3 substituent (s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl,  3 to 8-membered saturated heteromonocyclic group containing at least one nitrogen atom which may have phenyl having higher alkoxy, phenyl substituted with phenyl having lower alkoxy, 3 to 8-membered saturated heteromonocyclic group containing at least one nitrogen atom which may have phenyl having lower alkoxy (higher) alkoxy, 3 to 8-membered saturated heteromonocyclic group containing at least one nitrogen atom which.may have phenyl having lower alkoxy, and oxo;<br>
lower alkanoyl substituted with 1,2,3,4-tetrahydroisoquinoline having higher alkoxy and lower alkoxy carbonyl;<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing at least one oxygen atom which may have 1 to 3 substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy.<br><br>
naphthyl having lower alkoxy, naphthyl having<br>
higher alkoxy, phenyl having lower alkyl, phenyl<br>
having higher alkyl, naphthoyl having higher<br>
alkoxy, phenyl substituted with phenyl having<br>
lower alkyl, unsaturated 6-membered<br>
heteromonocyclic group containing at least one<br>
nitrogen atom which may have higher alkoxy, and<br>
oxo;<br>
lower alkanoyl substituted with unsaturated<br>
condensed heterocyclic group containing 1 to 3<br>
sulfur atom(s) which may have 1 to 3<br>
substituent(s) selected from the group consisting<br>
of lower alkoxy, higher alkoxy, lower alkyl,<br>
higher alkyl, higher alkoxy(lower)alkyl, phenyl<br>
having' lower alkoxy, phenyl having higher alkoxy,<br>
naphthyl having lower alkoxy, naphthyl having<br>
higher alkoxy, phenyl having lower alkyl, phenyl<br>
having higher alkyl, naphthoyl having higher<br><br>
alkoxy, phenyl substituted with phenyl having lower alkyl, afro oxo;<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 2 or more nitrogen atoms which may have 1 to 3 substituent(s) selected from the group containing of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy/ phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl,- naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl/ and oxo;  or<br>
lower alkanoyl substituted with saturated- 3 to 8-membered heteromonocyclic group containing at least one nitrogen atom which may have 1 to 3<br><br>
substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl, and oxo.<br>
A compound of claim 1; wherein<br>
R-'- is ar (lower) alkenoyl substituted with aryl which<br>
may have 1 to 3 substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl^ higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl, lower alkoxy(lower)alkyl, halo(lower)alkoxy, lower alkynyloxy, halo (higher) alkoxy, lower* alkoxy(higher)alkoxy, and oxo;<br>
naphthyl(lower)alkenoyl which may have 1 to 3 higher alkoxy;<br>
lower alkynyl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having<br><br>
lower alkyl, and oxo;<br>
ar(C2-C6)alkanoyl substituted with aryl having 1 to 3 substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl, phenyl having lower alkoxy(lower)alkoxy, and oxo, in which ar(C2-C6)-alkanoyl may have hydroxy, oxo, protected amino or amino; or<br>
(C2-C6)alkanoyl substituted with naphthyl having higher alkoxy.<br>
4.  A compound of claim 1, wherein<br>
R- is"aroyl substituted with heterocyclic group which may have 1 to 3 substituent (s) selected from the group consisting of lower alkoxy, higher alkoxy,^ lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl; phenyl having lower alkoxy(higher)alkoxy, phenyl having higher alkenyloxy, heterocyclic group substituted with phenyl having lower alkoxy, heterocyclic group, cyclo (lower)alkyl’ having phenyl, phenyl having cyclo(lowex)alkyl, phenyl substituted with heterocyclic group having lower alkyl and oxo, cyclo(lower)alkyl having lower alkyl^ phenyl<br><br>
substituted with phenyl having lower alkoxy, phenyl having heterocyclic group and oxo, in which aroyl may have halogen;<br>
aroyl substituted with aryl having heterocyclic(higher)alkoxy, in which heterocyclic group may have lower alkyl;<br>
aroyl substituted with aryl having lower alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkenyl(lower)alkoxy;<br>
aroyl substituted with 2 lower alkoxy;<br>
aroyl substituted with aryl having lower alkyl; or<br>
aroyl substituted with aryl having higher alkyl.<br>
5.  A compound of claim 1, wherein<br>
R-'- is aryloxy (lower) alkanoyl which may have 1 to 3<br>
substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl, and oxo;<br>
ar(lower)alkoxy(lower)alkanoyl which may have 1 to 3 substituent(s): selected from the group consisting of lower! alkoxy, higher alkoxy, lower alkyl, higher alkyl&gt; higher alkoxy(lower)alkyl, phenyl having lower: alkoxy, phenyl having higher alkoxy, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy phenyl stibstituted with phenyl<br><br>
having lower alkyl, and oxc; or<br>
arylamino(lower)alkanoyl which may have 1 to 3 substituent(s) selected from the group consisting cf lower alkoxyl, higher alkoxy, lower alkyl, higher alkyl, higher alkoxy(lower)alkyl, phenyl having lower aikoxy, phenyl having higher alkoxv, naphthyl having lower alkoxy, naphthyl having higher alkoxy, phenyl having lower alkyl, phenyl having higher alkyl, naphthoyl having higher alkoxy, phenyl substituted with phenyl having lower alkyl, and oxo.<br>
6,  A compound of claim 1, wherein<br>
R' is lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy;<br>
lower alkoxy(higher)alkanoyl, in which higher alkanoyl may have amino or protected amino;<br>
aroyl substituted with aryl ha'ing heterocyclic/ in which he.erocyclicoxy may have phenyl;<br>
aroyl substituted with cyclo(lower)alkyl having lower alkyl;<br>
indenylcarbonyl having higher alkyl;<br>
naphthoyl having lower alkyl;<br>
naphthoyl having higher alkyl;<br>
naphthoyl having lower alkoxy(higher)alkoxy;<br><br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy;<br>
aroyl substituted with aryl which has phenyl having lower alkoxy;<br>
aroyl substituted with aryl which has phenyl having lower alkoxy(lower)alkoxy;<br>
aroyl substituted with aryl having<br><br>
heterocyclicoxy(higher)alkoxy;<br>
aroyl substituted with aryl having phenoxy (lower) alkoxy;'<br>
aroyl substituted with aryl having heterocycliccarbonyl(higher)alkoxy;<br>
lower alkanoyl substituted with oxazolyl which has aryl having higher alkoxy;<br>
lower alkanoyl substituted with furyl which has aryl substituted with phenyl having lower alkoxy;<br>
lower alkanoyl substituted with triazolyl which has oxo and phenyl having higher alkyl;<br>
higher alkanoyl having hydroxy;<br>
higher alkanoyl having benzyl and hydroxy;<br>
3-inethyl-tridecenoyl; or<br>
(Cn-Cg)alkanoyl substituted with aryl having 'higher alkoxy, in which iC2-Cg)alkanoyl may have amino or protected amine,<br>
A compound of claim. 2,   wherein<br>
R- is lower alkanoyl substituted with pyridyl or pyridazinyl/ each of, which may have 1 to 3 substituent(s) selected from, the group consisting of higher alkoxy, higher alkoxy’ over; alkyl, phenyl having higher alkoxy, phenyl substituted with phenyl having lower alkoxy, piperazinyl substituted with phenyl   higher alkoxy, piperazinyl substituted with phenyl having lower alkoxy (higher) alkoxy,;' and piperazinyl substituted with phenyl having lower alkoxy;<br>
lower alkanoyl substituted with 1,2,3,4-tetrahydroisoquinoline having higher alkoxy and lower alkoxy carbonyl;<br>
lower alkanoyl-substituted with coumaran which may have 1 to 3 substituent(s) selected from the group consisting of higher alkoxy, and oxo;<br><br>
lower alkanoyl substitued with benzothiophenyl which may have 1 to 3 higher alkoxy;<br>
lower alkanoyl substituted with benzo[b]furanyl which may have 1 to 3 substituent (s) selected from the group consisting of higher alkoxy and lower alkyl;<br>
lower alkanoyl substituted with benzocxacclyi V7hich may have 1 to 3 substituent (s) selected from. the group consisting of higher alkyl, phenyl having lower alkoxy, phenyl substituted with phenyl having lower alkyl, and pyridyl having higher alkoxy;<br>
lower alkanoyl substituted with benzimidazolyl which may have 1 to 3 substituent (s) selected from the group consisting of higher alkyl, and phenyl having lower .alkoxy; or<br>
lower alkanoyl substituted with piperidyl or piperazinyl, each of which may have 1 to 3 substituent(s) selected from the group consisting of phenyl having higher alkoxy, and naphthoyl having higher alkoxy.<br>
8.  A compound of claim 3, wherein<br>
R- is phenyl(lower)alkenoyl substituted with phenyl<br>
which may have 1 to 3  substituent (s) selected from the group consisting of lower alkoxy, lower alkyl, higher alkyl, lower alkoxy(lower)alkyl, halo(lower)alkoxy, lower alkenyloxy, halo (higher)alkoxy, and lower alkoxy(higher)alkoxy;<br>
naphthyl (lower) alkenoyl which may have i to 5 higher alkoxy;<br>
lower alkynyl which may have 1 to 3 substituent(s) selected from the group consisting of naphthyl having higher alkoxy, and phenyl<br><br>
substituted with phenyl having lower alkyl;<br>
phenyl(C2-Cg)alkanoyl substituted with phenyl which has 1 to 3 substituent(s) selected from the group consisting of lower alkoxy, higher alkoxy, lower alkyl, higher alkyl, and phenyl having lower alkoxy(lower)alkyl,<br>
in which phenyl(C2-Cg)alkanoyl may have hydroxy, oxo, protected amino or amino; or<br>
(C2-Cg)alkanoyl substituted with naphthyl having higher alkoxy.<br>
A compound of claim 4,   wherein<br>
R* is benzoyl substituted with saturated 6-membered heteromonocyclic group containing at least one nitrogen atom which may have 1 to 3 substituent (s) selected from the group consisting of phenyl having lower alkoxy, phenyl having higher alkoxy, phenyl having lower allcyl, phenyl having lower alkoxy(higher)alkoxy, phenyl having higher alkenyloxy, piperidyl substituted with phenyl having lower alkoxy, piperidyl, cyclo(lower)alkyl having phenyl, phenyl having cyclo(lower)alkyl, and phenyl substituted with triazolyl having oxo and lower alkyl,<br>
in which benzoyl may have halogen; benzoyl substituted with unsaturated 5-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) which may have 1 to 3 substituent(s) selected from the group consisting of higher alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, phenyl having lower alkoxy(higher)alkoxy, and phenyl substituted with phenyl having lower alkoxy;<br>
benzoyl substituted with 5 or 6-membered heteromonoccyclic group containing 1 or 2 nitrogen<br><br>
atomics) which may have 1 to 3 substituent (s) selected from the group consisting of higher alkyl and phenyl having lower alkoxy;<br>
benzoyl substituted with 5-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and 1 to 2 sulfur atom(s) which may have 1 to 3 substituent(s) selected from the group consisting of phenyl having lower alkoxy, phenyl having higher alkoxy, cycle(lower)alkyl having lower alkyl, phenyl substituted with phenyl having lower alkoxy, phenyl having cyclo(lower)alkyl, phenyl having piperidine, and phenyl having lower alkoxy(higher)alkoxy;<br>
benzoyl substituted with phenyl having higher alkoxy substituted with unsaturated 3 to 8-membered heteromonocyclic group containing at least one nitrogen atom;<br>
benzoyl substituted with phenyl having higher alkoxy substituted with saturated 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) which may have lower alkyl;<br>
benzoyl substituted viiro phenyl having lower alkoxy(higher)alkoxy;<br>
benzoyl substituted with phenyl having lower alkenyl(lower)alkoxy;<br>
benzoyl substituted vita 2 lower alkoxy;<br>
benzoyl substituted with phenyl having lower alkyl; or<br>
benzoyl substituted with phenyl having higher alkyl.<br>
10.  A compound of claim 5, wherein  —-<br>
R-'- is phenyloxy (lower) alkanol which may have 1 to 3 higher alkoxy;<br><br>
phenyl(lower)alkoxy(lower)alkanoyl which may have 1 to 3 higher alkoxy; or<br>
phenyl amino(lower)alkanoyl which may have 1 to 3 higher alkoxy.<br>
11.  A compound of claim 1, wherein<br>
R-'- is benzoyl substituted with piperazinyl which may<br>
have 1 to 3 substituent(s) selected from the group consisting of phenyl having lower alkoxy, phenyl having higher alkoxy, phenyl having lower alkyl, phenyl having lower alkoxy(higher)alkoxy, phenyl having higher alkenyloxy, piperidyl substituted with phenyl having lower alkoxy, cyclo(lower)alkyl having phenyl, phenyl having cyclo(lower)alkyl, and phenyl substituted with triazolyl having oxo-and lower alkyl, in which benzoyl may have halogen;<br>
benzoyl substituted with isoxazolyl which may have 1 to 3 substituent (s) selected from the group ^'consisting of higher alkyl, phenyl having lower alkoxy, phenyl having higher alkoxy, phenyl having lower alkoxy(higher)alkoxy, and phenyl substituted with phenyl having lower alkoxy;<br>
benzoyl substituted with phenyl having lower alkoxy(higher)alkoxy;<br>
benzoyl substituted with,phenyl having lower alkyl;<br>
benzoyl substituted with phenyl having higher alkyl;<br>
phenyl(lower)alkenoyl substituted with phenyl which may have 1 to;3 substituent(s) selected from the group consisting of lower alkoxy, lower alkyl, higher alkyl, lower alkoxy(lower)alkyl,  —^ halo(lower)alkoxy, lower alkenyloxy, halo(higher)alkoxy and lower alkoxy(higher)alkoxy;<br><br>
benzoyl substituted with thiadiazolyl which may have 1 to 3 substituent(s) selected from the group consisting of phenyl having lower alkoxy, phenyl having higher alkoxy, cyclo(lower)alkyl having lower alkyl, phenyl substituted with phenyl having lower alkoxy, phenyl having cyclo(lower)alkyl, phenyl having piperidyl, and phenyl having lower alkoxy(higher)alkoxy; or<br>
benzoyl substituted with oxadiazolyl which may have 1 to 3 substituent(s) selected from the group consisting of phenyl having lower alkoxy, phenyl having higher alkoxy, phenyl having lower alkoxy(higher)alkoxy, higher alkyl and phenyl, substituted with phenyl having lower alkoxy.<br>
12,	A compound of claim 11, wherein<br>
R-*- is benzoyl substituted with phenyl having lower alkoxy(higher)alkoxy; or<br>
benzoyl substituted with phenyl having lower alkyl:<br>
13,	A compound of claim 11, wherein<br>
R-^ is benzoyl substituted Avith piperazinyl which may have phenyl having lower alkoxy;<br>
benzoyl substituted with isoxazolyl which may have phenyl having lower alkoxy;<br>
benzoyl substituted' with thiadiazolyl which may have phenyl having lower alkoxy(higher)alkoxy; or<br>
benzoyl substituted; with oxadiazolyl which may have phenyl having lower alkoxy.<br>
14,	A compound’ of claim 11, wherein<br>
R-^ is phenyl (lower) alkenoyl substituted with phenyl which may have lower alkoxy.<br><br>
15.  A process for the preparation of a polypeptide compound of the formula [I] :<br><br>
wherein<br>
R' is lower alkanoyl substituted with unsaturated<br>
6-membered heteromonocyclic group containing at ^ least one nitrogen atom which may have one or” more suitable substituent(s);<br>
lower alkanoyl substituted with 1,2,3,4-tetrahydro-isoquinoline having higher alkoxy;<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing at least one oxygen atom which may have one or more suitable substituent (s)^;<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group containing 1 to 3 sulfur atom(s) which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with unsaturated condensed heterocyclic group- containing 2-or more nitrogen atom(s) which may have one or more suitable substituent is);<br><br>
lower alkanoyl substituted with saturated 3 to 6-miembered heteromonocyclic group containing at least one nitrogen atom which may have one or more suitable substiruent(s);<br>
ar-dower)alkenoyl substituted with aryl which may have one or more suitable substituent(s);<br>
naphthyl(lower)alkenoyl which may have one or more higher alkoxy;<br>
lower alkynyl which may have one or more suitable substituent(s);<br>
(C2-C6) alkanoyl substituted with naphthyl having higher alkoxy;<br>
ar(C2-C6)alkanoyl substituted with aryl having one or more suitable substituent(s), in which ar(C2-C6)alkanoyl may have one or more suitable substituent(s);<br>
aroyl substituted with heterocyclic group which may have one or mere suitable substituent (s), ion which aroyl may have one or more suitable substituent (s);<br>
aroyl substituted with aryl having heterocyclic(higher)alkoxy, in which heterocyclic group may have one cry mere suitable substituent (s);<br>
aroyl substituted with aryl having lower alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkenyl(lower)alkoxy;<br>
aroyl substituted with 2 lower alkoxy;<br>
aroyl substituted with aryl having lower alkyl;<br>
aroyl substituted with aryl having higher alkyl;<br>
aryloxy(lower)alkanoyl which may have one or more suitable substituent-(s) ;<br>
ar(lower)alkoxy(lower)alkanoyl which may. have one or more suitable substituents (s);<br><br>
arylamino(lower)alkanoyl which may have one or more suitable substituent(s);<br>
lower alkanoyl substituted with pyrazolyl which has lower alkyl and aryl having higher alkoxy;<br>
lower alkoxy(higher)alkanoyl, in which higher alkanoyl may have one or more suitable substituent(s);<br>
aroyl substituted with aryl having heterocyclicoxy, in which heterocyclic may have one or more suitable substituent (s);<br>
aroyl substituted with cycle(lower)alkyl having lower alkyl;<br>
indenylcarbonyl having higher alkyl;<br>
naphthoyl having lower alkyl;<br>
naphthoyl having higher alkyl;<br>
naphthoyl having ■ lower alkoxy(higher)alkoxy;<br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxyjhigher)alkoxy;<br>
aroyl substituted with aryl having lower alkoxy(lower)alkoxy;<br>
aroyl substituted with aryl which has aryl having lower alkoxy;<br>
aroyl substituted with aryl which has aryl having lower alkoxy.(lower) alkoxy;<br>
aroyl substituted with aryl having heterocycliccxy(higher)alkoxy;<br>
aroyl substituted with aryl having aryloxy(lower)alkoxy;<br>
aroyl substituted with aryl having heterocycliccarbonyi(higher)alkoxy;<br>
lower alkanoyl substituted with oxazolyl which has aryl having higher alkoxy;<br>
lower alkanoyl substituted'with furyl wretch has aryl substituted with aryl having lower alkoxy;<br>
lower alkanoyl substituted with triazolyl which<br><br>
has oxo and aryl having higher alkyl; higher alkanoyl having hydroxy; higher alkanoyl having ar(lower)alkyl and hydroxy;<br>
3-methyl-tridecenoyl; or<br>
(C2-C6)alkanoyl substituted with aryl having higher alkoxy, in which (C2-C6)alkanoyl may have amino or protected amino/ and a pharmaceutically acceptable salt thereof, which comprises<br>
1)  reacting a compound of the formula :<br><br>
or its reactive derivative at the amino group or a salt thereof/ with a compound cf the formula :<br><br>
wherein R- is defined above,<br>
or its reactive derivative at the carboxy group or a<br>
salt thereof, to give a compound [l] of the formula :<br><br><br>
wherein R  is defined above, or a salt thereof.<br>
16-  A phaimaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt hereof in admixture<br><br>
with pharmaceutically acceptable carriers or excipients.<br>
17.	Use of a compound of claim 1 or a pharmaceutically<br>
acceptable salt thereof as a medicament.<br>
18.	A compound of claim 1 or i  pharmaceutically acceptable<br>
salt thereof for use as a medicament,<br>
19.	A method for the prophylactic and/or the therapeutic<br>
treatment' of infectious diseases caused by pathogenic<br>
—-  microorganisms which comprises administering a-compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.<br><br>
20.   A  polypeptide  compound,  substantially   as   hereinabove described and exemplified.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1286-mas-1995-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1jbGFpbXMgZmlsZWQucGRm" target="_blank" style="word-wrap:break-word;">1286-mas-1995-claims filed.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1jbGFpbXMgZ3JhbnRlZC5wZGY=" target="_blank" style="word-wrap:break-word;">1286-mas-1995-claims granted.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1jb3JyZXNwb25kbmVjZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">1286-mas-1995-correspondnece-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1jb3JyZXNwb25kbmVjZS1wby5wZGY=" target="_blank" style="word-wrap:break-word;">1286-mas-1995-correspondnece-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1kZXNjcmlwdGlvbihjb21wbGV0ZSlmaWxlZC5wZGY=" target="_blank" style="word-wrap:break-word;">1286-mas-1995-description(complete)filed.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1kZXNjcmlwdGlvbihjb21wbGV0ZSlncmFudGVkLnBkZg==" target="_blank" style="word-wrap:break-word;">1286-mas-1995-description(complete)granted.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">1286-mas-1995-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1mb3JtIDI2LnBkZg==" target="_blank" style="word-wrap:break-word;">1286-mas-1995-form 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">1286-mas-1995-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1mb3JtIDQucGRm" target="_blank" style="word-wrap:break-word;">1286-mas-1995-form 4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI4Ni1tYXMtMTk5NS1mb3JtIDYucGRm" target="_blank" style="word-wrap:break-word;">1286-mas-1995-form 6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzLTEyODYtbWFzLTE5OTUuanBn" target="_blank" style="word-wrap:break-word;">abs-1286-mas-1995.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="210630-improved-sachet-pouch.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="210632-a-radiopaque-glass-powder-for-use-in-dental-composites.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>210631</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1286/MAS/1995</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>50/2007</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>14-Dec-2007</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>08-Oct-2007</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>06-Oct-1995</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>M/S. ASTELLAS PHARMA INC</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>3-11, NIHONBASHI-HONCHO 2 CHOME, CHUO-KU, TOKYO 103-8411,</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>AKIRA YAMADA</td>
											<td>4-8-30, SAWADA, FUJIIDERA-SHI, OSAKA 583,</td>
										</tr>
										<tr>
											<td>2</td>
											<td>HISASHI TAKASUGI</td>
											<td>3-116-10 MOZU UMEKITA, SAKAI-SHI, OSAKA 591,</td>
										</tr>
										<tr>
											<td>3</td>
											<td>HIDENORI OHKI</td>
											<td>4-4-13-107, NAKASUJI, TAKARAZUKA-SHI HYOGO 665,</td>
										</tr>
										<tr>
											<td>4</td>
											<td>MASAKI TOMISHIMA</td>
											<td>3-33-5, GEIN, MINOO-SHI, OSAKA 562,</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07 K 1/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>9420425.2</td>
									<td>1994-10-07</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>9508745.8</td>
									<td>1995-04-28</td>
								    <td>U.K.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/210631-a-polypeptide-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 03:18:26 GMT -->
</html>
